<?xml version="1.0" encoding="utf-8"?>
<rdf:RDF
  xmlns:obo="http://purl.obolibrary.org/obo/"
  xmlns:owl="http://www.w3.org/2002/07/owl#"
  xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
  xmlns:ddiem="http://ddiem.phenomebrowser.net/"
  xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
  xmlns:dc="http://purl.org/dc/elements/1.1/"
>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1f6506ff-b304-41c0-aaae-53e78fff4451">
    <ddiem:uniprotId>Q16586</ddiem:uniprotId>
    <ddiem:keggEntryId>K12565</ddiem:keggEntryId>
    <rdfs:label>sarcoglycan alpha</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4bdca882-1828-4c20-b4cc-ba9e1cb3a002">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6442</dc:identifier>
        <rdfs:label>SGCA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ea1c2cd5-f9d5-47c9-807c-1e881d3f9a5b">
    <rdfs:label>insulin like growth factor 1</rdfs:label>
    <ddiem:keggEntryId>K05459</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d3cf86de-495f-4bba-9dc7-781aaa3b95ca">
        <rdfs:label>IGF1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3479</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P05019</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/7854f1aa-2c8c-459b-8097-20c567e43253">
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000352">
        <dc:identifier>ECO:0000352</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000352</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617347">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3794706b-3129-411d-9ba0-3e1dc3aeaef1"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/507</ddiem:iembaseUrl>
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE III</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/617347</dc:identifier>
        <ddiem:iembaseAccessionNumber>507</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c4f4f6e8-d1cb-4d8b-96e1-ab426850a2a7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d03d5f6-8630-402a-ae87-9d8ccd086ac5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/65d6195a-e099-4715-aa22-c59b4da3069e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dc13423a-aaf5-4f46-9296-60aeb97265d6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab02d6c9-b79c-4d95-bfd5-178cbb13a9ae">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:label>hypercholesterolemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000012>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0a3130f8-12e6-445e-befb-dbe553f599fa">
    <ddiem:uniprotId>P81172</ddiem:uniprotId>
    <ddiem:keggEntryId>K23106</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/533e6e2d-b463-4919-99a8-6bbf5172b68a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/57817</dc:identifier>
        <rdfs:label>HAMP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K23100</ddiem:keggEntryId>
    <rdfs:label>hemojuvelin/hepcidin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7a77ebec-ea75-4802-b8fc-28070f18b69f">
        <rdfs:label>HJV</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148738</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q6ZVN8</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/468280ad-3cbe-48c3-90aa-f79ba63c5607">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6c6ea88c-7453-43f0-bcd5-1f5aa3dce26e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5261</dc:identifier>
        <rdfs:label>PHKG2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphorylase b kinase gamma catalytic chain, liver/testis isoform</rdfs:label>
    <ddiem:keggEntryId>K00871</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.11.19</ddiem:ecNumber>
    <ddiem:uniprotId>P15735</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606812">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/174</ddiem:iembaseUrl>
    <rdfs:label>FUMARASE DEFICIENCY; FMRD</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/606812</dc:identifier>
    <rdfs:comment>The high fat, low carbohydrate diet may has a possible disease modifying effect. https://www.ncbi.nlm.nih.gov/pubmed/29052812</rdfs:comment>
    <ddiem:iembaseAccessionNumber>174</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/265b1bc1-3204-4f6a-8ed6-b7f2004fcb2c">
        <rdfs:label>FH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2271</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/89c768c9-3284-4a53-8a6c-ea936247fd6d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/79daa1d4-64f5-4578-b028-21c1505064f4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ebdb9a9e-1371-4217-85da-84b1a352c175"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7">
        <rdfs:label>seizures</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/29a4309e-6ccc-498d-b279-8d6ce22b2144">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6f774927-8fba-43f5-80d4-be854042353a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610768">
        <dc:identifier>https://www.omim.org/entry/610768</dc:identifier>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/342</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2953128e-bcb8-4afc-8add-a0ad11e9d4bc"/>
        <ddiem:iembaseAccessionNumber>342</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ebe2b0b6-d5c5-4dc0-a00b-6ba7c6648699">
    <ddiem:ecNumber>3.4.19.13; 2.3.2.2; 3.4.19.14</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5b33e140-904c-44a5-a0e7-7767275476ea">
        <rdfs:label>GGT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2678</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase</rdfs:label>
    <ddiem:uniprotId>P19440</ddiem:uniprotId>
    <ddiem:keggEntryId>K18592</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9257b351-24d2-46b0-89e3-32e7131ee610">
    <ddiem:ecNumber>1.2.1.88</ddiem:ecNumber>
    <rdfs:label>Δ1-pyrroline 5-carboxylate dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/716f860b-931b-410b-9ee3-645aee122431">
        <rdfs:label>ALDH4A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8659</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P30038</ddiem:uniprotId>
    <ddiem:keggEntryId>K00294</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/af0235c1-e633-4193-b1f5-9fd1a7ec7e6d">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222700">
        <rdfs:comment>General therapeutic management remains empirical with 3 major axes: prevention of hyperammonemia, nutritional supplementation and prevention of specific complications. There is a general consensus that a hypoproteinemic regimen should be initiated with an objective of 1 g/kg/d. associated with L-citrulline supplementation, L-carnitine 20-50 mg/kg/d., vitamins and other nutritional supplementation, if necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217205/  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  https://www.ncbi.nlm.nih.gov/pubmed/22402328/</rdfs:comment>
        <ddiem:iembaseAccessionNumber>51</ddiem:iembaseAccessionNumber>
        <rdfs:label>LYSINURIC PROTEIN INTOLERANCE; LPI</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/222700</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5e5b0eb9-3d28-465c-9a7c-4d9fb5950c17"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/51</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/409914f3-5c06-4b48-8ee5-30e827529ac2">
        <dc:identifier>HP:0000793</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000793</ddiem:url>
        <rdfs:label>membranoproliferative glomerulonephritis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9b2bc7e5-ba1c-4f8f-b238-38d55924b36a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/16cdcab8-7620-4e3f-bb5a-b2488d109991"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28087478</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/858a4bdb-d678-48de-875b-48aff56f81cf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d20c0ae8-eef1-47d1-8d38-dbe5fc85b46d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/113190c8-5dbc-457a-8cd5-e01deaba494d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e01bee0d-9752-4a63-8fa8-28edd454e2cb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a73b30d5-a61e-404a-ac7b-b1f4d4ea709b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b788ae74-6972-416d-9f3d-bdb7dca42be1">
        <dc:identifier>HP:0003162</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003162</ddiem:url>
        <rdfs:label>Fasting hypoglycemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5571766c-dacc-4147-b00a-6dc6463e21ef">
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:label>Sleep disturbance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007121">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007121</ddiem:url>
        <dc:identifier>ECO:0007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232400">
        <dc:identifier>https://www.omim.org/entry/232400</dc:identifier>
        <rdfs:label>GLYCOGEN STORAGE DISEASE III; GSD3</rdfs:label>
        <rdfs:comment>Managment guidelines for treating GSD3 can be accessed through https://www.ncbi.nlm.nih.gov/pubmed/20631546</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/842b7d1a-0598-4748-a6b3-f22a108c6b0c"/>
        <ddiem:iembaseAccessionNumber>487</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/487</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000010>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/673e8bde-e06d-412c-9f50-0036bb7efd0c">
    <ddiem:keggEntryId>K19331</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8WZ55</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4b5b743c-029c-4d85-9a9e-e4d8e75a100a">
        <rdfs:label>BSND</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7809</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>barttin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/36db5796-99d4-4795-8532-f5718aa4acda">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246650">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/33dbb7e3-b99d-4c62-8074-fcedc833e422"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1085</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/246650</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1085</ddiem:iembaseAccessionNumber>
        <rdfs:label>LIPASE DEFICIENCY, COMBINED</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469">
        <rdfs:label>Hypertriglyceridemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/37cea92d-a8a9-45cb-98e1-1177132bdf27">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/87f45f49-db02-456e-8a61-badc2a370edf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c9d0ee4a-77ce-4fa5-8b85-3e007835c2ea">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0d2620ac-da76-4ca3-9701-efbdc7af885f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5c8c5e8a-3a78-440c-977e-29774be9e889">
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/451bbd3a-512a-4a5d-8513-97be22d4cce9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5428</dc:identifier>
        <rdfs:label>POLG</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <rdfs:label>DNA polymerase subunit gamma-2</rdfs:label>
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1b89bc39-a90d-41ff-9473-975cfafeedd1">
    <rdfs:label>cystinosin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/21b0dd29-5e41-46a6-aad2-28a1acb7cd82">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1497</dc:identifier>
        <rdfs:label>CTNS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12386</ddiem:keggEntryId>
    <ddiem:uniprotId>O60931</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/657dcbf5-5995-475f-b307-8cb032f96960">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/0022510X89901123</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/931a6903-0271-4ef7-b8f0-d2f415ec0823">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/26b5b2c9-b572-4dc1-a24f-0ffcf8e340d8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/540000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8826c45-6040-4389-b8ef-56b99ce90527"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e83155a6-061f-4432-98fa-c0e3952993a9"/>
        <rdfs:label>MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/399</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/540000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/48ac681a-1269-4c1f-b31d-966bea304708"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d1343e00-ebd6-44c1-b822-449826c59320"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/60a52977-facf-4bca-a960-fb5a959058b7"/>
        <ddiem:iembaseAccessionNumber>399</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4e7fd70a-63d9-48eb-bf73-85e2b668072c"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/892699f3-d486-4cb2-89d1-b06121448607"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/14ac3602-9b5b-4c8a-a922-2757be07e81b"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5af56574-d352-42ab-a58a-01068008bf89"/>
        <rdfs:comment>MELAS syndrome can be caused by mutation in several genes, including MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2. https://www.omim.org/entry/540000</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9f49626f-8939-413c-a2ff-b4be64774004"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/888e7240-168b-42d8-938e-c3434a8f5b22">
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>Abnormal EEG</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f8e94a93-3bfb-419c-a7c6-05b41384c61d"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/eb25441e-e818-4028-9fdc-49bd119ad405">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>Atypical kinase COQ8A, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ef59f7d5-bc7d-4e76-9431-d7acac6fc881">
        <rdfs:label>ADCK3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/0c8dbde2-15d8-4a07-ad33-1e60713631ba">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0212c985-f816-47e4-995e-a214d71ae8cc">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:label>Hypoglycemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.researchgate.net/publication/307584174_Glycogen_storage_diseases_Diagnosis_treatment_and_outcome</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232200">
        <dc:identifier>https://www.omim.org/entry/232200</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/484</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/53a2e327-4eaf-4e72-85f7-7f39af24a3d5"/>
        <ddiem:iembaseAccessionNumber>484</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ia; GSD1A</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aad0232b-d068-4a7f-9f3e-4d30542b65e1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1d36a1f6-9ad2-4c1d-8d4e-1213ee17616d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d249f4af-7d79-441f-bd32-1ce29a700254">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/48ed57bb-e1cb-43b7-a328-f1e67eb1be46"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000010>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b6c8cc57-7c60-4091-829a-c375e3650f7e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b6bc371-02ee-47ee-bf6e-b855bd00de60">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001285</dc:identifier>
        <rdfs:label>Spastic tetraparesis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001285</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e5b73543-3fbe-43e4-9d38-9a61165743e0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d92a9077-3572-4cb4-a2e6-3982b0483afb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/486793e9-6544-41cf-a439-69426f635ff5">
        <rdfs:label>Epilepsy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18060820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6516bbb4-eaa2-41eb-98aa-3cdc2f03ec4c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fc934995-65ac-4357-a9f4-dc4d5c5e7053"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261630">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/5</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d5f42cff-6165-48f0-a0b5-b2f3b803d11f"/>
        <ddiem:iembaseAccessionNumber>5</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/261630</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5f058a04-868f-416f-9627-0e43af5a57af">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/88c55cd8-8ba4-4e9d-b961-ed41105b17ef">
        <rdfs:label>SLC25A13</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10165</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>citrin ( protein)</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6cf2a44e-33d0-435e-9871-619e0f5d617e">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610131">
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/942</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>942</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c7b26773-8744-4fb6-ba2b-243e892b1578"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/610131</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23248042</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/050e4ad7-9522-4300-8597-a6cd502a6274">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3cae0a3f-a2c0-4705-aeab-256058f358ec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/594e7498-bfea-44e8-839c-c110b82d67a3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6f3e036d-254f-4195-b26b-1743a44004e0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/761252a2-b41b-49a2-97ce-079be058fe8d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2966b3c3-8655-4a58-bf98-a62f24a980f0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74dda3e6-c2f9-4818-8d26-6ce8ea1b6f09">
        <rdfs:label>Mitochondrial epilepsy(Epilepsy)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/af7dd10f-dc0d-4e33-9e62-63410aa75611">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1dd1fa8d-18a2-4095-8559-5696ebb40344">
        <rdfs:label>ECM1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1893</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>Q16610</ddiem:uniprotId>
    <rdfs:label>extracellular matrix protein 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/a30617f6-897f-4df3-a6e7-d3c1a105139d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aad0232b-d068-4a7f-9f3e-4d30542b65e1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d249f4af-7d79-441f-bd32-1ce29a700254"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b686cb6-4b02-4c7d-ae7b-c7b4ef70476d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated Hepatic transaminases</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232700">
        <ddiem:iembaseAccessionNumber>490</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/490</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2d3dd430-d7e1-47b4-95e0-6a45f2238068"/>
        <dc:identifier>https://www.omim.org/entry/232700</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GLYCOGEN STORAGE DISEASE VI; GSD6</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000010>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/19fb172d-ede0-4926-b90d-8614991d0cd5">
    <rdfs:label>Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/842b7d1a-0598-4748-a6b3-f22a108c6b0c">
        <rdfs:label>AGL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/178</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01196</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.25; 3.2.1.33</ddiem:ecNumber>
    <ddiem:uniprotId>P35573</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dd0ec3a8-e42b-4d4c-ade0-d7df986d5ef7">
    <ddiem:ecNumber>1.3.8.6</ddiem:ecNumber>
    <ddiem:keggEntryId>K00252</ddiem:keggEntryId>
    <rdfs:label>glutaryl-CoA dehydrogenase, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/949e13ff-3469-4738-b3df-48c987a50efb">
        <rdfs:label>GCDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2639</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q92947</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9228da55-56e3-4482-aeb5-97c39324d100">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f1568f98-92a7-497f-bc12-1f308ce469bf">
        <rdfs:label>LDHB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3945</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.1.1.27</ddiem:ecNumber>
    <ddiem:keggEntryId>K00016</ddiem:keggEntryId>
    <ddiem:uniprotId>P00338</ddiem:uniprotId>
    <rdfs:label>lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c6e48377-c3d6-4099-b4c5-8455e51a4bcd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3939</dc:identifier>
        <rdfs:label>LDHA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2c63775d-5eaf-4ad8-a470-7dc327ce4a86">
    <ddiem:keggEntryId>K00626</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.9</ddiem:ecNumber>
    <rdfs:label>Acetyl-CoA C-acetyltransferase.</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/88163f4b-73f9-4fe7-a09d-286d709ceb40">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/38</dc:identifier>
        <rdfs:label>ACAT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P24752</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f604298b-a565-41f8-bc14-4443c435e34f">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/de0aba28-a544-48a6-b2cc-fd82834cde90">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2710a753-d32b-4b78-8d13-76da4478060a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20486940</dc:provenance>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28283348</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aad0232b-d068-4a7f-9f3e-4d30542b65e1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10404446</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/452d923e-c60b-4235-9b52-d6db74247206">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Dehydration</rdfs:label>
        <dc:identifier>HP:0001944</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001944</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606824">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4c99fb45-c018-4f5d-9e3d-fc8b2421e598"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/482</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/606824</dc:identifier>
        <ddiem:iembaseAccessionNumber>482</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Treatment rests with the avoidance of Glucse and galactose dietary sugars.https://www.ncbi.nlm.nih.gov/pubmed/28283348.  https://www.ncbi.nlm.nih.gov/pubmed/28753187</rdfs:comment>
        <rdfs:label>GLUCOSE/GALACTOSE MALABSORPTION; GGM</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07807f8d-12f4-4835-a651-9545dad1b532">
        <dc:identifier>HP:0002014</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Watery Diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5e147df8-9f21-4aa8-ab33-67e9780417b3">
    <ddiem:uniprotId>P48048</ddiem:uniprotId>
    <ddiem:keggEntryId>K04995</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/146de796-7979-46ab-bd73-1abc442f739f">
        <rdfs:label>KCNJ1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3758</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ATP-sensitive inward rectifier potassium channel 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ec14fca1-ad47-47dc-92a6-3b2a476ffe31">
    <ddiem:uniprotId>P20807</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/baf9a0ff-4966-4de3-ae6a-791b4e0622c2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/825</dc:identifier>
        <rdfs:label>CAPN3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>calpain 3</rdfs:label>
    <ddiem:keggEntryId>K08573</ddiem:keggEntryId>
    <ddiem:ecNumber>3.4.22.54</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/31e37e6f-7648-4108-bcdd-39a700588344">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e4a68535-d69a-43f3-b700-3d9c1a0acd7d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5fc1089d-cfb0-4839-9cdd-502d35ab9e3c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80dd7026-1d1c-4773-87fb-d76df28f49ab">
        <rdfs:label>Abnormal hemoglobin level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025546</ddiem:url>
        <dc:identifier>HP:0025546</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e974fe73-acaa-426b-8a9a-05168e3d2292">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/61d144c3-3515-463c-8fd8-25c87b51610d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c665a55-88d2-46a5-aa8e-dee18a15fd7e">
        <rdfs:label>Abnormal MCV level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025065</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025065</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613839">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/77b527ba-cef5-48be-b78b-fb30a1d97d8e"/>
        <dc:identifier>https://www.omim.org/entry/613839</dc:identifier>
        <rdfs:label>MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612932">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>501</ddiem:iembaseAccessionNumber>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XIII; GSD13</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612932</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/501</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5133eba0-47d4-4314-9dc0-19204a90bbe2">
        <rdfs:label>ENO3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2027</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/48581835-7231-4fd0-b083-ca71b4bc814a">
    <rdfs:label>Phospholipid-transporting ATPase ABCA1</rdfs:label>
    <ddiem:keggEntryId>K05641</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ab168b27-abdf-4466-b178-f141ffa61968">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/19</dc:identifier>
        <rdfs:label>ABCA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
    <ddiem:uniprotId>O95477</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/6372d3ef-c576-437e-9abf-60e25ef90857">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec52056d-a661-482c-8852-3b28db273dda">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002355</ddiem:url>
        <dc:identifier>HP:0002355</dc:identifier>
        <rdfs:label>Difficulty walking</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ce3a15e3-16b8-487e-9402-04eef77ad35f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be938cb3-be98-4597-8ab6-f018e51b2c8b">
        <dc:identifier>HP:0003234*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Secondary Carnitine deficiency( Carnitine deficiency)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231680">
        <dc:identifier>https://www.omim.org/entry/231680</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1257</ddiem:iembaseUrl>
        <rdfs:label>MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD</rdfs:label>
        <ddiem:iembaseAccessionNumber>1257</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b8a21aba-dd66-48e9-8119-75523d2f7a1f"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/731966c6-36e5-47b9-94b1-e5065a40b06e"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8f8c7290-4633-4db0-a3d4-f4a2858df666"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ac5799d5-cc35-4d20-8974-81ddc715cc9c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d162eed2-1cad-4bc0-b712-536bb794d1da"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/381fd0ec-d947-48ba-a99c-429ebef45eb2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Dysphagia</rdfs:label>
        <dc:identifier>HP:0002015</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26236614</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a066da68-5064-4c40-a651-d5c6ef299e87">
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b7b80e23-9def-4a47-a337-d9976e93ec7c">
        <rdfs:label>TWNK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56652</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <rdfs:label>twinkle mtDNA helicase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/64f91287-1bb4-4751-b67b-8a08b4dbc110">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e5b73543-3fbe-43e4-9d38-9a61165743e0"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e6e1448-b944-4dff-9f88-d8d8010c7fcf">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>seizure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/050e4ad7-9522-4300-8597-a6cd502a6274"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fc6ee103-58ec-4acf-817f-4f11d0b71796">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d84143a-7003-47d3-9f89-79c8feeb37b0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ed2038d9-528a-46b0-9a51-5776c90b9400"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246900">
        <rdfs:label>DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/246900</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/254632b4-5515-4da5-a1b7-3c48c91d3cd0"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72d43680-393f-45b9-9226-6175be214012">
        <rdfs:label>Oxidative stress</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025464</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14d29dac-847f-4efb-b83e-0a1e451c54ab">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1fb17853-bdb4-47f2-8a13-13885b755f9d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15938133</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd25d845-ced1-4b71-821f-6353f8e72be8">
        <dc:identifier>HP:0002354</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
        <rdfs:label>Memory impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ac058ea-cd8b-44c8-a217-8205d60958d9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>cognitive imapirment</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf1585c3-7d18-4525-b46e-b779fd9b24a0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Learning impairment</rdfs:label>
        <dc:identifier>HP:0001328</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001328</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71cfde11-6380-46ea-beee-7ca245d04288">
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>Behavioural abnormalites</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615287">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1124</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1124</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dd3df65d-b5dd-432f-a9aa-3dd4058b5a30">
        <rdfs:label>B4GAT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11041</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/615287</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ca330fe4-39a6-49bf-85fa-1c71bbcb93be">
    <ddiem:uniprotId>Q8WTS1</ddiem:uniprotId>
    <ddiem:keggEntryId>K13699</ddiem:keggEntryId>
    <rdfs:label>adipose triglyceride lipase (ATGL)</rdfs:label>
    <ddiem:ecNumber>2.3.1.51</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cdff7f52-fb89-4762-b053-b0a67d0d8ae6">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51099</dc:identifier>
        <rdfs:label>ABHD5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ff6e08db-a954-4150-96e5-1a5c96424a21">
    <ddiem:keggEntryId>K09478</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/de539fee-55e7-4bb7-9816-fc393915aceb">
        <rdfs:label>ACADSB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/36</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.8.5</ddiem:ecNumber>
    <ddiem:uniprotId>P45954</ddiem:uniprotId>
    <rdfs:label>3-hydroxy-2-methylbutyryl-CoA dehydrogenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/12eae07f-c0cc-4e4f-9b2f-6a8c8b6d9432">
    <ddiem:keggEntryId>K14710</ddiem:keggEntryId>
    <rdfs:label>zinc/iron-regulated transporter-like protein</rdfs:label>
    <ddiem:uniprotId>Q6P5W5</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eca75d3d-3f51-45c2-b613-658b7f73b9c5">
        <rdfs:label>SLC39A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55630</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2175c479-cdf1-4f4a-af74-08fb793c5160">
    <ddiem:ecNumber>3.1.3.4</ddiem:ecNumber>
    <ddiem:uniprotId>Q14693</ddiem:uniprotId>
    <ddiem:keggEntryId>K15728</ddiem:keggEntryId>
    <rdfs:label>Phosphatidate phosphatase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b9ed7797-e613-46f7-b5ac-3eb37ba5a2fb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23175</dc:identifier>
        <rdfs:label>LPIN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/585277f7-fa68-4397-9f25-a9a65aef50da">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891977</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/38be0675-ba8f-4b03-8801-a7f903e0e5e4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2e99b90d-bb55-4ca6-9b31-069fe0ca429e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d281a535-15f9-4603-ac34-65ae98e75eb0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>brain atrophy</rdfs:label>
        <dc:identifier>HP:0012444</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012444</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0001565">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0001565</ddiem:url>
        <dc:identifier>ECO:0001565</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204500">
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2</rdfs:label>
        <ddiem:iembaseAccessionNumber>306</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/204500</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/306</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/79adb2f9-3841-4561-963c-5d98128b826d"/>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/11fe30a6-63d7-48ad-9a8e-d65fead167c3">
    <ddiem:uniprotId>P12694</ddiem:uniprotId>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K00166</ddiem:keggEntryId>
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4f6252a4-bc41-47f3-85ce-d2200532e18c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/593</dc:identifier>
        <rdfs:label>BCKDHA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616538">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/616538</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2a24e563-0bd7-4ab5-9a27-146e340e18d9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1605</dc:identifier>
        <rdfs:label>DAG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/242600">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5a3eacd3-6ffc-4271-87ee-c11faaa0a05d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54716</dc:identifier>
        <rdfs:label>SLC6A20</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/76e9cd0a-d87f-4311-8e4d-50b23b2192c9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/340024</dc:identifier>
        <rdfs:label>SLC6A19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/798</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/242600</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>IMINOGLYCINURIA</rdfs:label>
    <ddiem:iembaseAccessionNumber>798</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ff623d77-78bb-4449-8d6d-3cb63bcc96a0">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0d825c19-e73b-49e6-87d3-e518f9adbafa">
        <rdfs:label>NSDHL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50814</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q15738</ddiem:uniprotId>
    <ddiem:keggEntryId>K07748</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.1.170</ddiem:ecNumber>
    <rdfs:label>NAD(P) dependent steroid dehydrogenase-like</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fd8eb6c8-3aa4-4f6a-995a-fdb5227a8499">
    <rdfs:label>DNA polymerase subunit gamma-2, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c7b26773-8744-4fb6-ba2b-243e892b1578">
        <rdfs:label>POLG2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11232</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UHN1</ddiem:uniprotId>
    <ddiem:keggEntryId>K02333</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/702171db-acfc-41a9-8ea6-0ee50368ae22">
    <ddiem:keggEntryId>K01084</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/53a2e327-4eaf-4e72-85f7-7f39af24a3d5">
        <rdfs:label>G6PC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2538</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glucose 6-phophatase</rdfs:label>
    <ddiem:uniprotId>P35575</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.3.9</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/8b44d216-df5d-4c46-877f-2510fcd24e39">
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca6824d1-2185-462d-9401-14dccc8e4291"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/735c9d35-5de3-49e5-a462-b93531fe6a8a">
        <rdfs:label>abnormal blood Phe levels</rdfs:label>
        <dc:identifier>HP:0010893</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010893</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc66167c-7869-4114-8874-5ea46ca7e768">
        <rdfs:label>Neurological abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d8dbcbc-6052-4ab2-bd22-a2dcca1b10b8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1fbb362d-b4c0-4b88-8f4e-6ea0c93cf0f0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a2b61387-b1b7-4463-9836-e5ec6d785004">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/666d7fd1-dcfe-4a7c-a666-7834798460e4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64b9e608-2964-47f9-a936-580660dd975f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high plasma phenylalanine level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <dc:identifier>HP:0004923</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f21b1dbf-5910-4cad-b1ba-32646706cc2e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040086</ddiem:url>
        <dc:identifier>HP:0040086</dc:identifier>
        <rdfs:label>High serum  prolactin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
  </obo:DDIEM_0000009>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8d52c9f9-a168-4994-ab99-c4f16125c97e">
    <ddiem:ecNumber>6.2.1.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K01900</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9P2R7</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0495dea3-0673-40e7-af0b-8197fb6e54c6">
        <rdfs:label>SUCLA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8803</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Succinyl-CoA synthetase ( beta subunit)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/07f9d191-45e5-48d6-893c-40400c9b1a00">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e81ca558-885c-4cc8-ae82-d14a22d068cf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b91bd5f5-0172-4abc-9ec3-29bad8660bab"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c748dead-2da4-4332-a3cc-bffd0c2481ee">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Study was suspended based on Sponsor Decision.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/218800">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/218800</dc:identifier>
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE I</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b0d83319-0110-4160-b080-56d5b443ca00"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c3bb39b2-0961-4b25-a0e2-0ba9a061d0bf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207900">
        <rdfs:label>ARGININOSUCCINIC ACIDURIA</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/15</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/caec044e-a0d6-4beb-8300-4f02630456ea"/>
        <ddiem:iembaseAccessionNumber>15</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/207900</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00345605</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/806148a2-f165-4997-b4f4-b5094244aa59">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b81615a0-259f-4806-865a-34d7ed20005d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f1a93807-f7ab-4a06-ac32-884eb698cd15">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c08cfb2f-0dad-4d77-bec9-3f214ee1e459"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e5ca86d-f24e-48fb-99ea-07ad3330f49f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:label>Hyperammonemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001987</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c558bd5f-14cd-4abc-a1ab-4b8c4ac6554c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/271245">
        <dc:identifier>https://www.omim.org/entry/271245</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b7b80e23-9def-4a47-a337-d9976e93ec7c"/>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/944</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>944</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Conventional antiepileptic drugs (phenytoin and phenobarbital) are ineffective in most affected individuals.</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/29a9ef5d-27a6-4582-b971-35f3b768ba4f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d">
        <rdfs:label>Seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d81f3043-d7a6-4592-a57b-306577f32c21">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3fbc5d5c-5008-46c8-84bb-598fd024acea"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/01ca818f-b5e2-4f5d-8d63-26982b4f8dda">
    <rdfs:label>4-hydroxyphenylpyruvate dioxygenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fc6ef6fa-d07c-460a-b11e-c1c1f11a3957">
        <rdfs:label>HPD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3242</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00457</ddiem:keggEntryId>
    <ddiem:uniprotId>P32754</ddiem:uniprotId>
    <ddiem:ecNumber>1.13.11.27</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/4b540c95-e491-4fdc-86ea-5bdd30f6f00c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46548bdd-00e3-42e2-9f2b-49ad41d58efc">
        <rdfs:label>Metabolic acidosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001942</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71a6d526-76b5-4335-858b-d3431cef0bf0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003678</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>Disease progression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be938cb3-be98-4597-8ab6-f018e51b2c8b"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231670">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/163</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/231670</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/949e13ff-3469-4738-b3df-48c987a50efb"/>
        <rdfs:comment>It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
        <ddiem:iembaseAccessionNumber>163</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLUTARIC ACIDEMIA I; GA1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/29da295f-7948-43b2-a0bb-ff65cedd0589">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/43f9b245-b11c-4e52-a233-b4d0f4936be0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e3a198d9-ef80-45c3-a2bc-e9a6a401d052">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e04e5cea-bc1a-4ad9-b5eb-a7e9b60b7b8b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/89af4d46-f6c8-4b92-be9a-29d5a8441c7b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ee00dd8-f35c-4f10-af44-837ff1df04c7">
        <dc:identifier>HP:0003074</dc:identifier>
        <rdfs:label>Hyperglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003074</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>W464X</obo:RO_0003304>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/37cea92d-a8a9-45cb-98e1-1177132bdf27"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/333a3281-1860-4af0-b70e-76ae48850d98">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/af9c9f2f-06f9-4455-8e04-16f3b5971344"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c9d0ee4a-77ce-4fa5-8b85-3e007835c2ea"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/65719f3f-930f-4c4b-a5b8-a5db750d7d71">
    <ddiem:uniprotId>Q96DA6</ddiem:uniprotId>
    <ddiem:keggEntryId>K09539</ddiem:keggEntryId>
    <rdfs:label>DnaJ heat shock protein family (Hsp40) member C19</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/56cca111-4334-4d55-98a5-0b7c992511e1">
        <rdfs:label>DNAJC19</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/131118</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/82863b66-b4dd-4ee2-8b22-7095fa205e00">
    <ddiem:uniprotId>O43772</ddiem:uniprotId>
    <rdfs:label>carnitine-acylcarnitine translocase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7416189a-e714-4f79-88d1-618623fa57c2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/788</dc:identifier>
        <rdfs:label>SLC25A20</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K15109</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/30267849-a99e-4f66-a4dd-07c12195ded2">
    <dc:provenance>https://link.springer.com/article/10.1007/BF00710419</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acf5e461-bbd4-4152-b836-cf8c35679142">
        <dc:identifier>HP:0001939 *</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
        <rdfs:label>Acute metabolic crisis ( Metabolism abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec57f2e9-f607-4061-b4da-0996016f8e79">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/30f0e103-d299-44ed-b0d7-e6d8e842c415"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/210200">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1d16342f-85a5-4e85-a441-7a47ad7ce6d4"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1284</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d3f3ef8f-ba54-4f89-b215-1eea4086b459"/>
        <dc:identifier>https://www.omim.org/entry/210200</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1284</ddiem:iembaseAccessionNumber>
        <rdfs:label>3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ab68474-3e4c-467d-87b7-a00e3fab2f23">
        <dc:identifier>HP:0001939 *</dc:identifier>
        <rdfs:label>Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612933">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/499</ddiem:iembaseUrl>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XI; GSD11</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612933</dc:identifier>
    <ddiem:iembaseAccessionNumber>499</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c6e48377-c3d6-4099-b4c5-8455e51a4bcd"/>
  </ddiem:Disease>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/10939b75-3f9a-4504-b17c-e1d0bda68368">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af78da97-93a3-489a-a4b7-ba270e01994e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <dc:identifier>HP:0003452</dc:identifier>
        <rdfs:label>Increased plasma iron concentration(Increased serum iron)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007764">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007764</ddiem:url>
        <dc:identifier>ECO:0007764</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604250">
        <ddiem:iembaseAccessionNumber>582</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/582</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/604250</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HEMOCHROMATOSIS, TYPE 3; HFE3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9a5fd82c-8790-49be-8f05-fc44881e6339"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4ff91c31-f861-49cb-8a63-8b6118848d82">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e9f9f595-225b-4794-9eaa-05e4c275ef4a"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000011>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/procedure_to_mitigate_dominant_effects_of_a_genetically_abnormal_protein">
    <dc:date>4.10.19</dc:date>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
    <obo:IAO_0000115>a procedure to suppress or mitigate the effects of a dominant alteration in a genetically abnormal protein by reducing or suppressing  transcription or translation of the abnormal protein gene or rna, or destabilising or otherwise inhibiting an abnormally increased activity or neoactivity of the abnormal protein.</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
  </owl:Class>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9b803aa3-d0a5-4e6b-b3b5-a3fce050b407">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c2d99e2-5cd6-4123-901b-21bde3603abf">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypocarnitinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <dc:identifier>HP:0003234</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04f8ae5a-f6ac-45c6-8daa-d1c1c2d06de0">
        <dc:identifier>HP:0045045</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma long-chain acylcarnitines</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ca782c5-9548-4e31-afc5-d79b97e17f37">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>developmental delay</rdfs:label>
        <dc:identifier>HP:0001263</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5296b6d3-94cf-496b-9f0f-851435fed790">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d8812d34-73d0-4a95-8c87-a35b2ca84de7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/212138">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/212138</dc:identifier>
        <rdfs:label>CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/229</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>229</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7416189a-e714-4f79-88d1-618623fa57c2"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17508264</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/095e2198-daf7-43c2-9b25-80b1d6b4a4c7">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2965c89c-2a34-4f3f-b25f-6592fe1aa518">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003288</ddiem:url>
        <dc:identifier>HP:0003288</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High resting plasma lactate concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5f5374c4-80be-4a26-978b-06092b9baab9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a0d82bd3-2fd1-4263-a7c7-d62671569587"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17080429</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55c8cd11-33b2-4250-b67c-a16c4842a23d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:label>Ankle weakness progression(Disease progression)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/545000">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/400</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8826c45-6040-4389-b8ef-56b99ce90527"/>
        <dc:identifier>https://www.omim.org/entry/545000</dc:identifier>
        <ddiem:iembaseAccessionNumber>400</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Mitochondrion-toxic agents, including mitochondrion-toxic AEDs, such as valproate, carbamazepine, phenytoin, and barbiturates, should be avoided as well as AEDs potentially enhancing the frequency of myoclonus, such as phenytoin, carbamazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, pregabalin, and oxcarbazepine.</rdfs:comment>
        <rdfs:label>MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a3fd8400-cda5-4571-9d88-560693d7c609">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c7be2207-9248-440c-b331-5c32d3323b2c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bc6e7cd6-c29a-4904-ab43-6912c237f57b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72d43680-393f-45b9-9226-6175be214012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/64247a2a-cabd-4bce-ad2c-f2c7d662d96e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266130">
        <dc:identifier>https://www.omim.org/entry/266130</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/512</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>512</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/223ec2a6-1a60-4517-a7d3-a1939f49cb3a"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0af6b331-5379-44d8-91e6-bf5a38fac107">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ae5ae804-8702-4f1a-8760-cffd550d86db"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/83992f89-d3a7-4521-9c2b-2191fd30e62a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac11091f-737b-4157-bc59-9aacdf5ffc3e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006785</ddiem:url>
        <rdfs:label>Muscle dystrophy</rdfs:label>
        <dc:identifier>HP:0006785</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cf733780-1834-4f7e-9487-4b2bf25147d5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8e2fda41-9a98-4afe-acf8-6691048aacf5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236670">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/899c3945-8096-4de9-ad36-f62164169513"/>
        <dc:identifier>https://www.omim.org/entry/236670</dc:identifier>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005542">
        <dc:identifier>ECO:0005542</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005542</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/da1df151-625f-4663-b0c0-d729b8dc08e5">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d1343e00-ebd6-44c1-b822-449826c59320">
        <rdfs:label>MTTC</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MTTC</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e83155a6-061f-4432-98fa-c0e3952993a9">
        <rdfs:label>MT-TL1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TL1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/14ac3602-9b5b-4c8a-a922-2757be07e81b">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TQ</dc:identifier>
        <rdfs:label>MT-TQ</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f8826c45-6040-4389-b8ef-56b99ce90527">
        <rdfs:label>MT-TK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/892699f3-d486-4cb2-89d1-b06121448607">
        <rdfs:label>MT-ND1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9c48bb3a-33d8-410e-8872-b51c8f214bab">
        <rdfs:label>MT-TE</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TE</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9f49626f-8939-413c-a2ff-b4be64774004">
        <rdfs:label>MT-ND6</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND6</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/48ac681a-1269-4c1f-b31d-966bea304708">
        <rdfs:label>MT-ND5</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND5</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/60a52977-facf-4bca-a960-fb5a959058b7">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS1</dc:identifier>
        <rdfs:label>MT-TS1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5af56574-d352-42ab-a58a-01068008bf89">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TH</dc:identifier>
        <rdfs:label>MT-TH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4e7fd70a-63d9-48eb-bf73-85e2b668072c">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS2</dc:identifier>
        <rdfs:label>MT-TS2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/bb52e193-b8d3-4bb2-813b-f5ceb9786fa4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c01fdea-ca33-4b35-96ef-e7c4a716ef3c">
        <rdfs:label>Abnormality of homocysteine metabolism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010919</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62d00bce-2b6f-463a-a5bd-e280fb3448ec">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low muscle tone</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <dc:identifier>HP:0001290</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d8dbcbc-6052-4ab2-bd22-a2dcca1b10b8"/>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eb931e2d-83c6-4a01-b88e-e0383a6f5b51">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/852e709e-5a72-4930-98af-18543e58901c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603174">
        <rdfs:label>HOMOCYSTEINEMIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/603174</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/133cda4f-2ec8-4686-a9c7-a6d97e1052a3"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/756163c6-1091-434b-9cb4-bb4f5dcef9a3">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3d0ea856-1bd4-4099-9b3f-e0fbdaa9aad9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b215f53-e162-409e-9d6b-33c6cd2ac1a3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05e320d8-273a-4b5f-a801-fc4122e9d849">
        <dc:identifier>HP:0000112</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
        <rdfs:label>Nephropathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6866321b-f658-4e71-92e2-9f228c404ca8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aa236b98-a541-4410-9759-0353fff1dee2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c968fe26-f631-4e6e-a0da-dc92017a71f3">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608747">
        <rdfs:label>INSULIN-LIKE GROWTH FACTOR I DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d3cf86de-495f-4bba-9dc7-781aaa3b95ca"/>
        <dc:identifier>https://www.omim.org/entry/608747</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/53074b27-41a6-408a-9f91-ff64b19ec8e3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ce87af78-8238-45c3-9238-56de6132438f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/187521ea-9398-4569-befd-adbbe1a09b22">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004322</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <rdfs:label>Short stature</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f419d28e-775e-4b39-bd36-87934855b06b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/003a8ea8-9554-41f2-84bf-15a95581e735"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/2deb1a39-da6f-48e6-950c-2247ccaad207">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aad0232b-d068-4a7f-9f3e-4d30542b65e1"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d249f4af-7d79-441f-bd32-1ce29a700254"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e63c3b73-4fe4-4202-b317-d4f434d93f0b">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Elevated hepatic transaminases</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/306000">
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXa1; GSD9A1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/492</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7d4822a8-b1ed-4777-9b36-3bede743d163"/>
        <dc:identifier>https://www.omim.org/entry/306000</dc:identifier>
        <ddiem:iembaseAccessionNumber>492</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
  </obo:DDIEM_0000010>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e630b949-9ddd-42ea-bc62-f652df930603">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4433da59-2fdc-4bd6-94d2-0e5b7ad05eb7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/338</dc:identifier>
        <rdfs:label>APOB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14462</ddiem:keggEntryId>
    <ddiem:uniprotId>P04114</ddiem:uniprotId>
    <rdfs:label>apolipoprotein B-48 + apolipoprotein B-100</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7633d0e2-1227-49b1-ad7e-13e1913edcf5">
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4a68535-d69a-43f3-b700-3d9c1a0acd7d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5301410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229100">
        <dc:identifier>https://www.omim.org/entry/229100</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/47</ddiem:iembaseUrl>
        <rdfs:label>GLUTAMATE FORMIMINOTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>47</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a380123b-573e-49cf-b8c0-c6d327958211"/>
        <rdfs:comment>The majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic. https://www.ncbi.nlm.nih.gov/pubmed/30740726</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b81e8ae-7557-4931-93ce-acf79f002414">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
        <rdfs:label>Megaloblastic anemia</rdfs:label>
        <dc:identifier>HP:0001889</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bf74d857-2aea-4fed-b1cc-3b6f2205144a">
    <rdfs:label>Tricarboxylate transport protein, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bd6e6b0a-d863-4ee1-91aa-b348138dd0e5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6576</dc:identifier>
        <rdfs:label>SLC25A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K15100</ddiem:keggEntryId>
    <ddiem:uniprotId>P53007</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/816d49b6-506d-456c-a747-63b78ebb8cda">
    <rdfs:label>ornithine aminotransferase</rdfs:label>
    <ddiem:uniprotId>P04181</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/653f2f1f-7a88-4d29-b47f-0ebd33eb020e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4942</dc:identifier>
        <rdfs:label>OAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.6.1.13</ddiem:ecNumber>
    <ddiem:keggEntryId>K00819</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614128">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>916</ddiem:iembaseAccessionNumber>
    <rdfs:label>LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f1568f98-92a7-497f-bc12-1f308ce469bf"/>
    <dc:identifier>https://www.omim.org/entry/614128</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/916</ddiem:iembaseUrl>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/5907f51f-b490-41f6-b970-a65fa721b340">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d973893-ad7e-4af7-bdd4-a40a25f6aa20">
        <rdfs:label>The study was terminated</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261515">
        <rdfs:label>D-BIFUNCTIONAL PROTEIN DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/71846663-b266-4838-96d3-73c362d79b00"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/274</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>274</ddiem:iembaseAccessionNumber>
        <rdfs:comment>No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/261515</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2affbe48-72e7-4a46-a544-7b6ead8660e9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bd7d6658-1ad6-479c-8950-ad9b759fb43f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc10c4c1-7259-4ecd-9558-342472b3222c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/63589499-8a5a-4421-88b7-9b87bd055888"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/37fe96a7-5279-41da-b033-f97045c21259">
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a94bcb4c-d724-4c97-85db-f121cee5e4d1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/249</dc:identifier>
        <rdfs:label>ALPL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Alkaline phosphatase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a455ceb2-c9e1-4cc0-a7ec-b8315000fa9f">
    <rdfs:label>arginine:glycine amidinotransferase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/425355a4-0532-4623-92dd-27eff1c11ae7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2628</dc:identifier>
        <rdfs:label>GATM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00613</ddiem:keggEntryId>
    <ddiem:ecNumber>2.1.4.1</ddiem:ecNumber>
    <ddiem:uniprotId>P50440</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f35a4874-8e8c-4521-867a-2748dbd517b4">
    <ddiem:ecNumber>3.5.2.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a6b68d00-3676-472f-95f7-f93be6128069">
        <rdfs:label>DPYS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1807</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q14117</ddiem:uniprotId>
    <ddiem:keggEntryId>K01464</ddiem:keggEntryId>
    <rdfs:label>dihydropyrimidinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614643">
    <dc:identifier>https://www.omim.org/entry/614643</dc:identifier>
    <ddiem:iembaseAccessionNumber>641</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/01c911d4-fc6d-425a-a041-dc644701090e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>ISPD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/641</ddiem:iembaseUrl>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/a62c19f7-e616-4a91-a6b9-9e86373d23ce">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256730">
        <dc:identifier>https://www.omim.org/entry/256730</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>305</ddiem:iembaseAccessionNumber>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/305</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4eb334f1-b852-4519-afda-8471b9659248"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14d29dac-847f-4efb-b83e-0a1e451c54ab"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/afc5eab7-3ee0-4e84-8709-3d0cb42ec2a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/194b84c2-fe62-4746-b18a-59c83d85b771"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/708a8921-63e3-420d-ac82-bd11fad277a2">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004372</ddiem:url>
        <dc:identifier>HP:0004372</dc:identifier>
        <rdfs:label>Defected alertness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee118783-11d0-48af-84e9-b7ad6b7577e7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000737</dc:identifier>
        <rdfs:label>irritability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997880</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4aee62e5-3271-4654-aaff-d6075893c9ea">
        <rdfs:label>granular osmiophilic deposits (GROD)</rdfs:label>
        <dc:identifier>HP:0003657</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003657</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe75071b-28ce-40a7-b7f0-569f0a73ba72">
        <dc:identifier>HP:0002353</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>Isoelectric electroencephalogram</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d4e6aae3-263c-496b-9bde-cb796be0cb18">
    <rdfs:label>adrenoleukodystrophy protein</rdfs:label>
    <ddiem:uniprotId>P33897</ddiem:uniprotId>
    <ddiem:ecNumber>7.6.2.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7629305a-8d81-4558-a300-c290578d3f27">
        <rdfs:label>ABCD1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/215</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05675</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3420f9d0-f31b-42bd-89a2-3b968fa5c35b">
    <ddiem:keggEntryId>K05048</ddiem:keggEntryId>
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/76e9cd0a-d87f-4311-8e4d-50b23b2192c9"/>
    <ddiem:uniprotId>Q9NP91</ddiem:uniprotId>
    <rdfs:label>solute carrier family 36 member 2 +solute carrier family 6 member 20 or solute carrier family 6 member 19</rdfs:label>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
    <ddiem:keggEntryId>K14209</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a22bca44-f2ba-48f0-a35f-7f041eb77c37">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/153201</dc:identifier>
        <rdfs:label>SLC36A2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q495M3</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5a3eacd3-6ffc-4271-87ee-c11faaa0a05d"/>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/df3513a7-b636-4406-8a2d-85344d8cf076">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e1b9054-be40-432b-a5f6-f1bad87f9e2f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012211</dc:identifier>
        <rdfs:label>Impaired renal function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210590</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e974fe73-acaa-426b-8a9a-05168e3d2292"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b179fcb4-6857-46ea-9349-a38d788a292a">
        <rdfs:label>Elevated total plasma homocysteine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <dc:identifier>HP:0002160</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277400">
        <ddiem:iembaseAccessionNumber>90</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/13218821-b07b-4fed-aa1f-a05769b073be"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/90</ddiem:iembaseUrl>
        <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/277400</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c1db53f-f606-4885-898a-780dd5e1f37e">
        <dc:identifier>HP:0011025</dc:identifier>
        <rdfs:label>Fatigue</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c5a2c07-4078-441f-954a-b65e06d04027">
        <dc:identifier>HP:0012213</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>decreased glomerular filtration rate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d8dbcbc-6052-4ab2-bd22-a2dcca1b10b8"/>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04e80d16-019a-49fc-b9bf-0eb4bfd92156">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
        <rdfs:label>High urine methylmalonic acid level</rdfs:label>
        <dc:identifier>HP:0012120</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/374f7c36-a72a-44bd-960a-108c8c06e730">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002395</ddiem:url>
        <dc:identifier>HP:0002395</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Lower limb hyperreflexia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77b44d90-1bbc-4a36-a0a0-30b9c8490102">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Spasticity</rdfs:label>
        <dc:identifier>HP:0001257</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74beb430-5140-4ad4-815c-9704b41dd24b">
        <rdfs:label>Haemolysis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001878</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210589</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb931e2d-83c6-4a01-b88e-e0383a6f5b51"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d64f18e6-a5e3-4454-8d02-53e9d9cdc316">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002039</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
        <rdfs:label>Anorexia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/128770be-34b3-47d6-9a93-c13638d73dc9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031258</ddiem:url>
        <rdfs:label>Delirium</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031258</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c580d46b-edcd-47d3-83f9-8de4ec5ffbf2">
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a43889a9-fecb-4774-b538-3f1d58860bc0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80270</dc:identifier>
        <rdfs:label>HSD3B7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>3-beta-hydroxy-delta-5-C27 steroid oxidoreductase</rdfs:label>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/87b35707-103a-4c82-b8c9-3dc51770ab86">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfe1de7d-ace7-4797-87f0-09766f7a9e68">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low brain creatine phosphate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5c4f256-76a7-40f9-9c7c-59322bd9bc4c">
        <rdfs:label>behavioral abnormalities</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/047dd5fe-2618-4609-bd6b-2b766fe91074">
        <rdfs:label>High plasma guanidinoacetate levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/486793e9-6544-41cf-a439-69426f635ff5"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f69ccca8-d9fe-43b8-89b5-8ce9bb307d07">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/465c0ad8-0034-4e32-a60d-c3fec47d2f72"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0850851-e96b-4d12-bbf2-ba9f0d74bc3b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025051</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low cerebral creatine</rdfs:label>
        <dc:identifier>HP:0025051</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612736">
        <ddiem:iembaseAccessionNumber>104</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/612736</dc:identifier>
        <rdfs:label>CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/104</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/05736fef-e4c4-4d2b-bafe-8b0a83052726"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5e79722b-c7ad-4191-9aee-cc3377b31640">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/286dc748-fa39-4a43-8374-5517aec1f85f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a9065d4-3680-473f-8a3b-61993fb45fb2">
        <dc:identifier>HP:0012113</dc:identifier>
        <rdfs:label>low urinary creatine excretion</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12557293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/579ead67-58ac-45a6-abb6-9cdff7eddc9e">
        <rdfs:label>abnormal coordination of movements</rdfs:label>
        <dc:identifier>HP:0011443</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011443</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
  </obo:DDIEM_0000009>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/654d1e96-1581-4a11-8626-84c80c7596ce">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/edfc19db-1900-46e7-94ec-45eb264f94af">
        <rdfs:label>Low quality of life (Constitutional symptoms)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/050e4ad7-9522-4300-8597-a6cd502a6274"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8bdb6b61-5b9f-4138-89c8-3d48de9078a8">
        <dc:identifier>HP:0002180</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:label>Myoclonus</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28686997</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d11aef92-5e55-4e97-9e1b-1a2e7a1a58a0">
    <ddiem:keggEntryId>K13990</ddiem:keggEntryId>
    <ddiem:uniprotId>O95954</ddiem:uniprotId>
    <rdfs:label>formiminotransferase cyclodeaminase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a380123b-573e-49cf-b8c0-c6d327958211">
        <rdfs:label>FTCD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10841</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.1.2.5; 4.3.1.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/501bac5e-d30a-4b04-807d-391d89d89798">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125700">
        <rdfs:label>DIABETES INSIPIDUS, NEUROHYPOPHYSEAL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/efd225b1-3930-4af1-ac38-246c0fd346b8"/>
        <dc:identifier>https://www.omim.org/entry/125700</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <rdfs:comment>This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8999c94b-1e42-42eb-b777-245c59a08e1a">
        <rdfs:label>chlorpropamide-induced hypoglycaemia (Hypoglycemia)*</rdfs:label>
        <dc:identifier>HP:0001943*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9317abc0-16c0-4985-b4d1-4a6d78fa7593">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42c4732b-18a4-4226-8353-f7b57d40b35b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77f7f9d9-f552-487f-b2ef-03a08fe3d998">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:label>Polyuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/caa8210e-27b3-455f-8261-931862f7d033">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/45de394e-39f0-48ac-bb6a-d3ae8b56fbcc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/800124c0-34d5-4d60-833a-39cc6276b512">
    <ddiem:uniprotId>O60313</ddiem:uniprotId>
    <ddiem:keggEntryId>K17079</ddiem:keggEntryId>
    <rdfs:label>mitochondrial dynamin like GTPase</rdfs:label>
    <ddiem:ecNumber>3.6.5.5</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/64bcc262-f1b5-41dc-9ca7-f192077fd531">
        <rdfs:label>OPA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4976</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9fb18bce-1725-411f-9fea-4169170d10f1">
    <ddiem:uniprotId>Q9UKY4</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.109</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e6b1d7d9-a9ea-494b-bee3-5d2881f599d9">
        <rdfs:label>POMT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/29954</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Protein O-mannosyl-transferase 2</rdfs:label>
    <ddiem:keggEntryId>K00728</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611881">
    <rdfs:label>GLYCOGEN STORAGE DISEASE XII; GSD12</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/500</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/13aca584-7fb2-4aab-af61-2efe2d35873c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/226</dc:identifier>
        <rdfs:label>ALDOA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>500</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/611881</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/2ad9a5a6-99d6-4ed1-b544-bbfa702d38e8">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b788ae74-6972-416d-9f3d-bdb7dca42be1"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e01bee0d-9752-4a63-8fa8-28edd454e2cb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f801ad8-7d75-4653-8d67-9d8187f0443a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>Sleep disturbance,Poor sleep quality</rdfs:label>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9da6d03b-025a-4ceb-996a-8a6a43d39af2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low quality of life(Constitutional symptoms)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
  </obo:DDIEM_0000010>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e90c3d1d-f7ff-4fbd-9394-745f17bc1daf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0212c985-f816-47e4-995e-a214d71ae8cc"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac5799d5-cc35-4d20-8974-81ddc715cc9c"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/763452f8-7da3-48d5-855f-888e089440d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bbc56010-c2aa-4125-befc-fa2dc5adcb44"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18203a13-4e24-4100-8ef0-c16e9db4095c">
        <dc:identifier>HP:0008315</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008315</ddiem:url>
        <rdfs:label>Decreased blood free carnitine</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b9a5535b-2a1c-4698-a6b8-5d875556eec5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/58e514b8-a976-423a-8f24-6b1538427fe0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04eeeac3-651f-49b2-bfdc-35c3ab9345b0">
        <rdfs:label>Elevated urine 5-oxoproline</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7be2207-9248-440c-b331-5c32d3323b2c"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e02aa49f-2390-40cc-b373-22e88233c8e6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/58cb955c-d387-474d-aeeb-006230a5fd68"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46548bdd-00e3-42e2-9f2b-49ad41d58efc"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a0acd813-62a9-4d2b-b38c-c9e9be5c8fde">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d246e1ff-2521-4ae3-8444-50179a6aa921">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10157</dc:identifier>
        <rdfs:label>AASS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ea59c236-d4cc-42c1-a6ce-8f31b399cfcc">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606762">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/567</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/06a5319a-a75f-482c-9458-11864f148605"/>
        <ddiem:iembaseAccessionNumber>567</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/606762</dc:identifier>
        <rdfs:comment>Treatments for hyperammonemia such as dietary protein limitation, arginine, benzoate, carbamoyl synthase activators (carglumic acid), and N-carbamoylglutamate have not been effective in reducing ammonia levels. https://www.ncbi.nlm.nih.gov/pubmed/15050973/</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6dc61da4-a737-4ddf-bae4-a604e96eed6b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/399206db-d805-4c86-aa4a-297f484ec544"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d60b73ee-efd8-40c7-b57d-dec68de6452e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypoglycemia</rdfs:label>
        <dc:identifier>HP:0001943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0ac9755c-32d6-4fa1-9ef0-97cc93ea4608">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c3911094-6b07-4e57-8d4d-8f8b83f3df3f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e6c159d1-406d-460e-bd9f-669ca66059f2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1e4137fb-1b86-4080-b233-6fc09ab809f3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4da86fe9-2408-4669-ad61-f86a8f620c6a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac5799d5-cc35-4d20-8974-81ddc715cc9c"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611283">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/742a6b15-d92f-4e1a-85df-9ab84bfb1e31"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/135</ddiem:iembaseUrl>
        <rdfs:label>ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY; IBDD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/611283</dc:identifier>
        <rdfs:comment>It is as yet uncertain whether IBD deficiency may cause significant morbidity in affected children and whether treatment is necessary. In view of the limited experience worldwide, careful monitoring of the children is recommended. https://www.ncbi.nlm.nih.gov/pubmed/15505379</rdfs:comment>
        <ddiem:iembaseAccessionNumber>135</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59df576e-1e87-4523-a651-486511645c75">
        <dc:identifier>HP:0001507</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Growth abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16857760</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611307">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3a51f0ad-e4f0-441a-80e7-605c835920d6">
        <rdfs:label>ANO5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/203859</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/611307</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12; LGMDR12</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6c810ca7-c29c-40bb-b246-c69120d2f03e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4145fe8d-a18c-4b44-a537-dee9f109d019">
        <rdfs:label>MTTP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4547</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P55157</ddiem:uniprotId>
    <ddiem:keggEntryId>K14463</ddiem:keggEntryId>
    <rdfs:label>microsomal triglyceride transfer protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300868">
    <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/300868</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9a37a2d2-872f-4547-9cf0-8a91ef76a95a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5277</dc:identifier>
        <rdfs:label>PIGA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
    <rdfs:comment>Ketogenic diet - A novel treatment for early epileptic encephalopathy due to PIGA deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27126216</rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3df7e671-9d3f-4870-99f9-474e56fb13b8">
    <ddiem:keggEntryId>K08239</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f9782f66-be62-441b-9c3c-0bdfb1dc8432">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79158</dc:identifier>
        <rdfs:label>GNPTAB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.8.17</ddiem:ecNumber>
    <ddiem:uniprotId>Q3T906</ddiem:uniprotId>
    <rdfs:label>(α) &amp;(β)GlcNAc-1-phosphotransferas</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d98e71cb-2c52-4e34-856f-0693e4b7e084">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/763452f8-7da3-48d5-855f-888e089440d4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72d43680-393f-45b9-9226-6175be214012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612073">
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/612073</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0495dea3-0673-40e7-af0b-8197fb6e54c6"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/503</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>503</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac5799d5-cc35-4d20-8974-81ddc715cc9c"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/c0253d1b-b116-4a43-b946-afcd02e80dd9">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/80b38d56-06f2-487c-b768-5027208c94bd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0474f3f0-38ad-45cd-ab9e-a0f72d0ed130"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607330">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/196</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/904c6b0c-8257-420c-bc0b-96d0d70e5b06"/>
        <ddiem:iembaseAccessionNumber>196</ddiem:iembaseAccessionNumber>
        <rdfs:label>LATHOSTEROLOSIS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/607330</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f525cfba-e833-4a32-a16b-83042d6153c3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal blood lathosterol level</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/563b9f24-45ce-43f3-9725-e8d2e5ad76ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9874c3ee-f7bd-431d-80ad-8d449b4d4a67"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30097991</dc:provenance>
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
  </obo:DDIEM_0000011>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/429cc1cd-b021-4aff-b414-846cf0273a8f">
    <ddiem:ecNumber>4.99.1.1</ddiem:ecNumber>
    <rdfs:label>ferrochelatase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/81853b9e-71f2-4435-8bd9-5614a6720ead">
        <rdfs:label>FECH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2235</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01772</ddiem:keggEntryId>
    <ddiem:uniprotId>P22830</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0b7d7c4f-3bbb-4753-ae9f-0715f003f327">
    <ddiem:ecNumber>1.14.16.1</ddiem:ecNumber>
    <rdfs:label>PHENYLALANINE HYDROXYLASE</rdfs:label>
    <ddiem:keggEntryId>K00500</ddiem:keggEntryId>
    <ddiem:uniprotId>P00439</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3260d6b2-3663-4d76-9133-5913e2cbe455">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5053</dc:identifier>
        <rdfs:label>PAH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8cfe8d7f-ed3f-478e-8d5c-acef5ccb6398">
    <rdfs:label>17β-hydroxysteroid dehydrogenase type 4</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/71846663-b266-4838-96d3-73c362d79b00">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3295</dc:identifier>
        <rdfs:label>HSD17B4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.1.1.n12; 4.2.1.107; 4.2.1.119</ddiem:ecNumber>
    <ddiem:keggEntryId>K12405</ddiem:keggEntryId>
    <ddiem:uniprotId>P51659</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c549cb06-e232-43cf-8fc5-1ff6124afbda">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4a68535-d69a-43f3-b700-3d9c1a0acd7d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29246599</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e02aa49f-2390-40cc-b373-22e88233c8e6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7c29098-6157-46dc-a703-0ed0cb643e8d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010919</dc:identifier>
        <rdfs:label>High plasma homocysteine level(Abnormal homocysteine level)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb931e2d-83c6-4a01-b88e-e0383a6f5b51"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/545fb743-0ec8-46fe-829d-1b01fd48b00c">
    <ddiem:uniprotId>Q16134</ddiem:uniprotId>
    <ddiem:uniprotId>P13804</ddiem:uniprotId>
    <ddiem:keggEntryId>K03522</ddiem:keggEntryId>
    <ddiem:keggEntryId>K00311</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.5.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8f8c7290-4633-4db0-a3d4-f4a2858df666">
        <rdfs:label>ETFA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2108</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/731966c6-36e5-47b9-94b1-e5065a40b06e">
        <rdfs:label>ETFB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2109</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P38117</ddiem:uniprotId>
    <ddiem:keggEntryId>K03521</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b8a21aba-dd66-48e9-8119-75523d2f7a1f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2110</dc:identifier>
        <rdfs:label>ETFDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f9a3aa3b-c9d9-4754-a89d-1c5dfa37ee6f">
    <ddiem:ecNumber>5.3.1.8</ddiem:ecNumber>
    <ddiem:keggEntryId>K01809</ddiem:keggEntryId>
    <rdfs:label>Mannose-6-phosphate isomerase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a15a5356-2f67-485a-93d7-46a1be505f73">
        <rdfs:label>MPI</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4351</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P34949</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/84889cb6-c7ee-4c8e-8f0f-4490bf749655">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2873525</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04e80d16-019a-49fc-b9bf-0eb4bfd92156"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0dc44b7-a8cd-4047-b6af-ad3212121248">
        <rdfs:label>Mental impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec52056d-a661-482c-8852-3b28db273dda"/>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f911a3a-7527-40cc-8075-7668665c0b06">
        <rdfs:label>Abnormal brain stem auditory evoked potentials</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0006958</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006958</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b179fcb4-6857-46ea-9349-a38d788a292a"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530304</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/584ce42e-087c-48ae-bc9f-1b5ac52c92ba">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>Psychiatric disturbances</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1367da0-7071-4a68-82ef-a94c140f6eca">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000726</dc:identifier>
        <rdfs:label>Dementia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e974fe73-acaa-426b-8a9a-05168e3d2292"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb931e2d-83c6-4a01-b88e-e0383a6f5b51"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55402b82-0cd1-4bd0-8de0-41297798358e">
        <rdfs:label>Abnormal visual evoked potentials</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000649</ddiem:url>
        <dc:identifier>HP:0000649</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52472773-b6b8-4394-a447-ec5306c8fbb8">
        <rdfs:label>Emotional lability</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
        <dc:identifier>HP:0000712</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d02fb99e-edf4-45c1-ab7c-2514c31e808b">
    <ddiem:uniprotId>O95427</ddiem:uniprotId>
    <ddiem:keggEntryId>K05285</ddiem:keggEntryId>
    <rdfs:label>GPI ethanolamine phosphate transferase 1</rdfs:label>
    <ddiem:ecNumber>2.-.-.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ab55da06-91bd-42b4-9117-0635daf739ba">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23556</dc:identifier>
        <rdfs:label>PIGN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/21a5e568-69e8-42c0-a9f5-022ab6aaae1f">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f69ccca8-d9fe-43b8-89b5-8ce9bb307d07"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/806148a2-f165-4997-b4f4-b5094244aa59"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/047dd5fe-2618-4609-bd6b-2b766fe91074"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
  </obo:DDIEM_0000009>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9893c4c3-a0af-4588-bdef-12e52a876125">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/49e0628c-ef07-4a2d-8a30-51f15cda87df">
        <rdfs:label>PYGM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5837</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <rdfs:label>Glycogen phosphorylase, Muscle form</rdfs:label>
    <ddiem:uniprotId>P11217</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2b931f7b-bde5-44da-8ffc-2eb66e3be8c3">
    <ddiem:uniprotId>P11182</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dbee52e1-0cde-469f-a7c1-ad658e5908bd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1629</dc:identifier>
        <rdfs:label>DBT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K09699</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.168</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/2f1ea557-f851-4fc7-8d05-c2d44e98a33b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069539</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/104aacf1-5f95-41ab-ba86-2970a83d2f0c">
        <rdfs:label>Metabolic stress</rdfs:label>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <dc:identifier>HP:0001942</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46548bdd-00e3-42e2-9f2b-49ad41d58efc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20807522</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16602101</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7557b262-80ab-45b1-adcc-2c2530e065c6">
        <rdfs:label>"abnormal Na+,K+-ATPase activity"</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7dda3dde-e6d2-43a7-92c5-0a26a7f7af05">
        <rdfs:label>High toxic acyl-CoA level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15624372</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8804338</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/243500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/56</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f0e24a9d-c416-45d5-830f-f4aaabd7ae5e"/>
        <rdfs:label>ISOVALERIC ACIDEMIA; IVA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/243500</dc:identifier>
        <ddiem:iembaseAccessionNumber>56</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c313389-428f-41d8-b208-894f85b48c83">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High 3-hydroxyisovaleric acid level (C5)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21290185</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17299485</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec57f2e9-f607-4061-b4da-0996016f8e79"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80fe9cc5-292e-4e32-9304-833eeb5a373f">
        <rdfs:label>Developmental delay</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/59323b07-e31b-4ed8-bea0-37df0540957b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aad0232b-d068-4a7f-9f3e-4d30542b65e1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258870">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/562</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/653f2f1f-7a88-4d29-b47f-0ebd33eb020e"/>
        <ddiem:iembaseAccessionNumber>562</ddiem:iembaseAccessionNumber>
        <rdfs:label>GYRATE ATROPHY OF CHOROID AND RETINA; GACR</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/258870</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1311351d-87c3-4d41-8107-bbe3aacc534a">
        <rdfs:label>low visual acuity</rdfs:label>
        <dc:identifier>HP:0007663</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11486915</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d01e942e-bd9e-4821-977b-148064ba0992">
        <rdfs:label>cystoid macular edema</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011505</ddiem:url>
        <dc:identifier>HP:0011505</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10896280</dc:provenance>
  </obo:DDIEM_0000009>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5fbe5624-9a9b-4207-b952-87acb13a9228">
    <ddiem:uniprotId>P15104</ddiem:uniprotId>
    <rdfs:label>Glutamine synthetase</rdfs:label>
    <ddiem:ecNumber>6.3.1.2; 2.3.1.225</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/223ec2a6-1a60-4517-a7d3-a1939f49cb3a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2752</dc:identifier>
        <rdfs:label>GLUL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01915</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/12513f4f-6c33-430f-9a4c-242e329c7e5c">
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/76e9cd0a-d87f-4311-8e4d-50b23b2192c9"/>
    <rdfs:label>Sodium-dependent neutral amino acid transporter B(0)AT1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ee7aa70b-6dba-440f-aa0e-443591e101cb">
    <ddiem:ecNumber>1.3.1.2</ddiem:ecNumber>
    <ddiem:uniprotId>Q12882</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/92cc6199-2985-4963-98bb-542f3e59b397">
        <rdfs:label>DPYD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1806</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00207</ddiem:keggEntryId>
    <rdfs:label>dihydropyrimidine dehydrogenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4ad04d2b-7e1f-431b-91de-171f1419f7a5">
    <ddiem:uniprotId>Q969N2</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6ee0847e-3470-43fe-beae-5eb5ce8afb41">
        <rdfs:label>PIGT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51604</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05292</ddiem:keggEntryId>
    <rdfs:label>GPI transamidase component PIG-T</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ea73d053-3899-4920-9572-ce8d5d0d51f8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ac495996-d401-47cc-9457-481d6bfd32a9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2203</dc:identifier>
        <rdfs:label>FBP1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.3.11</ddiem:ecNumber>
    <ddiem:uniprotId>P09467</ddiem:uniprotId>
    <rdfs:label>Fructose-1,6-bisphosphatase 1</rdfs:label>
    <ddiem:keggEntryId>K03841</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification">
    <obo:IAO_0000115>modification of the amount or stability of a transcript or the efficiency of translation of a transcript in order to reduce or increase the expression of a  genetically abnormal protein.</obo:IAO_0000115>
    <obo:IAO_0000115>any procedure designed to suppress or mitigate the effects of a recessive genetic change in an abnormal protein by modification of its transcription or translation, excluding those strategies which involve epigenetic modification or modification of the germline or somatic genome sequence. For example an abnormal Vmax of reaction, alteration of KM, failure to respond to positive  feedback, acquisition of neofunction.</obo:IAO_0000115>
    <dc:date>3.10.19</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:label>activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification</rdfs:label>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/84b4e101-fb32-48b7-8c1f-19a6ef75a581">
    <rdfs:label>Progressive ankylosis protein homolog</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fccb6ce4-1730-44e3-a117-00e8de1704c8">
        <rdfs:label>ANKH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56172</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K22734</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9HCJ1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/88618d90-8fc0-4d38-b776-ece048be9b8a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5b8a5259-8e67-4fb9-8f93-a7820cd4de23">
        <rdfs:label>ALDH6A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4329</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q02252</ddiem:uniprotId>
    <rdfs:label>3-hydroxyisobutyrate dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.2.1.18; 1.2.1.27</ddiem:ecNumber>
    <ddiem:keggEntryId>K00140</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5af3fb50-e951-4161-a757-779132d93acb">
    <ddiem:uniprotId>O00754</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ee5580bd-7602-45d1-83e7-e8161ecea5ac">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4125</dc:identifier>
        <rdfs:label>MAN2B1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12311</ddiem:keggEntryId>
    <rdfs:label>Alpha-mannosidase</rdfs:label>
    <ddiem:ecNumber>3.2.1.24</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/81116ade-0397-4ec3-81e9-b4e1873dcc7c">
    <rdfs:label>Dystroglycan</rdfs:label>
    <ddiem:keggEntryId>K06265</ddiem:keggEntryId>
    <ddiem:uniprotId>Q14118</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/2a24e563-0bd7-4ab5-9a27-146e340e18d9"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cfa2a464-cd5f-42d3-af80-9a87fdda5e3b">
    <ddiem:ecNumber>2.3.1.43</ddiem:ecNumber>
    <rdfs:label>lecithin-cholesterol acyltransferase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e878929c-ba13-47ae-96fb-30a54ef9f120">
        <rdfs:label>LCAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3931</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P04180</ddiem:uniprotId>
    <ddiem:keggEntryId>K00650</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b24e18d2-fff8-433c-889c-f055ff814ac6">
    <ddiem:uniprotId>Q9H3Z4</ddiem:uniprotId>
    <ddiem:keggEntryId>K09525</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e860c095-6120-4a4e-94d0-9f82cb52a987">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80331</dc:identifier>
        <rdfs:label>DNAJC5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>DnaJ homolog subfamily C member 5(cysteine string PROTEIN)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/75540bcc-07cd-4a29-9dc2-9178cb9266b9">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a439dd1c-7e03-4d1a-9432-37d4dbbaa673">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1374</dc:identifier>
        <rdfs:label>CPT1A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>carnitine palmitoyltransferase 1A</rdfs:label>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
    <ddiem:keggEntryId>K08765</ddiem:keggEntryId>
    <ddiem:uniprotId>P50416</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/03956dac-d779-434e-a154-ce250d26e9e0">
    <rdfs:label>Methylmalonic aciduria and homocystinuria type C protein</rdfs:label>
    <ddiem:ecNumber>1.16.1.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/13218821-b07b-4fed-aa1f-a05769b073be">
        <rdfs:label>MMACHC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/25974</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9Y4U1</ddiem:uniprotId>
    <ddiem:keggEntryId>K14618</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/8e2d568c-d5e9-4254-857c-501676723ba5">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5cf23e9e-7c23-44c2-bf7c-4d5e48bfd8e5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurological abnormality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b8fdf3ac-a47e-4c09-a7b0-6d6840e94392">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/57d2007c-2694-4dbc-aba9-d97f0c3eabb8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2b61387-b1b7-4463-9836-e5ec6d785004"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d919e2a8-ad4f-4d5a-8f5a-90515983762d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <rdfs:label>Abnormality of neurotransmitter metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012535</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c26daeb7-5816-4e84-82ab-fc473a172ef4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated blood phenylalanine concentration</rdfs:label>
        <dc:identifier>HP:0004923</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/457dba7b-a423-408d-ad33-67b1e563d01e">
    <rdfs:label>glycine N-methyltransferase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d6546af2-e4cc-42ed-9c91-64c06acace90">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27232</dc:identifier>
        <rdfs:label>GNMT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00552</ddiem:keggEntryId>
    <ddiem:ecNumber>2.1.1.20</ddiem:ecNumber>
    <ddiem:uniprotId>Q14749</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/eee70173-0970-4713-bf8a-f6d3500d6a68">
    <ddiem:ecNumber>2.4.1.-; 2.4.2.26</ddiem:ecNumber>
    <ddiem:uniprotId>Q8NBL1</ddiem:uniprotId>
    <rdfs:label>keratin 5/protein O-glucosyltransferase</rdfs:label>
    <ddiem:uniprotId>P13647</ddiem:uniprotId>
    <ddiem:keggEntryId>K13667</ddiem:keggEntryId>
    <ddiem:keggEntryId>K07605</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ab0e5d05-1f7f-4679-ac9b-ea0b6ebcef60">
        <rdfs:label>POGLUT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56983</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9362e5e3-cd84-45fb-9eb7-b758d1a63fe3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3852</dc:identifier>
        <rdfs:label>KRT5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608799">
    <dc:identifier>https://www.omim.org/entry/608799</dc:identifier>
    <ddiem:iembaseAccessionNumber>336</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/336</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/204236a2-7529-465f-a0da-ecba40a7f2e3">
        <rdfs:label>DPM1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8813</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/28882c51-5847-4131-83e4-954482bda975">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fb5b9b20-8986-4c0c-b7e7-0d439226a27c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/246243</dc:identifier>
        <rdfs:label>RNASEH1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Ribonuclease H1</rdfs:label>
    <ddiem:ecNumber>3.1.26.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K03469</ddiem:keggEntryId>
    <ddiem:uniprotId>O60930</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/488a63ef-6aa4-4748-ab4a-486422a3a105">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f60899b-8eb2-4bb9-b212-5c972230f695">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High CSF guanidinoacetate levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fd805776-08bc-4dc0-9316-0e34ee6c2416">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b3ffffca-9759-4993-900e-1537e947dd93"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/047dd5fe-2618-4609-bd6b-2b766fe91074"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f69ccca8-d9fe-43b8-89b5-8ce9bb307d07"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24071436</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e79722b-c7ad-4191-9aee-cc3377b31640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12557293</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoate did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785
Sodium benzoate has been proposed as an additional approach to reduce the production of GAA via conjugation with glycine to form hippuric acid which is rapidly excreted by the kidneys</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/89b8b023-b9c6-48ff-a76e-c758f0b372c3">
    <ddiem:ecNumber>2.7.6.1</ddiem:ecNumber>
    <rdfs:label>Ribose-phosphate diphosphokinase</rdfs:label>
    <ddiem:uniprotId>P60891</ddiem:uniprotId>
    <ddiem:keggEntryId>K00948</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/33a445a3-160b-46b7-a552-d8e558f9a3d6">
        <rdfs:label>PRPS1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5631</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/de85ea17-67bf-4d19-9fe0-6a730ef8be22">
    <ddiem:uniprotId>P48775</ddiem:uniprotId>
    <ddiem:keggEntryId>K00453</ddiem:keggEntryId>
    <ddiem:ecNumber>1.13.11.11</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e2d30fa5-1f6e-4370-bc30-da1ada9b161b">
        <rdfs:label>TDO2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6999</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tryptophan 2,3-dioxygenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3d5b8a32-a14f-4aae-914a-14c6da43dde4">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/16e261dc-4e0a-4d4a-af4e-4f2193459f14">
        <rdfs:label>PTPS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/4650859b-07db-4afd-9d36-58738b0bb4e3">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/918e2d4b-111d-4505-8798-c3912709c22c">
        <dc:identifier>HP:0031517*</dc:identifier>
        <rdfs:label>Verruciform plaques(verruciform xanthomas)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/011e7ebf-0cb3-4e47-b82a-5740f1f3c4b7">
        <dc:identifier>HP:0010783</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Erythema</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65f60935-00d2-4fe9-ab80-b6daf931a624">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>VX‐like lesions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e62a37ab-1d74-4790-8730-ae8b3790642a">
        <rdfs:label>Scaling Skin</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040189</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/308050">
        <ddiem:iembaseAccessionNumber>194</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/308050</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/194</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0d825c19-e73b-49e6-87d3-e518f9adbafa"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29341259</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6667e7bc-ad33-4fe4-9446-49b82dbfb658">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007431</ddiem:url>
        <dc:identifier>HP:0007431</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ichthyosiform erythroderma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0b784a6-0a31-4b3d-bdf9-c08ae7a83f69">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:label>Itchy skin</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000989</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/80b38d56-06f2-487c-b768-5027208c94bd"/>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/563b9f24-45ce-43f3-9725-e8d2e5ad76ff"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a105eebd-62dc-4426-ac0e-4e860819d9c9">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18203a13-4e24-4100-8ef0-c16e9db4095c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e02aa49f-2390-40cc-b373-22e88233c8e6"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/763452f8-7da3-48d5-855f-888e089440d4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04eeeac3-651f-49b2-bfdc-35c3ab9345b0"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7be2207-9248-440c-b331-5c32d3323b2c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/2830c8e0-aa7d-4e01-8bcd-6981c925823e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b37eca9-204c-4d05-b50d-58f035fdb565">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:label>Abnormal liver function tests</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002910</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4f06921-d3cd-439e-a0b0-62adabc4fa47">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal bilirubin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0d85c11-aba8-406c-8a92-a34512323f27">
        <rdfs:label>Liver biopsy abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc10c4c1-7259-4ecd-9558-342472b3222c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8707100</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2affbe48-72e7-4a46-a544-7b6ead8660e9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235555">
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/235555</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aa357bc2-b9d3-4de1-b961-44ca7ef23506"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/da1b9f68-a78c-4ef0-b40e-988620b3d746">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6e60acc3-ab70-4fb9-88b5-fcf184cee61a">
        <rdfs:label>PHKB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5257</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q93100</ddiem:uniprotId>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <rdfs:label>Phosphorylase b kinase regulatory subunit beta</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/71ca6d55-afde-40da-873b-e9fd620b2d46">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f03cc2b0-b0b0-4fac-8748-4c3f916114a5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6514</dc:identifier>
        <rdfs:label>SLC2A2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Solute carrier family 2, facilitated glucose transporter member 2</rdfs:label>
    <ddiem:uniprotId>P11168</ddiem:uniprotId>
    <ddiem:keggEntryId>K07593</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dfdee8b9-9677-4c3e-aeec-ee8cce8062d7">
    <ddiem:keggEntryId>K14425</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13621</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ca6c18eb-6392-4bf6-b8be-a0b84f985951">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6557</dc:identifier>
        <rdfs:label>SLC12A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Solute carrier family 12 member 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/359a755a-81e6-4386-9e18-f6a1024d2cb6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47faa3e4-8fc5-4f16-b2b8-82af34c847d5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Slow recovery</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012823</ddiem:url>
        <dc:identifier>HP:0012823*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/535000">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/402</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/535000</dc:identifier>
        <ddiem:iembaseAccessionNumber>402</ddiem:iembaseAccessionNumber>
        <rdfs:label>LEBER OPTIC ATROPHY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7d29a6a3-6974-4eb7-bd9f-d55adef8c65a"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7be2207-9248-440c-b331-5c32d3323b2c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e02aa49f-2390-40cc-b373-22e88233c8e6"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/931a6903-0271-4ef7-b8f0-d2f415ec0823"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/bcfbfa6d-7078-49a8-8061-c1e73dc852a0">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f1a93807-f7ab-4a06-ac32-884eb698cd15"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ec1494e-a059-4b99-9f98-438332dcfb79">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated serum pancreatic secretory trypsin inhibitor</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30cbef1b-0a45-41d1-997c-1d3cf77ec919">
        <rdfs:label>lethargy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001254</ddiem:url>
        <dc:identifier>HP:0001254</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9644fb9-db97-4d5b-a126-20d9d4ba57e4">
        <dc:identifier>HP:0001510</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c867f38-79cf-4506-8aba-dbb9a541f55a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001987</dc:identifier>
        <rdfs:label>hyperammonemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cea71286-ff27-4625-a01a-9058e78d3631">
        <dc:identifier>HP:0002039</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
        <rdfs:label>anorexia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603471">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/88c55cd8-8ba4-4e9d-b961-ed41105b17ef"/>
        <rdfs:label>CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2</rdfs:label>
        <ddiem:iembaseAccessionNumber>18</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/603471</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/18</ddiem:iembaseUrl>
        <rdfs:comment>Liver transplantation is the only radical treatment for CTLN2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/281ad466-0957-4af5-b68b-368f833747c6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
        <dc:identifier>HP:0011966</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated plasma citrulline level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2debe3b1-1ae3-4484-b703-b0d784b135fa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fe25ae68-9a3e-4522-b74e-8a985a0cb310"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/303228c7-769d-42e1-94a3-d84f0cb15f70">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004337</ddiem:url>
        <rdfs:label>Elevated threonine-to-serine ratio ( Abnormality of amino acid metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004337*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a9c71a8-49c4-4297-8cac-af9f7e4ea5ec">
        <rdfs:label>fatigue</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012378</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9de391b8-a475-48fa-90a3-16d5bcb112bd">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6aa2bda0-86b5-4802-839d-c204e7e60d94">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002072</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002072</ddiem:url>
        <rdfs:label>Chorea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300322">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1b1ebfc4-0372-4f92-b05e-a280f467c147"/>
        <ddiem:iembaseAccessionNumber>145</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/300322</dc:identifier>
        <rdfs:label>LESCH-NYHAN SYNDROME; LNS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/145</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6289fc90-15a9-4a86-8a90-6af49314e36f">
        <rdfs:label>Dystonia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001332</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2d20a3c7-91b4-4526-9c4b-22e2c4d151ef">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cb303eed-482f-45a1-bdbd-697516f589c0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/bd819115-f509-44bc-8e70-7b90de908e42">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613153">
        <ddiem:iembaseAccessionNumber>645</ddiem:iembaseAccessionNumber>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/613153</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bc50df2e-ece5-4281-a67a-389034aaffb8"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/645</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cf733780-1834-4f7e-9487-4b2bf25147d5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac11091f-737b-4157-bc59-9aacdf5ffc3e"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0003e3bd-62ad-4189-be31-7b773dc384d7">
    <rdfs:label>uridine diphosphate–glucuronyl transferase</rdfs:label>
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b0d83319-0110-4160-b080-56d5b443ca00">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54658</dc:identifier>
        <rdfs:label>UGT1A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/54107c7a-9472-458d-b6cb-8caddf5dceaa">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38a5ab40-7d49-4e3f-91bc-9632cb48e7bd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003530</ddiem:url>
        <rdfs:label>Glutaric acidemia</rdfs:label>
        <dc:identifier>HP:0003530</dc:identifier>
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4f4f6e8-d1cb-4d8b-96e1-ab426850a2a7"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f1a93807-f7ab-4a06-ac32-884eb698cd15"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3a198d9-ef80-45c3-a2bc-e9a6a401d052"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20923787</dc:provenance>
    <rdfs:comment>The combination was accompanied by Low L-lysine diet</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613724">
    <rdfs:label>LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY; LKDMN</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/613724</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1114</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/49761f31-637b-478c-b5d6-5e0f078de6c0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6342</dc:identifier>
        <rdfs:label>SCP2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>1114</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/742edcae-2a2d-469f-90f7-3426d7d469ec">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aa357bc2-b9d3-4de1-b961-44ca7ef23506">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6718</dc:identifier>
        <rdfs:label>AKR1D1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
    <rdfs:label>DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE</rdfs:label>
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/96ff9760-fcb4-44e0-93f8-c6ea066954d8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc455227-b676-41e7-8232-ecdc72cbd433">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/79d213a5-5b97-435b-a6bf-6971fce2292e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26917598</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602473">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/172</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cd9d0243-65de-4227-89b0-c346793f5c5c"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ENCEPHALOPATHY, ETHYLMALONIC; EE</rdfs:label>
        <ddiem:iembaseAccessionNumber>172</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/602473</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/04bd88f9-80ce-47e8-b8aa-961549b02aea">
    <rdfs:label>85/88 kDa calcium-independent phospholipase A2</rdfs:label>
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8a16ae66-a016-45fb-87ed-bc04e623e5c6">
        <rdfs:label>PLA2G6</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8398</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/878e2f98-f08f-426a-813b-c6fc46c4a9ba">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7b276dba-de35-49b4-822a-1aafdc6d18cf">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10577</dc:identifier>
        <rdfs:label>NPC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>NPC intracellular cholesterol transporter 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dd372ce4-6fef-4fa9-9483-441945c53ffa">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/41299985-4d17-40fb-beb7-52766e835cc9">
        <rdfs:label>D2HGDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/728294</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>D-2-hydroxyglutarate dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/278e7f83-d445-404a-97e6-08b50fc6fb4d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1d5a663d-22e3-4dfd-a70f-47392224c1fc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4864</dc:identifier>
        <rdfs:label>NPC1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>NPC intracellular cholesterol transporter 1</rdfs:label>
    <ddiem:uniprotId>O15118</ddiem:uniprotId>
    <ddiem:keggEntryId>K12385</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/56df1f63-5001-41a7-9223-3907ebcfeb58">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0baeacd9-ac6c-4714-a987-07abb47df2a1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a7dc9857-68ce-4138-b320-e155ad00437d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02612cc5-bbb0-459c-a738-679726a26952">
        <dc:identifier>HP:0003119</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of lipid metabolism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6692b6a2-c0af-4803-994e-7e41774037cb">
        <rdfs:label>Motor function impairment</rdfs:label>
        <dc:identifier>HP:0002275</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb92873b-bbc1-4163-8441-ee19e504b46e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0cddf4c7-698f-4bc3-bd41-5981c17abf99"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fe62520-5d05-4861-b861-fa6b569ca8cf">
        <dc:identifier>HP:0002180*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:label>Cerebeller neurodegeneration( neurodegeneration)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/257220">
        <dc:identifier>https://www.omim.org/entry/257220</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1d5a663d-22e3-4dfd-a70f-47392224c1fc"/>
        <ddiem:iembaseAccessionNumber>303</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/303</ddiem:iembaseUrl>
        <rdfs:label>NIEMANN-PICK DISEASE, TYPE C1; NPC1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23948640</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31248418</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79dbe2a3-cc42-4e4f-bd65-7e48cc7faa56">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased number of splenic myeloid cells</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1e77ac9-9d7d-4ea3-9c34-da4299e1e8eb">
        <rdfs:label>Splenomegaly</rdfs:label>
        <dc:identifier>HP:0001744</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25400034</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2e8db47f-953c-4f02-a129-47d1cdacd28b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b54a0656-7831-46aa-a018-b8d2a3f424ee"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:DDIEM_0000015>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e4ec9b78-21b9-480a-bf5c-5be875506954">
    <ddiem:uniprotId>P00492</ddiem:uniprotId>
    <rdfs:label>hypoxanthine phosphoribosyltransferase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1b1ebfc4-0372-4f92-b05e-a280f467c147">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3251</dc:identifier>
        <rdfs:label>HPRT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.2.8</ddiem:ecNumber>
    <ddiem:keggEntryId>K00760</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3776da34-aa66-4a35-94e8-5a8c6936986e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/62eaa588-96ae-4fcf-a958-02a88bf94669">
        <rdfs:label>SPR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6697</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <rdfs:label>GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/299cb842-d0c6-4f88-bcb3-49fc71249e2f">
        <rdfs:label>TH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7054</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
    <ddiem:uniprotId>P35270</ddiem:uniprotId>
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
    <ddiem:keggEntryId>K00072</ddiem:keggEntryId>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/25c33b37-04f5-44c5-88cb-f7b0784187e1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2643</dc:identifier>
        <rdfs:label>GCH1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.1.1.153</ddiem:ecNumber>
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/01682eb7-e85f-4de7-8d9d-4e7117cbcbd9">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/133fedd3-9df3-4e02-87bc-73023f9564fd">
        <rdfs:label>PIGM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/93183</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <rdfs:label>beta-alanine-alpha-ketoglutarate transaminase.</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/659f66ab-3167-4542-b325-7220904b00d1">
    <ddiem:ecNumber>2.3.1.7</ddiem:ecNumber>
    <rdfs:label>Carnitine acetyltransferase</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>P43155</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3561ca19-275f-426f-80b9-5b319d814557">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1384</dc:identifier>
        <rdfs:label>CRAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a368561c-9447-4248-86ea-b8f835844a11">
    <ddiem:keggEntryId>K21456</ddiem:keggEntryId>
    <ddiem:ecNumber>6.3.2.3</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7914090b-7d79-4be2-b5c7-1c6969a93ac9">
        <rdfs:label>GSS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2937</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P48637</ddiem:uniprotId>
    <rdfs:label>glutathione synthetase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b97f5188-5adf-4ca8-935e-4a2ce516c3d2">
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
    <rdfs:label>UDP glucuronosyltransferase family 1 member A1</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b0d83319-0110-4160-b080-56d5b443ca00"/>
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a4b0b2c5-2e9d-4fad-93a7-ab35e33ba299">
    <ddiem:uniprotId>P49638</ddiem:uniprotId>
    <rdfs:label>α-tocopherol transfer protein</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a1e90020-b91d-4c14-b945-946d40b1bff5">
        <rdfs:label>TTPA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7274</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/770f1ec8-058b-47f2-abbb-c3e32d4ea1d7">
    <ddiem:keggEntryId>K04728</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13315</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/556d62b0-e777-4c37-84b0-73bb91366e83">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/472</dc:identifier>
        <rdfs:label>ATM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ATM serine/threonine kinase</rdfs:label>
    <ddiem:ecNumber>2.7.11.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1f94b609-518e-4100-9f4f-8c55cb662408">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fa5a5dd2-c6f1-4b64-9b0d-4a657960c28d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10128</dc:identifier>
        <rdfs:label>LRPPRC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>leucine-rich pentatricopeptide repeat-containing protein</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/7cb82c3c-10de-4918-9f98-3aaf6b7a400c">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a724f22e-5d97-4043-bb2f-502fca95987b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6ffb08df-b6e4-4610-b457-9b896219b2b8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/06bb5e08-bf46-4161-bfff-312f611a57a4">
        <rdfs:label>Study is still recruiting</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f565eb33-acc8-4a84-b020-66f9c5ca8116">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7d4822a8-b1ed-4777-9b36-3bede743d163">
        <rdfs:label>PHKA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5256</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P46019</ddiem:uniprotId>
    <rdfs:label>Phosphorylase b kinase regulatory subunit alpha, liver isoform</rdfs:label>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/122c49f7-fd15-4060-a2b2-69069154f3df">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a01f0e38-2474-4fc1-9723-ba689a93919c">
        <rdfs:label>LBR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3930</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lamin B receptor</rdfs:label>
    <ddiem:ecNumber>1.3.1.70</ddiem:ecNumber>
    <ddiem:keggEntryId>K19532</ddiem:keggEntryId>
    <ddiem:uniprotId>Q14739</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/eb99f3e4-1325-43c0-bba2-4c1a8800fc70">
    <ddiem:ecNumber>3.1.-.-; 3.6.4.12</ddiem:ecNumber>
    <ddiem:keggEntryId>K10742</ddiem:keggEntryId>
    <rdfs:label>DNA replication ATP-dependent helicase/nuclease DNA2</rdfs:label>
    <ddiem:uniprotId>P51530</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2d8d6fe1-d4c5-4892-af48-f62582d7ba84">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1763</dc:identifier>
        <rdfs:label>DNA2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/65aee8a4-ec10-4d7e-acc5-cfdadb0c6040">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/91b5385a-0db8-438f-b80a-b807753fa580">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2720</dc:identifier>
        <rdfs:label>GLB1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12309</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.23</ddiem:ecNumber>
    <ddiem:uniprotId>P16278</ddiem:uniprotId>
    <rdfs:label>beta-galactosidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a319424d-0b39-4a19-bd70-c1af494c6aab">
    <ddiem:keggEntryId>K22283</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6fed21de-1c4a-428a-bb16-ffda13ef36ed">
        <rdfs:label>LIPC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3990</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.1.3</ddiem:ecNumber>
    <rdfs:label>hepatic lipase</rdfs:label>
    <ddiem:uniprotId>P11150</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/377fa9cc-aed7-4dfd-a271-aaace80bd7c3">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e974fe73-acaa-426b-8a9a-05168e3d2292"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb931e2d-83c6-4a01-b88e-e0383a6f5b51"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18848477</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04e80d16-019a-49fc-b9bf-0eb4bfd92156"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b179fcb4-6857-46ea-9349-a38d788a292a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d8dbcbc-6052-4ab2-bd22-a2dcca1b10b8"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215720">
    <rdfs:label>CITRULLINE TRANSPORT DEFECT</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/215720</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/98019f29-761e-4e34-9a7a-a2097e2785af">
        <rdfs:label>SAR1B</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51128</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2d930be5-be70-4505-b588-9a611ac149f7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef76b40a-c8e7-4c87-b4b2-a570ccd44641">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6659f8a4-f2b6-4bec-97ae-792bc4086ed2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e79722b-c7ad-4191-9aee-cc3377b31640"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec52056d-a661-482c-8852-3b28db273dda"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728770</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615156">
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 6; PEOA6</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/946</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/615156</dc:identifier>
        <ddiem:iembaseAccessionNumber>946</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2d8d6fe1-d4c5-4892-af48-f62582d7ba84"/>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7e29a693-56b3-48c0-9389-8e36aeb7f1da">
    <ddiem:uniprotId>P00450</ddiem:uniprotId>
    <ddiem:keggEntryId>K13624</ddiem:keggEntryId>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2590f5a9-b3c0-4476-8d35-3a037c376f55">
        <rdfs:label>CP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1356</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Ferroxidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f61c17eb-86e8-476b-ab12-e3f25cacf326">
    <ddiem:uniprotId>P02649</ddiem:uniprotId>
    <rdfs:label>apolipoprotein E</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3794706b-3129-411d-9ba0-3e1dc3aeaef1">
        <rdfs:label>APOE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/348</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K04524</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/467cbce9-31f9-49ab-a3a5-9c7f65570c62">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28288174</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/349fc753-4be8-48b2-9a63-5b636324c2a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/135516c5-c0c9-41b6-9204-0a46d083d489"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6d686d53-dd18-4408-a83b-b2854d4ef355">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8ec08c69-d2d9-48d9-8eb5-5c2ff7360ec1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/187521ea-9398-4569-befd-adbbe1a09b22"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1bac1898-6f6d-400a-92e3-d97bd5441246">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fb589cdb-ee40-4d81-8284-a548ccd6105f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607364">
        <dc:identifier>https://www.omim.org/entry/607364</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3fdce799-b951-475a-9ffa-1367eab9e29d"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>BARTTER SYNDROME, TYPE 3; BARTS3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ccb37b5a-5459-402f-9006-880ad6f3a73d">
    <ddiem:uniprotId>O43505</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/dd3df65d-b5dd-432f-a9aa-3dd4058b5a30"/>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f8826c45-6040-4389-b8ef-56b99ce90527"/>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K21032</ddiem:keggEntryId>
    <rdfs:label>Beta-1,4-glucuronyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1a772cfd-745a-4e0e-8e1a-eb08339b5fb9">
    <rdfs:label>sterol carrier protein 2</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/49761f31-637b-478c-b5d6-5e0f078de6c0"/>
    <ddiem:uniprotId>P22307</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.176</ddiem:ecNumber>
    <ddiem:keggEntryId>K08764</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/87cad790-4cd2-45d2-88df-9a23dead1d96">
    <rdfs:label>Adenosine deaminase</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/54ea5323-d50f-46c5-966b-ee5a7e062dd8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/100</dc:identifier>
        <rdfs:label>ADA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a99b0d4c-4170-4d9e-8c9d-9496b86732b9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9317abc0-16c0-4985-b4d1-4a6d78fa7593"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/274270">
        <dc:identifier>https://www.omim.org/entry/274270</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/159</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>159</ddiem:iembaseAccessionNumber>
        <rdfs:label>DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/92cc6199-2985-4963-98bb-542f3e59b397"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6516bbb4-eaa2-41eb-98aa-3cdc2f03ec4c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7136527f-9b90-4a00-8e3f-9eeab87cd911">
    <rdfs:label>Dihydrofolate reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/77b527ba-cef5-48be-b78b-fb30a1d97d8e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1719</dc:identifier>
        <rdfs:label>DHFR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P00374</ddiem:uniprotId>
    <ddiem:keggEntryId>K00287</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/65995f9b-7724-479d-8447-308a40ea0cf4">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26208971</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fa288dfb-051b-4956-bbac-6d75264a10e8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/764dfbac-9c68-4a90-bdcc-3761962ca0a6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac5799d5-cc35-4d20-8974-81ddc715cc9c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5e60aef-cb6c-44c0-b88a-b8e41cdf9fc4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Neurological impairment</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236792">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/08e79c95-d0c9-43bf-896a-5eb8fbb7d852"/>
        <rdfs:label>L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/236792</dc:identifier>
        <ddiem:iembaseAccessionNumber>165</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/165</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/026e774b-3488-4938-9074-615eb9d6ce2d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/92ec04de-1c6c-465e-b043-7c89dab1248f">
        <rdfs:label>FKTN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2218</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <rdfs:label>Fukutin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1e794de0-915b-4b4e-ab5f-3caca029e44b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/38282cec-6bac-4999-9967-e2518f52ec06">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11019</dc:identifier>
        <rdfs:label>LIAS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lipoic acid synthetase</rdfs:label>
    <ddiem:ecNumber>2.8.1.8</ddiem:ecNumber>
    <ddiem:keggEntryId>K03644</ddiem:keggEntryId>
    <ddiem:uniprotId>O43766</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/835b80b2-954d-4f1e-ae55-30026cfa6c78">
    <ddiem:keggEntryId>K23555</ddiem:keggEntryId>
    <ddiem:uniprotId>Q96S06</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/33dbb7e3-b99d-4c62-8074-fcedc833e422">
        <rdfs:label>LMF1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64788</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lipase maturation factor 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/61b73bb2-30dd-43e7-8ca6-c4304c050789">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a43889a9-fecb-4774-b538-3f1d58860bc0"/>
    <rdfs:label>3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE</rdfs:label>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e3b40c0c-34f7-41a8-a886-b077f712d6e5">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/caf3c17a-cc1b-45e8-bb87-ab4b1073f45d">
        <rdfs:label>FUCA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2517</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>a-L-fucosidase</rdfs:label>
    <ddiem:keggEntryId>K01206</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.51</ddiem:ecNumber>
    <ddiem:uniprotId>P04066</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/4a6d8d7f-a191-4444-a010-bb4fd2efd029">
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7be2207-9248-440c-b331-5c32d3323b2c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14d29dac-847f-4efb-b83e-0a1e451c54ab"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28a0c094-c9ce-4777-8f9d-02120c11c2b2">
        <dc:identifier>HP:0001877*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High erythrocyte turnover(Abnormality of erythrocytes)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/da15612b-62a8-47ed-a2e7-24690043995a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cb795bff-9895-45db-902a-a334d9340974">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5213</dc:identifier>
        <rdfs:label>PFKM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00850</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.11</ddiem:ecNumber>
    <ddiem:uniprotId>P08237</ddiem:uniprotId>
    <rdfs:label>ATP-dependent 6-phosphofructokinase, muscle type</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1480ef54-78d4-4bd6-bc0e-a139488674e9">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/01c911d4-fc6d-425a-a041-dc644701090e"/>
    <rdfs:label>D-ribitol-5-phosphate cytidylyltransferase</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b1e7232c-90e9-44fd-b8d5-448b09d7cf57">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5cf23e9e-7c23-44c2-bf7c-4d5e48bfd8e5"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac5799d5-cc35-4d20-8974-81ddc715cc9c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11382201</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c0881b7-e5e0-4434-b8b6-6e28a5bec3d8">
        <dc:identifier>HP:0030890</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030890</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperintensity of cerebral white matter on MRI</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82cda0c4-658a-4fbe-ba54-fff4c38b3da0">
        <rdfs:label>Abnormal EEG (focal epileptiform activity)</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/931a6903-0271-4ef7-b8f0-d2f415ec0823"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a6c7c71-cbbd-4b9f-ac4a-692ea07d9804">
        <dc:identifier>HP:0002401</dc:identifier>
        <rdfs:label>Stroke-like attacks</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3fef8bb6-16f1-4e11-924d-a18b907303ed">
    <ddiem:keggEntryId>K01835</ddiem:keggEntryId>
    <ddiem:ecNumber>5.4.2.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/42597ba4-2d97-4c72-8fc3-f1d974b1c4b4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5236</dc:identifier>
        <rdfs:label>PGM1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphoglucomutase-1</rdfs:label>
    <ddiem:uniprotId>P36871</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9e9dd0e4-5e4a-4e14-bd25-2c3710c7bb03">
    <rdfs:label>DNA polymerase subunit gamma-1</rdfs:label>
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/451bbd3a-512a-4a5d-8513-97be22d4cce9"/>
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/02ee0f04-752b-41e1-a2a9-e6f70d337fa9">
    <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5346fc1b-27e5-4deb-ab57-b62f2bac89e4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/48effd6e-f42c-4e36-9812-a417cb00fc64"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a3dc877-99e7-4aed-a8b2-de08766a4b9c">
        <rdfs:comment>The change was not statistically significant.</rdfs:comment>
        <dc:identifier>HP:0003107*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>High desmosterol levels (Abnormality of cholesterol metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602398">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/195</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>195</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/602398</dc:identifier>
        <rdfs:label>DESMOSTEROLOSIS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/02490355-db2e-4680-8348-f329b005cb64"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66e3605a-363f-4a02-b8ef-e813872339b9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>High desmosterol,cholesterol ratio</rdfs:label>
        <rdfs:comment>The change was not statistically significant.</rdfs:comment>
        <dc:identifier>HP:0003107*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28856097</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac5799d5-cc35-4d20-8974-81ddc715cc9c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/763452f8-7da3-48d5-855f-888e089440d4"/>
  </obo:DDIEM_0000012>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222730">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/49</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>49</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/222730</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5ff1c241-bba1-4ed4-9fd6-bdcddc58fd36">
        <rdfs:label>SLC1A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6505</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>DICARBOXYLIC AMINOACIDURIA; DCBXA</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/13732099-e075-408f-8c18-b55e0953e37b">
    <rdfs:label>mevalonate kinase</rdfs:label>
    <ddiem:keggEntryId>K00869</ddiem:keggEntryId>
    <ddiem:uniprotId>Q03426</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.36</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7a20083d-b8be-4dc2-9369-fc160da68ae4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4598</dc:identifier>
        <rdfs:label>MVK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ecf690a7-bc2f-4a09-8a0b-11fbe531df31">
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <rdfs:label>Fukutin-related protein</rdfs:label>
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bc50df2e-ece5-4281-a67a-389034aaffb8">
        <rdfs:label>FKRP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79147</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7d7cf592-743d-48ac-843d-1ba6a3ee707d">
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2412352c-e1e4-4bda-8fe5-ca54b580f917">
        <rdfs:label>Hyperphenylalaninemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80fe9cc5-292e-4e32-9304-833eeb5a373f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60c7d780-7542-4de3-8b69-e9b0668b6560">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
        <rdfs:label>Delayed receptive language</rdfs:label>
        <dc:identifier>HP:0010863</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b8fdf3ac-a47e-4c09-a7b0-6d6840e94392"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2b61387-b1b7-4463-9836-e5ec6d785004"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b5e60aef-cb6c-44c0-b88a-b8e41cdf9fc4"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d80052db-0724-45ab-bbee-67f5b72384e4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/724ac8a8-4f1a-4b53-99f8-10101c0e2c09"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/60b242b1-2a5f-4b9c-8156-41f03dedf5b7">
    <rdfs:label>beta-glucocerebrosidase</rdfs:label>
    <ddiem:keggEntryId>K01201</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.45; 2.4.1.-; 3.2.1.104</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/20e645ce-1935-4826-b4d5-d1df5b464a51">
        <rdfs:label>GBA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2629</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P04062</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a7762080-aba3-4c10-85ed-efc9d5e6c619">
    <ddiem:uniprotId>P54840</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e01ca8b3-03e2-4f0a-b2f5-cb41e71bfb54">
        <rdfs:label>GYS2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2998</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.11</ddiem:ecNumber>
    <ddiem:keggEntryId>K00693</ddiem:keggEntryId>
    <rdfs:label>glycogen synthase 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612937">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15; MDDGC15</rdfs:label>
    <ddiem:iembaseAccessionNumber>387</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/612937</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/387</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1baeca24-1eee-49e8-a8f1-e3e260fcbc4e">
        <rdfs:label>DPM3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54344</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/eddf1987-4b08-4a95-9cb3-d6e88d3be290">
    <rdfs:label>alpha subunit of muscle phosphorylase kinase</rdfs:label>
    <ddiem:uniprotId>P46020</ddiem:uniprotId>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f739b5b3-39f7-4cdc-a4c9-61c039d42ac4">
        <rdfs:label>PHKA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5255</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/48e49545-f394-435c-9781-aacbede4bcea">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac5799d5-cc35-4d20-8974-81ddc715cc9c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e45a224-f445-4743-ba6a-1c8ec0c846a1">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:label>High serum creatine kinase</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be938cb3-be98-4597-8ab6-f018e51b2c8b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ffebcfa-f201-410d-8e07-396d0d529147">
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Muscle weakness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f7272109-8b90-4090-a242-0784a4bcf819">
    <ddiem:uniprotId>O60494</ddiem:uniprotId>
    <rdfs:label>cubilin/amnion associated transmembrane protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b24bd528-f19f-4887-a98c-5f30a86767bb">
        <rdfs:label>AMN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/81693</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K18259</ddiem:keggEntryId>
    <ddiem:keggEntryId>K14616</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/863febbd-c179-42cb-a58a-8f84f9870a58">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8029</dc:identifier>
        <rdfs:label>CUBN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9BXJ7</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/13694867-8cb7-4011-9624-24080aba3437">
    <ddiem:uniprotId>Q9BZV2</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cd023b28-5cae-4db6-8631-41e7518d4e9a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80704</dc:identifier>
        <rdfs:label>SLC19A3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>thiamine transporter</rdfs:label>
    <ddiem:keggEntryId>K14610</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d1e27085-4e54-4192-bbc0-ea824a3754cf">
    <ddiem:ecNumber>6.4.1.4</ddiem:ecNumber>
    <ddiem:uniprotId>Q96RQ3</ddiem:uniprotId>
    <ddiem:keggEntryId>K01969</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d3f3ef8f-ba54-4f89-b215-1eea4086b459">
        <rdfs:label>MCCC1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56922</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01968</ddiem:keggEntryId>
    <rdfs:label>3 Methylcrotonyl-CoA carboxylase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1d16342f-85a5-4e85-a441-7a47ad7ce6d4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64087</dc:identifier>
        <rdfs:label>MCCC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9HCC0</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/57e2ea22-2a3a-4ea5-abc7-39c1fb3df10b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60afe3d2-9cf2-47de-9834-563bbf82fe83">
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:label>Sleep disturbance,Poor sleep qaulity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9da6d03b-025a-4ceb-996a-8a6a43d39af2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b788ae74-6972-416d-9f3d-bdb7dca42be1"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e01bee0d-9752-4a63-8fa8-28edd454e2cb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232220">
        <ddiem:iembaseAccessionNumber>485</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/98dac32e-fa22-4668-beb6-c66a55577eaa"/>
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ib; GSD1B</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/232220</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/485</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
  </obo:DDIEM_0000010>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a2383f96-3dbd-4307-b43d-839bc04ad31a">
    <ddiem:uniprotId>P07954</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/265b1bc1-3204-4f6a-8ed6-b7f2004fcb2c"/>
    <rdfs:label>Fumarate hydratase, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K01679</ddiem:keggEntryId>
    <ddiem:ecNumber>4.2.1.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8ae1e3fc-1f8b-49b0-bd4d-345530e9f443">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/efd225b1-3930-4af1-ac38-246c0fd346b8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/551</dc:identifier>
        <rdfs:label>AVP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P01185</ddiem:uniprotId>
    <rdfs:label>Hormone ( Arginine vasopressin)</rdfs:label>
    <ddiem:keggEntryId>K05242</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/69f2f801-00be-4bad-91c9-abe4432c5627">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613154">
        <ddiem:iembaseAccessionNumber>1125</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1125</ddiem:iembaseUrl>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/017bb7b9-8203-42bb-b2e7-3370a5124308"/>
        <dc:identifier>https://www.omim.org/entry/613154</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cf733780-1834-4f7e-9487-4b2bf25147d5"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac11091f-737b-4157-bc59-9aacdf5ffc3e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3d9cb7c4-71ed-4a49-99e2-b42d521ec100">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19285442</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5cf23e9e-7c23-44c2-bf7c-4d5e48bfd8e5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/414da705-6ce7-42fe-98e1-badd2f41f0b3">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012638</ddiem:url>
        <dc:identifier>HP:0012638</dc:identifier>
        <rdfs:label>Muscular abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246700">
        <dc:identifier>https://www.omim.org/entry/246700</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1083</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1083</ddiem:iembaseAccessionNumber>
        <rdfs:label>CHYLOMICRON RETENTION DISEASE; CMRD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/98019f29-761e-4e34-9a7a-a2097e2785af"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aa66b013-56bd-40ce-9b4c-2bf75a4e28d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/30df7df2-d253-4cdb-b5e5-d7fd9109889a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1f6a228-59a1-4f11-b4b6-25869ee170d7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000505</ddiem:url>
        <dc:identifier>HP:0000505</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Minor visual abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3bc5abcf-17b0-4278-9bc2-e6d9402720d2">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608896">
        <dc:identifier>https://www.omim.org/entry/608896</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c3f3c8d6-cfe0-4e86-9a39-50762f5265d4"/>
        <rdfs:label>SARCOGLYCAN, GAMMA; SGCG</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15252120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/34599644-47d9-464e-a099-6a9f9f379991">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b9e761da-05f0-4d26-bbdf-f6aca99e68aa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/11c85cf0-a2e0-480c-8e4b-96c4fee0e3b9">
    <ddiem:uniprotId>Q8IWY9</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/352d00f6-9608-48a1-8847-8e4e34c21ed2">
        <rdfs:label>CDAN1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/146059</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K19531</ddiem:keggEntryId>
    <rdfs:label>codanin 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ac15a7a6-f154-440e-a783-24fb4dcc5335">
    <ddiem:keggEntryId>K00700</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.18</ddiem:ecNumber>
    <ddiem:uniprotId>Q04446</ddiem:uniprotId>
    <rdfs:label>Limit dextrin alpha-1,6-maltotetraose-hydrolase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c551606d-8099-484e-a3f7-2993645c359a">
        <rdfs:label>GBE1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2632</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c1d1f50b-0401-40d7-9fe1-6d82a30342e4">
    <rdfs:label>galactokinase 1</rdfs:label>
    <ddiem:keggEntryId>K00849</ddiem:keggEntryId>
    <ddiem:uniprotId>P51570</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/02751a4b-5f97-41c4-997e-28786ceb20ab">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2584</dc:identifier>
        <rdfs:label>GALK1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.6</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/2bca1806-899b-4c3c-8d6b-5b17333ac65d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/613f3ae9-cb61-495f-8920-34d57ad9525c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low Hb level</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/698d32ca-e3b8-45aa-bbef-890811bc86a4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a6a13fe6-89b6-4686-8e06-1902282c219d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/105650">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2c9ee877-281a-432e-88e3-f289033312af"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4a2ad985-98ca-4536-9d6e-8a6b807686a4"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e48b64df-b5d8-4ef4-9480-6ab4f779a687"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4131d940-270e-4a14-a2ca-4561762dd1d4"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2945aa8b-5e58-4b8a-999f-780d250ac356"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DIAMOND-BLACKFAN ANEMIA 1; DBA1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3aff645a-5265-4422-a4f2-d252c7c63523"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aa90003a-a9ab-4958-98b2-34745e701bcc"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/da30b622-1447-4a11-9541-eacf92dc83d1"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eefd920c-1388-430c-a66d-ef005f3e9eec"/>
        <dc:identifier>https://www.omim.org/entry/105650</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fccd4431-c764-4f38-bb3d-6b72092bf414"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2dfb179c-d3d0-463e-964d-99caa4eeccb9"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2c093f1d-9c41-482d-9e28-396dd911a4be">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/357814c2-a93d-43b1-bb9f-4a64a74712a5"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000016">
    <rdfs:label xml:lang="en">functional complementation or a defective protein by stimulation</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that stimulates a component of the pathway or network in which a genetically defective defective protein is found, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:09:20+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fa5cbe6a-62eb-4a0e-9ed3-d2b9bed65f90">
    <rdfs:label>adaptor protein-2 σ-subunit</rdfs:label>
    <ddiem:keggEntryId>K11827</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b82bad66-5bda-418e-86d0-98a3b4dc38c5">
        <rdfs:label>AP2S1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1175</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P53680</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c858a705-a8b0-4fe0-8c28-efc165a686a3">
    <ddiem:uniprotId>Q02318</ddiem:uniprotId>
    <ddiem:ecNumber>1.14.15.15</ddiem:ecNumber>
    <rdfs:label>Cholestanetriol 26-monooxygenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0def1369-196f-4b86-a8bc-939a87048f17">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1593</dc:identifier>
        <rdfs:label>CYP27A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00488</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9e86c59d-3ff6-4c43-91aa-8adb7f88ef22">
    <ddiem:uniprotId>P15976</ddiem:uniprotId>
    <ddiem:uniprotId>P46783</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3aff645a-5265-4422-a4f2-d252c7c63523">
        <rdfs:label>RPS10</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6204</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02966</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02917</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4a2ad985-98ca-4536-9d6e-8a6b807686a4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6201</dc:identifier>
        <rdfs:label>RPS7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02868</ddiem:keggEntryId>
    <ddiem:uniprotId>P08708</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2dfb179c-d3d0-463e-964d-99caa4eeccb9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6223</dc:identifier>
        <rdfs:label>RPS19</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02976</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aa90003a-a9ab-4958-98b2-34745e701bcc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6165</dc:identifier>
        <rdfs:label>RPL35A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/da30b622-1447-4a11-9541-eacf92dc83d1">
        <rdfs:label>RPS24</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6229</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02993</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4131d940-270e-4a14-a2ca-4561762dd1d4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6231</dc:identifier>
        <rdfs:label>RPS26</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P39019</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2c9ee877-281a-432e-88e3-f289033312af">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2623</dc:identifier>
        <rdfs:label>GATA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02974</ddiem:keggEntryId>
    <ddiem:uniprotId>P62081</ddiem:uniprotId>
    <rdfs:label>40S ribosomal protein S19</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fccd4431-c764-4f38-bb3d-6b72092bf414">
        <rdfs:label>RPS17</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6218</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eefd920c-1388-430c-a66d-ef005f3e9eec">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6125</dc:identifier>
        <rdfs:label>RPL5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P62854</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e48b64df-b5d8-4ef4-9480-6ab4f779a687">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/and</dc:identifier>
        <rdfs:label>and</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02962</ddiem:keggEntryId>
    <ddiem:uniprotId>P46777</ddiem:uniprotId>
    <ddiem:uniprotId>P62913</ddiem:uniprotId>
    <ddiem:uniprotId>P62847</ddiem:uniprotId>
    <ddiem:uniprotId>P18077</ddiem:uniprotId>
    <ddiem:keggEntryId>K02947</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02932</ddiem:keggEntryId>
    <ddiem:keggEntryId>K09182</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2945aa8b-5e58-4b8a-999f-780d250ac356">
        <rdfs:label>RPL11</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6135</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dbfb6a1a-956e-4fa9-8a38-086858690a7e">
    <ddiem:keggEntryId>K13524</ddiem:keggEntryId>
    <ddiem:ecNumber>2.6.1.19; 2.6.1.22</ddiem:ecNumber>
    <ddiem:uniprotId>P80404</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d6ca18be-d8a3-44d9-b95b-dd46f7d8929c">
        <rdfs:label>ABAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/18</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>GABA-transaminase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2d8b96ee-2a59-4883-b2c8-088917b9a053">
    <ddiem:uniprotId>Q9NVS9</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e7455160-93fc-4af8-bfb4-5da2d32ec8ae">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55163</dc:identifier>
        <rdfs:label>PNPO</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Pyridoxamine 5'-phosphate oxidase</rdfs:label>
    <ddiem:keggEntryId>K00275</ddiem:keggEntryId>
    <ddiem:ecNumber>1.4.3.5</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/62ff5c8e-cdf0-4019-b1d9-c370044345f1">
    <ddiem:ecNumber>2.7.1.32; 2.7.1.82</ddiem:ecNumber>
    <rdfs:label>Choline/ethanolamine kinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1cd419ae-80d8-45bc-883b-c46bbb61b108">
        <rdfs:label>CHKB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1120</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9Y259</ddiem:uniprotId>
    <ddiem:keggEntryId>K14156</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3078f150-b90a-41d9-8bcf-76d7983f7498">
    <rdfs:label>glucokinase-4</rdfs:label>
    <ddiem:keggEntryId>K12407</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ec487ac1-31a4-4655-9b3c-a36646dff03a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2645</dc:identifier>
        <rdfs:label>GCK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.1</ddiem:ecNumber>
    <ddiem:uniprotId>P35557</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b2f024f1-5629-4c72-b0f8-da40c9214fc3">
    <ddiem:keggEntryId>K17547</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H5K3</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.183</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4ba17b95-c9a7-4c80-966f-253892b4d82d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84197</dc:identifier>
        <rdfs:label>POMK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Protein O-mannose kinase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615041">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2913720d-d18b-4f39-981d-d3aa2f206a00">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10329</dc:identifier>
        <rdfs:label>RXYLT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/640</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>640</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/615041</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8a2bc719-4f66-416f-bbda-4131b3c7af62">
    <ddiem:keggEntryId>K05666</ddiem:keggEntryId>
    <rdfs:label>Multidrug resistance protein-2</rdfs:label>
    <ddiem:uniprotId>Q92887</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ec09757c-bb91-4b11-b865-ebe56ace0677">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1244</dc:identifier>
        <rdfs:label>ABCC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>7.6.2.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2c15cd88-da40-425e-a35b-6753324c66ac">
    <rdfs:label>mitochondrial ribosomal protein L44</rdfs:label>
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/69aa418d-2138-43ea-8f4a-56e67e29b660">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/65080</dc:identifier>
        <rdfs:label>MRPL44</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/75571b3f-31f8-4040-a091-1a879b4e9a11">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/847ba465-0fcf-4bf1-a9bb-8682848b861b">
        <rdfs:label>CPS1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1373</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>6.3.4.16</ddiem:ecNumber>
    <ddiem:keggEntryId>K01948</ddiem:keggEntryId>
    <ddiem:uniprotId>P31327</ddiem:uniprotId>
    <rdfs:label>Carbamoyl-phosphate synthase (ammonia</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/97b4cb53-4571-416a-9d62-e5fcc785e595">
    <ddiem:uniprotId>P06737</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2d3dd430-d7e1-47b4-95e0-6a45f2238068">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5836</dc:identifier>
        <rdfs:label>PYGL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <rdfs:label>Glycogen phosphorylase, liver form</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7432a6ab-8f09-4466-80b5-262e596fc835">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3fdce799-b951-475a-9ffa-1367eab9e29d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1188</dc:identifier>
        <rdfs:label>CLCNKB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <rdfs:label>Chloride channel protein ClC-Kb</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/045917d2-fd9d-40ea-9235-661f6e44c6b2">
    <ddiem:keggEntryId>K07953</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9Y6B6</ddiem:uniprotId>
    <rdfs:label>Sar1b protein</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/98019f29-761e-4e34-9a7a-a2097e2785af"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/afa41c13-9ff9-4a90-a3c4-c1056f3b48e0">
    <ddiem:uniprotId>Q8NCR0</ddiem:uniprotId>
    <ddiem:keggEntryId>K09654</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.313</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/da6aeda1-acfd-4341-b30f-6bf35ea5e26d">
        <rdfs:label>B3GALNT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148789</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ae3426af-d2c5-4d4c-a86e-0b99df2d499b">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5f5374c4-80be-4a26-978b-06092b9baab9"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b8d904d-4dbd-4e00-b946-6603109d9ea3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal serum fast ORAC(oxygen reduced absorbance capacity)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5346fc1b-27e5-4deb-ab57-b62f2bac89e4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9af20b93-35c7-4892-93da-634d299acfe4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040088</ddiem:url>
        <rdfs:label>Abnormal lymphocyte counts</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040088</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208900">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/556d62b0-e777-4c37-84b0-73bb91366e83"/>
        <rdfs:label>ATAXIA-TELANGIECTASIA; AT</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/208900</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3e9b8fe6-e44b-417e-b81b-a81ba27f890a">
    <rdfs:label>Methylmalonic aciduria and homocystinuria type D protein, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2bb7cb65-ba53-465e-8ace-0e4c1176ee0b">
        <rdfs:label>MMADHC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27249</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9H3L0</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/1dc62dbd-b760-4c75-9760-a85644ff98d9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac5799d5-cc35-4d20-8974-81ddc715cc9c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ffebcfa-f201-410d-8e07-396d0d529147"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec57f2e9-f607-4061-b4da-0996016f8e79"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3229565</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614202">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/811d7432-fe85-48ad-8520-f10f3892b55c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11253</dc:identifier>
        <rdfs:label>MAN1B1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/614202</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/611</ddiem:iembaseUrl>
    <rdfs:label>MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15; MRT15</rdfs:label>
    <ddiem:iembaseAccessionNumber>611</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3b45ad98-8433-44cc-a718-e07603b6c9cb">
    <ddiem:keggEntryId>K01623</ddiem:keggEntryId>
    <ddiem:ecNumber>4.1.2.13</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/13aca584-7fb2-4aab-af61-2efe2d35873c"/>
    <ddiem:uniprotId>P04075</ddiem:uniprotId>
    <rdfs:label>aldolase, fructose-bisphosphate A</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a0387024-0326-4787-9fa1-48c9a380a51b">
    <ddiem:uniprotId>Q9Y276</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/20ac5ef8-9792-41bb-87ee-4700bd786d96">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/617</dc:identifier>
        <rdfs:label>BCS1L</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>ubiquinol-cytochrome c reductase complex chaperone</rdfs:label>
    <ddiem:keggEntryId>K08900</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6ae4c5bc-cdd6-4e35-9008-82291791b440">
    <obo:RO_0003304>W99L</obo:RO_0003304>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602485">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1289</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ec487ac1-31a4-4655-9b3c-a36646dff03a"/>
        <ddiem:iembaseAccessionNumber>1289</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/602485</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0212c985-f816-47e4-995e-a214d71ae8cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6dc61da4-a737-4ddf-bae4-a604e96eed6b"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3ed02313-776c-4e46-ac45-8b003bf60c8b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2c256e9f-0dc7-495b-ab38-6a4466916586"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ef8dcf73-89d8-48fe-aaef-c603c48bb98d">
    <rdfs:label>d-glycerate kinase</rdfs:label>
    <ddiem:uniprotId>Q8IVS8</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.31</ddiem:ecNumber>
    <ddiem:keggEntryId>K11529</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e6903f96-2582-4e00-b207-313d937b8860">
        <rdfs:label>GLYCTK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/132158</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/728a37eb-3f6e-4059-84f5-92ac45f81d13">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/133fedd3-9df3-4e02-87bc-73023f9564fd"/>
    <rdfs:label>GPI mannosyltransferase 1</rdfs:label>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248510">
    <ddiem:iembaseAccessionNumber>261</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9b6dc838-9e2b-4e8d-a21d-ee54cbf9ef4c">
        <rdfs:label>MANBA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4126</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/248510</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/261</ddiem:iembaseUrl>
  </ddiem:Disease>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_genome_editing">
    <obo:IAO_0000115 xml:lang="en">Modulation of the activity or stability of a genetically defective gene through direct modification of one or both endogenous alleles of the gene, using genome editing techniques such as CRISPR/Cas</obo:IAO_0000115>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by genome editing</rdfs:label>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </owl:Class>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9cfcaa9b-d0d1-4d73-84f6-5bd2866c0a1f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fd805776-08bc-4dc0-9316-0e34ee6c2416"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/69848ed9-d3b0-4a6a-9572-5fab9a84304b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e7626ec7-8215-4f6f-954c-b1c84943d9d1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bec13d4b-5e09-4c4b-a8ec-de298f94426a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <dc:identifier>HP:0000817</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>lack eye-eye contact</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8023faa-087e-4853-9c50-6a90ffa17924">
        <rdfs:label>social interaction defect</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000735</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a360719-e6c1-4d98-ba19-77c78cf8b54e">
        <dc:identifier>HP:0001433</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:label>Hepatosplenomegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55fc960e-0c11-4ab7-9713-b281f4562de0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>episodic behavioral abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0e62d44d-528b-40ec-bafe-4a009807b635">
    <rdfs:label>Beta-mannosidase</rdfs:label>
    <ddiem:keggEntryId>K01192</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.25</ddiem:ecNumber>
    <ddiem:uniprotId>O00462</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9b6dc838-9e2b-4e8d-a21d-ee54cbf9ef4c"/>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7c4099d2-b416-46ef-9275-da3fe78c530a">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2d20a3c7-91b4-4526-9c4b-22e2c4d151ef"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64b9e608-2964-47f9-a936-580660dd975f"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9eae12f2-e388-48e7-9ca5-ac7612ecff9c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0c460244-0065-49fe-8e77-b896df9b051c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2b61387-b1b7-4463-9836-e5ec6d785004"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/24bc152e-f0ae-452a-89af-858f66ba0e3e">
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
    <rdfs:label>prosaposin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2ba5130f-42dc-47eb-9173-78924e3e1a42">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5660</dc:identifier>
        <rdfs:label>PSAP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ac30e48c-fa5e-411f-bf1d-1f17e42dfd25">
    <ddiem:ecNumber>3.1.1.13</ddiem:ecNumber>
    <ddiem:uniprotId>P38571</ddiem:uniprotId>
    <rdfs:label>lysosomal acid lipase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4562c793-acae-4467-971f-dd63bad4b436">
        <rdfs:label>LIPA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3988</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01052</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d140bfcc-5e22-497b-b209-46c4e9325601">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/254632b4-5515-4da5-a1b7-3c48c91d3cd0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1738</dc:identifier>
        <rdfs:label>DLD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
    <rdfs:label>dihydrolipoamide dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/47289f9a-eb55-4762-930b-afaccd968512">
    <ddiem:keggEntryId>K19523</ddiem:keggEntryId>
    <ddiem:uniprotId>Q92523</ddiem:uniprotId>
    <rdfs:label>carnitine O-palmitoyltransferase 1, muscle isoform</rdfs:label>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/16731945-f72e-4cc3-8216-f566c2a4e776">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1375</dc:identifier>
        <rdfs:label>CPT1B</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/efa45e3f-1bb1-4324-828a-f6e1748e1645">
    <rdfs:label>cystathionine gamma-lyase</rdfs:label>
    <ddiem:ecNumber>4.4.1.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K01758</ddiem:keggEntryId>
    <ddiem:uniprotId>P32929</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bf723a27-1a27-4baa-af46-60f12e899773">
        <rdfs:label>CTH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1491</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239510">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/716f860b-931b-410b-9ee3-645aee122431"/>
    <dc:identifier>https://www.omim.org/entry/239510</dc:identifier>
    <rdfs:label>HYPERPROLINEMIA, TYPE II; HYRPRO2</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/38</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>38</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/df264732-d1a1-4805-885b-0d80ca447cb4">
    <ddiem:ecNumber>2.1.1.13</ddiem:ecNumber>
    <rdfs:label>Methionine synthase</rdfs:label>
    <ddiem:keggEntryId>K00548</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dc2e14c3-72b0-400f-ac08-fe380cc91c24">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4548</dc:identifier>
        <rdfs:label>MTR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q99707</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9c9acca5-54da-4884-9f88-ac7d73c103e9">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0f7d451a-d809-4917-b5bb-687965827b1b">
        <rdfs:label>APRT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/353</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P07741</ddiem:uniprotId>
    <ddiem:keggEntryId>K00759</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.2.7</ddiem:ecNumber>
    <rdfs:label>Adenine phosphoribosyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/755cf185-e246-47b0-9f4b-0cebf82ee09b">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/f8826c45-6040-4389-b8ef-56b99ce90527"/>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>Mitochondrially encoded tRNA lysine</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b43c506f-d085-430e-9459-3125f62847b1">
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/13969f6f-b5e8-458d-b2cd-3c70a8e04823">
        <rdfs:label>APOA5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/116519</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
    <rdfs:label>apolipoprotein A5</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b9debe16-4df3-417a-8c50-f3d45918141f">
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <ddiem:uniprotId>P21953</ddiem:uniprotId>
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit beta, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cb877c39-71ac-4134-9698-6ae4ad05207e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/594</dc:identifier>
        <rdfs:label>BCKDHB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00167</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/929563ff-3b50-40a9-9858-e7e2b9e232dc">
    <rdfs:label>Hydroxymethylbilane synthase.</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b91bae08-5eb4-44ee-b073-4ad773325916">
        <rdfs:label>HMBS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3145</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01749</ddiem:keggEntryId>
    <ddiem:uniprotId>P08397</ddiem:uniprotId>
    <ddiem:ecNumber>2.5.1.61</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d175b66d-e065-4fa0-b550-6cca80c74245">
    <rdfs:label>TRIPEPTIDYL PEPTIDASE I</rdfs:label>
    <ddiem:uniprotId>O14773</ddiem:uniprotId>
    <ddiem:keggEntryId>K01279</ddiem:keggEntryId>
    <ddiem:ecNumber>3.4.14.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/79adb2f9-3841-4561-963c-5d98128b826d">
        <rdfs:label>TPP1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1200</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bb87294e-5f6e-4b50-853d-a8addb7c08ac">
    <ddiem:uniprotId>P04424</ddiem:uniprotId>
    <rdfs:label>argininosuccinate lyase</rdfs:label>
    <ddiem:ecNumber>4.3.2.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/caec044e-a0d6-4beb-8300-4f02630456ea">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/435</dc:identifier>
        <rdfs:label>ASL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01755</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5f93be32-d9bd-4823-a767-89511b4df1d3">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4a4753e6-c2da-4f4a-aba7-483733cf6cfd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/14943264-34b9-44b1-a847-03244b8842b1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ab996365-e43c-428b-b15a-6c3b06c63921">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bc586e9d-c82f-4a73-80cd-233048164786"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/986744fb-a8ea-48a3-bda3-f693656608ff">
        <rdfs:label>stenotic coronary atherosclerosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001677</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001677</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05e72a41-a83f-47ba-a5f7-3ca1a0c8df80">
        <dc:identifier>HP:0001681</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>angina pectoris</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001681</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9e22468-7636-46f8-9371-0ef70c0c6488">
        <dc:identifier>HP:0000991</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>xanthomas</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000991</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3f1b5c5e-129b-437d-91c0-ce9c09c6202f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c4af54d5-624e-4ff6-beb7-94f2d075f529">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8869</dc:identifier>
        <rdfs:label>ST3GAL5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UNP4</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.99.9</ddiem:ecNumber>
    <rdfs:label>GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase</rdfs:label>
    <ddiem:keggEntryId>K03370</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/66da1656-61bc-4b7d-9c5e-22702439140f">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/89f43dda-fa23-427e-a77b-68a4c040eb6a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10020</dc:identifier>
        <rdfs:label>GNE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8fdd3961-aa1e-4a82-a0cd-b24f0e53665e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/45909c0a-0e82-4efa-b749-62bc4bf01e3d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/686</dc:identifier>
        <rdfs:label>BTD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>biotinidase</rdfs:label>
    <ddiem:uniprotId>P43251</ddiem:uniprotId>
    <ddiem:keggEntryId>K01435</ddiem:keggEntryId>
    <ddiem:ecNumber>3.5.1.12</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dc555b8a-4682-4764-ad73-c436b32bb49b">
    <ddiem:keggEntryId>K08105</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8NCH0</ddiem:uniprotId>
    <ddiem:ecNumber>2.8.2.35</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c3c6f8ff-917d-400a-8e47-b97899f3374f">
        <rdfs:label>CHST14</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/113189</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Dermatan-4-sulfotransferase-1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8f0c46eb-720c-40c5-b0fd-4576eb2542a1">
    <rdfs:label>MITOCHONDRIAL RIBOSOMAL PROTEIN L44</rdfs:label>
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/69aa418d-2138-43ea-8f4a-56e67e29b660"/>
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/43fd4ac1-04c2-4bea-9752-fbd581dfa298">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d0f97f5e-9645-4ed8-8cba-e72e1dd63afa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/119ae1fb-0617-4107-82cb-1a776bdcf7d3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18381602</dc:provenance>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162300">
        <dc:identifier>https://www.omim.org/entry/162300</dc:identifier>
        <rdfs:label>MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d50d411f-16c1-418d-99b4-00aa76486246"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/33760351-9bac-4d79-af63-f1864e350c3f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ac47c4ee-0fa9-4fa7-bed1-2974ea0ce7db"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26170630</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f11a97a3-87e6-4e06-82e2-946fb872ca83">
        <rdfs:label>neoplastic growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002664</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002664</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/babb0859-42fc-46e1-b0a3-882e7158103a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9a5fd82c-8790-49be-8f05-fc44881e6339">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7036</dc:identifier>
        <rdfs:label>TFR2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>transferrin receptor 2</rdfs:label>
    <ddiem:uniprotId>Q9UP52</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7ec162a8-fdb0-461f-8043-8e46791bef4f">
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
    <rdfs:label>Dihydropteridine reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d5f42cff-6165-48f0-a0b5-b2f3b803d11f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5860</dc:identifier>
        <rdfs:label>QDPR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6dfd5ebf-2eda-4758-b6b7-437f00c2da16">
    <rdfs:label>HMG-CoA lyase</rdfs:label>
    <ddiem:keggEntryId>K01640</ddiem:keggEntryId>
    <ddiem:ecNumber>4.1.3.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c5bbb9b7-a10a-4ae2-a7bc-0824bbe4fc21">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3155</dc:identifier>
        <rdfs:label>HMGCL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P35914</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fe6708d5-e067-40bd-b38e-ae46f211db01">
    <ddiem:uniprotId>P10746</ddiem:uniprotId>
    <ddiem:keggEntryId>K01719</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/62d53f1d-6ece-4706-8eb9-a0de6d3b6bd3">
        <rdfs:label>UROS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7390</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>uroporphyrinogen III synthase</rdfs:label>
    <ddiem:ecNumber>4.2.1.75</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ab5095e7-cece-4d6a-b2d6-66156400136f">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9317abc0-16c0-4985-b4d1-4a6d78fa7593"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f26925c-5562-455c-86d6-a44eb1c0b0c3">
        <rdfs:label>Generalized tonic convulsions</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010818</ddiem:url>
        <dc:identifier>HP:0010818</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/238700">
        <rdfs:comment>Lysine-restricted diet achieved a mild improvement of some signs but did not reverse cognitive impairment. The moderate decrease of plasma lysine concentrations after dietary treatment in the patients supports the need of increase lysine restriction.https://www.ncbi.nlm.nih.gov/pubmed/23890588</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/238700</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d246e1ff-2521-4ae3-8444-50179a6aa921"/>
        <rdfs:label>HYPERLYSINEMIA, TYPE I</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6516bbb4-eaa2-41eb-98aa-3cdc2f03ec4c"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2dd7049b-749e-48b5-b6e7-57c5293cdf34">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4c99fb45-c018-4f5d-9e3d-fc8b2421e598">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6523</dc:identifier>
        <rdfs:label>SLC5A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>sodium/glucose cotransporter protein called SGLT1</rdfs:label>
    <ddiem:uniprotId>P13866</ddiem:uniprotId>
    <ddiem:keggEntryId>K14158</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aaace744-725b-48dd-b007-a646b685752a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/94c1a8a2-2147-44e4-8ba1-899c5ab53da7">
        <rdfs:label>SLC25A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/291</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P12235</ddiem:uniprotId>
    <ddiem:keggEntryId>K05863</ddiem:keggEntryId>
    <rdfs:label>ADP/ATP translocase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ed380270-fa19-42a8-8d59-4652271656b8">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/1baeca24-1eee-49e8-a8f1-e3e260fcbc4e"/>
    <ddiem:uniprotId>Q9P2X0</ddiem:uniprotId>
    <ddiem:keggEntryId>K09659</ddiem:keggEntryId>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 3</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4e411cd3-237d-4d1c-9110-e42af32fa3df">
    <rdfs:label>Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/98dac32e-fa22-4668-beb6-c66a55577eaa">
        <rdfs:label>SLC37A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2542</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K08171</ddiem:keggEntryId>
    <ddiem:uniprotId>O43826</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605637">
    <dc:identifier>https://www.omim.org/entry/605637</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3dc8396e-ef9e-4fea-a3ca-bcad2a9c2b4b">
        <rdfs:label>MYH2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4620</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/06956006-dfe9-4a97-9c82-85a7c9919b5c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7a39dc9a-8d86-41c6-929a-52aac64d1546">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/270</dc:identifier>
        <rdfs:label>AMPD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P23109</ddiem:uniprotId>
    <ddiem:ecNumber>3.5.4.6</ddiem:ecNumber>
    <ddiem:keggEntryId>K01490</ddiem:keggEntryId>
    <rdfs:label>AMP deaminase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/fe34c415-2ec6-4782-a639-c7baa917faaf">
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46548bdd-00e3-42e2-9f2b-49ad41d58efc"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac5799d5-cc35-4d20-8974-81ddc715cc9c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10448086</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e79722b-c7ad-4191-9aee-cc3377b31640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14765544</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3fdd3c41-1338-4de4-97ea-3d4e63e2cb20">
        <rdfs:label>Lactic acidosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <dc:identifier>HP:0003128</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a71a273-c72b-43fa-ba09-fab8045cc438">
        <dc:identifier>HP:0001298</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Encephalopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a26f8f4-238b-4e21-bd0f-eadd3cdd68e6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002572</dc:identifier>
        <rdfs:label>Repeated vomiting</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/57b6b8b3-8058-4cde-9f72-10ad331a7709">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/95c5fca5-b04f-4ded-b798-a7d2be093a6a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:DDIEM_0000012>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/759b049b-9e2f-463d-b471-f037e00dd9ee">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2e5e560f-9599-4a61-a89f-7ef1910e34a8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7018</dc:identifier>
        <rdfs:label>TF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14736</ddiem:keggEntryId>
    <rdfs:label>transferrin</rdfs:label>
    <ddiem:uniprotId>P02787</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/086d96ba-b3ec-4e1d-b343-54e1edf13d96">
    <rdfs:label>guanidinoacetate methyltransferase</rdfs:label>
    <ddiem:uniprotId>Q14353</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/05736fef-e4c4-4d2b-bafe-8b0a83052726">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2593</dc:identifier>
        <rdfs:label>GAMT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.1.1.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K00542</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e693923e-07c6-4abb-bcad-68e471f22a3d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/30519c34-1b00-4f60-800f-517618c557ef">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3081</dc:identifier>
        <rdfs:label>HGD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q93099</ddiem:uniprotId>
    <rdfs:label>Homogentisate 1,2-dioxygenase.</rdfs:label>
    <ddiem:keggEntryId>K00451</ddiem:keggEntryId>
    <ddiem:ecNumber>1.13.11.5</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ccba4d91-245f-415a-a5ba-62fb97bfb90a">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a94bcb4c-d724-4c97-85db-f121cee5e4d1"/>
    <rdfs:label>tissue-nonspecific alkaline phosphatase (TNSALP)</rdfs:label>
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/32e40996-1ce5-454e-9b16-1d186511ff81">
    <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/340d185c-39f7-4626-affd-7691a7dfdf64">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/50f806f7-84b1-4fc1-a63a-3a33ece6a530"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/496af2a4-8ccc-4878-bb7d-5aba54f939ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b7fbc6c8-130d-4ee2-b364-dd369f5101cf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00214604</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02e95bba-0ca1-489c-99a6-4683524ef791">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>hypertriglycernemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b98a64ed-35b9-40f9-8619-88b35e2a06e5">
    <ddiem:uniprotId>Q30201</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3794a8fc-6499-4e2a-837f-e8e088e11afe">
        <rdfs:label>HFE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3077</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Hereditary hemochromatosis protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/59a54de1-1795-4e5f-9890-b4cdc2ac4f9c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bd99069c-3bd7-489a-920d-028a75480a6e">
        <rdfs:label>IDUA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3425</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>iduronidase, alpha-L</rdfs:label>
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c23f888f-5e5c-4583-900b-4d8e00922779">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e077811-6601-471b-b4af-87beea6ad564">
        <dc:identifier>HP:0002174</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002174</ddiem:url>
        <rdfs:label>Postural tremor</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/102ff31a-c1e7-4ab4-abce-2a9646d6681b">
        <dc:identifier>HP:0002067</dc:identifier>
        <rdfs:label>Bradykinesia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002067</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb746efc-9ab2-4fed-b9f8-d5487fadc425">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4ec70ffe-c318-4864-adbe-2a41920ab953"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6289fc90-15a9-4a86-8a90-6af49314e36f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83fcb716-f52e-4a81-a5fc-3aba7f60fd63">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <dc:identifier>HP:0001300</dc:identifier>
        <rdfs:label>parkinsonian symptoms</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2d20a3c7-91b4-4526-9c4b-22e2c4d151ef"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f89c0bc1-1d0b-48c8-bc09-58ac65e10780">
        <rdfs:label>Kinetic tremor</rdfs:label>
        <dc:identifier>HP:0030186</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030186</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ff34a728-1133-4ef8-88c7-a22f592bd3a8">
    <ddiem:uniprotId>P01009</ddiem:uniprotId>
    <ddiem:keggEntryId>K03984</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/967384fd-d3bd-4252-aa8a-fc5225bdd569">
        <rdfs:label>SERPINA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5265</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>alpha-1-antitrypsin (major plasma serine protease inhibitor)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/78148426-406a-4dba-b20a-353cffc0873a">
    <ddiem:keggEntryId>K04612</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1e3388b2-cfdd-420c-aac1-2ff8811e3c1a">
        <rdfs:label>CASR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/846</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>calcium-sensing receptor</rdfs:label>
    <ddiem:uniprotId>P41180</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e3a9ca66-07f0-451e-b8d3-94156840f217">
    <rdfs:label>Twinkle protein, mitochondrial</rdfs:label>
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b7b80e23-9def-4a47-a337-d9976e93ec7c"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/02fafed6-ae02-4ac6-937d-6dca6d6c4f9a">
    <ddiem:ecNumber>1.1.1.35; 1.1.1.51; 1.1.1.178</ddiem:ecNumber>
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase type II</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0539c86a-7208-45bf-ae40-b870c89fdba1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3028</dc:identifier>
        <rdfs:label>HSD17B10</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K08683</ddiem:keggEntryId>
    <ddiem:uniprotId>Q99714</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3ba3effe-922c-4840-a6c9-8fc9feb27486">
    <ddiem:ecNumber>3.5.1.23; 3.5.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K12348</ddiem:keggEntryId>
    <rdfs:label>acid ceramidase</rdfs:label>
    <ddiem:uniprotId>Q13510</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cec1947e-288f-47cb-bdf3-b1b3194567f5">
        <rdfs:label>ASAH1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/427</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230200">
    <ddiem:iembaseAccessionNumber>474</ddiem:iembaseAccessionNumber>
    <rdfs:label>GALACTOKINASE DEFICIENCY</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/02751a4b-5f97-41c4-997e-28786ceb20ab"/>
    <dc:identifier>https://www.omim.org/entry/230200</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/474</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609308">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/899c3945-8096-4de9-ad36-f62164169513">
        <rdfs:label>POMT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10585</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/609308</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b4612887-1786-4b67-8d29-06c528c3de35">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a70dd99-d145-4fe4-abb0-8cfc9f7ddf08">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000939</ddiem:url>
        <dc:identifier>HP:0000939</dc:identifier>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <rdfs:label>Osteoporosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2847ac9e-a635-4a44-919d-d0b0dd66f3fa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a177c6d0-1617-4266-95cc-4255ccbd1b61"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/99b27243-5345-4f9b-86e2-5e274e9fc5c7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/465a73e4-c540-468a-9df5-db1f9c698ae2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/122864f4-a599-46eb-82c3-8ef132fe558c">
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
    <rdfs:label>alpha-L-iduronidase</rdfs:label>
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/bd99069c-3bd7-489a-920d-028a75480a6e"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/79dc3626-ee86-45cc-8ff4-2b674957b53c">
    <ddiem:uniprotId>Q9HAC7</ddiem:uniprotId>
    <rdfs:label>succinate-hydroxymethylglutarate coA-transferase</rdfs:label>
    <ddiem:ecNumber>2.8.3.13</ddiem:ecNumber>
    <ddiem:keggEntryId>K18703</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ef720db8-d282-4336-95b9-e3699f62303a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79783</dc:identifier>
        <rdfs:label>SUGCT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615042">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/604</ddiem:iembaseUrl>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/615042</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>604</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/36d3f5d6-dd66-4a57-8b27-320f1509980d">
        <rdfs:label>DPM2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8818</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/98f02b80-4cda-460b-aadf-664e96648b1b">
    <ddiem:uniprotId>Q13825</ddiem:uniprotId>
    <ddiem:keggEntryId>K05607</ddiem:keggEntryId>
    <ddiem:ecNumber>4.2.1.18; 4.2.1.56</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ece186d0-e074-4774-a683-90d408e04e74">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/549</dc:identifier>
        <rdfs:label>AUH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Methylglutaconyl-CoA hydratase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c6bfc8be-8f42-407b-a7ae-62c5fa31e212">
    <ddiem:keggEntryId>K04635</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bbb76089-05b5-4d7c-8bed-edc92f96102e">
        <rdfs:label>GNA11</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2767</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P29992</ddiem:uniprotId>
    <rdfs:label>guanine nucleotide-binding protein (Gα11)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d8b319bf-6df0-4717-89c6-6f2149f28b7b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90093156-8fe8-4cb3-9361-d9b116448f6d">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:label>Cognitive impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b246b39f-948d-4966-892a-dda55610a32d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000967</ddiem:url>
        <rdfs:label>Petechiae</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000967</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac5799d5-cc35-4d20-8974-81ddc715cc9c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d1599a3-f6f5-439e-ac2d-f95982150adb">
        <dc:identifier>HP:0025356</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025356</ddiem:url>
        <rdfs:label>Psychomotor retardation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916321</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c200ffdf-5bbf-46c7-8d29-e089a1cfc5cc">
        <dc:identifier>HP:0004302</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Functional motor deficit</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/924948a3-6847-4f56-b4f8-d8b0709a5894">
        <rdfs:label>Chronic mucoid diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
        <dc:identifier>HP:0002028</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b9aaa36-d5d0-4030-ad3d-175bff1cfb2b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0045045</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
        <rdfs:label>Elevated plasma acylcarnitine levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_epigenetic_manipulation">
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <obo:IAO_0000115 xml:lang="en">Modulation of the level or specificity of expression of a genetically defective gene through modification of an epigenetic mark or process using chemical, biological or genetic means.</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by epigenetic manipulation</rdfs:label>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/091d671a-7639-4dd0-9588-9fd8161a6084">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cd9d0243-65de-4227-89b0-c346793f5c5c">
        <rdfs:label>ETHE1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23474</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K17725</ddiem:keggEntryId>
    <ddiem:uniprotId>O95571</ddiem:uniprotId>
    <rdfs:label>persulfide dioxygenase</rdfs:label>
    <ddiem:ecNumber>1.13.11.18</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/327784b5-4399-46d6-a3c7-70d4cdf5448b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/02ebf93c-547f-4769-b588-8afad3cfc329">
        <rdfs:label>GK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2710</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glycerol kinase</rdfs:label>
    <ddiem:keggEntryId>K00864</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.30</ddiem:ecNumber>
    <ddiem:uniprotId>P32189</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d7d49ea3-4671-4d30-a700-c0711708f515">
    <ddiem:ecNumber>1.5.5.2</ddiem:ecNumber>
    <rdfs:label>proline dehydrogenase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d24b17e9-3357-4a59-9ff0-b083ac836502">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5625</dc:identifier>
        <rdfs:label>PRODH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O43272</ddiem:uniprotId>
    <ddiem:keggEntryId>K00318</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/39f10b29-fb77-4290-9d0f-621aa7dcc3c3">
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/89395895-aff0-49be-a9e8-3586ba5fba2a">
        <rdfs:label>SLC35C1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55343</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
    <rdfs:label>guanosine 5'-diphosphate (GDP)-fucose transporter</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/36da3f85-d00d-4e77-b2f0-1eab07ffa521">
    <ddiem:uniprotId>P26440</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f0e24a9d-c416-45d5-830f-f4aaabd7ae5e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3712</dc:identifier>
        <rdfs:label>IVD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>isovaleryl-CoA dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.3.8.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K00253</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0e90802f-55d9-407b-ad55-af669607ff97">
    <ddiem:uniprotId>O75845</ddiem:uniprotId>
    <ddiem:ecNumber>1.14.19.20</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/904c6b0c-8257-420c-bc0b-96d0d70e5b06">
        <rdfs:label>SC5D</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6309</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00227</ddiem:keggEntryId>
    <rdfs:label>3-beta-hydroxysteroid-delta-5-desaturase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/f428de76-e953-436d-bb95-bce5733b5d52">
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc66167c-7869-4114-8874-5ea46ca7e768"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6ebc84ad-37ff-46ef-a428-1022d881d367">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f8b3d1df-d76d-4ff2-818e-3962c04aa8d3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51d39d68-6920-4a39-85ad-1aab1121e6ee">
        <rdfs:label>Disease progression (Progressive)</rdfs:label>
        <dc:identifier>HP:0003676</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/99b27243-5345-4f9b-86e2-5e274e9fc5c7"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aa66b013-56bd-40ce-9b4c-2bf75a4e28d4"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/200100">
        <rdfs:comment>The mainstays of treatment include adherence to a low-fat diet, and supplementation with essential fatty acids and high oral doses of fat soluble vitamins. https://www.ncbi.nlm.nih.gov/pubmed/24288038</rdfs:comment>
        <rdfs:label>ABETALIPOPROTEINEMIA; ABL</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/371</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4145fe8d-a18c-4b44-a537-dee9f109d019"/>
        <dc:identifier>https://www.omim.org/entry/200100</dc:identifier>
        <ddiem:iembaseAccessionNumber>371</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5296b6d3-94cf-496b-9f0f-851435fed790"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000011>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/550500">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MYOGLOBINURIA, RECURRENT</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aadcab51-2b8c-48d7-9c8d-eb3f8896eb6a">
        <rdfs:label>MT-CO3</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO3</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/550500</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/16974c24-405d-4c0c-b606-79d2acd4a4aa">
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/2ba5130f-42dc-47eb-9173-78924e3e1a42"/>
    <rdfs:label>Prosaposin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/20e49253-b58c-4980-bbac-7c642d8579f6">
    <ddiem:keggEntryId>K19480</ddiem:keggEntryId>
    <rdfs:label>anoctamin 5</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3a51f0ad-e4f0-441a-80e7-605c835920d6"/>
    <ddiem:uniprotId>Q75V66</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/71774b62-266a-4b5d-b4d2-d0561cb35a43">
    <ddiem:keggEntryId>K01689</ddiem:keggEntryId>
    <rdfs:label>enolase 3</rdfs:label>
    <ddiem:ecNumber>4.2.1.11</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5133eba0-47d4-4314-9dc0-19204a90bbe2"/>
    <ddiem:uniprotId>P13929</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/179850">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ab0e5d05-1f7f-4679-ac9b-ea0b6ebcef60"/>
    <dc:identifier>https://www.omim.org/entry/179850</dc:identifier>
    <rdfs:label>DOWLING-DEGOS DISEASE 1; DDD1</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615249">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4ba17b95-c9a7-4c80-966f-253892b4d82d"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1122</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1122</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/615249</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/creator"/>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/51430b06-5ae8-4462-b3e3-08c1f67764f3">
    <ddiem:uniprotId>Q04656</ddiem:uniprotId>
    <ddiem:ecNumber>7.2.2.8</ddiem:ecNumber>
    <rdfs:label>Copper-transporting ATPase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e76c72e6-eccc-42a1-adc0-80dfead8c7f2">
        <rdfs:label>ATP7A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/538</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K17686</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1cdab3a4-c4d0-4558-9a73-684b9734d340">
    <ddiem:keggEntryId>K10808</ddiem:keggEntryId>
    <ddiem:ecNumber>1.17.4.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3f3c7aa0-7598-486c-b7ce-8a66d5ceff70">
        <rdfs:label>RRM2B</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50484</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q7LG56</ddiem:uniprotId>
    <rdfs:label>Ribonucleoside-diphosphate reductase subunit M2 B</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/df25a61c-248b-4c81-a77b-a2893e7c4052">
    <ddiem:ecNumber>1.14.14.19; 1.14.14.32</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d5e675a0-0b5f-4965-b99d-b9288f6f3d7d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1586</dc:identifier>
        <rdfs:label>CYP17A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Steroid 17-alpha-hydroxylase</rdfs:label>
    <ddiem:keggEntryId>K00512</ddiem:keggEntryId>
    <ddiem:uniprotId>P05093</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/57e38dc2-bf91-4696-bfca-02aed197ad07">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162000">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1405</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a03d807b-0120-4e15-a52e-0b5c23bafc82"/>
        <rdfs:label>HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/162000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1405</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3c332815-b641-4cee-a3a9-9217f1e3be0b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d6e8190c-0fbc-4e44-9871-6c64e87253f7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8ad89e8-e71a-435b-b3f7-1ecc7a9ab0c6">
        <dc:identifier>done</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperurecemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/243ed329-3a10-4833-8292-10f2c0378134">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/503cb4ad-af94-4661-b115-a0cb51d7e86e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6cfa6681-7c56-4396-bf05-7c456a144273">
    <ddiem:ecNumber>3.2.1.113</ddiem:ecNumber>
    <ddiem:keggEntryId>K01230</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UKM7</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/811d7432-fe85-48ad-8520-f10f3892b55c"/>
    <rdfs:label>mannosidase alpha class 1B member 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6d44426f-b256-4405-906d-99ceb233b7da">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0049ebe7-c3eb-4602-b0a1-49ad2ccbd5e0">
        <rdfs:label>FA2H</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79152</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.18.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q7L5A8</ddiem:uniprotId>
    <ddiem:keggEntryId>K19703</ddiem:keggEntryId>
    <rdfs:label>fatty acid 2-hydroxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616479">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fb5b9b20-8986-4c0c-b7e7-0d439226a27c"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 2; PEOB2</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/616479</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0dc3a91d-21ca-489d-aa58-4792ae180f25">
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/8a16ae66-a016-45fb-87ed-bc04e623e5c6"/>
    <rdfs:label>Phospholipase A(2)</rdfs:label>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c59ebf74-7b17-4302-9ce8-250f663b6d49">
    <ddiem:keggEntryId>K01476</ddiem:keggEntryId>
    <rdfs:label>Arginase</rdfs:label>
    <ddiem:ecNumber>3.5.3.1</ddiem:ecNumber>
    <ddiem:uniprotId>P05089</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4e83f30f-c993-4567-b762-39495f94b593">
        <rdfs:label>ARG1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/383</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ae097a1d-87ed-4b26-bcde-4497bb91758c">
    <rdfs:label>methylenetetrahydrofolate reductase</rdfs:label>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/133cda4f-2ec8-4686-a9c7-a6d97e1052a3">
        <rdfs:label>MTHFR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4524</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614830">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2f685b6f-9e60-44e5-8607-ee01318288ef">
        <rdfs:label>POMGNT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84892</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1120</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1120</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/614830</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ed4dbc9b-9674-466b-b674-57b4ece72e14">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7f207302-4759-4193-96ac-99f45da9d80c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9382</dc:identifier>
        <rdfs:label>COG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>component of oligomeric golgi complex 1</rdfs:label>
    <ddiem:uniprotId>Q8WTW3</ddiem:uniprotId>
    <ddiem:keggEntryId>K20288</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fb325f96-11cb-417a-8f91-6faede5f2997">
    <rdfs:label>dolichol-P-mannose synthase 1</rdfs:label>
    <ddiem:uniprotId>O60762</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/204236a2-7529-465f-a0da-ecba40a7f2e3"/>
    <ddiem:ecNumber>2.4.1.83</ddiem:ecNumber>
    <ddiem:keggEntryId>K00721</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b1d4af98-9582-4da9-9bd2-aa34a15db95a">
    <rdfs:label>Phosphatidylinositol N-acetylglucosaminyltransferase subunit A</rdfs:label>
    <ddiem:uniprotId>P37287</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.198</ddiem:ecNumber>
    <ddiem:keggEntryId>K03857</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9a37a2d2-872f-4547-9cf0-8a91ef76a95a"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/42f0c55f-fe8d-402c-8ff2-e7b4364eb5ef">
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/25c33b37-04f5-44c5-88cb-f7b0784187e1"/>
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
    <rdfs:label>GTP cyclohydrolase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ffac9b8b-3bb9-4179-bc80-9d7dbf0e6264">
    <rdfs:label>Folate receptor alpha</rdfs:label>
    <ddiem:keggEntryId>K13649</ddiem:keggEntryId>
    <ddiem:uniprotId>P15328</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1832d378-b7ee-453d-8fbb-e216f1cceee1">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2348</dc:identifier>
        <rdfs:label>FOLR1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/536f52db-79cd-48a2-9e67-cbfcb8298fc4">
    <ddiem:ecNumber>1.1.99.2</ddiem:ecNumber>
    <rdfs:label>L-2-hydroxyglutarate dehydrogenase.</rdfs:label>
    <ddiem:keggEntryId>K00109</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9H9P8</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/08e79c95-d0c9-43bf-896a-5eb8fbb7d852">
        <rdfs:label>L2HGDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79944</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/285452dd-4698-46ba-85d7-53dc962ea87a">
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 4</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7d29a6a3-6974-4eb7-bd9f-d55adef8c65a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>MT-ND4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/68406991-c847-49d0-9a30-21c431b049df">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/43b5034a-74c2-4d2a-af72-d6993ad813ba">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>GIF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>gastric intrinsic factor</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4e29916b-6867-451b-8d2e-ac642cb34b08">
    <ddiem:uniprotId>Q15392</ddiem:uniprotId>
    <ddiem:keggEntryId>K09828</ddiem:keggEntryId>
    <rdfs:label>3-beta-hydroxysterol delta-24-reductase</rdfs:label>
    <ddiem:ecNumber>1.3.1.72</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/02490355-db2e-4680-8348-f329b005cb64">
        <rdfs:label>DHCR24</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1718</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b4299da2-daaa-4f0b-b619-40266f19af23">
    <rdfs:label>quinoid dihydropteridine reductase</rdfs:label>
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/d5f42cff-6165-48f0-a0b5-b2f3b803d11f"/>
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/63604983-f7c5-460f-bf6f-07cee8c4a714">
    <ddiem:ecNumber>4.1.1.28</ddiem:ecNumber>
    <rdfs:label>Aromatic-L-amino-acid decarboxylase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/923036a4-0769-4232-9b38-7c4271e5dcea">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1644</dc:identifier>
        <rdfs:label>DDC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01593</ddiem:keggEntryId>
    <ddiem:uniprotId>P20711</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5e7669c5-e40f-4387-b356-3969c102899e">
    <rdfs:label>GDP-fucose transporter 1</rdfs:label>
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/89395895-aff0-49be-a9e8-3586ba5fba2a"/>
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/02a6b13e-8f7b-4462-80a9-7e7636ae732c">
    <rdfs:label>Frataxin, mitochondrial</rdfs:label>
    <ddiem:uniprotId>Q16595</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dc4b2119-8642-4d2f-bec2-6602ac2e733c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2395</dc:identifier>
        <rdfs:label>FXN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K19054</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0d8f4329-9a29-41f9-8c78-fdaf42358358">
    <ddiem:uniprotId>Q00266</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7370ffb9-dd4a-4c62-84c6-e95e322c8b09">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4143</dc:identifier>
        <rdfs:label>MAT1A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.5.1.6</ddiem:ecNumber>
    <rdfs:label>S-adenosylmethionine synthase isoform type-1</rdfs:label>
    <ddiem:keggEntryId>K00789</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2e0ae805-d502-4d7d-8a9f-6d038d5a2c87">
    <ddiem:keggEntryId>K00902</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UPQ8</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2953128e-bcb8-4afc-8add-a0ad11e9d4bc">
        <rdfs:label>DOLK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/22845</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dolichol kinase</rdfs:label>
    <ddiem:ecNumber>2.7.1.108</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6555ba9c-fe7f-4d0e-9d37-599008fe7825">
    <ddiem:uniprotId>Q09428</ddiem:uniprotId>
    <rdfs:label>ATP binding cassette subfamily C member 8</rdfs:label>
    <ddiem:keggEntryId>K05032</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d9e8cf1c-17c6-44a8-ad22-9b9107eec857">
        <rdfs:label>ABCC8</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6833</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2827cb1d-8870-4424-abf9-5b2952446c83">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/017bb7b9-8203-42bb-b2e7-3370a5124308">
        <rdfs:label>LARGE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>LARGE xylosyl- and glucuronyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4379a88f-2e26-48ad-9474-d0fde5502786">
    <rdfs:label>alpha-galactosidase A</rdfs:label>
    <ddiem:ecNumber>3.2.1.22</ddiem:ecNumber>
    <ddiem:uniprotId>P06280</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a62edb38-d4d8-4466-9625-438e9c401b84">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2717</dc:identifier>
        <rdfs:label>GLA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01189</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1c2e39a1-4246-43e6-8c5b-2d9fe3ef8567">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b05a3e90-e2ba-4638-9eb9-6d3cee066d3d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54982</dc:identifier>
        <rdfs:label>CLN6</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>CLN6, transmembrane ER protein</rdfs:label>
    <ddiem:uniprotId>Q9NWW5</ddiem:uniprotId>
    <ddiem:keggEntryId>K12359</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dfdd1438-8cfe-4b92-a00c-071f04efa082">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ca2266be-5027-4717-812b-73991154d1ac">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10916</dc:identifier>
        <rdfs:label>MAGED2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Melanoma-associated antigen D2</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UNF1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/91b87f38-8aa1-4857-8522-90baeb317579">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/13969f6f-b5e8-458d-b2cd-3c70a8e04823"/>
    <rdfs:label>Apolipoprotein A-V</rdfs:label>
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/77a7ec0c-e6c3-4e55-9ae8-92c49279de34">
    <rdfs:label>protein O-mannosyltransferase 1</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/899c3945-8096-4de9-ad36-f62164169513"/>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2365c876-b17e-4b7e-8127-22db9dc66491">
    <ddiem:ecNumber>4.1.1.9</ddiem:ecNumber>
    <rdfs:label>malonyl-CoA decarboxylase</rdfs:label>
    <ddiem:keggEntryId>K01578</ddiem:keggEntryId>
    <ddiem:uniprotId>O95822</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bcde1144-2102-4d29-9b88-480e7835745a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23417</dc:identifier>
        <rdfs:label>MLYCD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/273d7401-4f65-456e-8510-4f64002a7f07">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3389144</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/698d32ca-e3b8-45aa-bbef-890811bc86a4"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67225409-5535-4740-96e9-75249fc044f9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001896</ddiem:url>
        <dc:identifier>HP:0001896</dc:identifier>
        <rdfs:label>Reticulocytopenia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1546717</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2503027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dfeeb20d-52da-4104-9757-6ead1ef98e11">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13119275-e491-49b6-90bf-e1d668899621"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/613f3ae9-cb61-495f-8920-34d57ad9525c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27329125</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6b6ded75-3917-4d88-8f1e-99d03bf73465">
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/bc50df2e-ece5-4281-a67a-389034aaffb8"/>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <rdfs:label>fukutin-related protein (FKRP)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0e8789c0-6d66-42db-9955-dfa77afcf8a0">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/41299985-4d17-40fb-beb7-52766e835cc9"/>
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
    <rdfs:label>cytochrome c oxidase assembly factor</rdfs:label>
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e03008fa-b26d-4957-b68d-3b353b6ff8ee">
    <rdfs:label>Deoxyguanosine kinase, mitochondrial</rdfs:label>
    <ddiem:ecNumber>2.7.1.113</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a0823f39-d254-42c5-8dd7-a15b1fc2daca">
        <rdfs:label>DGUOK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1716</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16854</ddiem:uniprotId>
    <ddiem:keggEntryId>K00904</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b3fc0c7c-c2da-4c72-b079-59a71fca7f43">
    <rdfs:label>Proto-oncogene tyrosine-protein kinase receptor Ret</rdfs:label>
    <ddiem:ecNumber>2.7.10.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K05126</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d50d411f-16c1-418d-99b4-00aa76486246">
        <rdfs:label>RET</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5979</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P07949</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/99d3d39d-388d-4ac4-818f-2d1ddc78476a">
    <ddiem:uniprotId>Q9NRA2</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/14bb194f-3521-472d-9bab-4f9565633c4a">
        <rdfs:label>SLC17A5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/26503</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>solute carrier family 17 member 5</rdfs:label>
    <ddiem:keggEntryId>K12301</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600627">
    <rdfs:comment>Hypertryptophanemia should be regarded as a benign condition</rdfs:comment>
    <rdfs:label>HYPERTRYPTOPHANEMIA; HYPTRP</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/600627</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e2d30fa5-1f6e-4370-bc30-da1ada9b161b"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/618</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>618</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d7dcd97e-1209-48b8-aee7-97bb4b960d30">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/89d4a413-c604-4f4a-aaf3-51662d17adaf">
        <rdfs:label>LMNA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4000</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12641</ddiem:keggEntryId>
    <ddiem:uniprotId>P02545</ddiem:uniprotId>
    <rdfs:label>lamins ( Lamins A and C)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611209">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7f207302-4759-4193-96ac-99f45da9d80c"/>
    <dc:identifier>https://www.omim.org/entry/611209</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/344</ddiem:iembaseUrl>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G</rdfs:label>
    <ddiem:iembaseAccessionNumber>344</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616896">
    <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 14 (CARDIOENCEPHALOMYOPATHIC TYPE); MTDPS14</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/64bcc262-f1b5-41dc-9ca7-f192077fd531"/>
    <dc:identifier>https://www.omim.org/entry/616896</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/07dabc6d-fd3a-4a8a-ace0-7a982d486b4d">
    <ddiem:uniprotId>P54259</ddiem:uniprotId>
    <rdfs:label>atrophin 1</rdfs:label>
    <ddiem:keggEntryId>K05626</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eb517cbd-1259-4be1-8430-ae8dcec95805">
        <rdfs:label>ATN1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1822</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1792f6a3-3fd4-491d-b9b4-7523c9b73e42">
    <ddiem:uniprotId>P61457</ddiem:uniprotId>
    <rdfs:label>pterin-4 alpha-carbinolamine dehydratase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3e1aec0a-65e3-4405-8bfa-60c379534827">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5092</dc:identifier>
        <rdfs:label>PCBD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.2.1.96</ddiem:ecNumber>
    <ddiem:keggEntryId>K01724</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7be6b439-3aeb-4508-84d8-1cbcce7a3547">
    <ddiem:uniprotId>P06132</ddiem:uniprotId>
    <ddiem:keggEntryId>K01599</ddiem:keggEntryId>
    <ddiem:ecNumber>4.1.1.37</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/768676e7-3a09-4df8-b201-b61ab3b16b9b">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/HEF</dc:identifier>
        <rdfs:label>HEF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a7c0af19-7b41-4eac-9d15-7bab3762c118">
        <rdfs:label>UROD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7389</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2607ea64-3d1f-4169-9ad3-e608ade98a45">
    <rdfs:label>Thymidine kinase 2, mitochondrial</rdfs:label>
    <ddiem:uniprotId>O00142</ddiem:uniprotId>
    <ddiem:keggEntryId>K00857</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6a16c836-dc7b-4a33-b14b-b6a2064a7a85">
        <rdfs:label>TK2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7084</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.21</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/64c5eb1f-a61a-4ac8-bed1-88fe1ec7bc7f">
    <ddiem:ecNumber>3.1.2.22</ddiem:ecNumber>
    <ddiem:keggEntryId>K01074</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4eb334f1-b852-4519-afda-8471b9659248">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5538</dc:identifier>
        <rdfs:label>PPT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>PALMITOYL-PROTEIN THIOESTERASE</rdfs:label>
    <ddiem:uniprotId>P50897</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/19756863-a3df-4773-9c72-aabd3215ad33">
    <ddiem:uniprotId>Q8NAT1</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/2f685b6f-9e60-44e5-8607-ee01318288ef"/>
    <ddiem:ecNumber>2.4.1.312</ddiem:ecNumber>
    <ddiem:keggEntryId>K18207</ddiem:keggEntryId>
    <rdfs:label>Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162350">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/309</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/162350</dc:identifier>
    <ddiem:iembaseAccessionNumber>309</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e860c095-6120-4a4e-94d0-9f82cb52a987"/>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/272200">
    <rdfs:label>MULTIPLE SULFATASE DEFICIENCY; MSD</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/301</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/22f440a4-5df9-4d66-b36c-45fc258afd93">
        <rdfs:label>SUMF1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/285362</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/272200</dc:identifier>
    <ddiem:iembaseAccessionNumber>301</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3b80ce06-68c2-4094-811e-94f6fc397eba">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/254632b4-5515-4da5-a1b7-3c48c91d3cd0"/>
    <rdfs:label>Dihydrolipoyl dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/632b5d82-52cb-4d84-8ce5-77b5d3f1bfb8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5e5b0eb9-3d28-465c-9a7c-4d9fb5950c17">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9056</dc:identifier>
        <rdfs:label>SLC7A7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UM01</ddiem:uniprotId>
    <ddiem:keggEntryId>K13867</ddiem:keggEntryId>
    <rdfs:label>Y+L amino acid transporter 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8ffe3f67-8091-4274-a74d-5ba35a98254d">
    <ddiem:keggEntryId>K01556</ddiem:keggEntryId>
    <ddiem:uniprotId>Q16719</ddiem:uniprotId>
    <ddiem:ecNumber>3.7.1.3</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/742fe0f7-37aa-4017-9192-b075cbc0c281">
        <rdfs:label>KYNU</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8942</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>kynureninase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d01e6368-51ee-48c2-8e1b-2f165313e659">
    <ddiem:ecNumber>1.8.3.7</ddiem:ecNumber>
    <ddiem:keggEntryId>K13444</ddiem:keggEntryId>
    <rdfs:label>Formylglycine-generating enzyme</rdfs:label>
    <ddiem:uniprotId>Q8NBK3</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/22f440a4-5df9-4d66-b36c-45fc258afd93"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a9c4e3b9-e555-468e-9ffd-a3475f3afb5a">
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
    <rdfs:label>Methylenetetrahydrofolate reductase</rdfs:label>
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/133cda4f-2ec8-4686-a9c7-a6d97e1052a3"/>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/44355d2b-02fd-4c81-be24-4c1c6d359c9e">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/299cb842-d0c6-4f88-bcb3-49fc71249e2f"/>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
    <rdfs:label>Tyrosine hydroxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/77c422a1-ef12-4e29-9489-ead07d98ca87">
    <ddiem:keggEntryId>K12389</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4c94be1a-9f11-4b65-87e6-133ce8f588e4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1201</dc:identifier>
        <rdfs:label>CLN3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q13286</ddiem:uniprotId>
    <rdfs:label>battenin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/70657f23-7d5e-452a-b121-7800b72894c9">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/62f00518-af54-47e0-94db-d088d324cd5f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1075</dc:identifier>
        <rdfs:label>CTSC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Dipeptidyl peptidase 1</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215140">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a01f0e38-2474-4fc1-9723-ba689a93919c"/>
    <rdfs:label>GREENBERG DYSPLASIA; GRBGD</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/197</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>197</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/215140</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/801f065a-70ed-4ea0-8d8d-9e997a19b991">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/2913720d-d18b-4f39-981d-d3aa2f206a00"/>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Ribitol-5-phosphate xylosyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/baef3fee-3d41-4b1d-8b82-1874a0086dd4">
    <ddiem:keggEntryId>K11538</ddiem:keggEntryId>
    <rdfs:label>isobutyryl-CoA dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.3.8.-</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/742a6b15-d92f-4e1a-85df-9ab84bfb1e31">
        <rdfs:label>ACAD8</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27034</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UKU7</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000014">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure to mitigate the immediate or future effects of the presence of a genetically defective protein which involves physical conditioning or anatomical modification.[PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:30+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <rdfs:label xml:lang="en">surgical or physical treatment procedure</rdfs:label>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/27042178-f3a6-439a-ae42-e32ef6399eb0">
    <ddiem:uniprotId>P43005</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5ff1c241-bba1-4ed4-9fd6-bdcddc58fd36"/>
    <ddiem:keggEntryId>K05612</ddiem:keggEntryId>
    <rdfs:label>Excitatory amino acid transporter 3</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a46c902e-f40b-47ff-8926-3d677f1313ac">
    <ddiem:uniprotId>P20933</ddiem:uniprotId>
    <rdfs:label>N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/053868a4-b29c-41de-9327-cc91f3926cfe">
        <rdfs:label>AGA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/175</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.5.1.26</ddiem:ecNumber>
    <ddiem:keggEntryId>K01444</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a9dfe0ba-48a5-4452-8796-0cb238cf4fe8">
    <ddiem:keggEntryId>K07299</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4194cb8f-7fc2-452d-b747-10585a0121ba">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6513</dc:identifier>
        <rdfs:label>SLC2A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glucose transporter protein type 1 (GLUT1)</rdfs:label>
    <ddiem:uniprotId>P11166</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/846bac6a-c83b-4252-a71c-99985f95d6b8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b4dfcf7b-ce23-45d7-866d-80ee354c4e5e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8291</dc:identifier>
        <rdfs:label>DYSF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dysferlin</rdfs:label>
    <ddiem:keggEntryId>K18261</ddiem:keggEntryId>
    <ddiem:uniprotId>O75923</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/72165b16-e43d-4db6-8ed9-66c82f5138db">
    <ddiem:keggEntryId>K01099</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c9fa1cb3-ff45-402b-b421-2cfe43808e50">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4952</dc:identifier>
        <rdfs:label>OCRL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>inositol polyphosphate 5-phosphatase OCRL-1</rdfs:label>
    <ddiem:uniprotId>Q01968</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.3.36; 3.1.3.56; 3.1.3.86</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f18c00f7-6965-4575-ad93-578d2d898e11">
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <rdfs:label>fukutin</rdfs:label>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/92ec04de-1c6c-465e-b043-7c89dab1248f"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/95081adf-ff57-4952-8a2e-2fa7345220f4">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a03d807b-0120-4e15-a52e-0b5c23bafc82">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7369</dc:identifier>
        <rdfs:label>UMOD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>uromodulin</rdfs:label>
    <ddiem:uniprotId>P07911</ddiem:uniprotId>
    <ddiem:keggEntryId>K18274</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/52f1c48c-9b66-41bd-9ec2-a0cec28a5994">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eecff73d-cb0b-4b4f-9b9d-ce2c8a01c3b9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>GALT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>beta-1,4-galactosyl transferase.</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b03aae81-4e02-4d0a-8562-a0008444bb84">
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/aa357bc2-b9d3-4de1-b961-44ca7ef23506"/>
    <rdfs:label>Aldo-keto reductase family 1 member D1</rdfs:label>
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/252500">
    <ddiem:iembaseAccessionNumber>299</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/299</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f9782f66-be62-441b-9c3c-0bdfb1dc8432"/>
    <rdfs:label>MUCOLIPIDOSIS II ALPHA/BETA</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/252500</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f5df4f7c-1340-44ec-90f2-e61a28cbfc04">
    <ddiem:uniprotId>P09172</ddiem:uniprotId>
    <ddiem:keggEntryId>K00503</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5fe04698-01ac-4a02-b46a-1d0725a5346f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1621</dc:identifier>
        <rdfs:label>DBH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.17.1</ddiem:ecNumber>
    <rdfs:label>dopamine beta (β)-hydroxylase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222748">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a6b68d00-3676-472f-95f7-f93be6128069"/>
    <ddiem:iembaseAccessionNumber>268</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/222748</dc:identifier>
    <rdfs:label>DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/268</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/92514d91-6d06-4923-a5f0-b14a24e61ba3">
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K09666</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8WZA1</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ad425382-3c33-426d-9ffe-48a36e92a35f">
        <rdfs:label>POMGNT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55624</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4ce68b06-03bc-4116-be13-c467f3aa8116">
    <ddiem:keggEntryId>K01697</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d0d85712-2a76-4d48-86ed-1a3b8f170ddb">
        <rdfs:label>CBS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/875</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>cystathionine beta-synthase</rdfs:label>
    <ddiem:uniprotId>P35520</ddiem:uniprotId>
    <ddiem:ecNumber>4.2.1.22</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0269f1a8-a0e4-4f48-affe-a5469bc4a62d">
    <rdfs:label>Cytochrome c oxidase subunit 1/Cytochrome c oxidase subunit 2/Cytochrome c oxidase subunit 3</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b8e26b82-3399-450a-9d35-10df1351327d">
        <rdfs:label>MT-CYB</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CYB</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/aadcab51-2b8c-48d7-9c8d-eb3f8896eb6a"/>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8ac3cd36-a840-488a-b5f3-69cce86a3fc8">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO1</dc:identifier>
        <rdfs:label>MT-CO1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e787f505-1fe9-4af1-ab3e-084f22bcc3a4">
    <rdfs:label>Aprataxin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/efa27a7e-30fa-4493-9f7d-8b2bdad62f9b">
        <rdfs:label>APTX</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54840</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K10863</ddiem:keggEntryId>
    <ddiem:uniprotId>Q7Z2E3</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.11.7; 3.1.12.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/884458d0-bc7b-4ee7-a577-587041619630">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/06a5319a-a75f-482c-9458-11864f148605">
        <rdfs:label>GLUD1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2746</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.4.1.3</ddiem:ecNumber>
    <ddiem:uniprotId>P00367</ddiem:uniprotId>
    <rdfs:label>Glutamate dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K00261</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b6fd7246-ae4e-4bb2-8cb7-62b5d215d0ba">
    <ddiem:uniprotId>P10619</ddiem:uniprotId>
    <ddiem:keggEntryId>K13289</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7873fb18-7572-4fe7-b65b-85d07594eaca">
        <rdfs:label>CTSA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5476</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.4.16.5</ddiem:ecNumber>
    <rdfs:label>Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5c2ec3d1-9780-4170-b487-718a9b7c87ae">
    <ddiem:uniprotId>Q9UKX2</ddiem:uniprotId>
    <ddiem:keggEntryId>K10352</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3dc8396e-ef9e-4fea-a3ca-bcad2a9c2b4b"/>
    <rdfs:label>myosin heavy chain 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d69a4768-8581-4dd6-b370-3877c9da450c">
    <rdfs:label>sodium chloride co-transporter/ chloride channel called ClC-Kb</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3fdce799-b951-475a-9ffa-1367eab9e29d"/>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <ddiem:keggEntryId>K14426</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6c01b1cd-798a-4cbc-8002-ea69826437b4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6559</dc:identifier>
        <rdfs:label>SLC12A3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P55017</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5452cdb2-1306-4070-97c0-ded35f1bc658">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/892699f3-d486-4cb2-89d1-b06121448607"/>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/19f0b135-4267-4064-9a38-86520daf5f1e">
        <rdfs:label>MT-ND4L</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND4L</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9f49626f-8939-413c-a2ff-b4be64774004"/>
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 1/mitochondrially encoded NADH 4L dehydrogenase/ mitochondrially encoded NADH dehydrogenase 6</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1b2b16df-6ea3-408a-a0f7-a590951af49e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/57822836-cd02-405a-9a15-bff1b505f801">
        <rdfs:label>NAGA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4668</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>alpha-N-acetylgalactosaminidase</rdfs:label>
    <ddiem:keggEntryId>K01204</ddiem:keggEntryId>
    <ddiem:ecNumber>3.2.1.49</ddiem:ecNumber>
    <ddiem:uniprotId>P17050</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bf36da37-26e4-4d3b-bd8c-7e1c9faafa6b">
    <ddiem:keggEntryId>K13511</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0b09e721-d659-4efc-9552-c7a49ebbd5d4">
        <rdfs:label>TAZ</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6901</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16635</ddiem:uniprotId>
    <rdfs:label>tafazzin ( Protein)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/11cdf19d-f4dd-429f-9032-a4763591b599">
    <ddiem:keggEntryId>K12564</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13326</ddiem:uniprotId>
    <rdfs:label>sarcoglycan gamma</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c3f3c8d6-cfe0-4e86-9a39-50762f5265d4">
        <rdfs:label>SGCG</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6445</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f9129e46-0a19-4e83-9d9a-f6bfe926f900">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1d5c4cc9-599f-42bc-8111-675f1aa36a9c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7156</dc:identifier>
        <rdfs:label>TOP3A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q13472</ddiem:uniprotId>
    <ddiem:ecNumber>5.6.2.1</ddiem:ecNumber>
    <rdfs:label>DNA topoisomerase 3-alpha</rdfs:label>
    <ddiem:keggEntryId>K03165</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4ea33512-56d9-48a2-824c-1c73fd4c3dfb">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9529b27d-c6ae-4ffb-a9e0-883ae2550118">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55157</dc:identifier>
        <rdfs:label>DARS2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01876</ddiem:keggEntryId>
    <rdfs:label>mitochondrial aspartyl-tRNA synthetase</rdfs:label>
    <ddiem:uniprotId>Q6PI48</ddiem:uniprotId>
    <ddiem:ecNumber>6.1.1.12</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ec2a349b-b8f8-46e3-886a-6df6f7ebba28">
    <ddiem:uniprotId>Q16836</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.1.35</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a6f3d19a-d7b5-4d73-b0f7-665b178b26ba">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3033</dc:identifier>
        <rdfs:label>HADH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00022</ddiem:keggEntryId>
    <rdfs:label>3-hydroxylacyl-CoA dehydrogenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fe32e227-f07d-455b-950b-24a62ac5d29b">
    <ddiem:keggEntryId>K00597</ddiem:keggEntryId>
    <rdfs:label>Methionine synthase reductase</rdfs:label>
    <ddiem:ecNumber>1.16.1.8</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a6f600ad-b992-4475-954e-e3b27a05672f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4552</dc:identifier>
        <rdfs:label>MTRR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UBK8</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/497580e5-ab89-47c6-9332-858f9782370e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/73505bfe-205e-41e5-8dfc-953d05495af3">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3030</dc:identifier>
        <rdfs:label>HADHA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K07515</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.-; 4.2.1.17; 1.1.1.211</ddiem:ecNumber>
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase</rdfs:label>
    <ddiem:uniprotId>P40939</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b563821f-7006-4ff1-80df-22dea91e90f0">
    <ddiem:uniprotId>O94777</ddiem:uniprotId>
    <ddiem:keggEntryId>K09658</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/36d3f5d6-dd66-4a57-8b27-320f1509980d"/>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611722">
    <rdfs:label>KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/611722</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2ba5130f-42dc-47eb-9173-78924e3e1a42"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>292</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/292</ddiem:iembaseUrl>
  </ddiem:Disease>
  <owl:Ontology rdf:about="http://purl.obolibrary.org/obo/">
    <owl:imports rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
  </owl:Ontology>
  <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000115"/>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/date"/>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e5fd5a55-6986-42ce-a4b7-78bbdf27deec">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/48a584ad-6104-4afc-893e-195e604fac4a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7b0d65c2-448c-49b7-a28d-7b2cc86d16e2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604290">
        <ddiem:iembaseAccessionNumber>872</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/872</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/604290</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2590f5a9-b3c0-4476-8d35-3a037c376f55"/>
        <rdfs:label>ACERULOPLASMINEMIA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ea72379-06cb-4c61-9aa7-08dfae4db435">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001738</dc:identifier>
        <rdfs:label>pancreatic dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001738</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a64eedc-c837-45a7-98e8-6957c6f4f17b">
        <dc:identifier>HP:0001410</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001410</ddiem:url>
        <rdfs:label>Liver dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08113a1c-c41e-45f5-a390-6a693b6c4f1e">
        <rdfs:label>tissue damage</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/00803d2e-1fbc-4e9b-9ad0-c8ffb90fbe51">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71d3ffd8-3465-4dc4-a1e0-28dc0ee47054">
        <rdfs:label>Low plasma membrane expression of R8Lin kidney</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb5909df-2f7a-4b4b-bd34-289c8db3dd35">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mislocalization of R8L</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c5a82bc-6521-4091-af69-46e168b88302">
        <rdfs:label>ER-associated degradation of R8L</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/34158e91-52cb-4850-865c-ebc8fba4447e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5ddfb152-0bac-498a-a449-1ee969ee6859"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4e62b4f-6170-401a-9efd-b5a397dbb8de">
        <dc:identifier>HP:0002900</dc:identifier>
        <rdfs:label>Hypokalemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602522">
        <rdfs:label>BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4b5b743c-029c-4d85-9a9e-e4d8e75a100a"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/602522</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54787913-b89e-46ae-9791-f733281f112c">
        <dc:identifier>HP:0000407</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Sensorineural hearing impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000407</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/afa176b7-e0b0-43b6-9719-fa2cf9641b11">
        <dc:identifier>HP:0200114</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Metabolic alkalosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200114</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/70dce652-239e-4028-adf4-e52874c8e000">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2c78c0bc-8270-40ea-b8c7-e4320a3176f7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74e9a744-cd74-47a2-8bf9-0b2a4a63953d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10630918</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73fbf58e-4fda-450e-9582-8ea0afe24160">
        <dc:identifier>HP:0001298</dc:identifier>
        <rdfs:comment>Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. The combination is suggested to given in presymptomatic patients to prevent brain damage.https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:label>Brain damage</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23326493</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cf2fb18-1216-4db2-bf9d-d436eafd01fb">
        <rdfs:label>Cerebral palsy</rdfs:label>
        <dc:identifier>HP:0100021</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100021</ddiem:url>
        <rdfs:comment>Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be938cb3-be98-4597-8ab6-f018e51b2c8b"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3a198d9-ef80-45c3-a2bc-e9a6a401d052"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
  </obo:DDIEM_0000010>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f5917ea-048d-490b-a33e-26ffafff6e1c">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/83e66d5a-c2d4-461d-8a26-d802c96f325c">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f7a9458-accb-4638-a81a-9314c57d3f5d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fc48503f-e081-4680-b75d-d07c2d0e8397"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/076079ac-f87b-4005-96ef-7561a6a159cd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7e1d2fa-36b9-4c6e-858d-0a8c65f33b44"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/456d3fa3-bac1-4038-9cd8-325a63675896"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf1fe05d-e41a-4560-b7c6-d774616f1d03"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/228000"/>
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1af21ce0-5ea8-485c-a43e-0e3d43b5fa70"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3beb7a4-4226-40e7-86e5-2e48ace693bf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6362bc14-acab-4df4-96ee-fd31dc9611a3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/401864ab-b737-47ae-9982-3219fc0d9421"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23681708</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>human recombinant acid ceramidase/human ACDase-encoding lentivector</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f5efccd9-0e62-4b6c-87e5-63d0803d4de0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfeeb20d-52da-4104-9757-6ead1ef98e11"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba963910-5c77-4de2-9e15-d2ace864f8c3">
        <dc:identifier>HP:0000938</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Osteopenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4809b2fc-fa67-4e01-ae6a-0759a8c92131">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal number of b cells</rdfs:label>
    <dc:identifier>HP:0010975</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010975</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/232b3a0e-ef73-4a5b-b798-24789515ae42">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607483">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/607483</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cd023b28-5cae-4db6-8631-41e7518d4e9a"/>
        <rdfs:label>THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0678e392-36a7-4da8-9825-434563e26dcc">
        <dc:identifier>HP:0001332</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>dystonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>Abstract</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d94d13aa-9a3b-4da5-a911-67c081405f3c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
    <dc:identifier>HP:0002155</dc:identifier>
    <rdfs:label>High serum triglyceride</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/95840af3-8e0c-4f42-bd31-88a328895158">
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0007121">
        <ddiem:url>http://purl.obolibrary.org/obo/EC0_0007121</ddiem:url>
        <dc:identifier>EC0:0007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609056">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/360</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/609056</dc:identifier>
        <rdfs:label>SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c4af54d5-624e-4ff6-beb7-94f2d075f529"/>
        <ddiem:iembaseAccessionNumber>360</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8d7e5a74-7777-4134-aade-bb02757631a0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/24ad36ac-3155-4378-8848-2a10dc6389df"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02234024</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23122763-3eaa-40d7-9de2-e5f7df7a0d06">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed Develoment</rdfs:label>
        <dc:identifier>HP:0001263</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/735e2d37-dddd-4b20-a807-9b2953cc34dd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12368988</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9bf308eb-2966-4bbc-9deb-a62086511e73">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010438</ddiem:url>
        <dc:identifier>HP:0010438*</dc:identifier>
        <rdfs:label>Interventricular septal thickning (Ventricular septum abnormality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18234531</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea383639-7595-43e2-9cbb-f9bf62242d61">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000570</dc:identifier>
        <rdfs:label>Saccadic ocular movement abnormality (Abnormality of saccadic eye movements)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000570</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069112</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771264</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bf2b946-bc5a-4181-b769-27870de96e5c">
        <rdfs:label>Nystagmus</rdfs:label>
        <dc:identifier>HP:0000639</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000639</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24ee95e2-2899-43db-a269-0599710d3a68">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High left ventricular mass index ( Left ventricular hypertrophy)*</rdfs:label>
        <dc:identifier>HP:0001712*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5cf23e9e-7c23-44c2-bf7c-4d5e48bfd8e5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771265</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f71708d-06a4-47b6-bf55-554c4c76f118">
        <dc:identifier>HP:0001251</dc:identifier>
        <rdfs:label>Ataxia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/931a6903-0271-4ef7-b8f0-d2f415ec0823"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07409c00-f7ed-4935-8a4e-fd80151b2df4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cerebellar dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229300">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1241</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dc4b2119-8642-4d2f-bec2-6602ac2e733c"/>
        <dc:identifier>https://www.omim.org/entry/229300</dc:identifier>
        <rdfs:label>FRIEDREICH ATAXIA 1; FRDA</rdfs:label>
        <ddiem:iembaseAccessionNumber>1241</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31ab77c1-de4f-4544-ada0-b578071b2893">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Disease progression (Rapid progression)*</rdfs:label>
        <dc:identifier>HP:0003678</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17826341</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11907009</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/24aae510-f7af-4fb2-bbb1-1f91ad4b9fb2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29684566</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/613f3ae9-cb61-495f-8920-34d57ad9525c"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
    <obo:RO_0003304>(c.356+3&gt;C)</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/76db9253-a470-48e2-9c14-01cda0c526dd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/254aae89-dd77-451f-9c56-a73158f6166c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.bloodjournal.org/content/128/22/2682</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e3b0fc2-a2d4-4924-8993-0e94b62c9de7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Thrombocytopenia</rdfs:label>
        <dc:identifier>HP:0001873</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d49ba23-6f45-4afa-8fb6-85f36321676b">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2c50e5fb-dc29-45f9-a799-04484c0e7d34">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d9d78765-6201-45e0-8e35-d16eb426abd7"/>
        <rdfs:label>rhPBGD</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55170631-fd19-485c-bdf2-ae981c969934">
    <rdfs:label>high facial soft tissue volume</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000287</ddiem:url>
    <dc:identifier>HP:0000287</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/ce18dcb4-df6e-43ad-87c4-11f0880615d7">
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c261ce57-0baa-4172-b5e2-84dc3acaf7ff">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000716</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Depression</rdfs:label>
        <dc:identifier>HP:0000716</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81ff73e2-c99e-450b-9a25-6b2fd6cd302f">
        <dc:identifier>HP:0000722</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000722</ddiem:url>
        <rdfs:label>Obsessive-compulsive behavior</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8664de68-78a6-4967-99d6-27323c61a0c5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ffbfc6a5-8cc0-47fc-9d47-d2b64067c19b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/128230">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/299cb842-d0c6-4f88-bcb3-49fc71249e2f"/>
        <rdfs:label>DYSTONIA, DOPA-RESPONSIVE; DRD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/25c33b37-04f5-44c5-88cb-f7b0784187e1"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/128230</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/62eaa588-96ae-4fcf-a958-02a88bf94669"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000015>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d8e5ae88-67ba-4b49-a998-33ec188e0672">
    <dc:identifier>DB13257</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13257</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/444b1463-7fdc-40e8-9c9f-7cfb945de7a5">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0bcb4648-c5f1-4621-a658-882975bc7ef9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/02d00a54-06fd-449a-a9b3-8265e8f1bd43"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33410a9c-27dd-43a9-ba15-07aa8cde5ce5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28895280</dc:provenance>
        <rdfs:comment>Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. "Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrin‐bound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Ferrous sulfate anhydrous</rdfs:label>
  </ddiem:Drug>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/9c8cb63d-0898-4eee-885a-d828e202b4fc">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176000">
        <dc:identifier>https://www.omim.org/entry/176000</dc:identifier>
        <rdfs:label>PORPHYRIA, ACUTE INTERMITTENT; AIP</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>112</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b91bae08-5eb4-44ee-b073-4ad773325916"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/112</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95fc7717-ee9a-42ab-ba7a-31dffa17d3ce">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatic metabolic abnormalities ( Metabolism abnormality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0028cae8-68f0-4de6-812b-d34994f9776d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/55d6d8e2-eae1-4eb0-afc9-f98720d9917f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3d67fcd-36dc-4ed4-9c4d-14f7cfa342be">
        <rdfs:label>Abnormal neuromotor function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002333</ddiem:url>
        <dc:identifier>HP:0002333</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19861948</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261100">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/863febbd-c179-42cb-a58a-8f84f9870a58"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/83</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/261100</dc:identifier>
    <ddiem:iembaseAccessionNumber>83</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b24bd528-f19f-4887-a98c-5f30a86767bb"/>
    <rdfs:label>MEGALOBLASTIC ANEMIA 1</rdfs:label>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/012c0892-50e6-4a5a-91d9-4dcd2797abc5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6fd9181d-01d1-483c-b55f-485b5708f459">
        <rdfs:label>Elevated intralysosomal cystine accumulation( abnormality of cysteine metabolism)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010918*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f140baef-c8c6-4cf1-99cf-adf75bf27b25">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000531</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000531</dc:identifier>
        <rdfs:label>corneal crystals</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23416144</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c2c49c1-20a9-4ded-afcc-c9bdd6fbcd34">
        <rdfs:label>Kidney disease progression ( Progressive disorder)*</rdfs:label>
        <dc:identifier>HP:0003678*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a292fcd-7c9b-4c12-bec8-b83ab52fcc7c">
        <rdfs:label>development of extra-renal pathologies ( Progressive disorder)*</rdfs:label>
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219800">
        <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/219800</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
        <rdfs:label>CYSTINOSIS, NEPHROPATHIC; CTNS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/21b0dd29-5e41-46a6-aad2-28a1acb7cd82"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc2c8c78-716a-4176-8e76-3c2f08daa963">
        <rdfs:label>Reduction of WBC cystine levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b25879fe-127a-4d20-9e96-33dba7b5099e">
        <rdfs:label>hypothyroidism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0000821</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89ca7e64-81d7-487b-84ab-2e798af1df5d">
        <rdfs:label>cystine accumulation in muscle parenchyma</rdfs:label>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0003358</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003358</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001803</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44e2f31d-d714-48e9-81ad-7364eab9758d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000095</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>glomerular damage</rdfs:label>
        <dc:identifier>HP:0000095*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/afc5eab7-3ee0-4e84-8709-3d0cb42ec2a9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc507244-3828-4fa8-a739-629dfc62fc60">
        <rdfs:label>shorter life expectancy</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/401864ab-b737-47ae-9982-3219fc0d9421">
        <rdfs:label>Delayed growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abfa0f42-a302-4867-a5f2-37062ffacb3c">
        <rdfs:label>renal function declines</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
        <dc:identifier>HP:0012622</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4898b44-13f3-4b28-9b64-59a805abd3e8">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
        <dc:identifier>HP:0000613</dc:identifier>
        <rdfs:label>Photophobia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9758713</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/c5283f9e-407d-40fd-bd5e-bbcbb376d4a9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29909971</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00b4f3fe-f90a-4027-bed9-5dacb977b0dd">
        <dc:identifier>HP:0002180</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurodegeneration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a5619aa-5542-4177-a7f3-252cdaa8b8f7">
        <rdfs:comment>In the mouse model syudy</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:label>Lysosomal stress (Abnormality of lysosomal metabolism)*</rdfs:label>
        <dc:identifier>HP:0004356</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f6e1b087-325a-44d2-8fe0-2e6eaf5e32bf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6be001bc-2562-4645-99af-c6918c03cc7a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256600">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/760</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/256600</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8a16ae66-a016-45fb-87ed-bc04e623e5c6"/>
        <rdfs:label>NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A</rdfs:label>
        <ddiem:iembaseAccessionNumber>760</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/06926a0a-4f79-413c-bde3-735a6afd2f3f">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cc4fe0e-ed25-4133-a86f-1c55820763c2">
        <rdfs:label>Thrombosis</rdfs:label>
        <dc:identifier>HP:0001977</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001977</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16767100</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/625c02b1-acb3-4e57-9b85-da57261450e6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/429889a4-bb3e-4d94-b761-460f7fdcfa38"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/307030">
        <rdfs:label>GLYCEROL KINASE DEFICIENCY; GKD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/133fedd3-9df3-4e02-87bc-73023f9564fd"/>
        <ddiem:iembaseAccessionNumber>542</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/307030</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/542</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/19d53538-bcfe-4f87-8793-f4a0afa5ba4b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a574e53a-6cc8-4e7e-893f-697f19ea5456">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Difficulty breathing</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
        <dc:identifier>HP:0002098</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613490">
        <rdfs:label>ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/967384fd-d3bd-4252-aa8a-fc5225bdd569"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/613490</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22282548</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c805dbce-4c64-4ebd-aed1-6c8bb3e47e22">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e47036a2-dc7a-4376-a8c7-faf700e57e2f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cee6cc7e-27e4-426b-be0d-0fe0eebd6656">
        <rdfs:label>Alveoli damage ( interstitial pulmonary abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006530</ddiem:url>
        <dc:identifier>HP:0006530</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78e37cba-c6c6-425a-a2bc-aa9cc48a5caf">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Lung inflammation (Abnormality of respiratory system)</rdfs:label>
        <dc:identifier>HP:0002086</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002086</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac907aa2-37d2-4aca-88de-1e9bbbfdba65">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002917</dc:identifier>
    <rdfs:label>Hypomagnesemia</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cc7bf555-eda7-450f-8fcc-b8b658494992">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b596b261-9d94-4338-a845-d41923d3ef10">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cf3083b4-2e96-4acd-a2b8-f86210065f02"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abe2805f-c6f0-4312-9170-ff10f6dd0d3d">
        <dc:identifier>HP:0004387</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004387</ddiem:url>
        <rdfs:label>GSD-associated enterocolitis(enterocolitis)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18172743</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a81c49c7-e87b-48fc-9678-996b3ed5c57b">
    <dc:identifier>HP:0003750</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
    <rdfs:label>lack of strenght</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/7e310935-23da-4d18-ab99-72ad7066c9f0">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236800">
        <rdfs:label>HYDROXYKYNURENINURIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/236800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/742fe0f7-37aa-4017-9192-b075cbc0c281"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5586569</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d578669f-f3c3-4891-9197-6ac5536cf73c">
        <rdfs:label>Low enzyme activity</rdfs:label>
        <dc:identifier>HP:0012379</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5bbaa4b7-fa65-4ef2-9dc5-8c289dc18ee6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/44d754b1-c581-491f-b8df-5c22ab8c4931"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/286dc748-fa39-4a43-8374-5517aec1f85f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00148</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/99d58273-5f2b-4de6-90cb-bb00c3a29d5f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66980f89-e96d-4a46-9c37-ef47b5b44405"/>
        <dc:provenance>https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e79722b-c7ad-4191-9aee-cc3377b31640"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/d02256a2-4e36-45e6-bba7-2230d1eb191a">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2579c085-8d6c-40cc-ab70-c360003f0644"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b805f834-b0c9-414f-9b23-42c16d2068dc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23770102</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6c9a4f7-e30f-4d03-838c-bcfa6da618ab"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c015589f-f648-47bc-80c1-96e1be5c946b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75d06370-abc8-4adb-9162-1ec99f29dee6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b4280f1-49b2-4418-a441-75c943ec66c0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0403f90-5fd6-4098-8ebe-fe02974d0886"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22386973</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8782994a-3851-469c-ae44-57e42d90889d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602360"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f9510e4-d7d0-4d58-a57e-eb6775c9beae"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20625172</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f41d2505-f39b-4a8b-a44b-8e1a0e5c71a1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca1b21e0-f1dd-4101-a903-4758b2248b1c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20682460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c06f6f01-74be-41ed-9cfc-79c68f87c75c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <dc:identifier>DB00148</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/91ad4a48-115f-42b8-8b90-d87e67a89f63">
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615395"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e79722b-c7ad-4191-9aee-cc3377b31640"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f6c451a-89ce-462b-9504-7e52b81caf2a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Creatine</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/3e6f64ab-81f0-4387-a3d1-38ae11979c0d">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18652077</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/45547f41-e755-4bf5-8324-a8c929a6e865"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e79722b-c7ad-4191-9aee-cc3377b31640"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e44f225e-65c2-4dc3-8469-2db7d845d8b6">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37d74f32-dcd7-4182-b424-94cbfbca562f">
        <rdfs:label>Carnitine deficiency</rdfs:label>
        <dc:identifier>HP:0003234</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcd805e5-edce-4bd4-b8a5-36e09f6d2f5e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
        <dc:identifier>HP:0100786</dc:identifier>
        <rdfs:label>Hypersomnia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/af7e4322-29f4-4b37-847e-7029295eaf11">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1bd89647-8017-45d7-b9cd-f49e48194520"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/763452f8-7da3-48d5-855f-888e089440d4"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9a5535b-2a1c-4698-a6b8-5d875556eec5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8886379c-78ff-4727-bff1-6b114435f567">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Jaundice</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000952</ddiem:url>
        <dc:identifier>HP:0000952</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a98f65eb-1f57-413a-94bb-fb17e1ea8255">
        <dc:identifier>HP:0001290</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypotonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3e7b87e-fea3-4831-9d25-85eade85fea4">
    <rdfs:label>Recurrent infection</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
    <dc:identifier>HP:0002719</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/57d2007c-2694-4dbc-aba9-d97f0c3eabb8">
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/1e5efce2-1b6a-4fcf-9da7-708c7ddb0fb4">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c3afb8d-9655-48fa-843e-f6fa9589a2dc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2412352c-e1e4-4bda-8fe5-ca54b580f917"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832064</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b8fdf3ac-a47e-4c09-a7b0-6d6840e94392"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c4472242-3ab7-44d9-bcc2-31cf3b222e90"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/63871d07-f8ad-4700-8d80-9abc3b0f445a">
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
        <obo:RO_0003304>P407S,A373T,R241C</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20971365</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261600"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01977820</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b8fdf3ac-a47e-4c09-a7b0-6d6840e94392"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699701381</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2412352c-e1e4-4bda-8fe5-ca54b580f917"/>
        <ddiem:failedToContributeToCondition>Homozygotes of R252W ,Homozygotes of IVS4-1G→A ,Homozygotes of R413P</ddiem:failedToContributeToCondition>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00360</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/3be1a038-9f47-4f1c-8e41-87bdf419a5d2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b8fdf3ac-a47e-4c09-a7b0-6d6840e94392"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8433887</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5cf23e9e-7c23-44c2-bf7c-4d5e48bfd8e5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f41387ef-a003-4160-87e1-056b791f2447"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/e7b5a576-199b-4362-a4fd-e103889f6285">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/429c7bfc-1f8f-4637-9218-a5876556aa2f"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a905453-b801-4f07-864d-a27f583f6de0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9760199</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9585615</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff2d375d-1ef9-42d4-9b88-f45f82e47546"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b8fdf3ac-a47e-4c09-a7b0-6d6840e94392"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/264070"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6289fc90-15a9-4a86-8a90-6af49314e36f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2412352c-e1e4-4bda-8fe5-ca54b580f917"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5f6b0a8e-ec7f-4adc-8b0d-e787a93f1715">
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b8fdf3ac-a47e-4c09-a7b0-6d6840e94392"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00935753</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/79ab3ecd-d255-40ee-838d-5fd353a9377a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/3f300374-32d4-42f1-a13e-65575b187c8d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9667588</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b8fdf3ac-a47e-4c09-a7b0-6d6840e94392"/>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005394-35/ES</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
        <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/430610de-90dd-44c1-96f4-6046f87918b8"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205003057</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <rdfs:label>Sapropterin</rdfs:label>
    <dc:identifier>DB00360</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b065e5e8-6364-4fb4-95ce-204a99a2d090">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20803213</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203700">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>411</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/411</ddiem:iembaseUrl>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/451bbd3a-512a-4a5d-8513-97be22d4cce9"/>
        <dc:identifier>https://www.omim.org/entry/203700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1407f8de-c763-41d3-8878-461fe72e4ddc">
        <rdfs:label>Status epilepticus</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6adb3af9-0a44-4596-a331-b8d175f3245f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1a647f38-57a5-4eeb-a7ba-d35102e654d7"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8ad83207-49cf-42a3-ba0a-a0c6b4622485">
    <dc:identifier>DB00594</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00594</ddiem:url>
    <rdfs:label>Amiloride</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6bb64284-d15e-4806-89e2-dab494d781f5">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8b1c9d6-9541-45e8-9988-ebadbade08bf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01146197</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe31fc67-b97e-4b51-a099-53e699b10cf4"/>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e5ac806-aacd-4ddc-9938-ad1ec6ea410b"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/32a66e8d-ff14-4b3b-bce6-717f0512cee7">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/61f7aa74-bb3a-4d77-9c24-68a4760ac7aa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f48800f-7681-484c-b337-155d20997483"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26b11f52-ba7e-428b-a954-99bf81889972">
        <dc:identifier>HP:0008222</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Female infertility</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008222</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/c9c2ada1-0115-4563-a289-cc7e5db7693b">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2b0001fd-303c-4642-8372-a9256f9ff82f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2ef41cd7-f966-4f40-8883-0064f49716ba"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24933563</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f8f91d1-a0b9-498d-a2a7-11adb1576836">
        <rdfs:label>Low PBGD expression in liver</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3754c395-7335-45c9-8056-b5e4f1d5c3e9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc8d258f-56c8-4e39-a9ec-6a24e91df84b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17c49188-302f-44d5-acf4-4b83764c200b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6428587f-7c15-40c5-a3f0-977291cb82ab">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/12b6d969-c94b-48a3-a696-f73b3504a207"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6866321b-f658-4e71-92e2-9f228c404ca8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27928778</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610198">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/610198</dc:identifier>
        <ddiem:iembaseAccessionNumber>1012</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1012</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/56cca111-4334-4d55-98a5-0b7c992511e1"/>
        <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2d7c388-f4d7-4f5e-add7-9dad0a4937af">
        <rdfs:label>Low ejection fraction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012664</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/c6a63e77-f816-4c80-a88e-c89ab3d72c0a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5efcc1e6-4a51-4bce-8ee4-6cf42a3d7285">
        <rdfs:label>GM3 ganglioside accumulation (Ganglioside accumulation )*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004345</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004345</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0611c07f-b765-46a3-b9cf-c1b8c2d1d51b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003495</ddiem:url>
        <dc:identifier>HP:0003495</dc:identifier>
        <rdfs:label>cortical GM2 ganglioside accumulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60de23d0-2b75-4192-af22-7079626081fa">
        <dc:identifier>HP:0040006</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:label>Mortality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208706</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cb92873b-bbc1-4163-8441-ee19e504b46e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71a6d526-76b5-4335-858b-d3431cef0bf0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/785d1019-0584-4b96-9496-557bc711bcd6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608158">
        <dc:identifier>https://www.omim.org/entry/608158</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b0d83319-0110-4160-b080-56d5b443ca00"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CoQ-RESPONSIVE OXPHOS DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/842abc51-8d7a-49b1-971e-b8bdcff2a40f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal liver function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c420fb2a-2262-4d4b-9aa1-4236c4259ac6">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/31797d6a-9fbe-4dc3-b132-d2ebc4936b36">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da7d8cc3-82fe-49c3-806e-b7a89c960a67"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0678e392-36a7-4da8-9825-434563e26dcc"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300438">
        <rdfs:comment>Treatment attempts with isoleucine and protein restriction did not clearly alter or improve the course of the disease despite reduction in the excretion of 2-methyl-3-hydroxybutyrate and tiglylglycine. https://www.ncbi.nlm.nih.gov/pubmed/22132097. https://www.ncbi.nlm.nih.gov/pubmed/11102558</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0539c86a-7208-45bf-ae40-b870c89fdba1"/>
        <dc:identifier>https://www.omim.org/entry/300438</dc:identifier>
        <rdfs:label>HSD10 MITOCHONDRIAL DISEASE; HSD10MD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/64</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>64</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60aa41b8-685d-4a94-a7eb-167c6d922521">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>tremor</rdfs:label>
        <dc:identifier>HP:0001337</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0ae8e41-57c7-439b-b218-21d47d149b8a">
    <rdfs:label>Synovitis</rdfs:label>
    <dc:identifier>HP:0100769</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100769</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c9efebe-ad53-48ae-b0b4-ce21bddca905">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
    <dc:identifier>HP:0002904</dc:identifier>
    <rdfs:label>High serum  bilirubin concentration</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cd0a65a0-5aaf-477d-9b8d-110468c62294">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfeeb20d-52da-4104-9757-6ead1ef98e11"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71a6d526-76b5-4335-858b-d3431cef0bf0"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24161764</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/13119275-e491-49b6-90bf-e1d668899621">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f5efccd9-0e62-4b6c-87e5-63d0803d4de0"/>
    <dc:identifier>DB00091</dc:identifier>
    <rdfs:label>Ciclosporin</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ba219a8b-ba12-4b68-ab2f-be9e1b1a77a2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ad3eb7e-adbf-41f1-a433-d295b9786c93"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfeeb20d-52da-4104-9757-6ead1ef98e11"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001749</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/480ad416-06bc-4698-abbd-9ebdf0d918de"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00091</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cd0a65a0-5aaf-477d-9b8d-110468c62294"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5daf8595-6925-4068-9596-f4d80758f407">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc93540d-a062-43d7-9d0a-cb6d35b22f81">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012531</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
        <rdfs:label>Pain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1934b4bf-1450-4629-8059-b0a9346eb5b3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:label>Pruritus</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000989</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7383c373-1c42-4efb-a866-f25a2b3a3c83">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5267d7f2-b156-45ea-95b1-2bec21e7b812"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/177000">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/81853b9e-71f2-4435-8bd9-5614a6720ead"/>
        <rdfs:label>PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1</rdfs:label>
        <ddiem:iembaseAccessionNumber>107</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/177000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/107</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27139922</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10eebb5a-df3a-4d0b-a0a8-35851eec2399">
    <rdfs:label>Interferon Alfa-2a, Recombinant</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00034</ddiem:url>
    <dc:identifier>DB00034</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b96910a6-90e3-488f-8714-0428d0c35ce8">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3b66edb-e7a0-470d-b38b-efb38be92189"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ee28b5c-a256-4951-b1ce-f0123b46572d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c6cb0da6-f100-47d4-9f9a-d75617bb4572"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/05d5f451-7757-4a68-9ae3-339d53d7aefe">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5673921-4a65-4e49-a976-672991a008a5">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <rdfs:label>diarrhoea</rdfs:label>
        <dc:identifier>HP:0002014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/94ec5b3d-dad0-4eb0-97b1-98ff07eae288">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d1a2d32a-10bd-4363-979c-5f4be5c8cebb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/912874a2-6e24-47ac-993e-c983d12ecc8a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
        <rdfs:label>dementia</rdfs:label>
        <dc:identifier>HP:0000726</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10540864</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17334708</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14169454</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfcfeb90-b50a-452f-a1cd-a19aca1d623a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>dermatitis</rdfs:label>
        <dc:identifier>HP:0011123</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/256aa048-1291-40ed-8ddb-48b8ac208a6b">
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>sensitivity to sunlight</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/797d5669-3118-4aee-a858-826c1c4eb8bc">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8be0effd-37a5-4d92-b6e4-40b5c862f18d">
        <rdfs:label>Gait instability</rdfs:label>
        <dc:identifier>HP:0002317</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002317</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/584ce42e-087c-48ae-bc9f-1b5ac52c92ba"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/784e2d90-670f-42bc-ae2b-95611c68b33c">
        <dc:identifier>HP:0007340</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Lower extremity weakness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007340</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e974fe73-acaa-426b-8a9a-05168e3d2292"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb931e2d-83c6-4a01-b88e-e0383a6f5b51"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdfs:comment>All patients received OHCbl (intramuscular injection; 0.5–1 mg/week) and betaine (oral administration; 1–3 g/day). Some patients also took oral administration of folic acid (10–30 mg/day) and compound vitamin B (20–60 mg/day)</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cec33ded-c520-4ec9-9ffe-e7cd24f7f687">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/56de1a0d-943e-4e1c-ace4-5b220c9738c3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d8dbcbc-6052-4ab2-bd22-a2dcca1b10b8"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f479a4a-bed1-45cd-bda8-e986b38f3a1d">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Restricted diffusion in the corpus callosum in MRI(Abnormality of the nervous system)*</rdfs:label>
    <dc:identifier>HP:0000707</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1594ddd3-373f-42e3-bd60-29a7918439e1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>disease control rate(  Rapid disease progression)</rdfs:label>
    <dc:identifier>HP:0003678</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/69ab7f4c-9f5d-47bc-bc42-ced988aa0f23">
    <rdfs:label>Asfotase alfa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09105</ddiem:url>
    <dc:identifier>DB09105</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f2735f95-bfb0-4125-93f7-ed968afb465b">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>"ENB-0040</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb7fde9d-2fac-4743-9bd0-50cc415f533c"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241510"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ee565eb-bdaa-48e6-a238-c9363318769e"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/096817af-6956-4825-8258-b04749cfc1e0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22397652</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f6463b8-5477-47ef-b085-cab9a87ac8cf"/>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144124</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8cd611dc-4724-4c81-8817-9b0d52ed3975"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/692b5bdb-c711-4763-b166-a1fe2520764c"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4192ed2c-8e44-47cb-8a78-2931002d19f2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/096817af-6956-4825-8258-b04749cfc1e0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2fb1ca65-c5ab-4286-8031-a48097ce898c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50d08471-0f96-4d07-b05a-3e2a9dc90b35"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c06f6f01-74be-41ed-9cfc-79c68f87c75c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a9c71a8-49c4-4297-8cac-af9f7e4ea5ec"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d523079-35bb-4aa9-85e1-5f9728d84d77"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30083035</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29405935</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9da23cd9-3e33-4e94-9bb4-7411aa1b3851"/>
        <dc:provenance>https://cdn.intechopen.com/pdfs/56869.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/939b295c-e30e-4890-b5db-98c6119376f7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6a792ec-cfbd-4140-bd1b-96e5847db826"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3bd4c8b-168a-4cc5-aed4-adec29f7fccc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
        <rdfs:comment>The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X18300174</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5dd17a8a-2e1f-46f4-9bd5-c5eca0138101"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba064729-83fa-46f3-a913-93c19e855f2c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/56135b5f-8863-4e75-81cb-7a6efd7b363f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8700879</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3483d07-cf46-452b-9f50-05127da5a1db">
        <rdfs:label>left ventricularc contractility abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0006670*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94eb09af-fb03-46a4-8416-5f545503fef9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001714</ddiem:url>
        <rdfs:label>ventricular hypertrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001714</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be80bb42-39b2-48dd-ba0f-a05ce0254a0f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <rdfs:label>cardiac dilation, Heart enlargment, cardimegaly</rdfs:label>
        <dc:identifier>HP:0001640</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30170069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/41c9e175-ceb9-4706-a0ee-74e95b0f42a7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3f52931a-0ab2-442d-83f1-68fc2c432700"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607014">
        <rdfs:label>HURLER SYNDROME</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/607014</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bd99069c-3bd7-489a-920d-028a75480a6e"/>
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cfb1a46-1af4-4201-9d49-be89d6628e1b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004356</dc:identifier>
        <rdfs:label>Lysosomal storage abnormalities(Abnormality of lysosomal metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2be2cf5a-f1f5-4c4e-999e-4aa67d40ab84">
        <rdfs:label>Left ventricle dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0030872</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030872</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8071c02-7357-40fd-8e47-f0351785a647">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
    <dc:identifier>HP:0002015</dc:identifier>
    <rdfs:label>Poor swallowing</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/12cfcc54-f4e0-4f84-b920-4d5cd3322042">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46548bdd-00e3-42e2-9f2b-49ad41d58efc"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c65fb4e2-8bb3-4dd0-be7f-49f3d8f771d8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ea2f9902-d8e2-4815-b788-ccfc059355cb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/db39fea1-5673-4794-a3fb-d90982d76b24">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d5bce564-04d5-4896-b670-ccd710edbf61"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0ef6ca69-95aa-4834-aac6-d589c6e53b81">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b2db3476-a813-46c2-9715-8b87f05baaae"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b20d0761-43fb-4b1a-ad80-504c63c79776">
    <dc:identifier>HP:0010836*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Copper accumulation in kidney(Abnormal copper levels)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c1d86c60-4f5c-48c6-adaf-45d4a50eae79">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eeddce78-d0fa-4b4d-ba7d-e3f4a6e3a460">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>photosensitivity</rdfs:label>
        <dc:identifier>HP:0000992</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12535027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2a1e63c8-741d-48d8-9ed5-6b999a78f69d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/638b890c-f99f-4069-8164-c921cfa57ff2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004831</dc:provenance>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37b39088-f7bf-4af5-adb4-714fab448a75">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High serum total cholesterol</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
    <dc:identifier>HP:0003124</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5f8ec830-b66f-4dca-8512-1607f9f87940">
    <dc:identifier>A11EB</dc:identifier>
    <rdfs:label>Vitamin B-complex with vitamin C</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EB</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/258037f7-6317-40b8-a13a-d6753aa36f08">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6546f832-f14d-4fb6-880d-57e2879774bc"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50310ee7-c2ed-4279-8b00-cfaf874e4044"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5699ec1d-3568-4a83-85f9-4556d6b0e49c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f738d10e-1ab1-4316-9743-5445913f5308">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c678abd6-6dec-4211-9c43-cd4b8cec3c46">
        <rdfs:label>Polyurea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000103</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/caa8210e-27b3-455f-8261-931862f7d033"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1517999</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/013d1715-45cf-4fa8-aaae-dbfc283013db">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/280544</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8bda332f-6e59-4cc7-88f2-8af9a3cdbfd3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/21993d28-82cf-4dd6-b72c-a3416e9344f4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2884ff3-8b6f-4c24-9503-945e0368d908">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:label>Mild asymptomatic hypoglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c80b4d8-49c5-406f-8f29-8cf409faf399">
        <rdfs:label>Hepatomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e63c3b73-4fe4-4202-b317-d4f434d93f0b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261750">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1258</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1258</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/261750</dc:identifier>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXb; GSD9B</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6e60acc3-ab70-4fb9-88b5-fcf184cee61a"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/0c3177a0-e58e-4cda-87c8-b4c3821fb3c3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301647</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccb82bf6-579c-43d9-90eb-a36075889b2d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001278</ddiem:url>
        <rdfs:label>orthostatic hypotension</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001278</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00889135</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/dopamine-beta-hydroxylase-deficiency</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/223360">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/101</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>101</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5fe04698-01ac-4a02-b46a-1d0725a5346f"/>
        <dc:identifier>https://www.omim.org/entry/223360</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ORTHOSTATIC HYPOTENSION 1; ORTHYP1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/99a4255e-e27d-4cf0-a66a-45bc128f4eb9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5baa9e38-12a1-4fde-89a7-04ec7cb1b4cf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c77d3480-7137-4cb2-ae41-b7a61de44342">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/375935</dc:provenance>
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6375a209-70ec-44d6-a039-693df2619c82">
        <dc:identifier>HP:0011123</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
        <rdfs:label>Dermatitis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30669644</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f037f60e-279e-4fac-8c14-80ac3cdb14de">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f38a91cf-d014-47fb-ba2b-07330a927831"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/201100">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>202</ddiem:iembaseAccessionNumber>
        <rdfs:label>ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/202</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/201100</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eca75d3d-3f51-45c2-b613-658b7f73b9c5"/>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/084be5f3-9a2f-4d10-932c-7602e0819670">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e5ca86d-f24e-48fb-99ea-07ad3330f49f"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e6c159d1-406d-460e-bd9f-669ca66059f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28281899</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237300">
        <ddiem:iembaseAccessionNumber>11</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/847ba465-0fcf-4bf1-a9bb-8682848b861b"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/11</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/237300</dc:identifier>
        <rdfs:label>CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1dca93ea-2a80-4679-8d98-70a118f4e18b">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
    <dc:identifier>HP:0002415</dc:identifier>
    <rdfs:label>progressive leukodystrophy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b08a29b6-f36f-4426-b492-cff976b32f65">
    <dc:identifier>HP:0030764</dc:identifier>
    <rdfs:label>ochronosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030764</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/ff345eb3-b2c3-452f-bb80-76b830eca4b9">
    <obo:RO_0003304>E1506K</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d60b73ee-efd8-40c7-b57d-dec68de6452e"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240800">
        <rdfs:label>HYPOGLYCEMIA, LEUCINE-INDUCED; LIH</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/240800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d9e8cf1c-17c6-44a8-ad22-9b9107eec857"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15356046</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6dc61da4-a737-4ddf-bae4-a604e96eed6b"/>
    <obo:RO_0003304>delSer1387</obo:RO_0003304>
    <obo:RO_0003304>R1353H</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88b3f71a-7c34-4b26-952f-b8ee454f0a19">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001367</ddiem:url>
    <rdfs:label>Joint disesae</rdfs:label>
    <dc:identifier>HP:0001367</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300100">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/280</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7629305a-8d81-4558-a300-c290578d3f27"/>
    <rdfs:label>ADRENOLEUKODYSTROPHY; ALD</rdfs:label>
    <ddiem:iembaseAccessionNumber>280</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/300100</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/48118ae8-251f-477a-9ac9-f44745b91bbb">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b365b3fd-5b65-457e-ba9b-7c3c37957f93">
        <rdfs:label>oxidative stress</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0af6b331-5379-44d8-91e6-bf5a38fac107"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1273a14c-4bcb-44de-ba40-4cd9b7c79a3e">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6c7a2505-61f5-4883-8cae-b3fc86e98923">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/27b478fd-e117-4279-b912-b55e04e93dc1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20375647</dc:provenance>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1978c0a9-7853-4491-97cd-557fdd693b86">
        <dc:identifier>HP:0000969</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <rdfs:label>Fluid retention</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d851c8d6-8ee2-4d5f-ae56-fb73008a0ef6">
        <dc:identifier>HP:0002027</dc:identifier>
        <rdfs:label>Abdominal pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b5a5dad-8e3d-4cb4-bb2a-ab9332728341">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatotoxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3cff02e-71d6-4a72-8a24-fa4a0efbbcfe">
        <dc:identifier>HP:0000992</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Photosenstivity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dbcd8c00-8708-40b6-8837-3ab92fef93ae">
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:label>Abnormal liver function test</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82fad1d8-c423-4ca0-8ccd-d96f204483b8">
        <rdfs:label>Pruritis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000989</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e453709-1902-49f1-b87e-498fd25f8c97">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <dc:identifier>HP:0025142*</dc:identifier>
    <rdfs:label>affected functional activity</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3b0b6531-fdc6-4c2d-b1a4-d4f77919f1d4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cbc2c8bf-43ee-4228-a2bf-df2e3479349a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/70211f92-aeb2-4fb0-a319-bf2be3987222"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253800">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/642</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>642</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/253800</dc:identifier>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/92ec04de-1c6c-465e-b043-7c89dab1248f"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/103b4639-ccef-4eb3-ad4a-75689c3cd154">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Fukutin function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21979053</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7268fc07-4cd0-4a8e-a008-ca15e525dd50">
    <dc:identifier>(DB00328</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6bb64284-d15e-4806-89e2-dab494d781f5"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00328</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ac7f0bd-f165-4718-8609-825368f2600f">
    <rdfs:label>Neuronal vacuolation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d379e882-191c-443e-9e89-1d94add44256">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27589827</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239500">
        <dc:identifier>https://www.omim.org/entry/239500</dc:identifier>
        <rdfs:label>HYPERPROLINEMIA, TYPE I; HYRPRO1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d24b17e9-3357-4a59-9ff0-b083ac836502"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/40</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>40</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/21b3c6b1-3bff-466a-9393-902243d29a1b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eb59c5bd-2320-4781-9b50-ee7e0c9e74be"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77cb7962-c35f-496b-be03-dc099e8e31c0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:label>Oxidative Stress</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/edbeda72-212b-4022-ab88-87d90e909058">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b8fdf3ac-a47e-4c09-a7b0-6d6840e94392"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2b61387-b1b7-4463-9836-e5ec6d785004"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdc4cd2b-ff8d-41e0-a268-646559eaf0cf">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004923</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:label>High plasma phenylalanine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430801</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ca782c5-9548-4e31-afc5-d79b97e17f37"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8885c161-9f2e-4176-8bcd-65856328bdbc">
        <dc:identifier>HP:0002329*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
        <rdfs:label>unalertencess</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b39cc8ff-70af-4e66-aa49-d2e48aa7a133">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Receptive language delay</rdfs:label>
        <dc:identifier>HP:0010863</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2d20a3c7-91b4-4526-9c4b-22e2c4d151ef"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d8dbcbc-6052-4ab2-bd22-a2dcca1b10b8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
  </obo:DDIEM_0000011>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000015">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:56+00:00</dc:date>
    <rdfs:label xml:lang="en">functional complementation of a defective protein by inhibition</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that inhibits  a component of the pathway or network in which a genetically defective protein is found, compensating for alteration of activity of that protein.[PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5a6c8862-92e8-4b4d-894d-64ba617594ce">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5699ec1d-3568-4a83-85f9-4556d6b0e49c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:label>Mitochondrial dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc87c48a-5be6-4597-b223-138087791eea">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/db40982a-b256-4930-8d94-d745b5bd075c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3a18c37-0706-4470-a6b4-41aa43faa79d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
        <dc:identifier>HP:0011925*</dc:identifier>
        <rdfs:label>Decreased cellular ATP level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/530000">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/530000</dc:identifier>
        <ddiem:iembaseAccessionNumber>398</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2ba5130f-42dc-47eb-9173-78924e3e1a42"/>
        <rdfs:label>KEARNS-SAYRE SYNDROME; KSS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/398</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/fbe7c50f-a4b9-47e1-a7fe-65f0fb0a49b5">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3fb596d-37ae-4f65-86f1-3f65ce9aba0f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002570</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002570</ddiem:url>
        <rdfs:label>increased fecal fat excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89339b70-96ee-4545-b773-79e308d15bc3">
        <rdfs:label>high plasma level of unconjugated bilirubin concentration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
        <dc:identifier>HP:0008282</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606785">
        <dc:identifier>https://www.omim.org/entry/606785</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b0d83319-0110-4160-b080-56d5b443ca00"/>
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE II</rdfs:label>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <rdfs:comment>Treatment of CNS type 2 is usually conservative with avoidance of drugs that displace bilirubin from albumin like penicillin, sulphonamides, salicylates, ceftriaxone and furosemide. https://www.ncbi.nlm.nih.gov/pubmed/23162302/
Affected patients should also avoid drugs that displace bilirubin from albumin such as penicillines, sulphonamides, salicylates, ceftriaxone and furosemide.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/be3a4a7b-f175-4b8c-9b04-048a5947c805">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bf380560-66f0-4dda-bce8-e21282edd54c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2eff508c-9aeb-4717-9780-9b516e0ec09c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008282*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
        <rdfs:label>low fecal excretion of unconjugated bilirubin (Unconjugated hyperbilirubinemia)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/33c557ca-587a-499b-a78f-b18cb76de1f9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b515477-9798-4f67-bebc-dd6316996118">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <dc:identifier>HP:0002630</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fat soluble vitamin  Malabsorption (Fat malabsorption)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615558">
        <dc:identifier>https://www.omim.org/entry/615558</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4433da59-2fdc-4bd6-94d2-0e5b7ad05eb7"/>
        <rdfs:label>HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d27f202c-0846-4ab1-9011-239f39fbfb60">
        <rdfs:label>Progressive ataxic retinopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
        <dc:identifier>HP:0000488</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ada95e7-5896-4b3b-85d5-5ba0cf629147">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <dc:identifier>HP:0002630</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fat soluble vitamin  Malabsorption</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aa66b013-56bd-40ce-9b4c-2bf75a4e28d4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebcd0a2d-7c6c-43ba-b72f-3cbb0cbb8c2f">
    <dc:identifier>HP:0011999*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011999</ddiem:url>
    <rdfs:label>Hallucinatory-paranoid state</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/560521f7-f44a-40ce-81ba-16e25940be53">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <rdfs:comment>The drug has some effects but hyponatremia is a troublesome side effect.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c40d0dc-0113-45a4-8bda-8f6a2247f068">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031951</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Short nocturnal tonic seizures</rdfs:label>
        <dc:identifier>HP:0031951</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594e7498-bfea-44e8-839c-c110b82d67a3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1178375-e493-4770-ae86-b203f9c6e494">
    <dc:identifier>HP:0009051</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high glycogen levels in muscles</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009051</ddiem:url>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/260ef807-5dae-44de-9bcf-08aca6c08880">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001735</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/55071bb5-2d93-4ce8-8bb8-eeb3661e51e7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5b8ba935-4a0f-4922-9d81-113b40ea21c1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9414260</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec9d67d7-9b15-4244-84cb-a869a9371234">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <rdfs:label>Abnormal enzyme,coenzyme activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012379</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/75d055df-1ede-423f-9312-4f04211a3f7e">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2d1b9663-5e85-490c-bcdc-8c717e69ef0e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c5ccdb5b-8fc8-45a9-879a-56412d13fb35"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://musculardystrophynews.com/resolaris-atyr1940</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c540aa5-84f4-4c10-a7bf-7219ee50fd5b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:label>Abnormal muscle function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02579239</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253601">
        <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 2; LGMDR2</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/253601</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b4dfcf7b-ce23-45d7-866d-80ee354c4e5e"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c46991d2-fbf7-43d4-9ce6-e6ecc7212865">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e6e1448-b944-4dff-9f88-d8d8010c7fcf"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57b6b8b3-8058-4cde-9f72-10ad331a7709"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253260">
        <dc:identifier>https://www.omim.org/entry/253260</dc:identifier>
        <ddiem:iembaseAccessionNumber>93</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/93</ddiem:iembaseUrl>
        <rdfs:label>BIOTINIDASE DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/45909c0a-0e82-4efa-b749-62bc4bf01e3d"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03269045</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/a9abff6f-fcf8-49e8-9e9a-973287886b6c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612319">
        <rdfs:label>SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/612319</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0049ebe7-c3eb-4602-b0a1-49ad2ccbd5e0"/>
        <ddiem:iembaseAccessionNumber>1054</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1054</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8f291ee2-c39c-40a1-8456-0147fd75e56e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f9bcaf3c-baca-4e7f-900f-4820e3927eef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000305">
        <dc:identifier>ECO:0000305</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000305</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eee06712-41db-4404-a838-6bd1f76cad66">
        <rdfs:label>Abnormality of circulating enzyme level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011021</ddiem:url>
        <dc:identifier>HP:0011021</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/02dc004d-17b9-4410-8b5f-9d7ac64a6414">
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e84b8d7b-16a4-4225-bcfb-a9a1c28af844">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42dc5e92-4c62-4b84-ab3b-1bd817752d2b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6ff6ec9-8be6-48da-b20f-5258b9ea02c2">
        <dc:identifier>HP:0004910*</dc:identifier>
        <rdfs:label>low proximal tubular reabsorption of bicarbonates</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004910</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/5ed21d6a-30ca-4ca7-8da9-e08b6ed50cf2">
    <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208400">
        <rdfs:label>ASPARTYLGLUCOSAMINURIA; AGU</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/208400</dc:identifier>
        <ddiem:iembaseAccessionNumber>258</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/053868a4-b29c-41de-9327-cc91f3926cfe"/>
        <rdfs:comment>As by 2016 Banning et al. mentioned "Currently, no treatment for AGU is available, although several preclinical studies aiming at enzyme replacement (ERT) or gene therapy have been published. Neither of these treatment options is expected to be available within the next few years</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/258</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb931e2d-83c6-4a01-b88e-e0383a6f5b51"/>
    <obo:RO_0003304>T122K</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d84a6e4-9fc0-4fe4-88c9-ffdb76ec1634">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low AGA activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0ed3bfb-0f5e-4b07-a662-8c8644bc8c1b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal AGA processing</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddb05d0b-2311-462d-bc93-c1da509945ec">
        <rdfs:label>Unstable AGA enzyme</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fee5408c-6a9d-4124-9e5a-9c7171cc7025">
        <rdfs:label>Misfolded AGA</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/79da0c2c-6fac-495a-bbb4-e0763265a620">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01a6b541-cc1c-494b-b5a9-477550887d3e">
        <dc:identifier>HP:0010918</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
        <rdfs:label>low intracellular cysteine*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b95aa945-bca5-4110-b114-70fead57dd81">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4950dcbd-0ef7-45f8-8e7a-d3a6fef555b9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b0e6698-8e8b-4c70-ae8b-7039dacdad90">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>behavioral abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/12757858</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231950">
        <dc:identifier>https://www.omim.org/entry/231950</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/214</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>214</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GLUTATHIONURIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5b33e140-904c-44a5-a0e7-7767275476ea"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d67aa3a-64fb-4c3a-bec4-42196c9a3e8d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003343</ddiem:url>
        <dc:identifier>HP:0003343</dc:identifier>
        <rdfs:label>GSH deficiency</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b907fa5-6f71-4f05-a4d3-f4d0789a56c8">
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal aspartate transaminase</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a72a674-2be8-44ea-b377-02c3240574e2">
    <rdfs:label>Abnormality of movement</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100022</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ad216af-c570-41ac-a78c-1b8971ae550c">
    <dc:identifier>HP:0012120</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Methylmalonic aciduria</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3513d0cd-d453-4c36-b238-3cde7a16fa56">
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d8edf2ee-82e3-4b72-bcdd-959d28bc9a69">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b769d425-22e3-4953-83c8-055cbfa6e6d8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03196765</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15262436-a18f-4e5f-b81e-696bf235f3f0">
        <rdfs:label>Elevated long chain fatty acids</rdfs:label>
        <dc:identifier>HP:0003455</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28200172</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39498903-9a18-4760-bddb-171a80af9947">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003199</dc:identifier>
    <rdfs:label>Low skeletal muscle mass</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003199</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b7fdec3-7bc3-4aa8-9cf5-60bfe842ad76">
    <dc:identifier>HP:0003800</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003800</ddiem:url>
    <rdfs:label>Muscle abnormality related to mitochondrial dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/46c9802d-4d94-4e48-b523-b81b21c4a62c">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/99b27243-5345-4f9b-86e2-5e274e9fc5c7"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25edc12f-c2a8-42f8-8d97-98690c9054d7">
        <dc:identifier>HP:0002630</dc:identifier>
        <rdfs:label>Malabsorption of lipid-soluble vitamins (Fat malabsorption)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bafdb7c3-d259-4649-b28b-032a13b3c43d">
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/f192467b-6277-42c7-b554-3f5bc1eff2c9">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d0504bf-c2a4-4ebf-883a-df810be03074"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2984f610-cd41-43bf-9832-0e2200957c91"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145980"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17803689</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/914f274b-76b2-4d89-9a8f-acaba9e8798e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b182f6b0-5893-4782-a857-145b5ff8a901"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28459040</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16882283</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44ff57d0-294d-48e1-9268-4f9993f73707"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/3e2ec155-c8d6-43aa-8beb-36e63ae9d878">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27050234</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600740"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9d01ce9-6a0a-4efa-b6c7-f8310fdab7ba"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2984f610-cd41-43bf-9832-0e2200957c91"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d983d5c2-1e08-4849-ae0b-bee1b594d10f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5dba5a9-61e2-48bb-b556-9aea28179b37"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <rdfs:label>Cinacalcet</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/3f221a1d-621a-42b3-8397-e2a1c769ef67">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d983d5c2-1e08-4849-ae0b-bee1b594d10f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5dba5a9-61e2-48bb-b556-9aea28179b37"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145981"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2984f610-cd41-43bf-9832-0e2200957c91"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28833550</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <dc:identifier>DB01012</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01012</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1731f966-5108-4bb9-82cc-b58438ba50e9">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d7932b8-d84e-41f6-acd3-c1c4f2bcd93b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003452</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <rdfs:label>Increased serum iron</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4739135</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/72a4e1a4-8045-4783-8a76-2b76c29967bf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dc11941f-cacf-47b5-b28f-a0ea0dc191af"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5080345</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12622622</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176100">
        <rdfs:label>PORPHYRIA CUTANEA TARDA</rdfs:label>
        <ddiem:iembaseAccessionNumber>114</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/114</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/768676e7-3a09-4df8-b201-b61ab3b16b9b"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a7c0af19-7b41-4eac-9d15-7bab3762c118"/>
        <dc:identifier>https://www.omim.org/entry/176100</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64ccb0b3-a203-4554-a77a-14b3a49df266">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated transferrin saturation</rdfs:label>
        <dc:identifier>HP:0012463</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012463</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/224486c3-b331-473e-983f-aa88f18b6cdf">
        <dc:identifier>HP:0010472*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <rdfs:label>Increased liver protoporphyrin concentration (Abnormality of the heme biosynthetic pathway)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6173993</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22985607</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4811840</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3ad03df-4adc-4688-8e69-2447ca4bb89b">
        <dc:identifier>HP:0012465</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012465</ddiem:url>
        <rdfs:label>Increased liver iron level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>C282Y/H63D  heterozygosity or compound heterozygosity /C282Y(Homozygous mutation)</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15441491</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/842abc51-8d7a-49b1-971e-b8bdcff2a40f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7324107</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9dabd739-0efe-4f2b-b847-3fff9b7e94c4">
        <rdfs:label>Increased serum ferritin</rdfs:label>
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602390">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HEMOCHROMATOSIS, TYPE 2A; HFE2A</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/581</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>581</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/602390</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7a77ebec-ea75-4802-b8fc-28070f18b69f"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/533e6e2d-b463-4919-99a8-6bbf5172b68a"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/40da2e40-466e-45ad-90db-1906ea504a26">
    <dc:identifier>DB00061</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a208105c-2cec-4a9e-b75d-cdcce56af54b">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/891ca67c-a98d-43ac-982e-1b4378be1b22"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4809b2fc-fa67-4e01-ae6a-0759a8c92131"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3e7b87e-fea3-4831-9d25-85eade85fea4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d69aa50e-9ccf-4997-8175-f25b37f88ebd"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/312b5078-83bb-4fc7-9b4c-d337c9cf5b2d"/>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071</dc:provenance>
        <rdfs:comment>Further data gathering is necessary to determine overall outcome of patients on long-term therapy "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9af20b93-35c7-4892-93da-634d299acfe4"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00061</ddiem:url>
    <rdfs:label>Pegademase</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c36d5a99-51cc-430b-9578-fe3fb1b0950f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29a4309e-6ccc-498d-b279-8d6ce22b2144"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220110">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/41299985-4d17-40fb-beb7-52766e835cc9"/>
        <ddiem:iembaseAccessionNumber>937</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/220110</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/937</ddiem:iembaseUrl>
        <rdfs:label>MITOCHONDRIAL COMPLEX IV DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2be1664c-a167-4dda-aae3-a7286d778f7a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Incoordination</rdfs:label>
    <dc:identifier>HP:0002311</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11e461e4-10fc-4ce5-a7f6-5b668083b859">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
    <rdfs:label>Decreased beta-galactosidase activity</rdfs:label>
    <dc:identifier>HP:0008166</dc:identifier>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/5a83de17-7c00-414b-9432-d1e4ebf40773">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607015">
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/607015</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
        <rdfs:label>HURLER-SCHEIE SYNDROME</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bd99069c-3bd7-489a-920d-028a75480a6e"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0a279e97-5aac-4424-a67c-fe1a8498fe81">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e2f4c504-4b96-4736-9750-1585db7ca454"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c417783f-7b02-4e9b-bf01-69c6aed9e6b4">
        <rdfs:label>Low IDUA activity(Abnormal enzyme activity)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <dc:identifier>HP:0012379</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29122734</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/ddad590a-676a-4dbb-921c-c5632ed3c253">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261640">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/4</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/16e261dc-4e0a-4d4a-af4e-4f2193459f14"/>
        <dc:identifier>https://www.omim.org/entry/261640</dc:identifier>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A</rdfs:label>
        <ddiem:iembaseAccessionNumber>4</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2d20a3c7-91b4-4526-9c4b-22e2c4d151ef"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d919e2a8-ad4f-4d5a-8f5a-90515983762d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effectshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d17e7677-c9d0-4f10-8423-8b391a2c5d68">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
    <dc:identifier>HP:0008344</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High plasma branched chain amino acids</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a351ee3-ae58-4078-b804-2e20236f3b50">
    <dc:identifier>HP:0012030</dc:identifier>
    <rdfs:label>Abnormal urinary steroid level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012030</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/03a1730c-bf7d-4069-8320-1e63534fd2c3">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245010">
        <ddiem:iembaseAccessionNumber>1110</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HAIM-MUNK SYNDROME; HMS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/245010</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1110</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/62f00518-af54-47e0-94db-d088d324cd5f"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/11533c24-7310-4305-9fe4-c149f8e0ab73">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ec9bb2a1-ddeb-4303-8cf6-233ca06eb71e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca54ef81-61b3-4825-a784-fab60a598013">
        <rdfs:label>Palmoplantar hyperkeratosis</rdfs:label>
        <dc:identifier>HP:0000972</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000972</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc28b508-7c15-482f-9c34-41a607328818">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cc5589cd-ee32-4a05-a4c0-c7d47d3f112a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5cc1584-39f2-4bdf-96df-335a316e3258">
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0002647</ddiem:url>
    <rdfs:label>decreased cholesterol absorption</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:0002647</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a16fb45-31d7-4f8f-9474-74c5e3d9f5e4">
    <dc:identifier>HP:0003676</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
    <rdfs:label>Disease progresssion</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a600bcb6-795c-48f8-8ecf-8c4ffa57b8ed">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/62fc0dff-e4ed-4649-af09-ae37c71106f1">
        <rdfs:label>Gentamicin C1a</rdfs:label>
        <dc:identifier>DB04729</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB04729</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fc924188-8bab-4e29-b3b8-3c2679712930"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000008 rdf:about="http://ddiem.phenomebrowser.net/b502f9a5-d3ea-4bff-8867-96c18d8592d8">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248360">
        <dc:identifier>https://www.omim.org/entry/248360</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MALONYL-CoA DECARBOXYLASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/177</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bcde1144-2102-4d29-9b88-480e7835745a"/>
        <ddiem:iembaseAccessionNumber>177</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10a9f1e2-8683-4b76-939a-05bfe729ffc3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High urinary malonic acid</rdfs:label>
        <dc:identifier>HP:0012120</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
  </obo:DDIEM_0000008>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/59548f91-9ae4-4861-b9e0-b699d2ca6f70">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24652768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24175354</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/41a9f5f7-0404-4406-b660-3f59146ca7c5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4d266870-6f77-4338-b833-ba2b43d623f3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12547874</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bbb6226-d212-479f-b472-adb420e7aa23">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low pancreatic zymogens</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/399f8129-b7c2-42de-b92c-8996abcd5265">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002574</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002574</ddiem:url>
        <rdfs:label>Acute episodic abdominal pain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176100"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/a947b60b-f3a0-412a-9675-ca6072e3e1c8">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3549e55a-43e0-4688-802b-ae240675a5ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c127406d-1822-4242-badc-87717a8c1882"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6aae251c-9833-4c59-9b02-7600114c3d31">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003710</ddiem:url>
        <dc:identifier>HP:0003710</dc:identifier>
        <rdfs:label>Exercise-induced muscle cramps</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44aed351-c0b8-43c5-ba00-625be5090017">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:label>Elevation of creatine kinase</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997711</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600890">
        <ddiem:iembaseAccessionNumber>178</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/178</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/73505bfe-205e-41e5-8dfc-953d05495af3"/>
        <rdfs:label>HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/600890</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000010>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8d750b0e-7d79-4233-a8e6-91edecaf2180">
    <ddiem:url>https://www.drugbank.ca/drugs/DB6756</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7807174a-9faf-4cf2-9fa2-fe0a6b8c19ec">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20356773</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
        <rdfs:comment>Due to prenatal diagnosis ofthe patient, early treatment with B vitamins and betaine had a favorable outcome. https://www.ncbi.nlm.nih.gov/pubmed/20356773</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f66608ee-ee6c-498d-b261-9bb8fe809044"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/822c17ac-70a9-40f4-9787-fea17d0b87d7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <dc:identifier>DB6756</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8a25cbc3-3c4d-4755-ba2a-fe8dc466fadd">
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54710675-83b0-48f6-99f9-28c14d98d914">
        <rdfs:label>Defected ClC-Kb expression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23772144</dc:provenance>
    <obo:RO_0003304>W610X</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d2c79ac1-decf-4d05-9560-05a7d89b17a8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/34163ee2-212e-44bd-93e9-2e8773db93cb"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/97f01d50-c8e0-4819-89a8-83c0325161fd">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145750">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/13969f6f-b5e8-458d-b2cd-3c70a8e04823"/>
        <dc:identifier>https://www.omim.org/entry/145750</dc:identifier>
        <rdfs:label>HYPERTRIGLYCERIDEMIA, FAMILIAL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc10c4c1-7259-4ecd-9558-342472b3222c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00465751</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2b78c331-1033-484e-8795-a4f210789582">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1719175</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f02480da-e665-417f-9aad-2bc7bbb2d178">
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:label>Neutropenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd2929e8-0d11-463c-9c24-6bc837e8b287">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002718</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
        <rdfs:label>Recurrent bacterial infection</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d69aa50e-9ccf-4997-8175-f25b37f88ebd">
        <rdfs:label>"Frequent, severe infections"</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002719</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec89e6c0-7a08-4281-8402-61623c0663f0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/52d0dcf9-0250-4aec-b8d1-ffaf63486d48"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1709246</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8447561</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/38d10556-4cb8-4b6c-b593-bc5fd4949dee">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dab324fb-c284-4ecb-a3fe-1bbd9915af28">
        <rdfs:label>Hypokalemia Metabolic Alkalosis</rdfs:label>
        <dc:identifier>HP:0002900</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC:0007121">
        <ddiem:url>http://purl.obolibrary.org/obo/EC_0007121</ddiem:url>
        <dc:identifier>EC:0007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/afa176b7-e0b0-43b6-9719-fa2cf9641b11"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/results</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601678">
        <rdfs:label>BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/601678</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ca6c18eb-6392-4bf6-b8be-a0b84f985951"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5694cbdf-a9ad-4937-a6c4-62d46ee79b36">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/61264fc0-e85f-41aa-ab61-8afe71ae0fba"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611105">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL</rdfs:label>
    <ddiem:iembaseAccessionNumber>446</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/446</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9529b27d-c6ae-4ffb-a9e0-883ae2550118"/>
    <dc:identifier>https://www.omim.org/entry/611105</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdc9e41e-aad6-4f78-8cd0-5e2d41a8fca6">
    <rdfs:label>high serum bilirubin level</rdfs:label>
    <dc:identifier>HP:0002904</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f218bb9-ffa8-4c54-b373-53f10dedb179">
    <dc:identifier>HP:0001510</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>growth faliure</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d50117e3-e3ed-4321-92ee-9f58a524b8ed">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased erythrocyte glycogen content</rdfs:label>
    <dc:identifier>HP:0001939</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3127a26-1d65-48d1-b161-15cb963c08c3">
    <rdfs:label>Abnormality of cardiovascular system physiology</rdfs:label>
    <dc:identifier>HP:0011025</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b081387e-7142-4e40-b05c-3a34d6f0a2bc">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/87c7851f-a65d-44d8-9635-3ee4caba33f9">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/151a4e92-8cf6-4f92-ab8f-b9d907e6482b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6f9db924-cfe5-43d0-b3d1-df58993c6498"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/939903a2-d532-4016-9f7b-a0fa55249d3d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/0431251d-d243-4c26-88e5-c5a22f88be21">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aa66b013-56bd-40ce-9b4c-2bf75a4e28d4"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/736e10c1-47fd-4ae0-9166-6143e27c9bc9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42d44b81-31ca-4c95-8a85-2510f5d4da20"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc10c4c1-7259-4ecd-9558-342472b3222c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/99b27243-5345-4f9b-86e2-5e274e9fc5c7"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec998174-5a50-412e-b983-d15f9853636e"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6f9db924-cfe5-43d0-b3d1-df58993c6498"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ffebcfa-f201-410d-8e07-396d0d529147"/>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Phylloquinone</rdfs:label>
    <dc:identifier>DB01022</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01022</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ac03822c-91b2-4f45-9b54-b905d4dddab0">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/63a36f6b-423e-4f79-b83b-fc1c2cf0bdc9">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd35b9f3-5c45-4ccc-bad2-98fc01894907"/>
        <dc:identifier>DB01234</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6eaf7ee1-38a1-4bc7-9a3d-1074ca908002"/>
        <rdfs:label>Dexamethasone</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01234</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c33b8ba9-dfd1-4578-965e-dc840d8bf5d0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008189</ddiem:url>
    <rdfs:label>low insulin senstivity</rdfs:label>
    <dc:identifier>HP:0008189</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/1c65e740-6eb3-49e0-a644-07d039a036ce">
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30208599</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee470567-8ae9-4b2a-a2a1-d4631979024d">
        <rdfs:label>Optic atrophy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000648</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000648</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/39112a4f-c73f-471c-822f-222d6b1e3407">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/76c55779-d21e-4b3a-b00a-98f6e5af3572"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/300ad90f-3655-4fe7-ba66-057e7c40a527">
        <dc:identifier>HP:0030532</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030532</ddiem:url>
        <rdfs:label>Abnormal visual acuity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd3b14f8-2e4f-4791-b9aa-bcf69887059c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low ATP synthesis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/facc55a6-64b8-4447-867d-1a44b41a7448">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90f21327-2750-4c46-a3dc-fa878e125d2c">
        <dc:identifier>HP:0003119*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:label>Increased free sphingosine accumulation(Abnormality of lipid metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48105f8a-a5a7-451a-ac9f-0aff85b5039f">
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:label>Rapid progression</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00b4f3fe-f90a-4027-bed9-5dacb977b0dd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26027824</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8071c02-7357-40fd-8e47-f0351785a647"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90093156-8fe8-4cb3-9361-d9b116448f6d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/48bc9d38-9d88-4136-9a6e-531a43ad413e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/49b3c591-fc14-41b8-a850-0cb3d64f0186"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed230f29-0244-436e-ace1-471e60e97f9d">
        <dc:identifier>HP:0001392</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001392</ddiem:url>
        <rdfs:label>Liver injury</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37e22a55-7827-4bfa-a5b1-21b30a69ff4e">
        <rdfs:label>Fine motor impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007010</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29429782</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fcfca63-7a28-47c2-97b3-d7aac1c5cf7a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High intraneuronal GSL storage</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/999779cf-d716-40f8-8ea9-29407dd500ca">
        <rdfs:label>Reduced life span (Mortality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040006*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fbc13c3-023d-4839-89c9-b88d971b29ce">
        <rdfs:label>Cholesterol sequestration (Abnormality of cholesterol metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <dc:identifier>HP:0003107*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fcb361a0-5422-4c32-b138-ed718598d967">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a55b4206-f48c-47fe-8d53-d0be72218971">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a7d9a496-e565-45b8-a46f-3da8e58afc5d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6336eab0-9726-4434-9a6f-615df63f9440">
        <dc:identifier>HP:0002902</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002902</ddiem:url>
        <rdfs:label>Hyponatremia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fdfe9725-9466-45cb-bb46-83019b6132ee">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6332e73c-df34-45fa-b56c-11055f51aa67">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a70b01f-5c45-4b72-ac2b-df87f9fd0330"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/727a886a-6723-41c2-9c05-0715e88a4c68"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a160f886-8031-48cf-8c08-61e0d1bfe511"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01362595</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02386267</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10959439</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fdaade5b-1b74-4825-a204-d212dfe1cd6b"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00149</ddiem:url>
    <rdfs:label>L-Leucine</rdfs:label>
    <dc:identifier>DB00149</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/57a6bf2a-574c-4118-a7a8-092c4d8ce78b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a1dd97f7-9e4e-4385-94ca-3f0b74afb362">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0da729ee-d08e-41a1-9d00-ffe38ca03e28"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15389992</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/982011f6-8bf4-4129-a942-c02ec400a582">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
        <rdfs:label>levodopa‐induced choreic dyskinesia(Dyskinesia)*</rdfs:label>
        <dc:identifier>HP:0100660*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/233910">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/3</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>3</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/25c33b37-04f5-44c5-88cb-f7b0784187e1"/>
        <dc:identifier>https://www.omim.org/entry/233910</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/876fe46b-340c-4766-9e98-2255f18e192a">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cdcf38c3-0a63-42d6-8555-035381b2c0c4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d7c51391-c766-44a5-94ce-879287db4284"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/889704f6-f1cd-4b9f-8bf7-89219b631837">
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>behavioural disturbance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28202261</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fc934995-65ac-4357-a9f4-dc4d5c5e7053">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cd1c2f18-b623-4992-941f-7e948ad1524c">
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03112889</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6516bbb4-eaa2-41eb-98aa-3cdc2f03ec4c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec52056d-a661-482c-8852-3b28db273dda"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bf7c31b5-278d-4253-9af8-78447f6eb699">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f5f805d-8509-48e7-ad71-beae600077d6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a735fbd-991f-48c4-9d84-efc4ba2506f0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275972</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ba7aba2-520f-496e-ac11-94b3935ccfa8"/>
        <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
        <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6516bbb4-eaa2-41eb-98aa-3cdc2f03ec4c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/23978571-f50c-44a7-b2f2-6d45d6441582"/>
        <dc:provenance>HP:0000750</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/042e571a-25de-45cc-bc39-c76f2ba77ab1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6516bbb4-eaa2-41eb-98aa-3cdc2f03ec4c"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/52b11812-7fb6-4cce-a6a9-b87cd22fd7b8">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
        <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6516bbb4-eaa2-41eb-98aa-3cdc2f03ec4c"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Valproic Acid</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bb64e69b-a0d6-4eb5-b932-201383993ac7">
        <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6516bbb4-eaa2-41eb-98aa-3cdc2f03ec4c"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00313</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a1aae468-62be-4e91-be9c-f090e134a32f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8964b843-5af1-4079-8c45-ee5d2c455c99"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00313</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ec4b8a35-1903-43b9-9c0d-fe81f44b8c6b">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6516bbb4-eaa2-41eb-98aa-3cdc2f03ec4c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d3c532e8-b946-495b-9690-a1b413f4c0af">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6516bbb4-eaa2-41eb-98aa-3cdc2f03ec4c"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
        <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78393129-1fff-4b51-bb69-c5400df391cd"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/250850"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e2f4c504-4b96-4736-9750-1585db7ca454">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a83de17-7c00-414b-9432-d1e4ebf40773"/>
    <rdfs:label>Nanotechnology-based gene therapy</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9700d529-d9e7-4092-807f-b129a799f787">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f218bb9-ffa8-4c54-b373-53f10dedb179"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f20cda8e-d4e9-4bd8-b0cf-b68671d099ff">
        <dc:identifier>HP:0100712</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100712</ddiem:url>
        <rdfs:label>changes in lumbar spine (LS)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8251af1c-46d1-4201-b402-911569c6c63a">
        <dc:identifier>HP:0004348</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
        <rdfs:label>abnormality in bone mineral density</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa153830-03f8-457a-920b-358d8c7c3c8c">
        <rdfs:label>thrombocytopenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230800">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20e645ce-1935-4826-b4d5-d1df5b464a51"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>288</ddiem:iembaseAccessionNumber>
        <rdfs:label>GAUCHER DISEASE, TYPE I</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/288</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/230800</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34baf317-d164-4578-96a8-86ad1803fb21">
        <rdfs:label>anaemia</rdfs:label>
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a013bdd-f0e9-45a7-b998-13420f1b7eec">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010885</ddiem:url>
        <dc:identifier>HP:0010885</dc:identifier>
        <rdfs:label>avascular osteonecrosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21bb856e-205a-4664-96a0-1bfd3bf600b2">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002653</dc:identifier>
        <rdfs:label>Bone pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002653</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29503270</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7256b2df-833a-4b95-9f36-39dd3b430766">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:label>hepatosplenomegaly</rdfs:label>
        <dc:identifier>HP:0001433</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/18b4bbbe-df59-4849-9806-78ab12676a2a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/722830d7-4181-46d5-bac9-c246b443ea2a"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b137b5c-88b6-45d8-9563-340e9e748257">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
    <rdfs:label>Low weight</rdfs:label>
    <dc:identifier>HP:0004325</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/61264fc0-e85f-41aa-ab61-8afe71ae0fba">
    <rdfs:label>Acetazolamide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/38d10556-4cb8-4b6c-b593-bc5fd4949dee"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5a876efa-0ac1-4813-a7ee-de52ce5044c1">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5694cbdf-a9ad-4937-a6c4-62d46ee79b36"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9c52a33-3d05-478a-9622-17a7d388b5f1"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00819</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6724ed96-3dc4-4f3f-a26f-0f46aaa19760">
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5694cbdf-a9ad-4937-a6c4-62d46ee79b36"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/908bffd8-ccc5-4323-b649-38092fbc6030"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00819</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/02bb2c5a-1d20-425a-9804-ff1172da4214">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/611105"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5694cbdf-a9ad-4937-a6c4-62d46ee79b36"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a669a65-fdfb-4818-a78a-f916450d781b"/>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21749991</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9da23cd9-3e33-4e94-9bb4-7411aa1b3851">
    <rdfs:label>respiratory insufficiency</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002093</ddiem:url>
    <dc:identifier>HP:0002093</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0e2bdd18-df46-4287-a3c8-91f8136b119f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abec3be9-cc4e-4320-bc0b-92ef68e4e87d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>movement disability</rdfs:label>
        <dc:identifier>HP:0100022</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd4a90df-730f-4ae4-a915-e9df35eecd93">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
        <rdfs:label>hyperprolactinemia</rdfs:label>
        <dc:identifier>HP:0000870</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1c66b905-7861-425c-ab5c-c634487728bd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c8ddd255-6782-47f1-b0ed-1415b11d4ee6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22325981</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa192c76-dfb1-4975-81ce-d4dcbd1de21e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
        <rdfs:label>dopamine deficiency</rdfs:label>
        <dc:identifier>HP:0012656</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a7fde2b-c307-4e44-a1d0-220acd7a9900">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:label>behavioral disability</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/478962b6-56b7-41b4-993b-0b88ee10ff47">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0ac9755c-32d6-4fa1-9ef0-97cc93ea4608"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0212c985-f816-47e4-995e-a214d71ae8cc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/5d2d00ad-d0bf-416c-b3dd-656d9f73a102">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/247dad1e-a2d8-49f9-9647-07b6db78142d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010472*</dc:identifier>
        <rdfs:label>Hepatic prophyria(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23016163</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41a9f5f7-0404-4406-b660-3f59146ca7c5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18c98805-c3f2-4939-85bb-984201700cbb">
    <dc:identifier>HP:0000488</dc:identifier>
    <rdfs:label>Retinopathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/c60543f3-b49a-46a5-ad4c-7a56c154f52c">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/70253860-4f06-4deb-b94b-d5827ae8d6c9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ee8f4b47-3a92-4d15-939a-8221981b24f0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0212c985-f816-47e4-995e-a214d71ae8cc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc2cce28-10f1-47bd-9a19-0d46dcfeb5df">
        <rdfs:label>Hyperlipidemia</rdfs:label>
        <dc:identifier>HP:0003077</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c80b4d8-49c5-406f-8f29-8cf409faf399"/>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a97a7bf3-8a67-4dc4-8202-3d8cbf21efcd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000105</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Enlarged kidney</rdfs:label>
        <dc:identifier>HP:0000105</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10625614</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/547aed08-65ac-43ba-9dfe-85e3e4b710a4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperuricemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f6768da-13be-44c6-a60f-ad80ef71d294">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Growth retardation</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/3ae50ce2-4819-4660-a95c-39cc4e11ff65">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0baeacd9-ac6c-4714-a987-07abb47df2a1"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cb92873b-bbc1-4163-8441-ee19e504b46e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6caaf0a-5ed5-48f7-b76f-89c41766cf99">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>elevated intraneuronal cholesterol(Abnormality of cholesterol metabolism)*</rdfs:label>
        <dc:identifier>HP:0003107*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78cd2c43-59bb-4b92-bd7e-e7c839ccf69e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
    <rdfs:label>Cataract</rdfs:label>
    <dc:identifier>HP:0000518</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/580d78fd-797d-460d-9a53-00fac4d3f7c4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c06f6f01-74be-41ed-9cfc-79c68f87c75c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:label>muscle weakness</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001324</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/213700">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0def1369-196f-4b86-a8bc-939a87048f17"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/183</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>183</ddiem:iembaseAccessionNumber>
        <rdfs:label>CEREBROTENDINOUS XANTHOMATOSIS; CTX</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/213700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2bcdc5d-4d05-434b-add1-1d6626b83e40">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010832</ddiem:url>
    <dc:identifier>HP:0010832*</dc:identifier>
    <rdfs:label>Neuropathic pain(Abnormality of pain sensation)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/68459880-66b7-47c7-a7dc-6c80820793f1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29702557</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da3cd38b-6b8b-4f26-9f3a-b8e929991dfe">
        <rdfs:label>Abnormal Golgi located fucosylation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fec0cb2b-05c4-4634-8e17-bf9c136e4ae1">
        <rdfs:label>low neutrophil count</rdfs:label>
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f02480da-e665-417f-9aad-2bc7bbb2d178"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0006609-4389-4a43-a4ef-681b8fe67bf8">
        <dc:identifier>HP:0010977</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010977</ddiem:url>
        <rdfs:label>defected phagocytic function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>the patient showed significant psychomotor improvement while on fucose therapy."</dc:provenance>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74c30c98-a37e-4c31-a502-67dc059c97c3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal selectin ligand function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266265">
        <ddiem:iembaseAccessionNumber>341</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/266265</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/341</ddiem:iembaseUrl>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/89395895-aff0-49be-a9e8-3586ba5fba2a"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>correction of the delayed psychomotor development was expected to be more difficult to achieve. However</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/94/12/3976.abstract</dc:provenance>
    <dc:provenance>http://www.jbc.org/content/282/14/10762.long#ref-14</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3fa1d8c2-2c10-4856-a12f-c36d20a13523">
        <dc:identifier>HP:0001263*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:label>atypical psychomotor development</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>"espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II)</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1e574776-c2a9-479b-bab6-e2b1d353efeb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7834cbee-6234-40c7-aa78-45697e564d8b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55acedca-97a2-4e6d-9517-08ee61f190e7">
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <rdfs:label>recurrent infection</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fcfaa93-1736-48cc-9e0e-aa129a1b5c5e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal expression of E- and P-selectin ligands</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17276979</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84522112-b666-43ab-b556-1257d33c3d5a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal fucosylation state of glycoconjugates.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fcaf960-aed6-437a-8bbb-fd255282ac48">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0500014</dc:identifier>
    <rdfs:label>Histologic abnormalities in liver(Abnormal test result)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5a45a84-b1fd-424e-b845-5c19477ec4ce">
    <dc:identifier>HP:0001263</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
    <rdfs:label>Delayed development</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/8c572c61-c618-4ef8-ab2d-1d0a164fbd2d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9559978c-f7e7-45d7-a09c-e9ac804b0a6b">
        <rdfs:label>Failure to thrive</rdfs:label>
        <dc:identifier>HP:0001508</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28053874</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/37d74f32-dcd7-4182-b424-94cbfbca562f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/611283"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a84e6db3-89a0-4b97-b736-f1388eb8d6a7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16906475</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e9d01e60-4081-4d37-9a22-9b3f21fe8cf9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d94e0b70-0eb9-438d-a127-db37f156ee93"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8503027-13c8-4d4b-98b4-eaa2ca0b5bc3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000718</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Aggressive behavior</rdfs:label>
        <dc:identifier>HP:0000718</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24001191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3be71b2f-4f09-43c4-94cf-f3fa94288bfc">
        <rdfs:label>Self-injurious behaviour</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
        <dc:identifier>HP:0100716</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24055166</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26b81adb-b2ac-40f3-b88e-d7b7bca5e522">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <rdfs:label>Lipid accumulation( Abnorality in lipid meabolism)*</rdfs:label>
    <dc:identifier>HP:0003119*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77701787-c6a8-473e-8893-a143208a9683">
    <dc:identifier>HP:0001019</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Erythroderma</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f87f8d10-25c9-4283-8296-1ca4dcf6b499">
    <rdfs:label>Pargyline</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/786b6abe-72c5-4add-a557-2c371622f45f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9f367694-96c1-443c-bdb4-fbc9f2693c5b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a98f65eb-1f57-413a-94bb-fb17e1ea8255"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <dc:identifier>DB01626</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01626</ddiem:url>
  </ddiem:Drug>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/70bc8794-e149-4435-9fe2-61993cf25c2f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/713cf798-4bbc-4b62-a0eb-b01c669db2a6">
        <rdfs:label>Abnormality of metabolism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/842abc51-8d7a-49b1-971e-b8bdcff2a40f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/410c3ded-968a-4c44-94c7-a83f34aef38c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/59d4cbf7-d48d-4087-9e5f-3ac427fa6e3a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c9efebe-ad53-48ae-b0b4-ce21bddca905"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/366178ee-4345-44f5-9799-dbdd26fcff64">
        <rdfs:label>Increased inflammatory response</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
        <dc:identifier>HP:0012649</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e44c4c46-102b-40b0-94ad-e6f73b742b4e">
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/275630">
        <ddiem:iembaseAccessionNumber>753</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/275630</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cdff7f52-fb89-4762-b053-b0a67d0d8ae6"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CHANARIN-DORFMAN SYNDROME; CDS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/753</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec998174-5a50-412e-b983-d15f9853636e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8b2e9d95-134a-48d1-ad8e-357d09a7ec22"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2b6ba49-1052-453b-9cde-64202b7ed5a3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>steatohepatitis</rdfs:label>
        <dc:identifier>HP:0001397</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88e84a21-9746-4ae6-b801-a875f7911ed9">
    <dc:identifier>HP:0009020</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal exercise physiology</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/146fa6a6-ec10-4469-949c-f559d427e3d6">
    <dc:identifier>HP:0030980*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low CSF glutamine level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1360b9ad-d615-405d-9f6b-6c6c864a75fb">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012500</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012500</ddiem:url>
    <rdfs:label>verrucous lesions</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6c433af9-025c-47aa-92b0-c9aeb3fc3e46">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/780d8690-46f9-4a54-adfd-c41b1bcb5a34">
        <dc:identifier>DB12890</dc:identifier>
        <rdfs:label>Dihydrexidine</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB12890</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4c0c8f96-3df2-477c-b258-a063e091bcf2"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/3781f25d-0e41-468b-91f4-fe21d4d5798c">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309400">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/199</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MENKES DISEASE</rdfs:label>
        <ddiem:iembaseAccessionNumber>199</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e76c72e6-eccc-42a1-adc0-80dfead8c7f2"/>
        <dc:identifier>https://www.omim.org/entry/309400</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8223785</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f5b0d62-7de3-4164-b784-63ab2da3ab62">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002344</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
        <rdfs:label>Neurologic burden</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652413</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfc1c827-8bf9-4aa1-93c5-bcc6bafa3d96">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025373</ddiem:url>
        <dc:identifier>HP:0025373</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Eplieptic discharge (Interictal EEG abnormality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28cb5e1f-aa8f-4653-8932-a542f0bf512c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012389</ddiem:url>
        <dc:identifier>HP:0012389</dc:identifier>
        <rdfs:label>Appendicular hyoptonia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10401004</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4e2ceb7-cb05-4016-a8a7-0bf632d42755">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Woolly hair</rdfs:label>
        <dc:identifier>HP:0002224</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002224</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>N1304S</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cde92aa1-74eb-4239-8178-850ec5d74b44">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:label>Low muscular tone</rdfs:label>
        <dc:identifier>HP:0001290</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a710785-b5db-428e-82cf-2cd1da18b92b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001508</dc:identifier>
        <rdfs:label>Poor weight gain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b01bbd78-e600-4f4c-b428-26260991444b">
        <dc:identifier>HP:0001010</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001010</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypopigmented skin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a53d53ff-fa62-415a-bb06-4ac939792237">
        <rdfs:label>Socio-cognitive abnormality(Neurodevelopmental abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012759*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <ddiem:failedToContributeToCondition>2757delAG</ddiem:failedToContributeToCondition>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <ddiem:failedToContributeToCondition>Q1385X</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001262</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9aff0f28-9c2b-4c31-b476-6b8f00dd8eed">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal brain electrical activity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <ddiem:failedToContributeToCondition>Del ex20–23</ddiem:failedToContributeToCondition>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93903192-2746-41a6-88b5-44531cf1b262">
        <rdfs:label>Neurological abnormalities.</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f45fd7d6-9bee-4699-b4e0-aa8330f0cbbb">
        <dc:identifier>HP:0003678</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Rapid disease progression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0003304>"IVS9,DS,+6T→G"</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/78a6ef55-ac25-4909-a9c8-57825e4bf052">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6c0b6cea-1c59-4663-b0b1-c66ed0d77c89"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>G666R</obo:RO_0003304>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/547f8ecc-1673-4378-ab2b-e2d8bdbc23ab">
    <dc:identifier>HP:0011197</dc:identifier>
    <rdfs:label>EEG with focal spike waves</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011197</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f8b3d1df-d76d-4ff2-818e-3962c04aa8d3">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_28384</ddiem:url>
    <dc:identifier>CHEBI_28384</dc:identifier>
    <rdfs:label>vitamine K</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/50fd261e-ceb9-4681-ba10-22cbb772af8f">
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6ebc84ad-37ff-46ef-a428-1022d881d367"/>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25edc12f-c2a8-42f8-8d97-98690c9054d7"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/84f0882a-ab54-46a0-9185-248a8f66fc00">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b81e8ae-7557-4931-93ce-acf79f002414"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e9b0ea3-d37f-41cc-b3a9-34b65dead40f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
        <rdfs:label>Low total RBC folate level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040087</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67a07278-7bed-48a5-b3bf-acc97dc48464">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012446</dc:identifier>
        <rdfs:label>Abnormal CSF folate level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d8dbcbc-6052-4ab2-bd22-a2dcca1b10b8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e271673-ef15-4778-ae4e-6046519606e9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001980</ddiem:url>
        <dc:identifier>HP:0001980</dc:identifier>
        <rdfs:label>Bone marrow megaloblastic changes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ac9a7e2-bd09-46b7-9c90-8051fff4e78b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012446</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <rdfs:label>Low 5-MTHF level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2712eb0-93d4-4717-97b3-33cbacd9054b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025454</ddiem:url>
        <dc:identifier>HP:0025454*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abscent 5-MTHF(Abnormal CSF metabolite level)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d83eb58-2a74-49c7-88be-f9be2254c0fa">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000565</ddiem:url>
    <dc:identifier>HP:0000565</dc:identifier>
    <rdfs:label>esotropia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/96d3ba48-54bd-407c-adab-d4193590591a">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec57f2e9-f607-4061-b4da-0996016f8e79"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7474896</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39be9aca-2c6d-460a-a537-afeb80bbc5cf">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>defected excertion of 3- MCG</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ab68474-3e4c-467d-87b7-a00e3fab2f23"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
  </obo:DDIEM_0000007>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fa31a7d8-bed4-4bc7-9e9e-90f5395ad1b9">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2a78df12-2475-494f-a72d-8062ca27a701">
        <dc:identifier>DB14502</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB14502</ddiem:url>
        <rdfs:label>Sodium phosphate, dibasic</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4284e134-ac0f-4ec3-bc16-561206e63a48"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7ccbabce-44f8-456c-94d0-d13390728ce0">
        <dc:identifier>DB09449</dc:identifier>
        <rdfs:label>Sodium phosphate, monobasic</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB09449</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4284e134-ac0f-4ec3-bc16-561206e63a48"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/af3a20b2-566d-4246-bc22-6d53d8cfe75f">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7a3f299-7398-48d8-a374-8eb2f176d267">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal ClC-Ka function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0003304>L155/ G345/ A349</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <ddiem:failedToContributeToCondition>G167A / F213A</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0003304>"L155A, G345S and A349E"</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1e733500-667b-4433-bec0-40f99be83f3f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2f0f62ff-c25d-4582-ad6e-bc1769527aca"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20649569</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000006 rdf:about="http://ddiem.phenomebrowser.net/4369b02f-6e9f-4be3-b472-0c63262c409b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2785251</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d80052db-0724-45ab-bbee-67f5b72384e4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa29cca4-0bf2-40cd-ac0c-1e9247cf0da1">
        <dc:identifier>HP:0007346</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007346</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Subcortical calcification</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/323ff71c-afe3-421d-a991-90ebec62bc52">
        <rdfs:label>Progressive basal ganglia calcification</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002135</ddiem:url>
        <dc:identifier>HP:0002135</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db4b50df-c3e7-47a9-b879-9db768ffb1b3">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>Seizure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000006>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/6c2bb701-f9ed-4d3c-a200-71936c83da2e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26157418-579a-4565-886b-77a67496560c">
        <rdfs:label>urolithiasis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000787</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000787</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9f1b69bd-af9e-4c12-a816-fa7c4992f362">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74cdff4b-823e-4172-b679-89397f4c29f2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3fa7adc9-7363-4a8e-bf13-1b1c80ffce4d">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
        <rdfs:label>Chronic kidney disease</rdfs:label>
        <dc:identifier>HP:0012622</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614723">
        <rdfs:label>ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0f7d451a-d809-4917-b5bb-687965827b1b"/>
        <dc:identifier>https://www.omim.org/entry/614723</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f229e06-448d-471b-9e4a-2d45db0d7e10">
        <dc:identifier>HP:0000790</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000790</ddiem:url>
        <rdfs:label>Hematuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb47b3a7-635a-44a4-bb5d-f2b09ad06b02">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100518</ddiem:url>
        <rdfs:label>Dysuria</rdfs:label>
        <dc:identifier>HP:0100518</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2ee3e7e-ed9f-4be6-8487-7bf9eadc0a54">
        <dc:identifier>HP:0000112</dc:identifier>
        <rdfs:label>crystalline nephropathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fd42896-46b0-46a0-a595-f262ad5379c2">
        <rdfs:label>Recurrent urinary tract infections</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000010</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5576d0a-5524-43ca-8b1f-5000b2e4299b">
        <rdfs:label>Elevated Urinary DHA excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0bd0d63c-edda-47e2-9eab-43d8618147d3">
    <rdfs:label>Isoniazid</rdfs:label>
    <dc:identifier>DB00951</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/46b4aabf-5ad8-403f-a5ee-05658b95f7eb">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01550705</dc:provenance>
        <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8583a1b5-e1ea-41c5-b62a-7df3e509eab3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24459c26-d408-4e20-ba9d-8ab34f430a3d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00951</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a51c88d-701c-49e1-82d0-53d60dfd74c2">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>impairment of reference</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72afb3e1-47c3-478a-8d2e-3d4c990c8afc">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal serum renin level</rdfs:label>
    <dc:identifier>HP:0040084</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/baab0737-274e-42c3-b7be-ce6f78735a07">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003679</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cardiomyopathy progrssion</rdfs:label>
    <dc:identifier>HP:0003679</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/99f5ca40-02b7-4e40-a193-b97a804f342c">
    <rdfs:label>Gene therapy (wild-type Ad-AGA)</rdfs:label>
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/de58d6d4-8dbb-45b7-ba84-786fa1c6875b">
        <rdfs:comment>The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c931eeb-b756-422d-8386-593a93504aa8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/98c7cf49-ad8d-4ca5-baf3-fcc1cd9f386d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16518877</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/32261513-76d0-4445-a8f8-d6f74f3f158a"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9930336</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85874332-8ee0-43d5-97a9-21f9e70689f9"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b807e186-d1ab-437d-8717-7fa03e676466"/>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5eea987d-7415-408d-beba-e033ba1a0189">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cf588126-fc65-4bf4-ab0b-8ce4d9d8cfbd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aa844496-c5d8-424a-ac50-9ef94bd84b20"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae1d1341-d71b-4d49-a3ac-7cfa3d89e4d3">
        <dc:identifier>HP:0004302*</dc:identifier>
        <rdfs:label>disability(Functional motor problems)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232600">
        <rdfs:label>GLYCOGEN STORAGE DISEASE V; GSD5</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/489</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/232600</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>489</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/49e0628c-ef07-4a2d-8a30-51f15cda87df"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88e84a21-9746-4ae6-b801-a875f7911ed9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18098237</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f56c2fbe-c27c-4d65-8825-8c601849cde7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
    <rdfs:label>muscle pain</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003326</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/13e02bb5-9877-4586-9140-daf64836ad5d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d8dbcbc-6052-4ab2-bd22-a2dcca1b10b8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734130</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ac1e0e3-741a-43fb-88ea-290e6c3d097d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010819</dc:identifier>
        <rdfs:label>astatic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010819</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09e02a0e-7f8c-4421-927b-0f2f9586c5b4">
        <dc:identifier>HP:0000735</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Impaired social interaction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7c92e70-ac43-44d9-b11a-e261ea41ae5a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
        <dc:identifier>HP:0002123</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myoclonic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e6e1448-b944-4dff-9f88-d8d8010c7fcf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613068">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/71</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/133cda4f-2ec8-4686-a9c7-a6d97e1052a3"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>71</ddiem:iembaseAccessionNumber>
        <rdfs:label>NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/613068</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68530370-8784-4910-964f-b65688a9e71f">
        <rdfs:label>Movement disorder</rdfs:label>
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727671</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/32381a97-5889-4541-b1c7-06d782817fa6">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/767f2382-f240-4bf8-97af-c39170350221">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated serum cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7964884</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fc448b6-0903-4bba-9a23-6d9d8ca3f488">
        <dc:identifier>HP:0001114</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001114</ddiem:url>
        <rdfs:label>Xanthoma</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71a6d526-76b5-4335-858b-d3431cef0bf0"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc10c4c1-7259-4ecd-9558-342472b3222c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/496af2a4-8ccc-4878-bb7d-5aba54f939ff"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/b817444d-69d9-4fc7-9649-a52c8ad12227">
    <obo:RO_0003304>A354V</obo:RO_0003304>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22202226</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/741c9a38-12e5-4c83-8d15-045ff4ea2ace">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low COX content and activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>A354V and C12775STOP</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220111">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/425</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>425</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/220111</dc:identifier>
        <rdfs:label>LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC</rdfs:label>
        <rdfs:comment>Antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death. Collectively, our results raise some concerns about the potential negative impact of a high-fat diet and of antioxidant treatments in LSFC patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383560/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fa5a5dd2-c6f1-4b64-9b0d-4a657960c28d"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eef50408-9a49-4c6c-9e25-a0885443d16c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8d33ca8f-6ac6-4333-9091-a2fe8f641273"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4290fbb-6e8b-46f0-937b-1b99abfd3649">
        <rdfs:label>acidotic crises</rdfs:label>
        <dc:identifier>HP:0001941*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2c742fd6-5610-4767-bfc5-e5cc43b9595c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1abf54e-42dc-4ab3-856b-da0069a12fda">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/40e5ed3b-b6be-4498-bd0b-2ba13c7111c3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb944501-67a1-48e3-b561-55a5f1c82503">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>No result is  added</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00244582</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230900">
        <rdfs:comment>By Knocking out RIPK3, we show that modulating the receptor-interacting protein kinase-3 (Ripk3) pathway markedly improves neurological and systemic disease in a mouse model of GD. https://www.ncbi.nlm.nih.gov/pubmed/24441827
Notably, Ripk3 deficiency substantially improved the clinical course of GD mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury.</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/230900</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20e645ce-1935-4826-b4d5-d1df5b464a51"/>
        <rdfs:label>GAUCHER DISEASE, TYPE II</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/306af4bb-5826-4735-adec-f388c35e8c17">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c26664bc-e9ee-4339-ae14-75b7e049f56f">
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fd01df13-69e6-455e-ab03-debd744d4e65"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67144ca8-202e-439a-89b2-26d822cab09e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14151</ddiem:url>
    <dc:identifier>DB14151</dc:identifier>
    <rdfs:label>Phosphorus</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7f6f7ddd-0da2-4856-8428-c5d0ab1d8bc4">
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33b898ff-f949-4643-8542-e2010fdec7a5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PL-induced cytotoxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/370af287-dd04-47be-80c5-52922ef40b0a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Optic nerve damage</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001138</ddiem:url>
    <dc:identifier>HP:0001138</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/72d7a23b-014f-40a0-8ffe-5bc25578e154">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11767031</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aa66b013-56bd-40ce-9b4c-2bf75a4e28d4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14749227</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94d8c039-c78e-4fdd-afba-60365bd829d3">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000546</ddiem:url>
        <dc:identifier>HP:0000546</dc:identifier>
        <rdfs:label>Retinal degeneration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72d43680-393f-45b9-9226-6175be214012"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/3e01e917-be00-4670-bad1-07d9256da75d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7182e1d2-795c-4398-adb2-16f4487fda25">
        <rdfs:label>Functional motoe deficit</rdfs:label>
        <dc:identifier>HP:0004302</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://n.neurology.org/content/90/15_Supplement/P3.327</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256600"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb5bdc11-1b2f-4938-87d4-0a42cdd0a100">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cafaa4c4-382a-4554-b297-a429340f857f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1711f456-0b6a-41cf-8ffd-f4d052472860">
        <rdfs:label>Chronic constipation</rdfs:label>
        <dc:identifier>HP:0012450</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012450</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64a795f0-6c53-4358-82ca-9652d2b347a6">
        <rdfs:label>Defective eye motor function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000496</ddiem:url>
        <dc:identifier>HP:0000496</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03570931</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1a49668-784a-4ca0-a066-e4a860b35096">
        <rdfs:label>Bulbar dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001283</ddiem:url>
        <dc:identifier>HP:0001283</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a57dd1e-220a-428d-998c-2d64137efa2e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002421</ddiem:url>
        <dc:identifier>HP:0002421</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor head control</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (“fireproof”) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/5176242c-ba0d-4bee-b331-64d42ffdc313">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/da78b722-6c35-4a3c-8560-5e086b7fb94c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/73c41e2b-8c2d-4f57-8c1e-92be9e791574"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609242">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/263</ddiem:iembaseUrl>
        <rdfs:label>KANZAKI DISEASE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/609242</dc:identifier>
        <ddiem:iembaseAccessionNumber>263</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/57822836-cd02-405a-9a15-bff1b505f801"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0005542">
        <ddiem:url>http://purl.obolibrary.org/obo/EC0_0005542</ddiem:url>
        <dc:identifier>EC0:0005542</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/016b579e-8739-46c4-9170-1862bde75bd5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal enzyme activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4f3429a4-e358-4f81-a73d-f5d1defd8e19">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/260920">
        <dc:identifier>https://www.omim.org/entry/260920</dc:identifier>
        <ddiem:iembaseAccessionNumber>191</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7a20083d-b8be-4dc2-9369-fc160da68ae4"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/191</ddiem:iembaseUrl>
        <rdfs:label>HYPER-IgD SYNDROME; HIDS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b596b261-9d94-4338-a845-d41923d3ef10"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24935455</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae1cb10d-825f-467e-86f9-3d5174b4ea5f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
        <dc:identifier>HP:0010978</dc:identifier>
        <rdfs:label>Abnormality of immune system physiology</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4858cd2a-a76b-405f-96fa-9d4eefa18727">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1d439aaf-d698-4d3c-8fb6-8b078b7a207e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd63c576-f445-4b81-bf91-33a0e70e6f27">
        <dc:identifier>HP:0001954</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
        <rdfs:label>periodic fever</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f0fb45d-e0a8-4a33-ab11-b71e929f877e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elbow skin thickening</rdfs:label>
    <dc:identifier>HP:0001072</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001072</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7cd22a83-1c97-4e4b-a2f6-6efbb5307c77">
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1228bea-da1c-4d61-911b-5c5712edc366">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0b17b137-aadf-4a0c-801d-50010d323702"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34baf317-d164-4578-96a8-86ad1803fb21"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4a68535-d69a-43f3-b700-3d9c1a0acd7d"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d51510a9-b960-490b-8524-89a040f9467b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cf9cef5a-4083-48fd-b900-751782184f5c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/39a83564-85eb-4518-b07b-a2768498e538">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b79a23ee-f02c-4221-9aad-3cbe3c103b2d">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c2c7564e-b75a-4b1f-80d9-f403b39b015f"/>
        <rdfs:label>Pitressin tannate in oil</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/169e27b1-7c4e-48cc-ab09-060319fc08ed">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6cf7ee8c-023d-4e5e-9549-11478072c8eb">
        <rdfs:label>low RBC count</rdfs:label>
        <dc:identifier>HP:0001877</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/075ea7c5-2db0-49ba-a58a-1a18ab692cb8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9ebc23ba-5a11-4248-8d40-47b4a96e26a8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01034592</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/99643801-5ccc-4c2b-a486-c237eed6f91e">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03508687</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2eafb20b-075e-4950-9a00-7a6856ee01ca">
        <dc:identifier>HP:0001397</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatic steatosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/328946c0-25c6-487b-93ab-979c8cc4e677">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3bf63761-3aa1-443b-8036-79a6dcd1fa2f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151660">
        <dc:identifier>https://www.omim.org/entry/151660</dc:identifier>
        <rdfs:label>LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2</rdfs:label>
        <rdfs:comment>Data regarding TZD therapy and the restoration of adipose tissue in lipoatrophic areas has been conflicting; it appears as though TZDs do not improve lipoatrophy in patients with FPLD2. https://www.ncbi.nlm.nih.gov/pubmed/19040647/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/89d4a413-c604-4f4a-aaf3-51662d17adaf"/>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bd39c6a-f24a-4b07-b3f9-c45a90f3776f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low tetrahydrobiopterin level</rdfs:label>
    <dc:identifier>HP:0040210</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040210</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5bbc2c9e-dbfe-48e3-ad18-e138546cc759">
    <dc:identifier>HP:0002148</dc:identifier>
    <rdfs:label>Hypophosphatemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0f6ad7bd-e3de-44b3-ac7d-d36554a72411">
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/324a45fb-96ff-43dc-91b3-2d76359590cd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007479</ddiem:url>
        <rdfs:label>Collodion membrane(Nonbullous congenital ichthyosiform erythroderma)*</rdfs:label>
        <dc:identifier>HP:0007479*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>"ENB-0040</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d185226-71e3-402e-b67d-7d1016159e2a">
        <rdfs:label>Scaling</rdfs:label>
        <dc:identifier>HP:0040189</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b077f10-14b4-4538-858a-ec2d5e686f7c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ichthyosis</rdfs:label>
        <dc:identifier>HP:0008064</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77701787-c6a8-473e-8893-a143208a9683"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e42592ce-0c43-4ba1-a4b1-87f708085a06">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/471e549c-1eb5-450d-b4b6-5e9d7aaed10a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dbc83467-50c3-4135-a5c8-9c2a86b30e4f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/30101edc-5346-49ff-826c-b3fb956c9543"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21981352</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a03aba8-f1c5-4188-a6af-b9cb71af82df">
        <dc:identifier>HP:0040189*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Diffuse scaling(Skin Scaling)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/011e7ebf-0cb3-4e47-b82a-5740f1f3c4b7"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28979034</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/b600de9d-68ff-46b2-8ef7-30be2d68f217">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02363946</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d9be565-79c1-47d0-94e6-11bca5a91c9b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/49a423b2-ec20-4b62-8a0f-bd6cedbabcf8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23527792</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4284e134-ac0f-4ec3-bc16-561206e63a48">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fa31a7d8-bed4-4bc7-9e9e-90f5395ad1b9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e682d02-7844-45d0-b09b-c4914d8c6f1b">
        <dc:identifier>HP:0100529</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
        <rdfs:label>Phosphate imbalance (Abnormality of phosphate homeostasis)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/99b27243-5345-4f9b-86e2-5e274e9fc5c7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea6b61b5-4a88-434a-bcaa-10d64e94d190">
    <dc:identifier>HP:0003201</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
    <rdfs:label>Rhabdomyolysis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1480dbcf-2f3d-4255-9884-d1723e21f81c">
    <obo:RO_0000056>
      <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/0e3cdeff-2e79-4d71-bbb7-fff5b788494e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d0ddfdb-8fef-4319-b4fe-3dfe5712d4f4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e63c3b73-4fe4-4202-b317-d4f434d93f0b"/>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
      </obo:DDIEM_0000010>
    </obo:RO_0000056>
    <rdfs:label>Complex carbohydrates+Beneprotein+Low fats</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/fd6d2bf9-683c-4775-adfe-92b95f683c2e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253600">
        <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/baf9a0ff-4966-4de3-ae6a-791b4e0622c2"/>
        <dc:identifier>https://www.omim.org/entry/253600</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/39b67193-466b-4b69-8f7d-383cc51b1efe">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b20386d0-145c-42df-afb4-da675a36161f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39601c0f-22a4-4e7c-ab6a-b7a91deda6ab">
        <rdfs:label>abnormal muscle strenght</rdfs:label>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c240f88-542c-4c6c-a8de-2c685fae07bd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003797</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Muscle atrophy</rdfs:label>
        <dc:identifier>HP:0003797</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dbbc555c-1bd1-4fe2-baff-2335f2500962">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal motor development</rdfs:label>
    <dc:identifier>HP:0001270</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2d03d5f6-8630-402a-ae87-9d8ccd086ac5">
    <rdfs:label>Clofibrate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00636</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/0994b1ac-dc96-4156-b870-4186849e4a9f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4f4f6e8-d1cb-4d8b-96e1-ab426850a2a7"/>
        <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc7784ce-2b56-4cb5-aadd-9619ce723c61"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b81e5f6e-74f4-4434-a292-2e2389411328">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884783</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68101e8f-05cb-42b8-8b1a-836b4f3b17df"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0112790a-4124-4a41-85bc-db93748b70c9"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4f4f6e8-d1cb-4d8b-96e1-ab426850a2a7"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00636</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/5d419c74-1d95-4c95-8a91-803aac92cc03">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4f4f6e8-d1cb-4d8b-96e1-ab426850a2a7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7483726</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c9efebe-ad53-48ae-b0b4-ce21bddca905"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235200">
    <dc:identifier>https://www.omim.org/entry/235200</dc:identifier>
    <ddiem:iembaseAccessionNumber>203</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3794a8fc-6499-4e2a-837f-e8e088e11afe"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/203</ddiem:iembaseUrl>
    <rdfs:label>HEMOCHROMATOSIS, TYPE 1; HFE1</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/410dd1bc-ac28-4b26-a791-e74895ec9bda">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001324</dc:identifier>
    <rdfs:label>Mueculoskeletal dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/ca84407d-b2d4-4a87-82b3-8a967fcd4349">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea835101-844a-4479-9d15-eb4a1dea965e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/87d89192-2231-4ad8-95b7-0370c6707142"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d9f61fa-98ef-4a62-8154-5e556864b7bd">
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:label>Low mean hemoglobin level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a09e003c-7885-4eb8-b1e0-275af1157274">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/340d185c-39f7-4626-affd-7691a7dfdf64"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6707ed15-86bf-45de-8842-08338374b6cf">
        <rdfs:label>High low-density lipoprotein (LDL)-C(Abnormality of lipid metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22798447</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26194979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c98382b2-1db6-4449-8975-319955ca5b33">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>High Apolipoprotein B (ApoB)(Abnormality of lipid metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12547874</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6eb4349-57c2-4af1-a603-26139d1117be">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>High atherogenic lipoprotein(Abnormality of lipid metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151670">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6fed21de-1c4a-428a-bb16-ffda13ef36ed"/>
        <rdfs:label>LIPASE, HEPATIC; LIPC</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/151670</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/b8537ed8-2ec6-4076-9ff0-6737624dea80">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3a7d9809-ffa7-4046-b625-9903879853b3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c5996faf-5642-4fa4-b7d1-bce2482eda82"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d60b73ee-efd8-40c7-b57d-dec68de6452e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff99d8e7-556b-437b-9cd7-f576d3c00232">
        <rdfs:label>hyperuricemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002149</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2397c42-2cd1-440c-9dbf-fe9849ef92e5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>obesity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001513</ddiem:url>
        <dc:identifier>HP:0001513</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f87dc0a-c82f-4272-810e-3dc661c28788">
        <rdfs:label>lactic acidemia</rdfs:label>
        <dc:identifier>HP:0003128</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9e483ca-e2b6-453f-b287-7bd6f5dd0d91">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <dc:identifier>HP:0003077</dc:identifier>
        <rdfs:label>hyperlipidemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee75fa6e-760b-435e-b41b-d7c535e8a840">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
        <rdfs:label>age-related insulin resistance(Insulin resistance)*</rdfs:label>
        <dc:identifier>HP:0000855*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28973635</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3c154bd-dbb7-4ca3-be2c-2f9c07df08f9">
    <dc:identifier>HP:0003141</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
    <rdfs:label>Increased low-density lipoprotein cholesterol concentration</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/da1cb120-d82a-4528-a244-71b3c32bd311">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ebcd0a2d-7c6c-43ba-b72f-3cbb0cbb8c2f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd925130-e077-49f5-bdeb-049e596278ea">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008765</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Auditory hallucinations</rdfs:label>
        <dc:identifier>HP:0008765</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125370">
        <dc:identifier>https://www.omim.org/entry/125370</dc:identifier>
        <rdfs:label>DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eb517cbd-1259-4be1-8430-ae8dcec95805"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12b19cb2-0e0c-4e13-882e-48ae16f76265">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000709</ddiem:url>
        <rdfs:label>Psychosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000709</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>"A limitation of this study is that we did not use quantative measures, such as the Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale, to evaluate severity of psychosis. This issue warrants further investigations for the benefit of SGAs to treat psychosis with DRPLA." https://www.ncbi.nlm.nih.gov/pubmed/29739138</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cdcf38c3-0a63-42d6-8555-035381b2c0c4"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7f72e186-6e9e-44ac-b162-a2326096dfac">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28662915</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604369">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1369</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/604369</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/14bb194f-3521-472d-9bab-4f9565633c4a"/>
        <rdfs:label>SALLA DISEASE; SD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1369</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/050e4ad7-9522-4300-8597-a6cd502a6274"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c7d9fd1-db4f-4d5a-b528-6253b09c1753">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <dc:identifier>HP:0002069</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>generalized tonic-clonic seizure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/dc8bee80-5fb6-4faf-989c-5bf5236dbf4f">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c32532dd-6cf9-4daa-8f8b-e7e9b1aa6152">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low 5‐MTHF level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9bc51c47-d930-4a11-a47d-39a6fa0b6c71">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>White matter alteration</rdfs:label>
        <dc:identifier>HP:0002500</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16365882</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d8dbcbc-6052-4ab2-bd22-a2dcca1b10b8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f907fcce-7f2e-43cb-b08e-fa22a01ed836">
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>deambulation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/200e9314-88ac-48bf-9bee-aabb518404f4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/16a27fce-4f1a-4c12-83d0-013dfbc4379a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ee77fbec-cfd9-4813-a7ec-4898537ae88e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1844763c-3418-4129-80e1-351e2015e88f">
        <dc:identifier>HP:0040006</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>mortality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29908244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09138b6b-fc17-47b6-b3c9-dd0344a27178">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001824</ddiem:url>
        <rdfs:label>Weight loss</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001824</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c8c7da9d-0460-4880-96f8-306f0ab18bcc">
    <rdfs:label>Estradiol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00783</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/7906959f-a5e9-40ea-8989-34a2f8a5371f">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c884f2d-7729-4738-9d4b-f122abfb89d8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7fc862ac-975d-4199-9afb-d491aaaf52cd"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <dc:identifier>DB00783</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/bf8534f5-d5c8-4bd8-84a1-11ae20089ea3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20943885</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7fc862ac-975d-4199-9afb-d491aaaf52cd"/>
        <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26448041</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5699ec1d-3568-4a83-85f9-4556d6b0e49c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0d51ebda-1951-4e61-a921-169b48bcd493">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2b6ba49-1052-453b-9cde-64202b7ed5a3"/>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3a91a4fb-9f92-46ac-b45e-0241af918852">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6d686d53-dd18-4408-a83b-b2854d4ef355"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4e62b4f-6170-401a-9efd-b5a397dbb8de"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/83a689b4-1518-409d-a1e5-5f9eea82e161">
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/94ec5b3d-dad0-4eb0-97b1-98ff07eae288"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c2d4b71-1b9c-4824-987e-e7985f053f33">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>hypoalphalipoproteinemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2b31ea5-c2ee-4503-860e-abfe8e287b7e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:label>Low HDL cholesterol concentration</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604091">
        <ddiem:iembaseAccessionNumber>379</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/604091</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/379</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ab168b27-abdf-4466-b178-f141ffa61968"/>
        <rdfs:label>HYPOALPHALIPOPROTEINEMIA, PRIMARY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9056694a-07aa-4158-9897-725af2d7eb22">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c9d0ee4a-77ce-4fa5-8b85-3e007835c2ea"/>
    <rdfs:comment>Poor compliance to the treatment was noticed</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7592a931-4ab0-4178-903f-d6c9c2b46793">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/010452d6-3bdd-46ee-b51a-c1ac5f16a261"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7bfd0f34-6e5b-48e8-ae35-1edacff4a468">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f6042bed-d34a-47be-82b1-f2ca408852c3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a05bb60e-fafd-46e4-b0af-508d04c4d9af">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7ffbd90e-d318-42f3-9fd3-e312b0d650db"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f3f6e103-685e-471b-b727-0c8ca8ed67b2">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3c332815-b641-4cee-a3a9-9217f1e3be0b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11df3b58-8376-4cab-a7ec-35c4f9843da8">
        <rdfs:label>High plasma uric acid levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002149</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9ca48ef1-a8d3-449d-aa16-0c603887a47f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff2d375d-1ef9-42d4-9b88-f45f82e47546">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>Growth failure</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/547aed08-65ac-43ba-9dfe-85e3e4b710a4"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5296b6d3-94cf-496b-9f0f-851435fed790"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fe25ae68-9a3e-4522-b74e-8a985a0cb310">
    <rdfs:label>Pyruvic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00119</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/084fd1c0-8da1-42a7-aedb-38c91cbec8b7">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a666bdd-5f17-4cc5-8c4d-cd42ae5534ba"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac87aea3-1b3b-45f9-91fc-589373b2af5c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/053042d6-8ae3-45ab-a817-ae417e1595b1"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2debe3b1-1ae3-4484-b703-b0d784b135fa"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72b71650-d5ce-4fbb-b844-cc2981103e33"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be605169-915b-4bc3-b71a-f42a1ece1f99"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/47649b0e-40d6-454d-aa89-308d7f929cf4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
        <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac87aea3-1b3b-45f9-91fc-589373b2af5c"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2debe3b1-1ae3-4484-b703-b0d784b135fa"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a666bdd-5f17-4cc5-8c4d-cd42ae5534ba"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/528d2054-6394-4632-92ce-94cfb4635674"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be605169-915b-4bc3-b71a-f42a1ece1f99"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/1578fea1-e481-4369-a9b1-ab8158bd26de">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2debe3b1-1ae3-4484-b703-b0d784b135fa"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c867f38-79cf-4506-8aba-dbb9a541f55a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <dc:identifier>DB00119</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/465c0ad8-0034-4e32-a60d-c3fec47d2f72">
    <dc:identifier>DB00129</dc:identifier>
    <rdfs:label>Ornithine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00129</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/e90114b1-98f0-4fba-9d38-4bf96c286c6d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
        <rdfs:comment>A competitive inhibition of AGAT activity via high-dose l-ornithine supplementation</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f69ccca8-d9fe-43b8-89b5-8ce9bb307d07"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ded8c866-aabe-40ae-baf3-60e7328ddb3c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9686828</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a108a020-5c0d-4015-b559-e4dccd703462"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11749046</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b0ae05fa-1957-44a8-ac1a-5aa99dce2bbf"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/54f3b8d5-0c1e-4f1f-8bb9-9371943a3e06">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/064a1a28-b67b-4367-82c3-31e84a94725c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
        <dc:identifier>HP:0011031*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>iron overload(Abnormality of iron homeostasis)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d84143a-7003-47d3-9f89-79c8feeb37b0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602390"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17124037</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/60410984-acce-4769-aebd-290766a0e015">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/643c087a-7e0c-49d2-8440-57d6162d96e3">
        <dc:identifier>HP:0003566</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003566</ddiem:url>
        <rdfs:label>Elevated prostaglandin E2</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e2bd033b-d6b6-423c-96d4-162f7e525d6f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2fde3d91-6902-46ca-a6c4-cd72c569e9cc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f942e0f-2e5a-4724-b0f4-30d515a67b4a">
        <rdfs:label>High calcium excretion in urine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
        <dc:identifier>HP:0002150</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4e62b4f-6170-401a-9efd-b5a397dbb8de"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/531bdcfd-780b-43a2-8147-7229cc9fb916">
    <dc:identifier>HP:0500014</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Histologic abnormalities in liver (Abnormal test result)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ca6824d1-2185-462d-9401-14dccc8e4291">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1b16a5e2-f912-48d1-8690-d3536d319107">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617070"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8d33c742-57ae-45e3-86a2-dcdee828dc35">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258450"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/115664cd-bb6e-4275-8ca6-c44cb58b13dd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/ec4801cf-1528-4261-ad7e-2059103afb53">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8824cd9-de48-4074-8af0-955fd6d830fa"/>
        <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia " LIDs can occur commonly in patients with DRD‐plus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of l‐dopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d919e2a8-ad4f-4d5a-8f5a-90515983762d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68530370-8784-4910-964f-b65688a9e71f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/5f2597cd-28f5-43f0-b3d6-fbef360cb75a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
        <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12391354</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0678e392-36a7-4da8-9825-434563e26dcc"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4c7b5039-ef4e-4a16-94f8-402d0e155518">
        <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ab8488e-3c7e-408c-98f5-7ebf50957730"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c200ffdf-5bbf-46c7-8d29-e089a1cfc5cc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
        <rdfs:comment>The drug has been used in two patients; in one patient it resulted in a tempoary improvment for 6 months, in the other it resulted in adverse effects and irritability with involuntary movements, and the treatment was discontinued.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01235</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/79176304-cbbe-494e-89eb-b8900b3e1ef2">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617069"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3dcb77f5-fce7-4d2a-b925-d60f827950ce">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/618098"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/16638328-c3c5-4d43-8866-a1350391d084">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609283"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01235</dc:identifier>
    <rdfs:label>Levodopa</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/be3bf51c-72c9-4138-bf10-f564246c9f05">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6289fc90-15a9-4a86-8a90-6af49314e36f"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
        <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c1db53f-f606-4885-898a-780dd5e1f37e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16908750</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07409c00-f7ed-4935-8a4e-fd80151b2df4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/115664cd-bb6e-4275-8ca6-c44cb58b13dd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/596fa10a-b37e-4454-b1a6-61e402b9e0ce"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9886460</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/749d14b0-72b7-4214-9981-071e354d7866">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612953"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a849d856-3663-470b-9d58-a6f4ee8ffd88"/>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25660576</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/65bd8472-40fa-4070-a352-da1e8202d1a2">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613077"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/49ef75e6-9a83-4a78-9b80-75d83d20f879">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/115664cd-bb6e-4275-8ca6-c44cb58b13dd"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609286"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c221886e-51b3-4a03-9371-68bf8e809753">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24943079</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb4d2913-9222-49ef-a4b0-16e606c7e3d3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/115664cd-bb6e-4275-8ca6-c44cb58b13dd"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/102ff31a-c1e7-4ab4-abce-2a9646d6681b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f523ffd8-3e7e-49d4-9bd7-212f4cc69edb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a779525-ef84-40d9-9afe-fc6f7e0ab824"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be5d3ec0-415a-44e6-a2d5-d90767e6baf7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1df30ffa-c93b-49ae-a7a9-aa490cdba2e0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30838265</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30941926</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/157640"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/84507a39-0f86-4fd0-9e8d-903ea8502e03">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0678e392-36a7-4da8-9825-434563e26dcc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/232b3a0e-ef73-4a5b-b798-24789515ae42"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3035daba-4609-4935-8c07-777bb6b8961c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>neurological abnormalities</rdfs:label>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/43288d54-b218-4a5b-9fa9-4481a8ffe48d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236200">
        <dc:identifier>https://www.omim.org/entry/236200</dc:identifier>
        <ddiem:iembaseAccessionNumber>27</ddiem:iembaseAccessionNumber>
        <rdfs:label>HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY</rdfs:label>
        <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/27</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d0d85712-2a76-4d48-86ed-1a3b8f170ddb"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20506325</dc:provenance>
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4dad8bc0-eb15-4e25-a668-ea86e55f236b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"The approach is likely unsuccessful due to reactive properties, intrinsic instability, and charged character of SAM."</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e9d01e60-4081-4d37-9a22-9b3f21fe8cf9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5cf654f9-b54e-4bc6-b871-e75c38a81e27">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011990</ddiem:url>
    <dc:identifier>HP:0011990</dc:identifier>
    <rdfs:label>Partial correction of neutrophil dysfunction</rdfs:label>
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d715a5a3-8237-42d8-ac8b-fdacb180b3d2">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203750">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/65</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/88163f4b-73f9-4fe7-a09d-286d709ceb40"/>
        <ddiem:iembaseAccessionNumber>65</ddiem:iembaseAccessionNumber>
        <rdfs:label>ALPHA-METHYLACETOACETIC ACIDURIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/203750</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1552-6569.2012.00772.x</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3ed02313-776c-4e46-ac45-8b003bf60c8b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ab80903-b20f-4b05-9ee0-76fcca9ad887">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946</ddiem:url>
        <dc:identifier>HP:0001946</dc:identifier>
        <rdfs:label>Ketosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>Abstract</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ec5182c5-a0ec-4c11-abbb-d3adfc880b0d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8850a3a5-bf8f-462b-8b1e-557956afbad5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000713</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Agitation</rdfs:label>
        <dc:identifier>HP:0000713</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0136eb65-9286-4521-9c3b-5388e39f33dc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4fb78ca1-b3d8-48de-b338-b0b82d11707a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d8503027-13c8-4d4b-98b4-eaa2ca0b5bc3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38ef63c8-b680-4c83-80e7-51c3cc5af66c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Complex partial seizure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8664de68-78a6-4967-99d6-27323c61a0c5"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c904919a-ca48-4555-b4f5-f358ec51bfae">
        <rdfs:label>Generalized convulsion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000007">
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:22+00:00</dc:date>
    <rdfs:label xml:lang="en">functional complementation of a genetically defective protein</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the composition or metabolic activity of the pathway or network in which the defective protein is found is modified, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a85f60e-5f77-4957-9f36-c099338caaa3">
    <rdfs:label>defect in skeletal mineralization</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0006462</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/39c3da32-c855-471b-b27b-45c88ffe1ea9">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55748b16-14a7-4ecf-9b3e-1a4ec6f4611e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005340</ddiem:url>
        <rdfs:label>spastic bladder</rdfs:label>
        <dc:identifier>HP:0005340</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7383c373-1c42-4efb-a866-f25a2b3a3c83"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23644316</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/611105"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e2c7bb17-e98f-4979-a801-666570e4ba78">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.medlink.com/scripts/mpdf/print_friendly.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29a4309e-6ccc-498d-b279-8d6ce22b2144"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/543ab79c-4662-404d-924f-90c4161f7471">
    <dc:identifier>HP:0001250</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <rdfs:label>Lip-smacking automatisms(Epilepsy)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84c45c6b-4615-4519-ae1a-0f50f840b008">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
    <rdfs:label>Reduced urinary osmolality</rdfs:label>
    <dc:identifier>HP:0003158</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/15f6cc84-3100-45c2-9063-dfe45f7888e8">
    <rdfs:label>Albiglutide</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/08f1170e-8b2d-439d-9722-48aeb62cf9ea">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7784d2b7-5d87-4fd9-a8d1-955b55b28414"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94696611-f597-4da8-9921-b5d36b412356"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e64f5b35-ff59-497e-84b9-024d13feae7f"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09043</ddiem:url>
    <dc:identifier>DB09043</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/ad6dbc44-ba31-4ce3-9c98-3d8954e5170f">
    <ddiem:failedToContributeToCondition>A209D-alpha</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>F364C- alpha</obo:RO_0003304>
    <obo:RO_0003304>Y368C- alpha</obo:RO_0003304>
    <obo:RO_0003304>Y393N- alpha</obo:RO_0003304>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248600">
        <rdfs:label>MAPLE SYRUP URINE DISEASE; MSUD</rdfs:label>
        <ddiem:iembaseAccessionNumber>1252</ddiem:iembaseAccessionNumber>
        <rdfs:comment>In vitro study in which a discussion about activation of MSUD E1 mutants by TMAO treatment was studied further by titrating the osmolyte concentration. The activation of E1 activity for the three type IA MSUD mutants Y368C- , F364C- , and Y393N- is insignificant below 0.4 M TMAO. Rapid rises in residual E1 activity were obtained at 0.5 M or higher TMAO concentrations. The highest degree of activation occurs at 1 M TMAO concentration for all three MSUD mutants, with Y368C- at 50%, F364C- at 39%, and Y393N- at 17% of the wild type specific activity. At higher than 1 M TMAO concentrations, elevated residual E1 activities decline precipitously.</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/248600</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1252</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dbee52e1-0cde-469f-a7c1-ad658e5908bd"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5db74629-8de5-420f-9c3f-2ffe0a98c9c5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/87972fe5-c397-43bf-af04-9441eae8d882"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11507102</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/846cdba9-2af2-4cb9-a06e-209477d912a7">
        <rdfs:label>No phenotypes were mentioned in the study. In vitro Study.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/b476e67b-24eb-4cb8-9d51-6a6132bcff16">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98530dec-e05a-4224-9b15-6db28ff87b08">
        <dc:identifier>HP:0003218</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003218</ddiem:url>
        <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
        <rdfs:label>orotic aciduria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb722318-c401-471a-8975-502b6bf37c8c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>intracellular defect of arginine</rdfs:label>
        <dc:identifier>HP:0005961</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c9ec8a8-de4b-4d6b-aa92-e64ce4a8beaa">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypolysinemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd16e11f-d2e4-446f-b984-191d8857eb9d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002152</ddiem:url>
        <dc:identifier>HP:0002152</dc:identifier>
        <rdfs:label>hyperproteinemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a4112a1b-4480-4405-a507-91a234d32c6a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c08cfb2f-0dad-4d77-bec9-3f214ee1e459"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b172c7b8-c525-4dd2-8f86-c3453fcf9c7b"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ce3a15e3-16b8-487e-9402-04eef77ad35f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7ac651de-d910-4ff0-8c6b-6aae081d11ff">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d81f3043-d7a6-4592-a57b-306577f32c21"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b791d81c-cada-4336-8576-df7ca32ee7bf">
    <dc:identifier>DB00232</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/43bbf76c-cc35-470c-ba17-8558e9ec532b">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b1a22c7f-1dcf-449a-91b3-0d20a8c12777"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6fad1f3-4154-407b-ab01-04394131e198"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/22b37368-1fec-4f79-9c6a-fd19a5ea86c5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8fcfff63-3e85-47c7-9f82-e242902fb9af"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3705d19d-529b-4578-82dd-b611a8051fba"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00232</ddiem:url>
    <rdfs:label>Methyclothiazide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7044cec3-83f0-4261-a374-ed44b4348882">
    <rdfs:label>Rimmed vacuoles</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003805</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003805</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba1dfe92-daf2-488a-944a-dfb0220cd874">
    <rdfs:label>speech impairment</rdfs:label>
    <dc:identifier>HP:0002167</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7851807e-6c03-434b-bf3f-41271a0d937a">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:label>elevated serum toxic intermediates (</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/46cfbf54-b4ba-414a-b63b-a5aad6d5b26f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29773783</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/842abc51-8d7a-49b1-971e-b8bdcff2a40f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02376751</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/278000">
        <ddiem:iembaseAccessionNumber>302</ddiem:iembaseAccessionNumber>
        <rdfs:label>LYSOSOMAL ACID LIPASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/302</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/278000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4562c793-acae-4467-971f-dd63bad4b436"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fa4815e-cc32-4c1d-b29a-79acec6a34ce">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma cholesterol level*</rdfs:label>
        <dc:identifier>HP:0003107</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/579d2782-bbbe-444d-91ed-78cfc64df477">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0723d5be-09bd-4a9a-bac8-8b4594e2e18c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/805ce8f2-56a6-4485-aaf2-5bc632257617">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:label>Dyslipidemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00320e0d-7fc1-4dcb-8134-4a85e855d3fa">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>hypertriglycemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c73fbc5-cb6c-4873-a147-ebc1b697cf27">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Sulfide toxicity</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/386e59fc-b0bd-4226-b675-071e358784ec">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e64f5b35-ff59-497e-84b9-024d13feae7f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040217</dc:identifier>
        <rdfs:label>high  HbA1c levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040217</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25734254</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60ee385f-bc8b-43c7-9edc-aea147a4ea4b">
        <rdfs:label>abnormal free fatty acid levels</rdfs:label>
        <dc:identifier>HP:0040300</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040300</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a3e0589a-437e-4bfe-a9d8-7dfdb05f4636">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c13f4902-6ff9-4bb5-b4d4-ed16b5146064"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00025883</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94696611-f597-4da8-9921-b5d36b412356">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0013277</ddiem:url>
        <dc:identifier>MP:0013277</dc:identifier>
        <rdfs:label>abnormal fasting glucose</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55170631-fd19-485c-bdf2-ae981c969934"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28993984</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f77edfd0-4417-45ab-a1c3-d7e3e936ec5a">
    <rdfs:label>Glyceryl Trierucate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12528</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/33aaf23a-6dfb-4f18-b5bc-805f5edf236a">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c04eff7f-45bb-44ff-8f68-2f168ca147c7"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00545597</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16009761</dc:provenance>
        <dc:provenance>https://www.myelin.org/tag/lenti-d</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71a6d526-76b5-4335-858b-d3431cef0bf0"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03727555</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/31cc2ef0-08d7-4342-a4b9-3e831375e883"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7666063</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/05b3ea4e-4b62-44c5-9030-5e1651ed2f04"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB12528</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7e9a82f6-59ff-45ab-9285-91622a1c7d91">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/942055-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253260"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77b44d90-1bbc-4a36-a0a0-30b9c8490102"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29da295f-7948-43b2-a0bb-ff65cedd0589"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0678e392-36a7-4da8-9825-434563e26dcc"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e31a20ab-ec66-42bb-b97a-e6215a559441">
    <dc:identifier>HP:0003645</dc:identifier>
    <rdfs:label>Abnormal aPTT level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57ac844f-8a5a-4c56-bbe6-d4f54cc77db3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030213</ddiem:url>
    <dc:identifier>HP:0030213</dc:identifier>
    <rdfs:label>Lack of emotional expressions</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/76d4f44f-d86e-4ac4-b6ff-9f4594a80a9b">
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/064a1a28-b67b-4367-82c3-31e84a94725c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03453918</dc:provenance>
    <rdfs:comment>Quercetin which is one of the polyphenols can reduce hepatic iron deposition in mice that were exposed to either ethanol or excess iron. They found that quercetin increased BMP6, intranuclear SMAD4, SMAD4 binding to the HAMP promoter, and hepcidin expression, which led to decreased hepatic iron levels and reduced iron-related damage. https://www.ncbi.nlm.nih.gov/pubmed/27393927</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d21f4d9f-897a-42bd-bee2-313d2e495634">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/23fa88af-b2f6-4727-9d82-a8d694170895"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8fa2b33d-08cb-4830-87ff-8f27333c9aa7">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14d29dac-847f-4efb-b83e-0a1e451c54ab"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebcfb905-faf1-4437-8164-cf12bfb7ab9e">
        <rdfs:label>high Lactic acid</rdfs:label>
        <dc:identifier>HP:0003648</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003648</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16376514</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f0f82032-2d11-4f4f-86f8-92dbb45565cd">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3e7b87e-fea3-4831-9d25-85eade85fea4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/302060">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0b09e721-d659-4efc-9552-c7a49ebbd5d4"/>
        <dc:identifier>https://www.omim.org/entry/302060</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/59</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>59</ddiem:iembaseAccessionNumber>
        <rdfs:label>BARTH SYNDROME; BTHS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f02480da-e665-417f-9aad-2bc7bbb2d178"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15098233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/257fc01b-1612-4b42-b0fc-fb68f1bc6a8c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/905e2f9d-7a40-4806-8204-cb9cc0d7f6e7"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3d342810-93c4-4d09-9b37-488e4de63ad3">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7d554dfe-6436-4b7d-8f12-f9f38ccfe7c1">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5857501d-2c5d-4301-a574-bd01bbe39174"/>
        <rdfs:label>Angiotensin II receptor blockers (ARBs), plain</rdfs:label>
        <dc:identifier>C09CA</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e8ce014-5337-4edc-9af2-2fdacd2487c2"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09CA</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dafe7f59-83a7-4142-9a8b-a84c4f520e20">
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C07</ddiem:url>
        <dc:identifier>C07</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/64da993a-aadd-46d6-b8bc-9e1b00bc8715"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e8ce014-5337-4edc-9af2-2fdacd2487c2"/>
        <rdfs:label>BETA BLOCKING AGENTS</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5857501d-2c5d-4301-a574-bd01bbe39174"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/70211f92-aeb2-4fb0-a319-bf2be3987222">
        <dc:identifier>C03</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3b0b6531-fdc6-4c2d-b1a4-d4f77919f1d4"/>
        <rdfs:label>DIURETICS</rdfs:label>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e8ce014-5337-4edc-9af2-2fdacd2487c2"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0bb1b2d6-1bd4-403e-bf55-4b6f082344d7"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c5656230-eccc-4130-8c3d-0e3af63838f9">
        <rdfs:label>ACE INHIBITORS, PLAIN</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5857501d-2c5d-4301-a574-bd01bbe39174"/>
        <dc:identifier>C09A</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a25941fc-8591-46ad-b4df-8675697ccc68"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e8ce014-5337-4edc-9af2-2fdacd2487c2"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09A</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1e4137fb-1b86-4080-b233-6fc09ab809f3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/084be5f3-9a2f-4d10-932c-7602e0819670"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7500d88e-d672-46fc-b193-14cf9087f531">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/243500"/>
        <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21403788</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e7ddb27-09ae-4b89-8094-06e05383ecb2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21207059</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e6c159d1-406d-460e-bd9f-669ca66059f2"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Carglumic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06775</ddiem:url>
    <dc:identifier>DB06775</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d29c3c5d-11fe-45f6-be40-a088ea0ffbcb">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44f4bd5b-292d-4e4a-8791-d72f2ca7494c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040126</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040126</dc:identifier>
        <rdfs:label>Low level of serum B12</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26958680</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14593474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18768530</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26040326</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0946873-1340-4856-88c4-f41e44254b5c">
        <dc:identifier>HP:0000953</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000953</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperpigmentation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23364648</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f0a64f4d-ebe3-4928-b22c-d5140d1182c8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/02cf2e1f-4a1f-4e97-a4e0-f60998e9d9f3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29572946</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22219566</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/765a2bf6-fb10-4827-a2cb-467bac20eda6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Normocytic anemia</rdfs:label>
        <dc:identifier>HP:0001897</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001897</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24222293</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7447991c-1cbc-4f65-850c-beae068987ee">
        <rdfs:label>Increased liver enzyme activities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002910</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea32eb8b-c5c2-4cca-aab9-7478965956d0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012120</dc:identifier>
        <rdfs:label>Abnormal methylmalonic acid level.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e5ca86d-f24e-48fb-99ea-07ad3330f49f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27942180</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc66167c-7869-4114-8874-5ea46ca7e768"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89936a2d-ad25-490d-9985-e8abe971f53b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Megalobalstic anaemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
        <dc:identifier>HP:0001889</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/186668ff-2260-43ed-b5cd-8df9efc9dae1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc1b44da-edf9-4e36-adba-a5d489d9bbe8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/951d351c-2c8f-426d-a5c8-4cc91d1e36e6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72d43680-393f-45b9-9226-6175be214012"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <rdfs:comment>Glutathione depletion indicates decreased potential for antioxidant capacity in IOSCA. Additionally, we analysed a blood sample of an IOSCA child patient who showed high creatine/creatinine ratio and low taurine and kynurenate. The significant depletion of kynurenate and the significant depletion of niacinamide are both consistent with depletion of NAD+thus both Clutathione and Nicotinamide riboside are considered as potential drugs for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373891</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/d775835d-9562-40c1-b333-00a12ef92a8b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6289fc90-15a9-4a86-8a90-6af49314e36f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815559</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605407">
        <dc:identifier>https://www.omim.org/entry/605407</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>SEGAWA SYNDROME, AUTOSOMAL RECESSIVE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/299cb842-d0c6-4f88-bcb3-49fc71249e2f"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2dfe5f8-89b4-48a5-a832-6060e7be4ed3">
        <dc:identifier>HP:0002194</dc:identifier>
        <rdfs:label>Delayed motor skills</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b80734a0-04ed-42c8-8cfb-31bf0dbb733e">
        <dc:identifier>HP:0001336</dc:identifier>
        <rdfs:label>Myoclonus jerk</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32525886-554b-4fd9-b06a-d6503206e01c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:label>Delayed mental development</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a57dd1e-220a-428d-998c-2d64137efa2e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3cd008ed-7626-46d7-bea9-dfbe46b6cec7">
        <dc:identifier>HP:0003785</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003785</ddiem:url>
        <rdfs:label>Decreased CSF homovanillic acid</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ef5a2a6-b755-4d1c-bcdc-507fb13d0b7e">
        <rdfs:label>lack of gross motor function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
        <dc:identifier>HP:0002194</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10585338</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c3bf8a7-5069-4bb9-baae-0e7f24cf6825">
        <rdfs:label>lack of eye contact</rdfs:label>
        <dc:identifier>HP:0000817</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11241071</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <ddiem:failedToContributeToCondition>(926T&gt;C</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20399390</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8817341</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10407773</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10753262</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9eae12f2-e388-48e7-9ca5-ac7612ecff9c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8e397e2-75b1-4586-9660-560171f5d567">
        <dc:identifier>HP:0002375</dc:identifier>
        <rdfs:label>Hypokinesia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1f200a8-e5b2-465b-a1de-13e5d2573629">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal epinephrine,norepinephrin ratio</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/9e7d0c47-4da1-4c9e-82d8-a91a3384b8d3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24509886</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1178375-e493-4770-ae86-b203f9c6e494"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/358d4f5d-ca39-46b4-9ec9-aedf0bfe9aa1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/12558b7a-64d3-45c1-9d9d-fc905c3a427d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54ccda15-37a6-429a-9e10-6d7ab9386947">
        <dc:identifier>HP:0001395</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>liver fibrosis progression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4dd980c2-b98b-4db9-b88b-9f5cdc39c4fe">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c9d0ee4a-77ce-4fa5-8b85-3e007835c2ea"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c4f4f6e8-d1cb-4d8b-96e1-ab426850a2a7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27710244</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/5a1fedd1-ea98-4518-a4f5-f5c11178d29a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc10c4c1-7259-4ecd-9558-342472b3222c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e857d894-b8d8-47cc-b036-382605898f20">
        <rdfs:label>Abnormal nerve conduction velocity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040129</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31115677</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d1d37ad-a769-4fb4-8e09-2c6616388ab6">
        <dc:identifier>MP:0001665</dc:identifier>
        <rdfs:label>chronic diarrhoea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001665</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25424010</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90093156-8fe8-4cb3-9361-d9b116448f6d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980151</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29260356</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e6e1448-b944-4dff-9f88-d8d8010c7fcf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68530370-8784-4910-964f-b65688a9e71f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2be1664c-a167-4dda-aae3-a7286d778f7a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/118c227e-a8ea-4159-8cc5-e0b8d566b2da">
        <dc:identifier>HP:0000518</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cataracts</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5565a352-cb9a-4ec3-b36c-02457715c05b">
        <rdfs:label>EEG abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fc448b6-0903-4bba-9a23-6d9d8ca3f488"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9cfcdc9d-8de1-4d95-bb84-ce60e570fddf">
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>neurological dysfunctions</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c7ccc84-3226-46ca-96f1-6d027ab90302">
        <rdfs:label>abnormal gait</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001288</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/767f2382-f240-4bf8-97af-c39170350221"/>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b805f834-b0c9-414f-9b23-42c16d2068dc">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>METABOLIC ENCEPHALOMYOPATHY</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5cdd5561-e4e8-4405-91d1-55932ec62ff3">
    <dc:identifier>HP:0003737</dc:identifier>
    <rdfs:label>Mitochondrial myopathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003737</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7c50b122-5ab3-4be1-b3aa-0a36f039c0bb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241500">
        <rdfs:label>HYPOPHOSPHATASIA, INFANTILE</rdfs:label>
        <ddiem:iembaseAccessionNumber>561</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/241500</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/561</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a94bcb4c-d724-4c97-85db-f121cee5e4d1"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17395561</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/db4b50df-c3e7-47a9-b879-9db768ffb1b3"/>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/ed3467fb-0061-49b0-ab5c-fb4a563bbc03">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92e348a2-0dda-4b97-9ed4-700f24c6cf13">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002011</ddiem:url>
        <dc:identifier>HP:0002011</dc:identifier>
        <rdfs:label>nervous system abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee1eea35-e14e-4d21-83df-40e723727876">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>neurologic dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30358967</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/18c98805-c3f2-4939-85bb-984201700cbb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/98328939-f4f9-4f06-abd3-fed149764c04">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d84143a-7003-47d3-9f89-79c8feeb37b0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64dae8ca-de48-40da-939f-823ef8b6f13f">
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:label>high plasma ferritin</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/224120">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/352d00f6-9608-48a1-8847-8e4e34c21ed2"/>
        <rdfs:label>ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/224120</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2059e8e3-76ca-46dc-87d0-00a2adcaefc3">
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11940-017-0473-2</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88f9501e-1d48-4fb3-972b-a9629f5a70b1">
        <rdfs:label>abnormal fat metabolism</rdfs:label>
        <dc:identifier>HP:0004359</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a5586b2-afeb-451d-b0d7-3c5f07770d7f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f37fad38-4595-4d67-8603-60a71bec098e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a8ec049-57e7-4e4d-91b1-e81ee3728423">
        <rdfs:label>abnormal carbohydrate metabolism*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011013</ddiem:url>
        <dc:identifier>HP:0011013</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02432768</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3f3ecfa4-0675-4c5c-b599-579bb1cfba84">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46548bdd-00e3-42e2-9f2b-49ad41d58efc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9a5535b-2a1c-4698-a6b8-5d875556eec5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/37ba3b21-a610-4843-9391-82891b895245">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263800">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GITELMAN SYNDROME; GTLMNS</rdfs:label>
        <ddiem:iembaseAccessionNumber>889</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/889</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/263800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3fdce799-b951-475a-9ffa-1367eab9e29d"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6c01b1cd-798a-4cbc-8002-ea69826437b4"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf5330f8-eb2c-478d-96a3-aef3215410a3">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000934</dc:identifier>
        <rdfs:label>chondrocalcinosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000934</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6adb3af9-0a44-4596-a331-b8d175f3245f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9c52a33-3d05-478a-9622-17a7d388b5f1">
        <dc:identifier>HP:0002917</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypomagnesemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0da729ee-d08e-41a1-9d00-ffe38ca03e28">
    <rdfs:label>Amantadine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00915</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/40ddf261-c4f9-4d62-b821-3c05e6a9db15">
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f71708d-06a4-47b6-bf55-554c4c76f118"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22550086</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a849d856-3663-470b-9d58-a6f4ee8ffd88"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fb9c8f74-7dd5-4c41-a040-86404bbec8fb"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a1dd97f7-9e4e-4385-94ca-3f0b74afb362"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00915</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/57a6bf2a-574c-4118-a7a8-092c4d8ce78b"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/347ea08b-ddfd-4cc9-b27f-9628a5a75c3a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15251700</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/37cea92d-a8a9-45cb-98e1-1177132bdf27"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b4a86e98-f1ae-47db-9386-5d7efd66b9ae">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/698d32ca-e3b8-45aa-bbef-890811bc86a4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65d5bfc4-cad1-42a2-8c11-5fca621284fb">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001260</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
        <rdfs:label>dysarthria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb4d43f5-e6dc-427c-97ab-477aabbe6aa9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>dysphagia</rdfs:label>
        <dc:identifier>HP:0002015</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25674260</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f24b861b-9da1-4da8-aaf1-e9ce487d9e3f">
        <dc:identifier>HP:0009071</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Inflammatory myopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009071</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e045a94a-1921-4f78-9f15-aaedbe77fe2d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000467</ddiem:url>
        <rdfs:label>neck muscle weakness</rdfs:label>
        <dc:identifier>HP:0000467</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/368173d6-afc0-43ac-9289-4994c84c34dd">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d586aff7-ddd4-4175-9a47-5d89b7b3c275">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/79094c0e-5053-49a4-898d-61a9b740036a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/251aff7b-51ef-4637-8f16-42cb88138cfc">
        <rdfs:label>Decreased lung function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005952</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3e7b87e-fea3-4831-9d25-85eade85fea4"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f33981e-c888-4957-8523-b6fc9a8ab61b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Progressive emphysema</rdfs:label>
        <dc:identifier>HP:0002097</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002097</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000006 rdf:about="http://ddiem.phenomebrowser.net/b255c57e-97de-4df3-875a-9ba9c020dc98">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33410a9c-27dd-43a9-ba15-07aa8cde5ce5">
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:label>High ferritin level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37e34207-078e-4b47-8727-7c5986051207">
        <rdfs:label>Low NADH,NAD ratio(Mitochondrial dysfunction)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003287</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17702040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16269021</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3832887-f8c6-44b1-b638-34959b691031">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low Frataxin expression level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d51510a9-b960-490b-8524-89a040f9467b"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72d43680-393f-45b9-9226-6175be214012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffc3263e-7b22-49f1-a0c1-bad021ce0784">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High urinary 8-hydroxydeoxyguanosine level(Abnormality of DNA repair)*</rdfs:label>
        <dc:identifier>HP:0003254</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b5e60aef-cb6c-44c0-b88a-b8e41cdf9fc4"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5910e23d-dea9-4e57-a106-d146ce277af6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012378</dc:identifier>
        <rdfs:label>Tiredness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000006>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5eb8c926-24d7-434e-bf43-d7462984ca55">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated Tau-p level in CSF</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d526343c-4945-4159-9439-0aacdc982722">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
    <rdfs:label>scaling</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040189</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/0416cbe5-b97c-4548-8f9b-51c5fc3ab99a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7a26bec-0de2-46b0-93c2-cea724e7ceca">
        <rdfs:label>Neuropathy</rdfs:label>
        <dc:identifier>HP:0009830</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231530">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>236</ddiem:iembaseAccessionNumber>
        <rdfs:label>3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/236</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a6f3d19a-d7b5-4d73-b0f7-665b178b26ba"/>
        <dc:identifier>https://www.omim.org/entry/231530</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00840112</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c997e538-736f-4b36-85fc-35ef34b0130f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045010</ddiem:url>
        <rdfs:label>Abnormality of peripheral nerves</rdfs:label>
        <dc:identifier>HP:0045010</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/430610de-90dd-44c1-96f4-6046f87918b8">
    <dc:identifier>HP:0004923</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high serum phenylalanine</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2f9d7323-ef0b-4196-8635-eded467df1f1">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/73e23a2e-2e62-4e73-8bd7-713e2a25ee1c">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/755fe4f3-e5e1-4a18-8093-be045b6d29cf"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01783</ddiem:url>
        <rdfs:label>Pantothenic acid</rdfs:label>
        <dc:identifier>DB01783</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/40dda43a-a1e4-459f-b182-5d569a828550">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c8f5ddda-9ac2-4574-96fb-17abdf682fa6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74b2582f-9765-40e4-a79f-f5c35887f36e"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6f998dc8-cdb8-42d1-835a-2f5698928a6f"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da3bbf3c-7ef5-4230-86ed-19dc8451ef5d"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/02b0e854-46d5-4f70-bab2-4ff2d37b415d"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da7d8cc3-82fe-49c3-806e-b7a89c960a67"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0678e392-36a7-4da8-9825-434563e26dcc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df8ec75c-4ac9-43bd-8d15-295a8ebddae5">
        <dc:identifier>HP:0001257</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
        <rdfs:label>spasticity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603358">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20ac5ef8-9792-41bb-87ee-4700bd786d96"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/208</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/603358</dc:identifier>
    <ddiem:iembaseAccessionNumber>208</ddiem:iembaseAccessionNumber>
    <rdfs:label>GRACILE SYNDROME</rdfs:label>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1d059b63-c309-4ec8-8c27-1571749b8074">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bef4a995-7947-4958-afbb-7d6ea8be68f4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0c2a14a2-2e6f-4035-bff8-69252d6a65e0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72d43680-393f-45b9-9226-6175be214012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00528151</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29b2b044-fdce-4971-b811-19d5135a0d72">
    <rdfs:label>Neutropenia with IBD</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875+HP_0002037</ddiem:url>
    <dc:identifier>HP:0001875+HP:0002037</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca2f82a6-c38f-4758-afd1-ea2cf35ada1f">
    <rdfs:label>Abnormal kidney function</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
    <dc:identifier>HP:0012211</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7e8d1447-e396-4fcf-8749-5b14cbb6bad7">
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/43a11825-7b92-42a3-8af2-1f9b362559b9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/90c7967b-33d1-4fd5-b8d0-5ffaa8abc304"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d31a0a3-e9ad-4dcf-86c5-32ef215e8715">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
        <dc:identifier>HP:0012656</dc:identifier>
        <rdfs:label>Low dopamine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3c0bb9b6-1bf0-40a3-893b-71418de573cf">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/187521ea-9398-4569-befd-adbbe1a09b22"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/99b27243-5345-4f9b-86e2-5e274e9fc5c7"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/227810">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/481</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>481</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f03cc2b0-b0b0-4fac-8748-4c3f916114a5"/>
        <rdfs:label>FANCONI-BICKEL SYNDROME; FBS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/227810</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aa548e8d-59b2-496f-a079-9925b0fcf9e1">
    <dc:identifier>DB12273</dc:identifier>
    <rdfs:label>Ecopipam</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/92584cc7-d29c-477c-aa56-6b52d48f3c90">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88ceaa3c-010a-4830-b2e7-c1c9caa0dedb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b864d7aa-9258-4b8b-870d-c97b5b68e1b8"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01751802</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12273</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/24ad36ac-3155-4378-8848-2a10dc6389df">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95840af3-8e0c-4f42-bd31-88a328895158"/>
    <dc:identifier>DB12351</dc:identifier>
    <rdfs:label>Siagoside</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12351</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7bf20db5-fe65-4371-8f6a-c99a8f321263">
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e974fe73-acaa-426b-8a9a-05168e3d2292"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236270">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/236270</dc:identifier>
        <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a6f600ad-b992-4475-954e-e3b27a05672f"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/31</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>31</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0672df24-ab67-4e18-9099-fa40a82aad18">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/341539e4-f7d4-4843-87b7-783f37edb4d2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b224b948-1057-46ab-b3e2-976c066b9553"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ab0e7e5-86fc-4993-9746-d711b7b65a5a">
        <dc:identifier>HP:0001640</dc:identifier>
        <rdfs:label>Cardiomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7c36d3c-7db3-4a58-8ab2-34860143b2de">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Developmetal delay</rdfs:label>
        <dc:identifier>HP:0001263</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20981509</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fb8780a-6e40-446b-9154-1cd3fbe2251a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abormal liver size</rdfs:label>
        <dc:identifier>HP:0002240</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6428587f-7c15-40c5-a3f0-977291cb82ab"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c79f762-e8ad-4bbe-9623-51bd5b5f2b2e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Reduced ejection fraction</rdfs:label>
        <dc:identifier>HP:0012664</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc8d258f-56c8-4e39-a9ec-6a24e91df84b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae057ac2-d774-4139-82c6-150972ed8ae8">
    <rdfs:label>abnormal nucleotide sugars</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3eefe8ba-1d90-4a62-b12b-c951ba1d35a4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0f26ed8-826c-4c3a-98c4-bae06bc0abee">
        <dc:identifier>HP:0010978</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
        <rdfs:label>hemophagocytic-lymphohistiocytosis (Abnormality of immune system physiology)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7383c373-1c42-4efb-a866-f25a2b3a3c83"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/da773fbf-f333-4830-85ac-4411eb42e130">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19011501</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/80b38d56-06f2-487c-b768-5027208c94bd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/288a203c-bb4a-40c5-800b-7026da82d13b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Periodic fever</rdfs:label>
        <dc:identifier>HP:0001954</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2249d6d4-77f8-4a7a-8c6e-b54419b82903">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017326</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7084d78-f647-4792-a1fd-ddea4af062cb">
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>low quality of life(Constitutional symptom )*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8d9b2ae0-ea7c-4d1c-9326-e7abfb700d03">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/116596db-d7fd-49e7-8a45-4a76352f16e9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207800">
        <dc:identifier>https://www.omim.org/entry/207800</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/16</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>16</ddiem:iembaseAccessionNumber>
        <rdfs:label>ARGININEMIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4e83f30f-c993-4567-b762-39495f94b593"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28a56229-9da8-472e-b642-974c7dce184e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>growth impairment</rdfs:label>
    <dc:identifier>HP:0001510</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f6e4a3ab-c1d8-4a48-8a09-127373522b7a">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aa2f2744-8837-440d-aeb3-69f1eb0030ef">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c7e12c80-e68c-4cd3-911e-011bf3a62492"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6cf7ee8c-023d-4e5e-9549-11478072c8eb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001962</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/be9cc7be-4c51-49e6-8c40-a89d4d2e94ae">
    <dc:provenance>https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b6954b6-c53c-4df2-a320-fe897d25f0a7">
        <dc:identifier>HP:0009020</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
        <rdfs:label>Exercise-induced muscle fatigue</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/705dfa9e-6f5b-490c-b8c4-9d1db9bcb2c5">
        <rdfs:label>Exercise-induced myalgia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003738</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003738</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/03d7bda3-c296-497a-9a22-569dbdf3039e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fa069145-b1d9-447d-91b6-d39339c47e3c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/074b291c-34cf-4aa8-8049-1f969eafd44a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003690</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003690</dc:identifier>
        <rdfs:label>Limb muscle weakness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5db5288a-7ab4-4a05-999c-8658b3c45607">
        <dc:identifier>HP:0003394</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003394</ddiem:url>
        <rdfs:label>Muscle cramps</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615511">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7a39dc9a-8d86-41c6-929a-52aac64d1546"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/615511</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6c45dfe-5080-421c-ac81-e8cf760faa35">
    <rdfs:label>Central nervous degeneration</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0007009</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007009</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f76e45e-a412-4d56-b741-82a8fa593cee">
    <dc:identifier>HP:0001508</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Failurre to thrive</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/8e2d9875-b3bf-4dd1-8b85-877238b530ef">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5db1f51a-8465-4e4d-8b66-a1ebeb133640">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myopathy</rdfs:label>
        <dc:identifier>HP:0003198</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4efe5af2-4b7d-48a2-9c3b-bb7c3ac82ed3">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0200125</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
        <rdfs:label>Mitochondrial respiratory chain defects</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19891905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e66a692a-8334-496b-bd66-ee3e95ec1e1c">
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e62a37ab-1d74-4790-8730-ae8b3790642a"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4722d276-c292-4746-969e-8bd762684ad3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f21ac548-34f7-4f1f-9804-80c42d38c66f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c50fccc4-35bc-4166-b28d-7cbddfac3216">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/68cbdee6-0461-46e8-ba52-61e4786eb004">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ade38c9e-9ef4-4e53-9585-dd0f848f8ecc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/520000">
        <dc:identifier>https://www.omim.org/entry/520000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e83155a6-061f-4432-98fa-c0e3952993a9"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/409</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8826c45-6040-4389-b8ef-56b99ce90527"/>
        <ddiem:iembaseAccessionNumber>409</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9c48bb3a-33d8-410e-8872-b51c8f214bab"/>
        <rdfs:label>DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2bcdc5d-4d05-434b-add1-1d6626b83e40"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97dffd65-e589-4c5f-973d-4f52bf03e1dd">
    <dc:identifier>HP:0003119</dc:identifier>
    <rdfs:label>abnormal plasma lipids levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/546062e7-b391-493b-84f3-d9228b9ac30e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6fc83a59-ad79-4374-9dab-0a96169b4b82">
        <dc:identifier>HP:0000789</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>infertility</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000789</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b67ba8dd-4cdc-4005-a1a2-fcc7b50c6f48">
        <dc:identifier>HP:0000969</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>edematous</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/00fb3d4b-effc-4ccc-b51f-09bf639897c0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/54015d46-01a7-40f9-b4df-85f27db5edd5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8390cfdd-d958-4c34-8b74-ddb4a4bf9e70">
        <dc:identifier>HP:0002311</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>incoordination</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256540">
        <rdfs:label>GALACTOSIALIDOSIS; GSL</rdfs:label>
        <ddiem:iembaseAccessionNumber>319</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/256540</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7873fb18-7572-4fe7-b65b-85d07594eaca"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/319</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe65c90c-4db0-4c89-9eda-137b38f6bba4">
        <rdfs:label>gait abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001288</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/025178d2-4bee-4909-9a87-7175496a7f6a">
    <rdfs:label>keto-analogues of essential amino acids</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/5bff8bbf-4535-4fde-a8a7-72c41b5aec8a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/668730</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/01ae9994-c9c4-4b52-aa94-7d0ac290e9d8"/>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a8ea370-9fd1-424a-9d8f-2b983ed93412"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0a15d53-320c-4529-b7fb-836eea805513"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e6e1448-b944-4dff-9f88-d8d8010c7fcf"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/a78fdd24-3239-4e47-a86e-7325aac37737">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c86e3e20-9491-4086-98d7-16b56fffd456">
        <rdfs:label>absence of flow-mediated dilatation of brachial artery</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0740fdf-8787-4103-8f61-4a818f741142">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cardiac hypertrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ad4ad647-bec6-4076-9d14-0a242f00fa51">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a0e22046-1c95-40ce-9bf9-4a646208ce62"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f221b76c-ea67-4dc4-9192-548f4362ad35">
        <rdfs:label>endothelial dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b3cfb3c-5f2c-4b2d-9be8-4dbd71dd120d">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
        <dc:identifier>HP:0000822</dc:identifier>
        <rdfs:label>hypertension</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22541557</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a883f259-41b1-4624-a614-6a4d278cd75f">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236795">
        <rdfs:label>3-HYDROXYISOBUTYRIC ACIDURIA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/236795</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5b8a5259-8e67-4fb9-8f93-a7820cd4de23"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da2c300a-2a6b-4d0a-8c36-7bf5b1509cd3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:label>acidemia</rdfs:label>
        <dc:identifier>HP:0001941</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <dc:provenance>http://eknygos.lsmuni.lt/springer/365/81-92.pdf</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/803b0366-6346-4a3c-afd0-858dfad05149">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7df80011-ec12-46f5-a173-69889f03af0e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b28d3294-53af-49cc-a58e-56d19d39dd3b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03517085</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/970cdbd7-fa80-4ce9-a9c3-7efea495d197">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"The study is still recruting. The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level."</rdfs:label>
        <dc:identifier>done</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/44aec5f7-7115-4f9f-98e3-62a17040c99e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607765">
        <dc:identifier>https://www.omim.org/entry/607765</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a43889a9-fecb-4774-b538-3f1d58860bc0"/>
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7915305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec998174-5a50-412e-b983-d15f9853636e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b37eca9-204c-4d05-b50d-58f035fdb565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bbc56010-c2aa-4125-befc-fa2dc5adcb44">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/799c9f0f-ca27-461d-9cf2-daa8cea953b7">
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/763452f8-7da3-48d5-855f-888e089440d4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d17e7677-c9d0-4f10-8423-8b391a2c5d68"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00152</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00152</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/1d08f315-ef71-48b8-abf6-f28bd5424fe8">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/325a4743-3c73-437a-8861-86511897e97c"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/763452f8-7da3-48d5-855f-888e089440d4"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0003304>p.I480M</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/849aef92-961d-49b5-a1bb-29f3bfbe93da"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d58a0e40-487e-42f3-bda9-b693b1144852"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10448086</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/b1e685e3-492c-4d26-a96d-4615eb5b1326">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31061755</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/21f39591-67bd-4376-958c-8b2293090c4c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/763452f8-7da3-48d5-855f-888e089440d4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7bd0fcec-d36e-47c9-b38e-6ba8a7a9d2ac"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57b6b8b3-8058-4cde-9f72-10ad331a7709"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27749535</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6289fc90-15a9-4a86-8a90-6af49314e36f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4a60771-697f-4d37-b21f-3dbcacfefe4a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607483"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d9e2589-33a4-4bc8-8783-faa23ee710b7"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/f57a2d2d-bbeb-4147-a241-2c05a1f7ef00">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/763452f8-7da3-48d5-855f-888e089440d4"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a9b6e05-b885-45ee-9b02-fe9537e17fec"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Thiamine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8cabbd0-db80-42bd-a538-a8e5a605462a">
    <rdfs:label>concentration of myo-inositol in brain</rdfs:label>
    <dc:identifier>HP:0025460</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025460</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8ddd8d7c-d571-49c6-8ea3-044711acf277">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3edf6b46-c41a-4506-80fd-38108914c6b3">
        <rdfs:label>AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/64da993a-aadd-46d6-b8bc-9e1b00bc8715"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09</ddiem:url>
        <dc:identifier>C09</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/0c0ca672-8f6f-4ae7-9e2f-3ce2c2c32044">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17213282</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0003304>Ala176Thr/Val423Ala/Val522Ala</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>N461L</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b68e0ae2-8ae6-4ecf-b1b7-c6c80d105f59">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003260</ddiem:url>
        <rdfs:label>High bone turnover markers</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003260*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22218563</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc93540d-a062-43d7-9d0a-cb6d35b22f81"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4c39de1-03eb-4d11-8d87-d30c88896668">
        <rdfs:label>High serum pyridoxal 5'-phosphate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4970f229-8c91-48a6-bbb8-0cb0f12d2081">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001832</ddiem:url>
        <rdfs:label>metatarsal stress fractures</rdfs:label>
        <dc:identifier>HP:0001832</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27042741</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68e6fc88-837c-40b3-8fb4-3bfdacb141e1">
        <dc:identifier>HP:0001376</dc:identifier>
        <rdfs:label>mobility problems</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9965cee7-7ac5-440b-b28c-085c12dca123">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002756</ddiem:url>
        <rdfs:label>stress fractures(Pathologic fracture)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002756*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089612</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2a0f4ad-ab18-44b6-9f81-df753950e743">
        <rdfs:label>proximal femur pseudofractures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100036</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100036</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a85f60e-5f77-4957-9f36-c099338caaa3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0003304>D378V /G339R/E191K/A176T/V423A</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1530944-558c-46d8-b523-75be19282154">
        <rdfs:label>High urine phosphoethanolamine</rdfs:label>
        <dc:identifier>HP:0003239</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003239</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26245849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9445fe57-93d3-4b15-b4ea-e4c60273b5fb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5920a7a1-99d8-413a-8ba5-4753c944d584"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>compound heterozygotes for a p.G339R and p.E191K ALPL mutation</obo:RO_0003304>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/748e48a6-0baa-4378-b828-754b897d0317">
    <dc:identifier>C03D</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d367ff26-f337-450e-9b28-4a4a03ac8338">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3f6768da-13be-44c6-a60f-ad80ef71d294"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77ef2c5f-2eda-4be7-94bc-2c34daf7d1d4"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7fa6e39b-1512-425c-a49a-8262191e1924"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de50c17d-fb59-4518-bae6-8e89cc225562"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07475bdb-9b39-4c3e-abf7-c3ab4def0aa4"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>POTASSIUM-SPARING AGENTS</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03D</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7c21636-6998-49c3-9e7a-bb1509bbb98e">
    <dc:identifier>HP:0001931</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
    <rdfs:label>hypochromic anemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10e48954-ca8d-4bc9-b75a-ba1bae880e6e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000742</ddiem:url>
    <dc:identifier>HP:0000742</dc:identifier>
    <rdfs:label>Self-mutilation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/74f10a4c-7eab-4303-9cad-ceb43232ff3b">
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6114296b-cba0-4ef8-b9ec-bd2017c865b8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6ff27127-1cda-442f-ae19-e18f931a74a4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/c848dbdd-6d35-425d-b5eb-543b7b43cc71">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e83e10c2-1ad6-49b5-be44-07674b81d3c7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/62236951-8d8f-4c64-935a-5d15dfa0836e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03395704</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a11ea68-7318-430d-85e0-b1478a07873a">
        <dc:identifier>HP:0003452</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum iron</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e32829b3-63b1-4c75-aec3-61cf2dd4d655">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/80771d11-86f2-4f85-98f6-c095d0f46162">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6dd012eb-b538-45e1-bce3-508b27c29ee4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc5f3738-202c-45c5-aa81-b2e18e6bab7b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>decreased visual acuity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37a9b792-2839-4653-b08c-c92f4f1b861a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011506</ddiem:url>
        <rdfs:label>choroidal neovascularization</rdfs:label>
        <dc:identifier>HP:0011506</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28560651</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0849756-bb41-4fd5-af92-c1704f333782">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal central vision</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000504</ddiem:url>
        <dc:identifier>HP:0000504</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/30e66cb0-3cf1-4889-950b-2b936523ae55">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb54ceb7-1162-4393-a0db-45db8545a655">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/11b77c2b-db56-47f4-97f7-5a582732d164"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e63c3b73-4fe4-4202-b317-d4f434d93f0b"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
  </obo:DDIEM_0000010>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb730ef1-3b9d-4b49-8066-073296723a9c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>cardiomyopathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
    <dc:identifier>HP:0001638</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0403f90-5fd6-4098-8ebe-fe02974d0886">
    <rdfs:label>behavior al abnormalities</rdfs:label>
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7c4642e9-8122-437b-b0d1-c7c867785b21">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The drug is effective in conjuction with phototherapy</rdfs:comment>
    <dc:provenance>http://pediatrics.aappublications.org/content/86/1/152</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/crigler-najjar-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4a0ccf0-7a5b-490d-89cc-5d46d43d251e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e378d3f7-6819-456a-9c68-365a33487c39"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.nature.com/articles/pr1989488</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2904adea-f119-4ecf-8d0d-e92fb8eee54f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:label>High serum bilirubin level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9827841d-3dfd-4848-be8f-712db601d6b5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a022f667-7b78-4785-ad71-7d17165b60f4">
        <rdfs:label>Accumulated  urine porphobilinogen</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
        <dc:identifier>HP:0012217</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d81f666a-ce2a-4d49-a57a-65e1cd5933b3">
        <rdfs:label>Accumulated  plasma porphobilinogen</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/964a1b62-6af3-4386-b8c7-23ade95c5c78">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eec268b8-2442-4651-81e2-e6c7bdcbfc9f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17375984</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de50c17d-fb59-4518-bae6-8e89cc225562">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
    <rdfs:label>Salt wasting</rdfs:label>
    <dc:identifier>HP:0000127</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/bdd63169-fed9-4b95-acae-2c6c07b1a7d9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5346fc1b-27e5-4deb-ab57-b62f2bac89e4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35de1c37-15e9-4830-9997-5f47d6fa18c7">
        <rdfs:label>Fatty liver</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <dc:identifier>HP:0001397</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d33a55b3-9a8b-4fbf-8ee4-96607d77a517">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001395</dc:identifier>
        <rdfs:label>Liver fibrosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/189c057f-7092-4f91-a70f-94b07bf148c8">
        <rdfs:label>DNA hypermethylation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606664">
        <ddiem:iembaseAccessionNumber>25</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCINE N-METHYLTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/25</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d6546af2-e4cc-42ed-9c91-64c06acace90"/>
        <rdfs:comment>Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high. https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/606664</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01e54ee0-cf0f-4785-bc73-f1a786fef3b3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <dc:identifier>HP:0001397</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Liver steatosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4a9b03b9-0df0-4783-9e8a-2fade7fd0b10">
    <obo:RO_0003304>T65I</obo:RO_0003304>
    <obo:RO_0003304>W99R</obo:RO_0003304>
    <obo:RO_0003304>M197I</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19336674</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6dc61da4-a737-4ddf-bae4-a604e96eed6b"/>
    <ddiem:failedToContributeToCondition>GK-Y214C(De novo muttation)</ddiem:failedToContributeToCondition>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0003304>A456V</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0003304>(Val455Met) at codon 455</obo:RO_0003304>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0003304>V452L</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602485"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a956fc1e-9cea-4107-a9e4-a2476bf668b1">
        <rdfs:label>https:,www.ncbi.nlm.nih.gov,pubmed,19336674</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0003304>S64Y</obo:RO_0003304>
    <obo:RO_0003304>G68V</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>Y214C</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15277402</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15133749</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d60b73ee-efd8-40c7-b57d-dec68de6452e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0212c985-f816-47e4-995e-a214d71ae8cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <ddiem:failedToContributeToCondition>ins454A</ddiem:failedToContributeToCondition>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/b2b54444-1bfc-4e79-ac85-c707a62bf08f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5571766c-dacc-4147-b00a-6dc6463e21ef"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb742914-fd2d-439b-82f2-b3ca2eae676e">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012535</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <rdfs:label>Defected neurotransmitter homeostasis in the CNS</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/df8ec75c-4ac9-43bd-8d15-295a8ebddae5"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2a8287bb-acf5-4575-aeef-21955a33873a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef2ab2ac-5eb0-41ff-b892-e6e23b122df9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dbbc555c-1bd1-4fe2-baff-2335f2500962"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6245ada-3da1-4d9d-a0da-57e5fb8bfd8d">
    <rdfs:label>Excretion of heme precursors(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010472</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/1e164de4-66cf-4889-9155-eee42f7f8909">
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b4c2da9-e17c-4f5f-b3af-6d2cab453169">
        <rdfs:label>abnormal energy production in damaged mitochondria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003287</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/312648e7-8dbb-42cd-aef9-d2afa62716b2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d8d4a879-0d19-47b2-8e27-00e116a4328b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c1db53f-f606-4885-898a-780dd5e1f37e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b365b3fd-5b65-457e-ba9b-7c3c37957f93"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03098797</dc:provenance>
    <dc:provenance>https://mitochondrialdiseasenews.com/2018/03/09/stealth-biotherapeutics-completes-enrollment-elamipretide-trial-barth-syndrome</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0225fda0-3f44-41ab-a90b-178cc46931c6">
    <rdfs:label>linear growth velocity(Abnormality of body height)*</rdfs:label>
    <dc:identifier>HP:0000002*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/926f7bfd-6090-491d-afbb-b8ec08d2d475">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9e4a5c5-cce7-4ca7-8126-b04723330884">
        <rdfs:label>Progressive ataxic neuropathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003434</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003434</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94d8c039-c78e-4fdd-afba-60365bd829d3"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72d43680-393f-45b9-9226-6175be214012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b6c45dfe-5080-421c-ac81-e8cf760faa35"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615558"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bbbf6ffc-d007-40cd-8d69-ab30b5853fac">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:label>Neuromuscular degeneration</rdfs:label>
        <dc:identifier>HP:0002180</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/127e4edc-775e-450e-8918-fdf8839439cc">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f97b7e6d-05ad-4f5a-bff2-b8962d785a37">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010836*</dc:identifier>
        <rdfs:label>Low brain copper levels (Abnormal copper levels)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/399edf1d-5f1f-4a37-9e7f-8f1a7ca74787">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003287*</dc:identifier>
        <rdfs:label>Brain mitochondrial abnormalities (Mitochondrial dysfunction)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a042d90-1880-49ef-8bcf-f9cd97a50927">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <rdfs:label>Abnormal brain neurochemical levels (Abnormality of neurotransmitter metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012535*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3d44b338-9121-49ea-86cf-84722e7ace57">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5dd317b9-1321-4a92-9686-ad141ec2d172"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a638eb8-4574-431d-a7e5-bd3af01ecb8f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <dc:identifier>HP:0001507</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal growth</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4699ba3-48c9-4d10-bd73-11ffd8bcbc18">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological abnormalties</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c3afb8d-9655-48fa-843e-f6fa9589a2dc">
        <rdfs:label>Behavioral abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/fe4373b0-e5cf-47d0-ac55-b5e3a823c73e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16819396</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/531bdcfd-780b-43a2-8147-7229cc9fb916"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f33d84a-f034-4c90-9692-bf6fd9e135e2">
        <rdfs:label>synthesis of atypical bile acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb4b8d08-ed5e-48b1-ba28-addaf342519f">
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>Hepatic Biochemical abnormalities (Laboratory abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e09394f6-c891-4181-9b29-ca8fee2eadd2">
        <rdfs:label>Bile flow defect</rdfs:label>
        <dc:identifier>HP:0001396</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1577015c-ec04-4d58-a075-721981db8c6e">
        <rdfs:label>Cirrhosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001394</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001394</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373615</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8ca5ec2-1090-4d34-a1d8-63374e7f06b4">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001396</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <rdfs:label>Defected bile flow</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/daf22bbc-aa22-4c9c-bf6f-b26ac4d8e247">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>production of toxic intermediates</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e97708a-47c5-4b36-98a6-8f1312c0e6ea">
        <rdfs:label>progression of the disease (Rapidly progressive)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-1</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42d44b81-31ca-4c95-8a85-2510f5d4da20">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002630*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:label>fat soluble vitamin malabsorption(Fat malabsorption)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2affbe48-72e7-4a46-a544-7b6ead8660e9"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19daca8f-36a4-4988-a4bd-08e0342eab77">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Atypical bile acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b81615a0-259f-4806-865a-34d7ed20005d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06819</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/4cbd2435-80fb-429d-a6f2-96860d402fd2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/806148a2-f165-4997-b4f4-b5094244aa59"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e5ca86d-f24e-48fb-99ea-07ad3330f49f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ec592649-f44b-41f3-b160-0d5408910a7d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/806148a2-f165-4997-b4f4-b5094244aa59"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17442906</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB06819</dc:identifier>
    <rdfs:label>Phenylbutyric acid</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9ee3208f-5d6e-4366-ab8a-86f80711882a">
        <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26865117</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c867f38-79cf-4506-8aba-dbb9a541f55a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/806148a2-f165-4997-b4f4-b5094244aa59"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/ca0a2e7b-d3bf-4d1f-b3ff-bf067e3e6501">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d17e7677-c9d0-4f10-8423-8b391a2c5d68"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ecb471e2-f982-4819-8f1f-3ef7e05bc070"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/806148a2-f165-4997-b4f4-b5094244aa59"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fac8d097-d1ea-49b0-bbeb-aac190d18a11">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/09138b6b-fc17-47b6-b3c9-dd0344a27178"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00514046</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22665903</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307225</dc:provenance>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39498903-9a18-4760-bddb-171a80af9947"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d03f960-24fc-4cc1-92d2-510bca5568e7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040063</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040063</dc:identifier>
        <rdfs:label>Decreased adipose tissue</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2354309-ea5c-4ac6-9e0c-c8cf6b40053c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Short Progression-free survival</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>M918T</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/21bb856e-205a-4664-96a0-1bfd3bf600b2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22025146</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20371662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23543666</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d0f97f5e-9645-4ed8-8cba-e72e1dd63afa"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b82fa27b-6319-4f1d-ae4c-b35d1bd0b45b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:label>low quality of life ( Constitutional symptom)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23766359</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27650489</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc93540d-a062-43d7-9d0a-cb6d35b22f81"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/debe6cd3-af90-4862-9901-3dee15f48773">
        <dc:identifier>HP:0003528</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003528</ddiem:url>
        <rdfs:label>Elevated calcitonin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f45290b-46ab-434b-8d12-cdbb6d92c80e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031029</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031029</dc:identifier>
        <rdfs:label>Increased plasma CEA</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ca3dac5-cf6a-4dcf-822a-c46471e99c7e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Objective response rate (ORR)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1594ddd3-373f-42e3-bd60-29a7918439e1"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/afb95316-b6ed-42c0-82b7-4cc0ab863e8b">
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/025ce3d7-120e-437d-8984-76666dd810a3">
        <rdfs:label>high-anion gap acidosis</rdfs:label>
        <dc:identifier>HP:0001941*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e216bbe-1070-480c-97ab-acf7bbd81d1d">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
    <dc:identifier>HP:0000938</dc:identifier>
    <rdfs:label>osteopenia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d50c25d2-1803-4355-9569-cd1f0c2837be">
    <rdfs:label>High total cholesterol</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003124</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/df00d891-b86c-4693-b490-ef6114b02947">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28717435</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f98af070-4eb0-4632-9be0-17471fd3efef">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d9e135a6-2782-437b-8e76-3e4157d17bc7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0003304>m.8344A &gt; G</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7c92e70-ac43-44d9-b11a-e261ea41ae5a"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b3e710c2-4afe-4297-96d8-f0cb4c6bcaf2">
    <rdfs:label>Chlorpromazine</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a6efaada-d21f-44df-9bf1-a386a82e7bbb">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10222465</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0942cfb5-8246-4bee-897c-ee609fbeb042"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb7c9a63-48ab-457c-a702-00a1356ab236"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00477</ddiem:url>
    <dc:identifier>DB00477</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af204d25-8065-4dd1-96b3-93b4250a2c39">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
    <rdfs:label>Abnormal fasting triglycerides</rdfs:label>
    <dc:identifier>HP:0002155*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0efdc51b-ad6f-4b01-addd-8efcdd65e62b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcadaaa4-51ad-4146-a294-3dfae15004f4">
        <rdfs:label>Sleep apnea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010535</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea208935-5c93-4ef4-a96c-5a851d99ad84">
        <rdfs:label>pulmonary regurgitation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010444</ddiem:url>
        <dc:identifier>HP:0010444</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607014"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5523b5a8-dcd9-4edf-a703-649eb4ca4127">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal apnea–hypopnea index</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6eb6a9b-504c-4ef7-bb73-a2e28e981484">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
        <rdfs:label>brain MRI abnormalities</rdfs:label>
        <dc:identifier>HP:0002500</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aa16214d-2a07-421d-89a1-cedd8d6ac1a3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3f57ac71-bbf8-4138-bf09-68a35836eca9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f128b92-2ab8-464c-8a06-cfbe71a234b4">
        <rdfs:label>Abnormality of joint mobility</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011729</ddiem:url>
        <dc:identifier>HP:0011729</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a360719-e6c1-4d98-ba19-77c78cf8b54e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0caddaa9-6ca1-4dba-976b-b1f1f4f61f1a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005180</dc:identifier>
        <rdfs:label>tricuspid regurgitation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81a3f688-9001-4c8b-99b1-5aa2d08fa352">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low exercise endurance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8154598-d2cb-42a5-b7ab-4697d333e141">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003541</ddiem:url>
        <dc:identifier>HP:0003541</dc:identifier>
        <rdfs:label>Urinary glycosaminoglycan excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11172140</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1d1d5f7-739e-4c4c-aec6-645fb0856ed2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002119</ddiem:url>
        <dc:identifier>HP:0002119</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>brain ventricular dilatation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/efb2e7b9-ae4a-4445-90de-29da310fbe75">
        <dc:identifier>HP:0030953</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030953</ddiem:url>
        <rdfs:label>conjunctival irritation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46998fab-f8e9-4ae9-af25-1c9ee355c715">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000969</dc:identifier>
        <rdfs:label>pitting edema</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31630958</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/441366cf-6ee8-4a20-a631-40f814f6e7e7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
        <rdfs:label>white matter abnormalities</rdfs:label>
        <dc:identifier>HP:0002500</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5314c99d-5825-46d9-9c6d-b098d60a0871">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012763</ddiem:url>
        <rdfs:label>dyspnea at rest</rdfs:label>
        <dc:identifier>HP:0012763</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f908098-efc9-48d9-98fd-0049f07ea13e">
        <rdfs:label>photophobia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
        <dc:identifier>HP:0000613</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7e340a5-e3e7-4970-9c52-f872f378350a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002189</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002189</ddiem:url>
        <rdfs:label>Daytime somnolence</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a27e37dd-bcd8-4294-8a9c-511edee2c932">
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>impaired Visual acuity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19748810</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc4cb609-48a6-4bb3-9f40-fe0fc8d50787">
        <dc:identifier>HP:0002877</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002877</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Nocturnal hypopnea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98b9c3f2-104b-4e55-ad1e-3dba69a0f20f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>low quality of sleep</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/069f5cf7-1e7a-4a4b-a568-bb9b9bb7e107">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1142c5d3-2a72-4508-91f5-cbc4cb8167ed">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cf61cdbc-ba59-42cc-942f-78c41fe16473"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>It significantly reduces the inhibitory effect of sulfide on cytochrome c oxidase, resulting in higher rates of respiration and sulfide oxidation in rat mitochondria.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0005272811001447#bb0230</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c73fbc5-cb6c-4873-a147-ebc1b697cf27"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0c460244-0065-49fe-8e77-b896df9b051c">
    <dc:identifier>DB01037</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01037</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d775835d-9562-40c1-b333-00a12ef92a8b"/>
    <rdfs:label>Selegiline</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f9510e4-d7d0-4d58-a57e-eb6775c9beae">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <dc:identifier>HP:0012759*</dc:identifier>
    <rdfs:label>Low developmental score</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4a69408f-cdc4-413b-b4e5-248bebc5d96a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/073d8403-1258-494f-8caf-1dbfc69094d3">
        <dc:identifier>HP:0002900</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <rdfs:label>hypokalemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f8b1c9d6-9541-45e8-9988-ebadbade08bf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d8dfd25e-7c8a-4b44-91d7-172a4cc21ab9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK442019</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bb033c64-dd1c-4f17-9507-b7ef22eba861">
    <rdfs:label>Perampanel</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08883</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/483eabe8-360a-43da-965e-6c34546cc885">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28856097</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4fb6897-3f0d-4969-8bb9-fb94b69dd85b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2e214ac-3274-49e9-b455-2e81bad0e420"/>
        <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a11f2379-f4d5-4fe8-97a7-fa116a975dd2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/246a144a-bb7e-480d-9ad4-bb36f6616554"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB08883</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/849aef92-961d-49b5-a1bb-29f3bfbe93da">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000508</ddiem:url>
    <rdfs:label>Ptosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000508</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a7f1ffd7-1158-46ce-be15-0bfc78a01036">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f9052d4f-0ed7-4451-abf8-ca34001ad4a0">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01025</ddiem:url>
        <dc:identifier>DB01025</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d2ff69e0-8709-4d51-816d-ad0b632f396f"/>
        <rdfs:label>Amlexanox</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f6042bed-d34a-47be-82b1-f2ca408852c3">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c5f3a7a6-c9dc-4cd2-8c3d-732ca1a307c8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930475</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7bfd0f34-6e5b-48e8-ae35-1edacff4a468"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39026671-7172-48ac-97ae-211e9fc7ff5b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01039</ddiem:url>
    <dc:identifier>DB01039</dc:identifier>
    <rdfs:label>Fenofibrate</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/00974e4c-668a-4a28-8a63-e5340b092a7d">
        <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39a13856-8663-47ad-8a45-cf249c6f14e3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7bfd0f34-6e5b-48e8-ae35-1edacff4a468"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16830281</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/ac013902-12d7-47f3-beb8-dec68e9eb576">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24524914</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7bfd0f34-6e5b-48e8-ae35-1edacff4a468"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612953">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8a16ae66-a016-45fb-87ed-bc04e623e5c6"/>
    <rdfs:label>PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/612953</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8b7d2f89-bb27-420e-891f-3dc8b3d187d6">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3008974c-0363-4fdb-ad5c-30716d7975f5">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000486</dc:identifier>
        <rdfs:label>strabismus</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000486</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29555514</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253280">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/354</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ad425382-3c33-426d-9ffe-48a36e92a35f"/>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3</rdfs:label>
        <ddiem:iembaseAccessionNumber>354</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/253280</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d83eb58-2a74-49c7-88be-f9be2254c0fa"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b0552196-66d2-4101-842f-6ef5fb8e4673">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cb86af9f-ebe9-46bf-a999-804df84b7357"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/209300">
    <rdfs:label>ATRANSFERRINEMIA</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/206</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>206</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/209300</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2e5e560f-9599-4a61-a89f-7ef1910e34a8"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ee75eb3-561f-4d78-81fc-77a72375c62e">
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <rdfs:label>Autoimmune encephalopathy(Encephalopathy)*,(Autoimmune disorder)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298,HP_0002960</ddiem:url>
    <dc:identifier>HP:0001298*,HP:0002960*</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2e5caf2d-7e4e-4fff-ab0c-3c61a8ade337">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8cb3a162-53c8-441c-a766-cb018fe99ce7">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/666902b3-ae73-4541-8829-00227108b30c"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00909</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/912d4571-a9bd-41ea-ab33-a3a4443769a3"/>
        <rdfs:label>Zonisamide</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3b2955b-70cb-4be4-91c0-f81cab44a37e"/>
        <dc:identifier>DB00909</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42bfcffd-a21f-48bb-afba-1a64b2649cff">
    <rdfs:label>Prokinetic agents</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/200d5497-eb72-4573-a53e-2cc65f194e06">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/83542bc4-38a5-4491-bd94-f134015c679e"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/69b34a45-baec-483b-80ba-b59eed7299e9"/>
        <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19a6babe-e5eb-499f-99f7-63ddf5bb016c"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/cec66c8c-60a8-48d0-bba4-fcaffcd6840c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e631a25-1adc-41df-b078-58146bef2144">
        <rdfs:label>Secondary NAD+ deficiency in leucocytes</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5346fc1b-27e5-4deb-ab57-b62f2bac89e4"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3d2a50c5-1732-4ae4-b098-b941eaba31ab">
    <dc:identifier>B01A</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5857501d-2c5d-4301-a574-bd01bbe39174">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c57e210d-9381-44a0-bfc9-d1866b338683"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f921a694-0939-47e6-881e-4d44c131b001"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9af2057-b0b4-4092-a67f-cdff1f460f67"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01A</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/ddccfdfd-7b31-46f8-9c4d-1a50e9fd92e3">
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0003304>c.914 T &gt; A</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d3e2514-0784-4398-8773-c1aefc618024">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
        <dc:identifier>HP:0004359*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Fatty acid oxidation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>c. 1393_1479del-Del exon</obo:RO_0003304>
    <obo:RO_0003304>c.1528G &gt; C</obo:RO_0003304>
    <obo:RO_0003304>c.180 + 3A &gt; G</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
    <ddiem:failedToContributeToCondition>c.1528G &gt; C</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>C2129-2A &gt; C</obo:RO_0003304>
    <obo:RO_0003304>c.982G &gt; A and c.1072C &gt; A</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3859ccef-a4cf-4315-94cb-cc0c88a71d5e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4c5d1be6-cabe-4c2d-96cd-df5e4fe5c901"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ef58c82-6b55-4627-a6d1-2e403ac30346">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9d3fc971-5173-4d1b-b498-26ec8fcfa86d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/be3a4a7b-f175-4b8c-9b04-048a5947c805"/>
    <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17957158</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/89339b70-96ee-4545-b773-79e308d15bc3"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74b2582f-9765-40e4-a79f-f5c35887f36e">
    <rdfs:label>Benzodiazepine</rdfs:label>
    <dc:identifier>DB12537</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12537</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/40dda43a-a1e4-459f-b182-5d569a828550"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/02b0e854-46d5-4f70-bab2-4ff2d37b415d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01219</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/40dda43a-a1e4-459f-b182-5d569a828550"/>
    <rdfs:label>Dantrolene</rdfs:label>
    <dc:identifier>DB01219</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/022079c5-4c8c-42ce-bb33-1a15523a3342">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00331</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5da9774a-4b57-48a7-880e-3d6a1e791f17">
        <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17994020</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ae4e0247-d611-42b7-8091-d2d71056b765"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00331</dc:identifier>
    <rdfs:label>Metformin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cb303eed-482f-45a1-bdbd-697516f589c0">
    <rdfs:label>Carbidopa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ddad590a-676a-4dbb-921c-c5632ed3c253"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/27ec1f6d-8999-4c45-ad4f-c061485bb1f3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/60aa41b8-685d-4a94-a7eb-167c6d922521"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2d20a3c7-91b4-4526-9c4b-22e2c4d151ef"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/edbeda72-212b-4022-ab88-87d90e909058"/>
    <dc:identifier>DB00190</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00190</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/be3bf51c-72c9-4138-bf10-f564246c9f05"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9b4e8a62-bf89-4721-a1df-cd48265164ec">
    <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ff74535-36b2-4090-ac47-60ccea1b3c6f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>mitochondrial dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28317891</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7569b878-33bb-4800-a6d2-eda4e9997502">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a5586b2-afeb-451d-b0d7-3c5f07770d7f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01993186</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/547f8ecc-1673-4378-ab2b-e2d8bdbc23ab"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02036853</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/069c749e-be23-42b2-adba-fd6c4098401f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
        <rdfs:label>Dyskinesia</rdfs:label>
        <dc:identifier>HP:0100660</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26982753</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e29a34f8-fd6a-4303-92d0-a94279e86c9d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:label>movement disorders</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02960217</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3f0d7cd-0e10-4140-b657-408a17ce41b7">
        <rdfs:label>Nonepileptic paroxysmal abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606777">
        <ddiem:iembaseAccessionNumber>480</ddiem:iembaseAccessionNumber>
        <rdfs:comment>The currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27781560/ https://www.ncbi.nlm.nih.gov/pubmed/22812641/ https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract
Clinical exacerbation in Glut 1 DS could happen with certain AEDs based on their mechanism of action or effects on the Glut 1 transporter. Common AEDs known to inhibit the Glut 1 transporter in vitro, for example, 1) phenobarbital https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract , 2) Valporate https://www.ncbi.nlm.nih.gov/pubmed/16149077?dopt=Abstract 3) Benzodiazepines https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract are relatively contraindicated in Glut 1 DS. https://www.ncbi.nlm.nih.gov/pubmed/22812641/
In addition, combination therapy of KD and carbonic anhydrase inhibitors—for example, topiramate, zonisamide, and acetazolamide—may increase risk of non–anion gap metabolic acidosis and urolithiasis, and should be avoided if possible https://www.ncbi.nlm.nih.gov/pubmed/20466520?dopt=Abstract</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/606777</dc:identifier>
        <rdfs:label>GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/480</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4194cb8f-7fc2-452d-b747-10585a0121ba"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aa844496-c5d8-424a-ac50-9ef94bd84b20">
    <dc:identifier>DB00178</dc:identifier>
    <rdfs:label>Ramipril</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5eea987d-7415-408d-beba-e033ba1a0189"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00178</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bdba2e41-fbcd-4ab5-bb62-2319ec964d28">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d64fa266-bedf-48ff-badb-73126d34d1b6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/212ef555-70cd-4feb-91c6-b3aa9a294ca6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29395598</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d01e942e-bd9e-4821-977b-148064ba0992"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5694cbdf-a9ad-4937-a6c4-62d46ee79b36"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cf492b00-c36d-482c-8571-7aecc0a5d1ff">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33ac0217-8869-480c-a88a-b76df9fd8d09">
        <dc:identifier>HP:0012100</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012100</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal circulating creatinine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <rdfs:comment>The increased creatine/creatinine ratio in adult IOSCA patients, as well as in the IOSCA child patient who is motorically as active as her age‐mates, suggests an important role of creatine metabolism in the disease pathogenesis. Creatine synthesis is a major methyl group user, utilizing the same 1C/methyl pool as transsulfuration cycle, and thus, the creatine supplementation in IOSCA and IBM should be studied thus creatine is considered as a potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373890</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/6226a622-bfe2-4c7a-a266-1dedf4f8ea18">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c2d4b71-1b9c-4824-987e-e7985f053f33"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/496af2a4-8ccc-4878-bb7d-5aba54f939ff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24854628</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT00458055</dc:provenance>
    <obo:RO_0003304>R219K</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3c154bd-dbb7-4ca3-be2c-2f9c07df08f9"/>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2b31ea5-c2ee-4503-860e-abfe8e287b7e"/>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/6b890cc5-fa76-4ba7-87a0-449aa5195280">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c9253f19-bfaa-4303-bec9-ee4a3d10a839">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c9debeff-8288-447f-811a-ab401a7a8aa6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/202110">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>125</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d5e675a0-0b5f-4965-b99d-b9288f6f3d7d"/>
        <dc:identifier>https://www.omim.org/entry/202110</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/125</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f37827c3-7d9d-4fcf-816c-fc291584b05b">
        <dc:identifier>HP:0000141</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000141</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Amenorrhea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c884f2d-7729-4738-9d4b-f122abfb89d8">
        <rdfs:label>Puberty and gonadal disorders</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008373</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008373</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615181">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/615181</dc:identifier>
    <ddiem:iembaseAccessionNumber>1121</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1121</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/da6aeda1-acfd-4341-b30f-6bf35ea5e26d"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9db00aeb-b7e5-483e-999c-2d27b2dd37aa">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001958</ddiem:url>
    <dc:identifier>HP:0001958</dc:identifier>
    <rdfs:label>Nonketotic hypoglycemia</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ff5748d8-9f09-42b4-889f-92a3f677d6bf">
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318010</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3e7b87e-fea3-4831-9d25-85eade85fea4"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4358cebd-d072-4344-bdac-dfdf24e12a65">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ab6affd1-d3e1-4f5a-85f0-44c23f3e9a71"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7256a76c-8b15-4b0e-9c66-241802629bf6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b8fdf3ac-a47e-4c09-a7b0-6d6840e94392"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2b61387-b1b7-4463-9836-e5ec6d785004"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5b7bd8a3-d5ed-4e68-8e9d-00d2b88bc128">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d4b3a0c8-8b31-45e5-beea-c82d4e74eadc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64b9e608-2964-47f9-a936-580660dd975f"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/50521a69-46e0-4f91-b34f-bef4d46b94c6">
    <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2dcdf96b-9958-4ddb-999b-e87356a9dd2a">
        <rdfs:label>Abnormal renal function</rdfs:label>
        <dc:identifier>HP:0012211</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005242">
        <dc:identifier>ECO:0005242</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005242</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3d0ea856-1bd4-4099-9b3f-e0fbdaa9aad9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49f38314-d097-49e3-9ea8-fdf3e83e196a">
        <dc:identifier>HP:0003676*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:label>Renal disease progression( Progressive disorder)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05e320d8-273a-4b5f-a801-fc4122e9d849"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20195241</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/960b82ea-83d3-4382-a688-b20704f8febe">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65d6195a-e099-4715-aa22-c59b4da3069e"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6667e7bc-ad33-4fe4-9446-49b82dbfb658"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/563b9f24-45ce-43f3-9725-e8d2e5ad76ff"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e153fa60-4c8f-48cb-85f4-ecf4b29a2205">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cutaneous abnormalities</rdfs:label>
        <dc:identifier>MP:00011911</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_00011911</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a48fda36-7f88-4aa5-8bd1-2a4a9ce402eb">
    <rdfs:label>Poor appetite</rdfs:label>
    <dc:identifier>HP:0004396</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ebdebf38-4954-419c-af26-14b60ea97211">
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c78afb9-e7b3-4069-a792-20aee781da03">
        <rdfs:label>Delayed motor development</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
        <dc:identifier>HP:0001270</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b0552196-66d2-4101-842f-6ef5fb8e4673"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ed2038d9-528a-46b0-9a51-5776c90b9400">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00746</ddiem:url>
    <rdfs:label>Deferoxamine</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/974dfcc6-87ed-4829-883f-abfba027a82e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8187613</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d84143a-7003-47d3-9f89-79c8feeb37b0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7c21636-6998-49c3-9e7a-bb1509bbb98e"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/523a68a1-b369-4e4a-a32b-1df48d17cefa">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29134618</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/064a1a28-b67b-4367-82c3-31e84a94725c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d84143a-7003-47d3-9f89-79c8feeb37b0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/54f3b8d5-0c1e-4f1f-8bb9-9371943a3e06"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/98328939-f4f9-4f06-abd3-fed149764c04"/>
    <dc:identifier>DB00746</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/132bafbc-3a2a-4be7-9f80-9cd23937ba36">
    <rdfs:label>White matter changes</rdfs:label>
    <dc:identifier>HP:0007103</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007103</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/33dbc0d5-44a4-46e7-a845-bd5fa44d7590">
    <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608643">
        <ddiem:iembaseAccessionNumber>100</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/100</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/923036a4-0769-4232-9b38-7c4271e5dcea"/>
        <dc:identifier>https://www.omim.org/entry/608643</dc:identifier>
        <rdfs:label>AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ce7a089-b63d-4606-b90f-984794a27050">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>boost residual AADC activity with a cofactor excess</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5bbaa4b7-fa65-4ef2-9dc5-8c289dc18ee6"/>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/494806d5-37fd-4edc-bb63-25412f6784dd">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00947960</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a5586b2-afeb-451d-b0d7-3c5f07770d7f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f56c2fbe-c27c-4d65-8825-8c601849cde7"/>
    <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263570">
        <rdfs:label>POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/263570</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c551606d-8099-484e-a3f7-2993645c359a"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d68ad91-3d6c-49b6-88d4-6dcd4cf0eda9">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012378</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:label>Lack of energy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be591fd8-91fc-4a86-a148-870b628a8e98">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <dc:identifier>HP:0011025</dc:identifier>
        <rdfs:label>defective heart function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617070">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a0823f39-d254-42c5-8dd7-a15b1fc2daca"/>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 4; PEOB4</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/617070</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb4db383-456d-4556-a99d-670ba5e12b3e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
    <dc:identifier>HP:0001386</dc:identifier>
    <rdfs:label>swollen joint</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2c53e357-9915-48d4-ad83-6f418e96730a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/263deca9-66ef-425b-b802-2ae970fccb5e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
        <rdfs:label>renal salt wasting</rdfs:label>
        <dc:identifier>HP:0000127</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/272020d3-5ddc-442f-b2e3-21b4c88a8b5f">
        <dc:identifier>HP:0004324</dc:identifier>
        <rdfs:label>weight gain</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/668d86ab-470d-4b38-b147-016a643b6eac">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>proximal tubule salt losses (Proximal tubular defect)</rdfs:label>
        <dc:identifier>HP:0000114</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acad12a5-7b29-4223-b747-aed7076d01ab">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:label>polyuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000103</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/349fc753-4be8-48b2-9a63-5b636324c2a9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/144650">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE V</rdfs:label>
    <ddiem:iembaseAccessionNumber>1086</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/13969f6f-b5e8-458d-b2cd-3c70a8e04823"/>
    <dc:identifier>https://www.omim.org/entry/144650</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1086</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0b17b137-aadf-4a0c-801d-50010d323702">
    <rdfs:label>Iron</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/da615ced-a035-4bcb-af8e-f543b559c17d">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02979249</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f22226b2-7e51-42e1-842f-cf141a6db181"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1228bea-da1c-4d61-911b-5c5712edc366"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01592</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9b6a3c9c-1bd8-4589-84bf-411ea5e72a25">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1228bea-da1c-4d61-911b-5c5712edc366"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e02aa49f-2390-40cc-b373-22e88233c8e6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1fa53f0a-a8dd-4fad-aed9-5acaff3798ee"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB01592</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/5615946a-6dd8-4c41-8142-2a7e2168d764">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/69848ed9-d3b0-4a6a-9572-5fab9a84304b"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <rdfs:comment>Citrulline should be given in "Low-dose" as of 100 mg/kg/d.  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  
Adjusting l-citrulline dosage may be crucial, as excessive citrulline may worsen intracellular arginine accumulation  leading to harmful effects. https://www.ncbi.nlm.nih.gov/pubmed/22402328/ https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e5ca86d-f24e-48fb-99ea-07ad3330f49f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10a18bf8-94d0-4ad1-acbe-55502bf2bc73">
    <rdfs:label>Naproxen</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/da0c785e-311c-4acb-a9f4-90771c90f722">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.nejm.org/doi/full/10.1056/NEJM197807132990214</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/073d8403-1258-494f-8caf-1dbfc69094d3"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45f61106-65f3-4899-b6bb-ce04fdcddc6a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00788</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/79a99ba7-efc6-43ac-9698-70bd8b500b89">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07da2db9-fa15-4f72-bbf2-58f43f73d95f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f93fb2ef-4fcd-4817-b472-8e096ed9d975"/>
        <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45f61106-65f3-4899-b6bb-ce04fdcddc6a"/>
        <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00788</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/28ab16ce-eb07-4cd7-b778-37f87ad0c837">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45f61106-65f3-4899-b6bb-ce04fdcddc6a"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118610"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05da1106-be65-4c86-ad4c-913cb5994dfe"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17541659</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1d36a1f6-9ad2-4c1d-8d4e-1213ee17616d">
    <obo:RO_0000056>
      <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/35728f07-9efa-4510-8935-59b743739982">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aad0232b-d068-4a7f-9f3e-4d30542b65e1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e63c3b73-4fe4-4202-b317-d4f434d93f0b"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9559978c-f7e7-45d7-a09c-e9ac804b0a6b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d249f4af-7d79-441f-bd32-1ce29a700254"/>
      </obo:DDIEM_0000010>
    </obo:RO_0000056>
    <rdfs:label>NA</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f34be7d1-9cc6-4f4a-87c6-ff0429271202">
    <rdfs:label>Reduced electron transport chain activity(Decreased activity of mitochondrial respiratory chain)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008972</ddiem:url>
    <dc:identifier>HP:0008972*</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8d4c8048-d350-4fe4-98b1-2eaead55fd24">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0367c648-cabd-4a55-9bcc-b0f4dcf6e97f">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fbefa59d-6274-4746-9809-cd1243da470f"/>
        <rdfs:label>Complex Carbohydrates</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/e168e8e3-9532-412f-a6ce-01182ec7b9dd">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/234500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/50</ddiem:iembaseUrl>
        <rdfs:label>HARTNUP DISORDER; HND</rdfs:label>
        <ddiem:iembaseAccessionNumber>50</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/234500</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/76e9cd0a-d87f-4311-8e4d-50b23b2192c9"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4eb92dd4-4132-4fe7-be2d-f5c4517cb6b9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
        <rdfs:label>Chronic diarrhea</rdfs:label>
        <dc:identifier>HP:0002028</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25526748</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/94ec5b3d-dad0-4eb0-97b1-98ff07eae288"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cded2475-016f-40ed-9c40-151373c1d5da">
        <dc:identifier>HP:0001019</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
        <rdfs:label>Exfoliative erythema</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18f139db-8dfa-44fc-8fd4-ecb603619f69">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003073</ddiem:url>
        <rdfs:label>Hypoalbuminemia</rdfs:label>
        <dc:identifier>HP:0003073</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/967e1522-1169-4186-a259-9b3a2be46b6f">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0e150a74-d580-4ab2-bdcb-f354a2b8ba4e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/05b61bfb-65a2-4ba2-9a2d-c3e32c59760d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30765910</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27509102</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30875019</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75e0e733-b76d-48c7-97da-b647e53d33bb">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma lyso-globotriaosylsphingosine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301500">
        <ddiem:iembaseAccessionNumber>296</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/296</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a62edb38-d4d8-4466-9625-438e9c401b84"/>
        <rdfs:label>FABRY DISEASE</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/301500</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
    <ddiem:failedToContributeToCondition>"E48K, R49P, S65I, I117S, G183V, G261D, G271S, S276G, R342Q (n=8), L414S"</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5b42b1f-a71d-4397-9a4d-6c54f9c69211">
        <rdfs:label>Left ventricular hypertrophy</rdfs:label>
        <dc:identifier>HP:0001712</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64452c71-10f1-4949-b76a-db76479c157f">
        <rdfs:label>High mean number of GL-3 inclusions,kidney interstitial capillary(KIC)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <obo:RO_0003304>"p.D33G/p.L36W (n=2)/p.D55V/p.Q57L /p.G85D/p.R112H/G144V/p.I253T (n=4)/p.G258R (n=2) ,.A156T (n=3)                             p.P293T (n=2) /p.C174R                                                                                                           p.F295C                                                                  p.G183D (n=2)                                    p.L300P                                                                      p.M187I                                                                             p.R301Q   (n=3)                                                                           p.P205T (n=2)                                p.I317T                                                                  p.Y216C (n=3) /                             p.D322E (n=2)                                                    33p.L243F                                                                              p.G325R (n=2)/p.G373S / p.D244N/ p.R356W"</obo:RO_0003304>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/05b2d37f-6b75-4a47-81e2-62075236b85c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21685bb8-0f2e-4b84-bb24-057e425d9c43">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012647</dc:identifier>
        <rdfs:label>Abnormal inflammatory response</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30225156</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2445ffee-829b-4530-9093-43fdd2d3c005">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bfe6e931-ffba-4eb6-972d-c6bc4572b6dd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56645760-0f2d-4eeb-b2bf-1a9944c64af0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
        <rdfs:label>Fever</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001945</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad1e0a05-ec86-4718-b56c-c89b839ddc06">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000155</dc:identifier>
        <rdfs:label>Oral ulceration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25173351</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c1db53f-f606-4885-898a-780dd5e1f37e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc93540d-a062-43d7-9d0a-cb6d35b22f81"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48a09e4b-48ab-417f-8a1d-652f7b68b456">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
    <dc:identifier>HP:0002353</dc:identifier>
    <rdfs:label>Abnormal Awake EEG</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3b0ce0ba-6d45-4999-b0e3-529cb646d373">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/6241a59f-6edf-401a-b2f6-d5469c06d384">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12727399</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1dca93ea-2a80-4679-8d98-70a118f4e18b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb730ef1-3b9d-4b49-8066-073296723a9c"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/954230de-a684-45bd-b295-b98179dc1cd0"/>
        <rdfs:comment>Synergism inmproves results</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a00aa2d-0876-47eb-9699-bfe138bbed8a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c74e1b2-646b-4e52-a6ea-d0caf1b5e915"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <dc:identifier>CHEBI_113373</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_113373</ddiem:url>
    <rdfs:label>sodium beta-hydroxybutyrate</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/4c0c8f96-3df2-477c-b258-a063e091bcf2">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6c433af9-025c-47aa-92b0-c9aeb3fc3e46"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d666e3de-fd61-401d-9366-ba37ee0d8278">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022*</dc:identifier>
        <rdfs:label>Voluntary movement abnormalities(Abnormality of movement)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a5c9d49-d0ac-489f-890f-b84c91c592e9">
        <rdfs:label>Oculogyric crisis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010553</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a57dd1e-220a-428d-998c-2d64137efa2e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a98f65eb-1f57-413a-94bb-fb17e1ea8255"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d62c06cf-1be7-4bc3-bc70-a3a3d4ab3e30">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002459</ddiem:url>
        <rdfs:label>Autonomic dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002459</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/02a421e5-5d74-4d02-9915-4367ab618a5d">
    <rdfs:label>Serine</rdfs:label>
    <dc:identifier>DB00133</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ca638ca2-125f-4ecc-b72c-ae3e4316b434">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8ca3e429-bbd6-4164-81cc-b4b8cb293d07"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00133</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0bef26f2-f61f-4e94-888d-c5286ce3cdce">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56afbaba-ca38-437f-985f-0ada5f600482">
        <rdfs:label>Abnormal cardiac protein (TAZ) expression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f4ff20e0-7074-4a27-9b56-4f1b02848e5e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c91dec14-f180-420c-a418-2488d32fd771"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/410dd1bc-ac28-4b26-a791-e74895ec9bda"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30788385</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5699ec1d-3568-4a83-85f9-4556d6b0e49c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f8215a69-50b6-4b22-9923-24bf885d5d49">
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27718492</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a212a56-60ec-4265-8408-335ae9eca2e9">
        <rdfs:label>Short Stature</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <dc:identifier>HP:0004322</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f419d28e-775e-4b39-bd36-87934855b06b"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6ac43cf-368a-4d00-bff2-d49192892a90">
    <dc:identifier>HP:0000962</dc:identifier>
    <rdfs:label>hyperkeratosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000962</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/97574d18-611b-4ce6-ac16-677d4f1aad50">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25852896</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72afb3e1-47c3-478a-8d2e-3d4c990c8afc"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/349fc753-4be8-48b2-9a63-5b636324c2a9"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c51aa641-7e8a-40f0-98ed-7f6c5e5d09a5">
        <dc:identifier>HP:0004319</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004319</ddiem:url>
        <rdfs:label>Abnormally reduced levels of aldosterone</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ca782c5-9548-4e31-afc5-d79b97e17f37"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7ca0c5a-f23e-45a5-a016-77a4d004e2e3">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000847*</dc:identifier>
        <rdfs:label>high plasma RAAS activity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000847</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219750">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/21b0dd29-5e41-46a6-aad2-28a1acb7cd82"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CYSTINOSIS, ADULT NONNEPHROPATHIC</rdfs:label>
    <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/219750</dc:identifier>
  </ddiem:Disease>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/3e4ae2b6-c9bc-4a7a-8b4a-16c9b8e62a13">
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24882a8f-6836-4291-894e-9001a429316d">
        <dc:identifier>HP:0031884</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031884</ddiem:url>
        <rdfs:label>Abnormal CSF glucose levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/70f04571-a617-4641-9fae-a82c782f4bba">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7fa5c056-cc23-412b-9886-24e786235007"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3364b111-978f-4b2a-8375-b48139066be9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal motor function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <dc:identifier>HP:0004302</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606777"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0bf23d14-cfcc-48a9-9213-86e4b6413ff1">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007166</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
        <rdfs:label>Paroxysmal exertion-induced dyskinesia (Paroxysmal dyskinesia)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/465a73e4-c540-468a-9df5-db1f9c698ae2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c0bb9b6-1bf0-40a3-893b-71418de573cf"/>
    <dc:identifier>DB11094</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/76f0deae-1b0a-451b-859a-3f69a744ba56">
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ddad58a5-e21d-41f9-b684-23075c7b7022"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24787057</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/99b27243-5345-4f9b-86e2-5e274e9fc5c7"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/46c9802d-4d94-4e48-b523-b81b21c4a62c"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c4ec2e37-0228-4c25-a7bf-cf7fae4a262b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24137761</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/99b27243-5345-4f9b-86e2-5e274e9fc5c7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53f31c32-df23-43a5-9808-5810e5726528"/>
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/327ab938-ee5e-4d7e-a5a7-13444c6ef11e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e216bbe-1070-480c-97ab-acf7bbd81d1d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7979e2e-d0f3-4bed-af39-314165185e46"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/99b27243-5345-4f9b-86e2-5e274e9fc5c7"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Vitamin D</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11094</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/9000ed50-6c2d-4361-b429-70078cd00572">
        <dc:provenance>https://www.semanticscholar.org/paper/Hypophosphatasia%3A-A-Systemic-Skeletal-Disorder-by-Orimo/5d135fbc68735a3e95d3b313fc0636f10215b300</dc:provenance>
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/99b27243-5345-4f9b-86e2-5e274e9fc5c7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03b4bc1c-7eb4-4301-8e88-bb129b4476f9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/00731be4-0dea-40b7-9550-24193a1d46fb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d69aa50e-9ccf-4997-8175-f25b37f88ebd"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00618abf-f36b-4e3d-9324-cbe203b9e58d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neutropenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/afb96df8-7972-4485-9ef0-45bd443b2e60">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Poor motor coordination</rdfs:label>
    <dc:identifier>HP:0002275</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/e5b76842-75fe-40a2-8109-5a2fe4a8b690">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10581232</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac5799d5-cc35-4d20-8974-81ddc715cc9c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000012>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000011">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:06:25+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure involving enteral, parenteral or transdermal provision of small molecules closely related to the products or end processes of a genetically defective protein. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">metabolite replacement</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/9f14dd22-7b77-44ff-b1b5-7cddbc1e1a76">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef76b40a-c8e7-4c87-b4b2-a570ccd44641"/>
    <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11687750</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8652022</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f87dc0a-c82f-4272-810e-3dc661c28788"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2579c085-8d6c-40cc-ab70-c360003f0644">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
    <dc:identifier>HP:0001263</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>psychomotor retardation</rdfs:label>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/4d028282-089e-45d1-814f-040d909f77c0">
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S152500161632250X</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b7cecc8a-3b76-44a1-baa0-17324d7a6d65">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c363a680-deb3-4e5d-997d-b31d37d91265"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f78daf9-b473-4c13-82eb-7a463b2c1fe4">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011804</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:label>abnormal muscle function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613153"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/c3158450-3608-4e7e-b22c-d5dc9d0e8003">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10468611</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3801ab7d-75a9-4c5f-9eb9-afe35ecc6dc5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/522ea7f9-df67-4c0c-8cc8-c5fcb5ce96fd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62a19b29-9cc4-4a7e-b3e8-1b1bf99eb2f4">
        <rdfs:label>UDP-glucuronosyltransferase gene defect</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/831f6d35-a1fa-44ff-8579-db3c78e66530">
    <dc:identifier>HP:0012279</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012279</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low plasma serine levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/00e06947-ff12-453f-a4c8-e5446482552c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01015)</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2a269430-1536-4a53-900b-f7165d52a3d9">
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e42592ce-0c43-4ba1-a4b1-87f708085a06"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07c2259f-20df-4f9c-ad9a-9e7425ce0691"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/795aab8d-b8cc-4cc4-9991-60257a7c3e7d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8cadf86b-bc9c-4584-a372-5a9385103eaf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21393975</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3336696-d296-41bf-8b08-ed0126981836"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB01015)</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/30942e63-41ed-4e84-87c0-fbf423fb9cdf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e5b73543-3fbe-43e4-9d38-9a61165743e0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b45ea33-600a-40a0-961d-069626c0cf82">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>limb hypertonia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002509</ddiem:url>
    <dc:identifier>HP:0002509</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ce2d2e8-1297-4519-b2ad-86d97ecb8628">
    <dc:identifier>HP:0010903</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
    <rdfs:label>Abnormal plasma glutamine levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dc13423a-aaf5-4f46-9296-60aeb97265d6">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/33a7d7bd-a44c-407d-a08b-bee3ea32df9b">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc7784ce-2b56-4cb5-aadd-9619ce723c61"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65d6195a-e099-4715-aa22-c59b4da3069e"/>
        <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Lovastatin</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/194dd838-7c52-4039-97e8-92f24eef27c7">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65d6195a-e099-4715-aa22-c59b4da3069e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089986</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16949688</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d565de12-cbcf-4d13-b441-dee9ec3de9fb"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
        <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0d71802-13b2-4b22-8f3b-77d7ef9c217f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00227</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/3edb819d-901f-40cb-a7b3-33beadfabeae">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9fc149df-2bb5-4290-add6-547eb15d4707"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65d6195a-e099-4715-aa22-c59b4da3069e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca4b058c-b246-4024-b150-fd2641fd34f0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2949c60d-dc79-4947-81bd-7a88f405e2df"/>
        <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39026671-7172-48ac-97ae-211e9fc7ff5b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00227</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c771aa17-a542-4aee-8660-b6d993a04a42">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00705939</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14bf998d-880d-4286-8c54-aa66d5278aaa">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Trial is no longer available</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1abf54e-42dc-4ab3-856b-da0069a12fda"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a108a020-5c0d-4015-b559-e4dccd703462">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Slow background activity in the EEG(EEG abnormality)*</rdfs:label>
    <dc:identifier>HP:0002353*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/308ee8d8-c8c5-4039-8805-05a848a5dcfc">
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/ee34d50d-e59c-4180-ab33-0640e6131a14">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e9370a5b-bad3-4b41-9ae6-ce809837861b"/>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b7c74f92-c768-4091-8ddc-622f5b1f00e5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <rdfs:label>N-Acetyl-L-Glutamate</rdfs:label>
    <dc:identifier>DB04075</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04075</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ec890bbb-a952-48a9-9d2e-f59c74852474">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/140350">
        <dc:identifier>https://www.omim.org/entry/140350</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fc6ef6fa-d07c-460a-b11e-c1c1f11a3957"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/22</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>22</ddiem:iembaseAccessionNumber>
        <rdfs:label>HAWKINSINURIA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d2ca97b8-c346-444d-bb4f-7c71ca4384f2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/98b32afb-474b-4a67-82d0-ecf5049c9b74"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5bbc2c9e-dbfe-48e3-ad18-e138546cc759"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0757f199-d9dc-4f21-97d3-4be93340a776">
    <rdfs:label>Impaired nerve conduction</rdfs:label>
    <dc:identifier>HP:0040129</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f818105a-884a-4f7e-aad7-37946348c7be">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6978e9bd-803c-4c18-820f-5c35e608922b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fae7f8ce-ef90-45cb-9a99-42df4e2a4d8b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bca20b1-d84b-4a52-93e5-6ef95adbb3a2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Psychiatric disturbance</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d7554828-8f5f-4efe-b047-a7d37bb80304">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e3299020-98cd-4a96-9eda-51318c18a8df">
        <rdfs:label>Phenylacetic acid</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB09269</ddiem:url>
        <dc:identifier>DB09269</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5e4bdb5c-f07c-4f34-803b-f1deb7f077cc"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5e4bdb5c-f07c-4f34-803b-f1deb7f077cc">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c867f38-79cf-4506-8aba-dbb9a541f55a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d7554828-8f5f-4efe-b047-a7d37bb80304"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99c0c47c-06cf-4459-8984-45623cb5f83c">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001336</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
    <rdfs:label>myoclonuic Jerk</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bef67d5b-641e-4ff7-82f2-6b117f1de8fa">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/07c5e497-bece-4bc9-805c-810b8c90eb6a">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0798c296-0721-4d8a-9ae1-e9877ed55ff0"/>
        <rdfs:label>Taurine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/38aa475f-f568-4e55-a3fb-2d2ee7c80a58"/>
        <dc:identifier>DB01956</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01956</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/a1dde7d5-017f-444a-a1b1-052bdae12134">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41a9f5f7-0404-4406-b660-3f59146ca7c5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02922413</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/355908ca-f560-4799-a1ab-3d0f8c810a75">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001649</ddiem:url>
        <rdfs:label>tachycardia</rdfs:label>
        <dc:identifier>HP:0001649</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/590ca4fe-d2d7-4d59-956d-25dca0fc33da">
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>abnormal mental status</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8b479f0-2367-447a-b668-de4f6ba5d606">
        <rdfs:label>pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
        <dc:identifier>HP:0012531</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27e87084-d1b3-4c7d-91c7-00bb686de0c6">
        <dc:identifier>HP:0011009</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011009</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Acute attack</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b3cfb3c-5f2c-4b2d-9be8-4dbd71dd120d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/18d514f9-7381-4bd3-a36c-a20b9ad47d32">
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22fafdf8-4c44-4176-9f08-af1010a5a76b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
        <dc:identifier>HP:0008166</dc:identifier>
        <rdfs:label>Abnormally decreased rate of beta-galactosidase activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17164772</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230650">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/91b5385a-0db8-438f-b80a-b807753fa580"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE III</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/230650</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ad182f1d-dc01-4250-930f-d9e6074aea5b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a1345ce3-00e4-49a5-89e5-386f54baa0aa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7321cdc3-9cef-4253-a8cb-ce308972349d">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2583520d-d3be-4570-a15f-80c607fb8f5a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>secondary carnitine deficiency</rdfs:label>
        <dc:identifier>HP:0003234*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ffebcfa-f201-410d-8e07-396d0d529147"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba78cf77-e14e-4b91-a29c-176fa3da3088">
        <rdfs:label>high  short chain acyl-carnitine metabolite level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <dc:provenance>https://link.springer.com/article/10.1023%2FA%3A1024031714659</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfb26d15-7024-45b8-9923-cc5c26edd92b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased ROS production</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
    <dc:identifier>HP:0025464</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/34beb861-100d-4d24-b3d1-0027f2259a96">
    <obo:RO_0003304>homozygous frameshift mutation (c.1844_1845insG) in the C-terminus of mitochondrial atypical kinase COQ8A</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7c42181-7590-4f9d-94b3-a80d1a860292">
        <dc:identifier>HP:0002167</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
        <rdfs:label>Speech problem</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8bdb6b61-5b9f-4138-89c8-3d48de9078a8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66980f89-e96d-4a46-9c37-ef47b5b44405">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012211</dc:identifier>
        <rdfs:label>exercise intolerance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/60aa41b8-685d-4a94-a7eb-167c6d922521"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6289fc90-15a9-4a86-8a90-6af49314e36f"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612016">
        <rdfs:label>COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/612016</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ef59f7d5-bc7d-4e76-9431-d7acac6fc881"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0003304>comp. htz c.1523 T &gt; C exon13 + del exons 3 to 15 p.Phe508Ser</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26818466</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ce30491-0a4c-443c-bff4-e30c0244e58b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>Neurological abormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/152839f9-ceca-4a65-900f-7c3d9b82b3af">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>dysarthric speech</rdfs:label>
        <dc:identifier>HP:0001260</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18319074</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21b4460e-e1ef-4b55-a626-354d3acb0164">
        <dc:identifier>HP:0003128</dc:identifier>
        <rdfs:label>hyperlactatemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>Homozygous deletion (c.1511_1512delCT) that leads to a premature truncation of the protein (p. Ala504fs)</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c1db53f-f606-4885-898a-780dd5e1f37e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d162f61-f3d9-47ba-813c-bba83fda4bd1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
        <rdfs:label>High ataxia score ( Ataxia)*</rdfs:label>
        <dc:identifier>HP:0001251*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b42bab0a-54af-4c63-ba40-c15e53fe7dfd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002066</dc:identifier>
        <rdfs:label>ataxic gait</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cefad17c-eeba-4ff2-9a97-24eeecbe9dea">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
        <dc:identifier>HP:0001336*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myoclonic abnormalities(Myoclouns)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>Hetero c.[1541A→G] + [1750_1752 delACC]</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a93f5c32-2884-4541-8bae-cef2a760ab8e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0004144</ddiem:url>
        <dc:identifier>MP:0004144</dc:identifier>
        <rdfs:label>Drawing inabiliity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>G272D https://www.ncbi.nlm.nih.gov/pubmed/18319072</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29159460</dc:provenance>
    <obo:RO_0003304>Homozygous deletion (c.504del_CT)</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1df30ffa-c93b-49ae-a7a9-aa490cdba2e0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <dc:identifier>HP:0001288</dc:identifier>
        <rdfs:label>Gait abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>comp. htz c.[895C &gt; T] + [1358delT] exons 7 and 11 p.[Arg299Trp] + [ Leu453Argfs*24]</obo:RO_0003304>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/547bbe19-d1d7-4b1e-bb2f-99b203e07e28">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c8c0d9f6-1365-4682-9fc3-d185f535f5a6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/af09704b-b6a2-4a20-b93d-5ee3f4a64277"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>S466L /I278T</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1cdc586e-0792-410c-b1cf-466633453272">
        <rdfs:label>Homocystinuria</rdfs:label>
        <dc:identifier>HP:0002156</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002156</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff536d55-de08-4b86-ac77-56274cd5ee4a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Hcy level</rdfs:label>
        <dc:identifier>HP:0010919*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/090c8b74-b1de-4527-9058-d05d6d69ade7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7b0648fa-d5c1-43f7-bd32-abc95e3d0c51">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/02e28a23-86ad-4104-8880-f1f5123b0b3d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a70fdc7f-6f23-4e85-aac5-fce9432c9539">
        <rdfs:label>thirst</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
        <dc:identifier>HP:0001959</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://academic.oup.com/jcem/article/98/10/3958/2833930</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4659ea93-68f1-4882-b7d0-a06ddb1babc7">
        <rdfs:label>polydipsia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001426</ddiem:url>
        <dc:identifier>MP:0001426</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c4ee235-99ff-4388-a71e-2cd40b6479ac">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
    <rdfs:label>Low myocardial function</rdfs:label>
    <dc:identifier>HP:0001638</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8175a131-b2aa-404a-8dcc-6095c47077de">
    <dc:identifier>DB01026</dc:identifier>
    <rdfs:label>Ketoconazole</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/cce495c0-e729-49c7-b92c-114a3bc48c44">
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>"ENB-0040</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/965cbc70-a08d-41ca-8ddd-9b4f06a54ab2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e153fa60-4c8f-48cb-85f4-ecf4b29a2205"/>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01026</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7925b91c-ee08-4443-8cf8-a314262ae038">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal ALT level(Abnormal liver enzymes)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/43143756-b976-491b-b749-4bb94f224b75">
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5296b6d3-94cf-496b-9f0f-851435fed790"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ca782c5-9548-4e31-afc5-d79b97e17f37"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/797bc606-d9ff-4ce5-951a-f75bf797d8e0">
    <rdfs:label>Oculomotor apraxia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000657</ddiem:url>
    <dc:identifier>HP:0000657</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f22226b2-7e51-42e1-842f-cf141a6db181">
    <dc:identifier>HP:0012187</dc:identifier>
    <rdfs:label>high erythrocyte protoporphyrin levels</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e575b2cb-1f62-430f-a6ee-d5ba838c8f65">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3035daba-4609-4935-8c07-777bb6b8961c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6b4ae746-06bc-4614-8ebd-60cb3cf0367f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/761252a2-b41b-49a2-97ce-079be058fe8d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4a542af1-180f-4d60-a46e-5ff208349158">
    <dc:identifier>DB00994</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/01276c37-b82e-49f1-911d-e0f836725f6e">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5a5a4dbc-6065-41dc-8f3c-85f4ec23ccc1"/>
        <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ce56794-5fce-477b-abb6-1fed99e36f4b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14d29dac-847f-4efb-b83e-0a1e451c54ab"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Neomycin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00994</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/0b543719-3c9d-4d9b-8495-db6592f9e40f">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88b3f71a-7c34-4b26-952f-b8ee454f0a19"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b08a29b6-f36f-4426-b492-cff976b32f65"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26891864</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00107783</dc:provenance>
    <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203500">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/30519c34-1b00-4f60-800f-517618c557ef"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/23</ddiem:iembaseUrl>
        <rdfs:label>ALKAPTONURIA; AKU</rdfs:label>
        <ddiem:iembaseAccessionNumber>23</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/203500</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/706c2209-a3a6-4772-b5e4-ba483ca0abbd">
        <rdfs:label>High circulating HGA (homogentisic acid)level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0846e61-057d-4e40-8357-065a507ce73a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ffd07f4d-c0a6-4ab7-984d-4310ab1c6b92"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd078890-d786-4409-80e1-76d60bc64230">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:label>Disease progression (Rapidly progressive)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/573e1e98-415f-4db0-9bf6-2a36ee84dcb1">
    <dc:identifier>HP:0001744</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
    <rdfs:label>Splenomegly</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e1e162bb-2474-4218-957e-949418eab82b">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/21d282d1-aa6f-407d-b839-ff7628398c92">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d4645af7-7d71-4681-836a-2380df08e471"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28708224</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3970cb96-abf4-4bce-a656-386c8fe78f7e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4518518e-8f15-434c-b097-109e23a95b50"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d01e942e-bd9e-4821-977b-148064ba0992"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69b34a45-baec-483b-80ba-b59eed7299e9">
    <rdfs:label>Epigastric pain</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0410019</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0410019</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7fa35c00-1795-431c-b811-27221d4d8fc3">
    <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/be4ae9df-db61-499b-89b6-153394e7fa8f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fe0a4a89-cd56-4af8-ba22-50306057efbc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc4a3c97-99ff-4649-ae84-e5b8d941f690">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>NO revealed clinical benefit</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004450</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/95f91432-f11d-4aee-89ba-ed8f261ef29a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/619406ba-2265-43af-8600-22884ea26874"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fd685e66-03b8-440d-ad0e-98aac136eb65">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614080">
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1145</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/614080</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1145</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ab55da06-91bd-42b4-9117-0635daf739ba"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594e7498-bfea-44e8-839c-c110b82d67a3"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b72292e2-af0a-48ee-8d8b-53af923fc616">
    <rdfs:label>Afamelanotide</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0e5a6a71-8d36-45b5-bf4a-32918d1e43f2">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/011e7ebf-0cb3-4e47-b82a-5740f1f3c4b7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/937eccef-c2d9-430e-957c-924bd352bf50"/>
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28003770</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5a658d41-9109-4732-bd29-cd2b74e76b71"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB04931</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04931</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e02a3859-f26a-4e60-b046-a78611a24273">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
    <dc:identifier>HP:0003201</dc:identifier>
    <rdfs:label>rhabdomyolysis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/34163ee2-212e-44bd-93e9-2e8773db93cb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8a25cbc3-3c4d-4755-ba2a-fe8dc466fadd"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04263</ddiem:url>
    <dc:identifier>DB04263</dc:identifier>
    <rdfs:label>Geneticin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3dce3c7e-f61a-4367-98d9-3385fe71302e">
    <dc:identifier>HP:0002240</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
    <rdfs:label>Enlarged size of the liver</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/78760dff-2dab-49c6-b2ca-27b8bbe117b1">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3453de63-4852-4f4a-a399-f603813dc8d2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/93293824-f33b-4cbd-9e7d-a403627f8bcb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ed338e67-b629-45e1-a2a2-ada78b25fa49">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00476</ddiem:url>
    <dc:identifier>DB00476</dc:identifier>
    <rdfs:label>Duloxetine</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e5d1a249-83bf-4199-b90f-a06cee0f0574">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c261ce57-0baa-4172-b5e2-84dc3acaf7ff"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c239d38d-9c47-499b-8fee-6b42421c4c11"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f23aaa9-c55e-4a04-9178-f5e0559f8f0a">
    <rdfs:label>Abnormal walking distance</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/3dee552a-7bd4-4c64-8687-bb80fcbd9750">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a57dd1e-220a-428d-998c-2d64137efa2e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a98f65eb-1f57-413a-94bb-fb17e1ea8255"/>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7a47fc4c-5ccd-47a0-b159-e9bab1b3cbf3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6269d9ae-f9c3-4bfd-8fad-888bd6153955"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a5c9d49-d0ac-489f-890f-b84c91c592e9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45708849-6084-4015-a87e-c6c5cd04fc0d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:label>Voluntary movement abnormalities (Abnormality of movement)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d62c06cf-1be7-4bc3-bc70-a3a3d4ab3e30"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/4a4f3f49-9494-4490-924f-5c66dd5cef58">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cdc9e41e-aad6-4f78-8cd0-5e2d41a8fca6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23162302</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e5b73543-3fbe-43e4-9d38-9a61165743e0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8c1c00e7-c0c7-4deb-8a25-6d24e477f86d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5296b6d3-94cf-496b-9f0f-851435fed790"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X16302044</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9bd387f-d7ea-4044-b79f-c788e7bd1959">
        <dc:identifier>HP:0004395</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004395</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Malnutrition</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c3c736d-82d6-40bb-ade0-93202da33a79">
        <rdfs:label>Low weight,growth</rdfs:label>
        <dc:identifier>HP:0004325</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58202caf-abf6-4f14-af2d-bd1c59aab05f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <rdfs:label>Diarrhea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ee4e95ef-ce26-4d8f-be35-50ec9240ff00">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ebbb5f2-7d14-4c56-af15-bffea1c5b8db">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum osmolality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84c45c6b-4615-4519-ae1a-0f50f840b008"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/95a869c6-fe60-4386-89c1-c9446c201f15">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/db5906e6-ef64-447b-84b7-c88f806fee89"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10510995</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68101e8f-05cb-42b8-8b1a-836b4f3b17df">
        <dc:identifier>HP:0000103</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ployuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/c375259f-1d38-45a5-a86c-1cc2f7a5e048">
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e81ca558-885c-4cc8-ae82-d14a22d068cf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c9efebe-ad53-48ae-b0b4-ce21bddca905"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b5db0363-d1b5-4643-b4f1-f4e98a7c72eb">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28279226</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3859ccef-a4cf-4315-94cb-cc0c88a71d5e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd3063ac-c6e3-419e-b901-104bea4db9a3">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001635</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <rdfs:label>Cardiac dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32834279-a78b-4611-b95d-4e393f2cc4a8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003546</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Exercise intolerance</rdfs:label>
        <dc:identifier>HP:0003546</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd65a028-207e-4294-a036-940c16756000">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100709</ddiem:url>
    <rdfs:label>Oligodendrocyte loss</rdfs:label>
    <dc:identifier>HP:0100709</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fcea0c81-e7de-4426-9571-113e6aaa4bd4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff99d8e7-556b-437b-9cd7-f576d3c00232"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9af5b0ab-7325-47e5-8188-18fe445761b0">
        <dc:identifier>HP:0001997</dc:identifier>
        <rdfs:label>gouty arthritis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001997</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3c332815-b641-4cee-a3a9-9217f1e3be0b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17065067</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42dc5e92-4c62-4b84-ab3b-1bd817752d2b">
    <dc:identifier>DB01324</dc:identifier>
    <rdfs:label>Polythiazide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/02dc004d-17b9-4410-8b5f-9d7ac64a6414"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d864cf0d-5534-4718-98b1-eed879a79a30">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e84b8d7b-16a4-4225-bcfb-a9a1c28af844"/>
        <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94ef31d2-07aa-4f6f-b72a-694e9a426c8d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01324</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a4187e57-15ff-4dc0-8dca-457fac6874b2">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66980f89-e96d-4a46-9c37-ef47b5b44405"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0538935b-069d-4e55-be6d-d56dec6deb1e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/65e8e7d8-ea52-417e-9c76-3add2cb21f25"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0cac478-455b-42e5-97d4-92395015e5aa">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High amount of aspartylglucosamine in brain tissue (( Metabolism abnormality)*)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c41b780b-b823-4875-8d26-9d6f321898db">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001298*</dc:identifier>
    <rdfs:label>Relapse of hyperammonemic encephalopathy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5baa9e38-12a1-4fde-89a7-04ec7cb1b4cf">
    <dc:identifier>DB06262</dc:identifier>
    <rdfs:label>Droxidopa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0c3177a0-e58e-4cda-87c8-b4c3821fb3c3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06262</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/325eda88-4454-4525-8f26-016ff6406192">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300559">
        <rdfs:label>GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D</rdfs:label>
        <ddiem:iembaseAccessionNumber>563</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f739b5b3-39f7-4cdc-a4c9-61c039d42ac4"/>
        <dc:identifier>https://www.omim.org/entry/300559</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/563</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/32834279-a78b-4611-b95d-4e393f2cc4a8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18401027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0ac9755c-32d6-4fa1-9ef0-97cc93ea4608"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/30d8601e-8146-4593-8b7e-f0d233489104">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02d00a54-06fd-449a-a9b3-8265e8f1bd43">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased hemoglobin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa153830-03f8-457a-920b-358d8c7c3c8c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1e32cf9-dc26-446e-a6f5-4a0a6acad75c">
        <rdfs:label>High spleen volume</rdfs:label>
        <dc:identifier>HP:0001744</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01685216</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231005">
        <dc:identifier>https://www.omim.org/entry/231005</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GAUCHER DISEASE, TYPE IIIC</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20e645ce-1935-4826-b4d5-d1df5b464a51"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/752fd6af-4b0d-49df-8732-8f40d34973cb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:label>high liver volume</rdfs:label>
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/18b4bbbe-df59-4849-9806-78ab12676a2a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03519646</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc1746d2-0477-4cda-912f-b447777fe5da">
    <rdfs:label>Metabolism abnormality</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001939</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ce87af78-8238-45c3-9238-56de6132438f">
    <rdfs:label>Mecasermin</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f4594b8a-0cb4-46dc-a915-cffc4f3d63c5">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2c74d52-3d61-47b9-a754-dab5c86fad42"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c34ac0d3-da03-455f-bf65-0ac98bf67c70"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6be6eb4a-3e07-49ed-9fac-311b94d9b412"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10323388</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75547b05-14b2-43f1-a7bc-d2f01c837f32"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53074b27-41a6-408a-9f91-ff64b19ec8e3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10770174</dc:provenance>
        <rdfs:comment>The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of "increlex " supply.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b850fd26-6dab-49f5-ad0d-b23802d823f9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6738eb64-670a-4254-9265-930e94329078"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14549815-3c49-4595-ba88-ded24fce6861"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c33b8ba9-dfd1-4578-965e-dc840d8bf5d0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/caa3f8f5-4663-4677-8bfd-40fe1f28d593"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cab6bbf8-c4ec-401b-8d75-c8407368557a"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01277</ddiem:url>
    <dc:identifier>DB01277</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/68d44795-fc3c-4a06-a8aa-c8473107cde8">
    <rdfs:label>Taliglucerase alfa</rdfs:label>
    <dc:identifier>DB08876</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8e0c86bb-c4fe-472a-b453-17d580b020f8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22916340</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/140274f6-7b7c-4c13-b011-40847adf8ae1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28131618</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1e77ac9-9d7d-4ea3-9c34-da4299e1e8eb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34baf317-d164-4578-96a8-86ad1803fb21"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27839981</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c80b4d8-49c5-406f-8f29-8cf409faf399"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa153830-03f8-457a-920b-358d8c7c3c8c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01422187</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/811f329e-3c0b-4d33-9fdb-46d3bb4a141e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29388611</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eccc5e3c-4652-4c3a-9247-42e4725569a8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
        <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03021941</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08876</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa139826-4b67-4efc-a92c-3c414537639b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased muscle mass</rdfs:label>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/3deb9538-a69e-413f-9107-99b75c70a89e">
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95ce1026-4fea-4053-b01d-d9278dca3b44">
        <rdfs:label>Growth Failure</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16672983</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/71304bc9-2ec3-42e7-8bbb-fed31c103436">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca391e15-bc7f-474c-9667-19877ef6e369"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc2cce28-10f1-47bd-9a19-0d46dcfeb5df"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0212c985-f816-47e4-995e-a214d71ae8cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/76909eab-7335-46b6-9079-2f9b80e8ff4d">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/935e2d1f-a1f8-4262-a814-8a949899e972">
        <dc:identifier>DB00542</dc:identifier>
        <rdfs:label>Benazepril</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b51ac73c-3f7d-42fa-9768-c06f64fca88b"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00542</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/c354036a-c94c-425c-a662-1fc271d272d5">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/563b9f24-45ce-43f3-9725-e8d2e5ad76ff"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a3dc877-99e7-4aed-a8b2-de08766a4b9c"/>
    <dc:provenance>https://jhu.pure.elsevier.com/en/publications/inborn-errors-of-cholesterol-biosynthesis-6</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10959439</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151800">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8826c45-6040-4389-b8ef-56b99ce90527"/>
    <rdfs:comment>The surgical management  is the only effective treatment for the case. Patients are usually instructed to stop alcohol consumption. https://www.ncbi.nlm.nih.gov/pubmed/1696085/ https://www.ncbi.nlm.nih.gov/pubmed/8210195/</rdfs:comment>
    <rdfs:label>LIPOMATOSIS, MULTIPLE SYMMETRIC; MSL</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/151800</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87556a3b-4cf9-4417-b772-d84f47654da6">
    <rdfs:label>abnormal glucocerebroside level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003656</ddiem:url>
    <dc:identifier>HP:0003656</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a00aa2d-0876-47eb-9699-bfe138bbed8a">
    <dc:identifier>HP:0006670</dc:identifier>
    <rdfs:label>Impaired myocardial contractility</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/4f3df1f0-60a1-49fc-a3b7-9a8701b6884c">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261000">
        <ddiem:iembaseAccessionNumber>80</ddiem:iembaseAccessionNumber>
        <rdfs:label>INTRINSIC FACTOR DEFICIENCY; IFD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/261000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/43b5034a-74c2-4d2a-af72-d6993ad813ba"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/80</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e02aa49f-2390-40cc-b373-22e88233c8e6"/>
    <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f194c1c1-24c2-4296-b82e-1f284326c44f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low levels of serum vitamin B12</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100502</ddiem:url>
        <dc:identifier>HP:0100502</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82c17ddf-4f6e-4fd6-8462-04b8805c8105">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004312</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004312</ddiem:url>
        <rdfs:label>Abnormal reticulocyte count</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0943c910-c868-4fe2-aa69-1861a28b2e31">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0020062</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0020062</dc:identifier>
        <rdfs:label>Low Hemoglobin concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fced4dff-20fa-4009-b01d-189287c6bf0d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High RBC's mean corpuscular volume</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025548</ddiem:url>
        <dc:identifier>HP:0025548</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25308559</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27ee30c9-c4b3-4848-b6d7-6d75b331a4b6">
    <dc:identifier>HP:0005952</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
    <rdfs:label>Low pulmonary function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36d22bbe-f844-4f09-9083-04eb5a447b85">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hypoglycosylation of serum glycoproteins</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c926b7d5-4a78-48de-b42b-7fec5f5dd29f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10601810</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f34be7d1-9cc6-4f4a-87c6-ff0429271202"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26823911</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5db1f51a-8465-4e4d-8b66-a1ebeb133640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625994</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d81c1e5f-9291-42d5-9d2a-8f54bc5b6e79">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddec95bd-2926-4150-9c21-f6f203f5807f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatomeglay</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <dc:identifier>HP:0002240</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8bda332f-6e59-4cc7-88f2-8af9a3cdbfd3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3483883</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b686cb6-4b02-4c7d-ae7b-c7b4ef70476d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d50117e3-e3ed-4321-92ee-9f58a524b8ed"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9559978c-f7e7-45d7-a09c-e9ac804b0a6b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45547f41-e755-4bf5-8324-a8c929a6e865">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002071</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002071</dc:identifier>
    <rdfs:label>Extrapyramidal movement disorders</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e04e5cea-bc1a-4ad9-b5eb-a7e9b60b7b8b">
    <rdfs:label>L-Glutamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/70dce652-239e-4028-adf4-e52874c8e000"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/afd4d844-03a2-4706-9e67-08318e3055f7">
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <rdfs:comment>Synergism inmproves results</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ea4a58b-49d3-41b9-8f6f-1f753b1e2d98"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e3a198d9-ef80-45c3-a2bc-e9a6a401d052"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e631a25-1adc-41df-b078-58146bef2144"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dcc78ddf-e6da-4633-99a8-984e12ba8e9e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/57ac844f-8a5a-4c56-bbe6-d4f54cc77db3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5304b6f9-6d6f-4cc7-acbc-cb87d25dac2f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/146fa6a6-ec10-4469-949c-f559d427e3d6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ce2d2e8-1297-4519-b2ad-86d97ecb8628"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <dc:identifier>DB00130</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00130</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/161c729c-b280-4ec2-b592-fb08d5c7893e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/805ce8f2-56a6-4485-aaf2-5bc632257617"/>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1801793</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a4043433-6a3a-4d0f-a504-0999c06a1e31">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6e222f0a-d5e3-4fde-a44a-e3ba58688673"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/80b38d56-06f2-487c-b768-5027208c94bd"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/842abc51-8d7a-49b1-971e-b8bdcff2a40f"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f68ad24-746b-450e-8d2d-0eb9b3f11623">
    <rdfs:label>Abnormal plasma aldosterone</rdfs:label>
    <dc:identifier>HP:0040085</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040085</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f8e94a93-3bfb-419c-a7c6-05b41384c61d">
    <dc:identifier>DB09270</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/580d78fd-797d-460d-9a53-00fac4d3f7c4"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/34beb861-100d-4d24-b3d1-0027f2259a96"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5baadc85-f7b3-4210-a0d8-e640a68c8da7">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a81c49c7-e87b-48fc-9678-996b3ed5c57b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208920"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28277561</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/30b67605-197d-4c02-960d-49813bb084a8">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609056"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/483cfb09-ea90-455d-bfc0-364abe822163"/>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22990144</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/babe350b-02f7-469c-915d-fecb22e1a3dc"/>
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/afb95316-b6ed-42c0-82b7-4cc0ab863e8b"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/48ecc416-f0ef-4263-9045-52bfe4cff618">
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5cdd5561-e4e8-4405-91d1-55932ec62ff3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b02b79e0-6533-4495-b577-b4e8e67f46e3"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/444af7df-253d-4971-90ab-c3e52a0ba0b5">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72d43680-393f-45b9-9226-6175be214012"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86cef96e-5909-46c2-8e14-032c9f42de2a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c78ddc35-5a9e-469e-b5ff-9569e616d40a">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13cd34df-9210-4e67-9672-ce6f900776e5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ffebcfa-f201-410d-8e07-396d0d529147"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Ubidecarenone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/785d1019-0584-4b96-9496-557bc711bcd6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c926b7d5-4a78-48de-b42b-7fec5f5dd29f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09270</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/b70a4ff6-6db6-42b6-90a2-61bbd8847ecb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3e36b88-de38-42d8-9ea4-c28f73f7ec3b">
        <rdfs:label>Low growth rate (Abnormal growth)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001507*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d249f4af-7d79-441f-bd32-1ce29a700254"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0212c985-f816-47e4-995e-a214d71ae8cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15669684</dc:provenance>
    <dc:provenance>PMC2676979</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/255120">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a439dd1c-7e03-4d1a-9432-37d4dbbaa673"/>
        <ddiem:iembaseAccessionNumber>228</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/255120</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/228</ddiem:iembaseUrl>
        <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000010>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/c41079fd-d00c-4d0b-a918-c3db2b9aba58">
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240600">
        <dc:identifier>https://www.omim.org/entry/240600</dc:identifier>
        <rdfs:comment>GS deficiency has a good long term prognosis: it is usually associated with a normal intellectual outcome, symptoms can be prevented if the condition is recognized and treated by avoidance of prolonged fasting and tolerance to fasting improves with age. https://www.ncbi.nlm.nih.gov/pubmed/12794686
Patients are treated with a diet high in protein with complex, low glycemic index carbohydrates. Since gluconeogenesis is intact, protein supplementation provides gluconeogenic precursors that can be used for endogenous glucose production. In turn, there is also less dependence upon fatty acid oxidation, and accumulation of free fatty acids and ketones is prevented. This not only reduces systemic acidosis, but prevention of hyperketonemia also enhances gluconeogenesis since more alanine can be released from skeletal muscle. https://www.ncbi.nlm.nih.gov/pubmed/106027
Simple carbohydrates should be limited since they can increase blood lactate concentrations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e01ca8b3-03e2-4f0a-b2f5-cb41e71bfb54"/>
        <rdfs:label>GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/497</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>497</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/638814a3-2101-4e72-ba79-89f8654d369a">
        <rdfs:label>Nocturnal Hypoglycemia(Hypoglycemia)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <dc:identifier>HP:0001943*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0fabf7f-1195-463e-9880-85a254430421">
        <rdfs:label>Poor sleep quality(Sleep disturbance)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002360*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e01bee0d-9752-4a63-8fa8-28edd454e2cb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
  </obo:DDIEM_0000010>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3e013f14-ee35-488c-b9d3-5c8ba2fbbaca">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4475203f-8670-407c-a1da-2f81ca59f1e2">
        <dc:identifier>HP:0012029</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012029</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal urinary steroids levels(Abnormality of urine hormone level)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1934b4bf-1450-4629-8059-b0a9346eb5b3"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a351ee3-ae58-4078-b804-2e20236f3b50"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b37eca9-204c-4d05-b50d-58f035fdb565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7dd01000-6c0e-4f52-a2ca-36d4549f5d38">
        <rdfs:label>Ill-being (Constitutional symptoms)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc10c4c1-7259-4ecd-9558-342472b3222c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8b06da0b-5948-4e5e-abd4-1a26bf90831e">
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae003dba-ac36-477e-aa89-b2abf7295626">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fat malabsorption</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <dc:identifier>HP:0001324</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2596948</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aa786eca-c4e5-4bcd-a4a2-e9c409b7013d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bb29d0d0-6dde-4b22-a443-b2cad37d0b49"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/bd4bd56f-ca60-4909-beb6-4e85b97b3786">
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <ddiem:failedToContributeToCondition>MCCB-(IVS16þ1G&gt;A)/ MCCB-missense mutation E99Q Homozygous mutation</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6de9720f-208d-4a49-a5f4-0c4ad22a5ccc">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>EEG abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
    <obo:RO_0003304>MCCA-R385S(heterozygote mutation)</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/438321da-7963-4ab7-8690-5f1aa3887810">
        <rdfs:label>Organic aciduria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001992</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>"heterozygote missense mutation, MCCA-R385S"</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57b6b8b3-8058-4cde-9f72-10ad331a7709"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/679d2c84-3e2d-4d7d-9ca8-4a3e22355ccc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002521</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002521</dc:identifier>
        <rdfs:label>Hypsarrhythmia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e7491583-00c9-43bf-bfa1-a2d1a88a4b01">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9317abc0-16c0-4985-b4d1-4a6d78fa7593"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9756b4bd-f558-4cb7-916c-87e16ba341e8">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98f0c8ed-777f-4a18-afc1-f28ee683e547">
        <rdfs:label>hepatomegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7316426-c820-4288-986f-f5b1edc131cc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal liver function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c80b4d8-49c5-406f-8f29-8cf409faf399"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/842abc51-8d7a-49b1-971e-b8bdcff2a40f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28697823</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc10c4c1-7259-4ecd-9558-342472b3222c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6fad1f3-4154-407b-ab01-04394131e198">
    <rdfs:label>acute congestive heart failure</rdfs:label>
    <dc:identifier>HP:0001635</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/3a8ebf2a-0689-41b0-8229-70b5aa8ed15b">
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/257fc01b-1612-4b42-b0fc-fb68f1bc6a8c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27783330</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27ee30c9-c4b3-4848-b6d7-6d75b331a4b6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b41ebe6-0912-407c-97cc-c62d9d3d19af">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006517</ddiem:url>
        <dc:identifier>HP:0006517</dc:identifier>
        <rdfs:label>Pulmonary Alveolar Proteinosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/84088f7e-93b1-4aef-a01f-2793b3baa165">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f1a93807-f7ab-4a06-ac32-884eb698cd15"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c867f38-79cf-4506-8aba-dbb9a541f55a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a71a273-c72b-43fa-ba09-fab8045cc438"/>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd078890-d786-4409-80e1-76d60bc64230"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.jstage.jst.go.jp/article/kanzo1960/43/11/43_11_492/_article</dc:provenance>
  </obo:OGMS_0000112>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/1d6010b1-ff17-4977-8719-7ab7c37448da">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/34599644-47d9-464e-a099-6a9f9f379991"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa139826-4b67-4efc-a92c-3c414537639b"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608099">
        <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 3; LGMDR3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4bdca882-1828-4c20-b4cc-ba9e1cb3a002"/>
        <dc:identifier>https://www.omim.org/entry/608099</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c4a69331-cd7c-4b12-b857-45834af1d474">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0f2c3e5-612a-4829-89ed-abc90f21f534">
        <rdfs:label>erythema</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010783</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b077f10-14b4-4538-858a-ec2d5e686f7c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82fad1d8-c423-4ca0-8ccd-d96f204483b8"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dbc83467-50c3-4135-a5c8-9c2a86b30e4f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d526343c-4945-4159-9439-0aacdc982722"/>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28636073</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f21ac548-34f7-4f1f-9804-80c42d38c66f">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_26537</ddiem:url>
    <dc:identifier>CHEBI_26537</dc:identifier>
    <rdfs:label>retinoid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e66a692a-8334-496b-bd66-ee3e95ec1e1c"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0bc14c38-9393-4874-ba4d-5a564d2cc99c">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77b44d90-1bbc-4a36-a0a0-30b9c8490102"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29da295f-7948-43b2-a0bb-ff65cedd0589"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16549399</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3bd4c8b-168a-4cc5-aed4-adec29f7fccc">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0006462</dc:identifier>
    <rdfs:label>poor skeletal mineralization</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6f3e036d-254f-4195-b26b-1743a44004e0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00776</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fd685e66-03b8-440d-ad0e-98aac136eb65"/>
    <rdfs:label>Oxcarbazepine</rdfs:label>
    <dc:identifier>DB00776</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b4c75cf9-e5c9-4689-a059-0726307c517f">
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/594e7498-bfea-44e8-839c-c110b82d67a3"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/560521f7-f44a-40ce-81ba-16e25940be53"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263700">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/111</ddiem:iembaseUrl>
    <rdfs:label>PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/263700</dc:identifier>
    <ddiem:iembaseAccessionNumber>111</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/62d53f1d-6ece-4706-8eb9-a0de6d3b6bd3"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/54bf7bf9-1a8f-4e6e-a906-4b0523267392">
    <rdfs:label>Macular cystoid changes</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008028</ddiem:url>
    <dc:identifier>HP:0008028</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/91b50b1d-630e-459c-87ec-383fded7e5ee">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fd805776-08bc-4dc0-9316-0e34ee6c2416"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c867f38-79cf-4506-8aba-dbb9a541f55a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f392dc1-5378-4ad8-a0e1-019a374edb35">
    <dc:identifier>HP:0001510</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Delayed Growth</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/52d0dcf9-0250-4aec-b8d1-ffaf63486d48">
    <dc:identifier>DB00099</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2b78c331-1033-484e-8795-a4f210789582"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00099</ddiem:url>
    <rdfs:label>Filgrastim</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c83ae905-2fde-4b68-8fff-e29d61dcd589">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28617415</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae057ac2-d774-4139-82c6-150972ed8ae8"/>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d75b061-be0b-43d3-b982-70bedcefd24f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
        <dc:identifier>HP:0001976</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal Antithrombin-III levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/22e0e709-24d8-409a-97dc-e1a1a4104cdb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4a894dbf-1b4c-4a47-b176-9241557444bb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab8c5dc9-4887-4c64-bc67-9c29864c3fe6">
        <dc:identifier>HP:0001976</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
        <rdfs:label>Abnormal Antithrombin-III levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7555578c-3447-4b02-a3ca-84a122c620b2">
        <rdfs:label>abnormal activated partial thromboplastin time</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
        <dc:identifier>HP:0003645</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24499211</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf093591-5169-444b-b942-45f327164bec">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Abnormal AST level (Abnormal liver enzymes)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7925b91c-ee08-4443-8cf8-a314262ae038"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b907fa5-6f71-4f05-a4d3-f4d0789a56c8"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614921">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>600</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/42597ba4-2d97-4c72-8fc3-f1d974b1c4b4"/>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/614921</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/600</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e31a20ab-ec66-42bb-b97a-e6215a559441"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0de55fce-8972-48ae-901c-0624bb5ce6ac">
        <rdfs:label>"abnormal alanine transaminase,"</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/145b0442-4a46-4eb2-83a2-db98b4fd7f77">
    <dc:identifier>H02</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=H02</ddiem:url>
    <rdfs:label>CORTICOSTEROIDS FOR SYSTEMIC USE</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fbe4cda1-6437-4cbc-968b-d860bab1c0ef">
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf867fb9-960a-40c9-8366-17048bd603f6"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9af2057-b0b4-4092-a67f-cdff1f460f67"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8169752f-c6c8-488a-a327-0dd5a89c7d5e"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617069">
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6a16c836-dc7b-4a33-b14b-b6a2064a7a85"/>
    <dc:identifier>https://www.omim.org/entry/617069</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a1c87669-9ce0-46f9-adfd-6d643f47552f">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/df5642f6-2e54-4255-ba71-c48ca30485fd">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3a066dd-96ac-42e1-832e-ad91dceebadd"/>
        <rdfs:label>Recombinant human palmitoyl-protein thioesterase 1 ( PPT1)</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/b04c51da-c6f8-477b-afba-204236505da6">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6f15562-afde-4d2e-a771-b2397f4ee2c9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <rdfs:label>short stature</rdfs:label>
        <dc:identifier>HP:0004322</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9559978c-f7e7-45d7-a09c-e9ac804b0a6b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5615bba0-eb2a-47ef-bab4-892f64dc6c95">
        <dc:identifier>HP:0012378</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low energy level(Tiredness)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301760</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59aed410-15a3-49f8-9840-c814899bd006">
        <dc:identifier>HP:0011015</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011015</ddiem:url>
        <rdfs:label>Abnormal blood glucose concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b686cb6-4b02-4c7d-ae7b-c7b4ef70476d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d249f4af-7d79-441f-bd32-1ce29a700254"/>
  </obo:DDIEM_0000010>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/895fe58e-b5e8-4aaa-9482-1c4df26c1989">
    <rdfs:comment>Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/40878c0c-9c88-4071-9fd2-d1fda78d761e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/275d7605-0c5f-437d-9e57-353496b9268e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ec022a2-4cd2-4a71-bdfd-953e57dfdc64">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low serum ICFBP level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d60b73ee-efd8-40c7-b57d-dec68de6452e"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609283">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/94c1a8a2-2147-44e4-8ba1-899c5ab53da7"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1372</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/609283</dc:identifier>
    <ddiem:iembaseAccessionNumber>1372</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 2; PEOA2</rdfs:label>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9f33e1b7-ae88-4703-ba24-8ef056d4a7e7">
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/146458eb-00fe-48ed-920b-fcc667190e13">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012592</ddiem:url>
        <rdfs:label>Albuminuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012592</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f704fd10-ddb4-40bd-bff2-3d7d520db299">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/36ac6404-db4a-45ea-9ee9-c16adbd7592f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14690254</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08386018-db9e-4e01-bf56-8167cfb2e9d5">
        <dc:identifier>HP:0000100</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000100</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>glomerular proteinuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/53de7f24-964f-4e91-944d-bc4fc4f46296">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/805ce8f2-56a6-4485-aaf2-5bc632257617"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5bf212a7-a34b-417c-82d5-42b2d25b540a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b55d3d3d-7cb1-4f61-9b83-db583f26833f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/842abc51-8d7a-49b1-971e-b8bdcff2a40f"/>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/29a9ef5d-27a6-4582-b971-35f3b768ba4f">
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/6a213de6-8f0f-45f5-be99-14d32feaaab3">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/791e510a-5f54-4c05-93ab-1f3548766b07"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7028650</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29757052</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17565677</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/a29c1208-04e4-4966-9322-332223cee083">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ce7a089-b63d-4606-b90f-984794a27050"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/966594d1-ec09-4824-8f16-d537457f55ec">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f585f4d9-275b-4b03-b885-f3a280b4a1c4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/11766663-79c4-4620-8c2e-c789594f448f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/82d348da-208f-49bd-b2dc-3be8fbba82bf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/81f26cc2-f9cd-42e7-a22c-31491a42b510"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/831f6d35-a1fa-44ff-8579-db3c78e66530"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e70960bb-b275-4007-8447-f68b8849d11b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/543ab79c-4662-404d-924f-90c4161f7471"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e612443-097f-4c53-8280-28075ce6154b"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
        <obo:RO_0003304>R229W</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fb77fc2f-4453-45a0-8455-f512d214482b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e407d11-6262-4ea7-ba1b-e3457be44973"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237400"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/55a2795d-51ea-47bf-a4f7-b352b45a2c7a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22334182</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95aabe0a-2bdf-49c5-ba22-395caf6eb429"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41bd6022-5769-4127-b1f3-bae9666bebc5"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66980f89-e96d-4a46-9c37-ef47b5b44405"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/99280d43-9c6b-4461-8cf2-e76ed5f09b29">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890588</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/606dc152-2594-4f33-95e0-849ab6748d60"/>
        <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:DDIEM_0000009>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/2436c5f4-f930-46eb-9feb-96678a52fc42">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29119254</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ea6d9d9-8d88-40a3-8ea2-ecbcc1e4a717"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
        <obo:RO_0003304>"P49L, A114V, I278T, R266K, or R336H"</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <ddiem:failedToContributeToCondition>"R125Q, E176K, T191M, T262M, or G307S"</ddiem:failedToContributeToCondition>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <dc:identifier>DB00165</dc:identifier>
    <rdfs:label>Pyridoxine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00165</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/3993045f-5b72-43a9-b34a-085d6c924529">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219500"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6475ebb3-e284-46c3-85eb-6f05f15c21fe"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
        <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/417288</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/20584029</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c53d2f9-0050-499a-9603-3123e89fb8f0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb4d2913-9222-49ef-a4b0-16e606c7e3d3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/76fb6939-8dc9-4298-ae45-08d5f9673f18"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6de9720f-208d-4a49-a5f4-0c4ad22a5ccc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c50b122-5ab3-4be1-b3aa-0a36f039c0bb"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ea126d05-2792-4edf-b1c9-b354d0c1d6c6">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24173411</dc:provenance>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2e0af97b-b69c-4e56-b3ab-2b135c560a56">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5922b398-4400-4fa1-8bef-48c13a5ed888">
        <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94505e12-4dcd-469d-8401-cfce82fbf6cc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2bae0e9-fec0-4c02-8455-01c251e0eff2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19289295</dc:provenance>
        <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/299f3f53-15bf-4f10-b641-1a0b1d039682"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22341584</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22658375</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07da2db9-fa15-4f72-bbf2-58f43f73d95f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b0ae8e41-57c7-439b-b218-21d47d149b8a"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Anakinra</rdfs:label>
    <dc:identifier>DB00026</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00026</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/81918e46-a09f-4651-b2b3-9ff3a21e2ab9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20712835</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28e98e6b-c12b-4260-9883-35237087b7d5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f93fb2ef-4fcd-4817-b472-8e096ed9d975"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d712f439-7393-4324-affa-fa99ca89c832"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cb86af9f-ebe9-46bf-a999-804df84b7357">
    <dc:identifier>DB00083</dc:identifier>
    <rdfs:label>Botulinum toxin type A</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ebdebf38-4954-419c-af26-14b60ea97211"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b7d2f89-bb27-420e-891f-3dc8b3d187d6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00083</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b88d257c-99c4-4a31-91ba-3b9c2b47a261">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/afd06ebc-0f57-4746-bcd1-ef1ce4fd2ebf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b0552196-66d2-4101-842f-6ef5fb8e4673"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1e8d7fc0-18fe-4d44-9ee9-8b40243c06f3">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e942979c-d58b-40f6-8098-6c36a4e899fc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f60efebb-4955-4bfd-a8ca-5fa6f1c858c8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7148673d-633f-4aa9-9416-93e8f29b6764">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
        <rdfs:label>Hypertension</rdfs:label>
        <dc:identifier>HP:0000822</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <dc:provenance>https://www.orpha.net/consor/cgi-bin/ResearchTrials_ClinicalTrials.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14549815-3c49-4595-ba88-ded24fce6861">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000855</dc:identifier>
        <rdfs:label>Insulin resistance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/817dfd47-a510-4baf-8122-f4c84bfc2b1d">
    <rdfs:label>High VLDL-triglycerides</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003362</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc613b33-87ae-42d0-9201-faeb2f731a6f">
    <rdfs:label>Decreased activity of mitochondrial complex IV</rdfs:label>
    <dc:identifier>HP:0008347</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008347</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/eacb9cc8-cb87-4bda-a082-a5bc735ad27f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83e3b1c5-282a-496d-b6db-bf1a4c6e9cba">
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:label>cognitive deficits</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/49ba89bf-43be-4366-a70a-d5a2685f74db">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1f6a4e42-d3d4-48bc-88de-9ae88f0d48e6"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/155e839b-8a1a-46a3-b8d8-a218bc3a7c9b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4488d66a-da28-4505-9f11-3dbb52c30732">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased 3-methylcrotonylglycine excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a649389b-8a03-4a0e-9041-1c4963f457d6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal Biotinidase activity in plasma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29a4309e-6ccc-498d-b279-8d6ce22b2144"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6de9720f-208d-4a49-a5f4-0c4ad22a5ccc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/112f7eb3-2c33-4aca-8279-2bb218310d42">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased 3-hydroxyisovaleric acid excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/dd81c200-2a49-4037-b1d1-752e6a423483">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4799bbf0-0920-4b06-aa0a-71ca155c67bd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003200</ddiem:url>
        <rdfs:label>Mitochondrial proliferation in the muscle</rdfs:label>
        <dc:identifier>HP:0003200</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/32834279-a78b-4611-b95d-4e393f2cc4a8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c438fb5a-0b06-4d91-bd38-69bcf2084698">
        <rdfs:label>Fatiguability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
        <dc:identifier>HP:0003750</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac5799d5-cc35-4d20-8974-81ddc715cc9c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3fdd3c41-1338-4de4-97ea-3d4e63e2cb20"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5db1f51a-8465-4e4d-8b66-a1ebeb133640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1742906c-6665-4a33-a675-b6b22e5b693e">
    <dc:identifier>DB00700)</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00700)</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6bb64284-d15e-4806-89e2-dab494d781f5"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/84e5134b-678f-4252-b020-81b3f9b60912">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/57341834-3574-43e2-b0aa-d17691d8e50a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fe537ea2-944c-4d8d-8658-7dbd161209b3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b7fdec3-7bc3-4aa8-9cf5-60bfe842ad76"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03432871</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dbf2cca4-075b-4f5b-823f-48d760186d5a">
    <rdfs:label>Kidney stones</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/589b6c55-c697-4ff1-949b-172be6a4426c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54bf7bf9-1a8f-4e6e-a906-4b0523267392"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/300ad90f-3655-4fe7-ba66-057e7c40a527"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2798ff1a-2a44-4dac-b14d-e9cc1affca61">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
        <rdfs:label>Intraretinal cystoid spaces (Retinal disease)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000479*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6e22013f-3755-4efe-9973-91c7a32a4f0d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2f0e86c3-bce8-4a46-bbea-a28a21c09773"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6362bc14-acab-4df4-96ee-fd31dc9611a3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal sphingosine level(Abnormality of lipid metabolism)*</rdfs:label>
    <dc:identifier>MP:0009587</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0009587</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c44e9878-2271-49dc-85b6-f8807b8bffb1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:label>accumulating substance aspartylglucosamine from ( Metaboic abnormality)*</rdfs:label>
    <dc:identifier>HP:0001939*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca1b21e0-f1dd-4101-a903-4758b2248b1c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>cognitive dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
    <dc:identifier>HP:0100543</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fb589cdb-ee40-4d81-8284-a548ccd6105f">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a25941fc-8591-46ad-b4df-8675697ccc68">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6d686d53-dd18-4408-a83b-b2854d4ef355"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233707</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/601678"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1bac1898-6f6d-400a-92e3-d97bd5441246"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b70249f-40f2-4fda-b392-c3860527ef0f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/efb19376-26e4-41e7-93d2-3270bdd30f9d"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00421</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00421</ddiem:url>
    <rdfs:label>Spironolactone</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d271fa0b-3356-4a83-986e-2604015d9867">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/99c0c47c-06cf-4459-8984-45623cb5f83c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/79daa1d4-64f5-4578-b028-21c1505064f4"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26232052</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b49ea9af-7109-47e3-8bf2-132a9a807cb0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <dc:identifier>HP:0001249</dc:identifier>
        <rdfs:label>Poor intelligibility</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/162a5250-5ce9-4709-9f23-ac17cf5bfe11">
        <dc:identifier>HP:0007010</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor fine motor skills</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70c79b02-245b-4d58-885d-d573f1a61f9a">
        <rdfs:label>Voice tremor</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012477</ddiem:url>
        <dc:identifier>HP:0012477</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/5bccca2b-e447-4bd8-a8f1-41d64c34678b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118600">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fccb6ce4-1730-44e3-a117-00e8de1704c8"/>
        <dc:identifier>https://www.omim.org/entry/118600</dc:identifier>
        <rdfs:label>CHONDROCALCINOSIS 2; CCAL2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/243ed329-3a10-4833-8292-10f2c0378134"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7520501</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d1289a6-4d67-494b-9fb5-bd54001f3d3e">
        <dc:identifier>HP:0100529</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
        <rdfs:label>Abnormality of phosphate homeostasis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/51500251-46c2-4679-b6ea-feffa22e7293">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a4043433-6a3a-4d0f-a504-0999c06a1e31"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec95bc91-55d7-4805-bfb7-e438de010416">
        <dc:identifier>HP:0012187</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <rdfs:label>Abnormal  protoporphyrin enterhepatic circulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c18ae31d-8268-4e9f-a97b-d59e505abeef">
    <rdfs:label>retinal dystrophy</rdfs:label>
    <dc:identifier>HP:0000556</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000556</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/38fec408-49db-42a2-8d1f-d6e4e9e0ef72">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25879fe-127a-4d20-9e96-33dba7b5099e"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef15784b-6a56-45fb-be97-edce61d5b0b0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f77882a1-bccb-4c7c-b9eb-b53d7bb7c075"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f9dc2fcd-e93b-44f6-9aeb-9f822575d7db">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/de0aba28-a544-48a6-b2cc-fd82834cde90"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66980f89-e96d-4a46-9c37-ef47b5b44405"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25832663</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ee28b5c-a256-4951-b1ce-f0123b46572d">
    <rdfs:label>Abnormal upregulated enteral iron uptake (Abnormality of iron homeostasis)*</rdfs:label>
    <dc:identifier>HP:0011031*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/1dfcb8da-ac04-42b2-bba1-a13ee6e8ba81">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d914ddb2-7792-401f-ae00-79d1307241a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/88aaf58f-dee6-4010-84b1-f62902452642"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25474440</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3035daba-4609-4935-8c07-777bb6b8961c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d249c8f-3e2d-490e-af7b-0d16f013ed72">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurotoxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23388701</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca1b21e0-f1dd-4101-a903-4758b2248b1c"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/df0c1302-4e51-4f27-897e-089753d0f409">
    <dc:identifier>DB01329</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8ebae734-6796-4005-89a4-9985aa196547">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/21685bb8-0f2e-4b84-bb24-057e425d9c43"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e1e31d92-5abd-4692-aa23-3d7c1ab5bd8a"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01329</ddiem:url>
    <rdfs:label>Cefoperazone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77db340b-64c5-4f81-a749-27c4a8238c92">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
    <rdfs:label>high serum ferritin concentration</rdfs:label>
    <dc:identifier>HP:0003281</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220120">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e6903f96-2582-4e00-b207-313d937b8860"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>D-GLYCERIC ACIDURIA</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/220120</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fa069145-b1d9-447d-91b6-d39339c47e3c">
    <rdfs:label>Ribose-5-phosphate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02053</ddiem:url>
    <dc:identifier>DB02053</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/be9cc7be-4c51-49e6-8c40-a89d4d2e94ae"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a08640c-6a82-492c-865c-d8022abd0728">
    <rdfs:label>Disease progression(Retinopathy)</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
    <dc:identifier>HP:0003676</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5bce9469-dd75-40d7-982a-8ab32d3edd37">
    <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/311a6fe0-8fb7-4440-8e05-b60c06230890">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>apoptosis induced in chondrocytes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14d29dac-847f-4efb-b83e-0a1e451c54ab"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3b9ec1c3-0518-4317-9475-231316b53d11">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bba4ead5-67e2-4927-a66b-78d8f9d05dc0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:label>Increased urine output</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01280188</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/acad12a5-7b29-4223-b747-aed7076d01ab"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5380c406-a6e7-4641-a3bd-9e51bb83eda8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/956037de-9e37-421b-bb86-97727822104e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/626447</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d4b3a0c8-8b31-45e5-beea-c82d4e74eadc">
    <rdfs:label>Entacapone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7256a76c-8b15-4b0e-9c66-241802629bf6"/>
    <dc:identifier>DB00494</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00494</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/28f83b4c-421d-4536-9695-1141c8578b39">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3127a26-1d65-48d1-b161-15cb963c08c3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4905b446-7d5f-42c9-a114-9e8db973bf53">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bf935035-e181-4bd6-8511-d70e7dea246e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0d441434-a972-40dd-8306-680662213563">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2847ac9e-a635-4a44-919d-d0b0dd66f3fa"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0515b4fc-9bbc-4f16-abf6-8db321bf8def">
        <rdfs:label>Calcium makes phototherapy more efficient</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4214c438-dde2-4add-b71b-f931a4a14b5e">
    <rdfs:label>Abnormal mental status</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100543</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/b13a6653-d80c-4746-bd2a-8234f0897b2c">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d919e2a8-ad4f-4d5a-8f5a-90515983762d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65331037-b160-4124-a8d5-f8f77f014974">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
        <rdfs:label>Abnormality in serotonin turnover (Abnormality of circulating hormone level)</rdfs:label>
        <dc:identifier>HP:0003117</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2b61387-b1b7-4463-9836-e5ec6d785004"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
  </obo:DDIEM_0000011>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610006">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/63</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/de539fee-55e7-4bb7-9816-fc393915aceb"/>
    <rdfs:label>2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>63</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/610006</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/a550e427-b9cc-4d67-bd91-d734ebacb544">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cb746efc-9ab2-4fed-b9f8-d5487fadc425"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d62c06cf-1be7-4bc3-bc70-a3a3d4ab3e30"/>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a98f65eb-1f57-413a-94bb-fb17e1ea8255"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a57dd1e-220a-428d-998c-2d64137efa2e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/45708849-6084-4015-a87e-c6c5cd04fc0d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a5c9d49-d0ac-489f-890f-b84c91c592e9"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a301c207-034e-4b3a-85fe-247165c87102">
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bbfa84bb-053f-470b-92f6-0159510823c8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b533850-ad9a-4e16-ba09-12f05a345b48"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca2f82a6-c38f-4758-afd1-ea2cf35ada1f"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT02795676</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ffadd795-6de5-4111-8c40-bba94a087334">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/729db1c2-2157-43e9-87e2-649bf5b70293"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0ae05fa-1957-44a8-ac1a-5aa99dce2bbf">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
    <rdfs:label>Epileptic seizures</rdfs:label>
    <dc:identifier>HP:0001250</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7daf9f2a-428a-4718-80c5-ca02ec625382">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9e3a5f02-2976-4c0b-a38b-92f6ef2ac41e">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/68b6384c-e743-4eeb-99e7-73c8f204b279"/>
        <rdfs:label>dimethyldithiocarbamic acid anion</rdfs:label>
        <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_84293</ddiem:url>
        <dc:identifier>CHEBI_84293</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ddc6bcb-25ac-40b8-b2f3-89979a9ef550">
    <dc:identifier>HP:0001271</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Diabetic polyneuropathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001271</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/288ba401-5b26-41bd-95a5-28a8970e2636">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602541">
        <dc:identifier>https://www.omim.org/entry/602541</dc:identifier>
        <rdfs:label>MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC</rdfs:label>
        <ddiem:iembaseAccessionNumber>1047</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1047</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1cd419ae-80d8-45bc-883b-c46bbb61b108"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a9b6e05-b885-45ee-9b02-fe9537e17fec">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <dc:identifier>HP:0003287*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309000">
    <ddiem:iembaseAccessionNumber>1061</ddiem:iembaseAccessionNumber>
    <rdfs:label>LOWE OCULOCEREBRORENAL SYNDROME; OCRL</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1061</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/309000</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c9fa1cb3-ff45-402b-b421-2cfe43808e50"/>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1d83b479-72a1-4db8-a7a0-96077ce2dcdb">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fdffb76a-5a3d-4338-9a2e-28fcb1851f26">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/24286b28-37e9-4723-b1a8-bd22b77d036f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756474</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90571320-fd28-40bc-88bd-9585589747e1">
        <dc:identifier>HP:0000819</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
        <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
        <rdfs:label>Diabetes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/10422376-d10a-40c2-b012-09a24ab25c75">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/de2b202e-982c-4474-bea0-620d3ec343db">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/93e7080f-5501-4957-b112-15ee0ae8e6f2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f68ad24-746b-450e-8d2d-0eb9b3f11623"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4460a274-ab5f-44d4-b235-594e79335a01">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011042</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of potassium homeostasis</rdfs:label>
        <dc:identifier>HP:0011042</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7148673d-633f-4aa9-9416-93e8f29b6764"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7720804b-de65-4500-8c74-1124f3db8022">
        <rdfs:label>Abnormal circulating renin</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040084</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/908bffd8-ccc5-4323-b649-38092fbc6030">
    <dc:identifier>HP:0002872*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002872</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>"Epileptic apnea(Apneic episodes precipitated by illness, fatigue, stress)"</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/9aa4f1fb-bb58-4678-ba46-babcfa5fe5ec">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ab996365-e43c-428b-b15a-6c3b06c63921"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/43a180c5-ea30-49b4-b7be-9a483c0d2f8e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3facbf9b-d428-4c22-a842-f30cddff22a1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/806e3708-08cf-46b3-988a-e0debec1640b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6f15562-afde-4d2e-a771-b2397f4ee2c9"/>
  </obo:DDIEM_0000010>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/90759ed4-c6ce-44ba-bc20-73d7e8e02364">
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525311</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2bea802f-6dfe-4987-a50f-11bd196cf79c">
        <rdfs:label>Hyperbilirubinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2bcaf70b-9a84-4e20-b38e-fd3d49f19c95">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c866c760-2fc0-44cf-9ea3-6a2a189c9078"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b3eb8cc-8331-4bc4-b045-a9512ae83379">
    <rdfs:label>Low quality of life</rdfs:label>
    <dc:identifier>HP:0025142</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/44d97c1e-b3df-4f99-9aab-f8cda85c6b88">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/adee26c6-0c0d-49f5-a455-8b24d40b8608">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/364b99a2-befb-490f-8d54-1695c2d59c54"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/164198d7-4bd7-4ffa-aa89-aa7659f2a7de"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699704245</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277460"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9762aca0-6dfb-47b0-a91a-7d592c8b130e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>D-alpha-Tocopherol acetate</rdfs:label>
    <dc:identifier>DB14002</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14002</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/35cf5313-7721-4e4d-9ce2-9ed31ab815c2">
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8e2e3efd-8234-402d-ad2e-8d9828a0c0b0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0da634fd-b049-463c-b137-09954d0da1df"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/058c9b0c-f619-46df-8163-4c09e0c234e1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
    <dc:identifier>HP:0000127</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Renal salt wasting</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8ca3e429-bbd6-4164-81cc-b4b8cb293d07">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/02a421e5-5d74-4d02-9915-4367ab618a5d"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3eeddbb2-c79d-4e72-95f2-cdececb5320a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High remnant-like particle (RLP)-TG</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/00ac772a-310b-47df-973b-fc5ded34edac">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00215605</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d4ac070-d5d6-4ab3-b7f3-1ee3dc0c9776">
        <rdfs:label>phospholylation of RET</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/51a6e370-9305-4c2f-b443-ae4618606bbc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a91ecba0-fbeb-4b3d-af05-cd1ce6b94a43"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2200f9ef-2fa9-45d9-ba53-ba23fc086091">
        <rdfs:comment>Overall survival (OS), was found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85; 95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients treated with cabozantinib a 20.68% longer survival period compared to the placebo group. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_    ....</ddiem:url>
        <dc:identifier>MP:    ....</dc:identifier>
        <rdfs:label>overall survival( premature death)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2354309-ea5c-4ac6-9e0c-c8cf6b40053c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/debe6cd3-af90-4862-9901-3dee15f48773"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21606412</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24002501</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/623aa266-6658-4c7f-b2bf-8a13b9be95e2">
        <rdfs:comment>The estimated tumor response rate for cabozantinib and placebo is 28% and 0%, respectively, with results varying independently on RET-status, thus making it a promising treatment option. https://www.ncbi.nlm.nih.gov/pubmed/24002501</rdfs:comment>
        <rdfs:label>Low tumor response rate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35cb7ecc-cbf7-44d3-96d1-52a5b20f2d4d">
    <rdfs:label>Thrombotic microangiopathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/eb4bda6a-5dc3-4023-adde-5b76ede316e7">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/321437a3-4fc4-4d8a-a542-ddaa9179fa43">
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:label>Liver biochemical abnormalities (Laboratory abnormalities)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f33d84a-f034-4c90-9692-bf6fd9e135e2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e09394f6-c891-4181-9b29-ca8fee2eadd2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40e6b264-8fb9-4ffd-9d71-0ded242e4a1b">
        <rdfs:label>fat soluble vitamin malabsorption (Fat malabsorption)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/719be918-f12b-464a-ba5e-840a09945b35">
        <rdfs:label>production of toxic bile acid metabolic intermediates</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd078890-d786-4409-80e1-76d60bc64230"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a430a55-9d3b-4d13-b9d2-8754c148148f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>fat soluble vitamin malabsorption*</rdfs:label>
        <dc:identifier>HP:0002630</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5fcaf960-aed6-437a-8bbb-fd255282ac48"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0931554d-7597-4463-81b2-2668970b0225">
        <rdfs:label>biochemical abnormalities</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c7cae44-983b-41e7-9023-8aa9c90cc0c8">
        <dc:identifier>HP:0001396</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected bile flow(Cholestasis)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2affbe48-72e7-4a46-a544-7b6ead8660e9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ed4bd14-e0c5-4029-8f65-fc504d4dcc9a">
        <rdfs:label>Atypical bile acid synthesis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/235a5ba2-df56-44f6-bea3-f02c84c5d334">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>production of bile acid toxic intermediates</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b98fc710-5afd-46bc-a7ab-bbb89bff96a4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
        <dc:identifier>HP:0500014</dc:identifier>
        <rdfs:label>Histological abnormalities (Abnormal test result)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/a428b82b-392a-4feb-a455-013b5ade52f3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6042a300-0d8e-4810-8fd4-2ccb7ff97e5c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/38af40a0-600c-4667-b5b2-19ba4adba65a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e5ca86d-f24e-48fb-99ea-07ad3330f49f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Cell-and-Gene-Therapy-for-Carbamoyl-Phosphate-1-Zhang-Li/2099b4f31e1fe5e8825f03deff088f7702694f02</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/2cd0b598-86ef-4c46-8b81-8f2df64b9a9c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05d76b5c-9c84-4ad0-b2d1-033ddd09cc35">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040144</ddiem:url>
        <dc:identifier>HP:0040144</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>L-2-hydroxyglutaric aciduria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac5799d5-cc35-4d20-8974-81ddc715cc9c"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24321868</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/afb96df8-7972-4485-9ef0-45bd443b2e60"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90093156-8fe8-4cb3-9361-d9b116448f6d"/>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6fc32a45-a1b6-4922-8f5e-f41e4ae2137e">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a70dd99-d145-4fe4-abb0-8cfc9f7ddf08"/>
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/67738040-ccaa-4bd4-8719-a193a35a6dab">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b83872f5-6828-4989-beb3-dfa1e21ac050"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2847ac9e-a635-4a44-919d-d0b0dd66f3fa"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/b1cbfbe1-3710-4def-be37-30b20d774082">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/132bafbc-3a2a-4be7-9f80-9cd23937ba36"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/abff5eb3-a6b8-4527-b4b1-f7fa3a90bdf8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/de290e85-1aa6-4319-9ddf-01429e8dca6a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246450">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/246450</dc:identifier>
        <ddiem:iembaseAccessionNumber>62</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c5bbb9b7-a10a-4ae2-a7bc-0824bbe4fc21"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/62</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
  </obo:DDIEM_0000009>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3581032c-5db2-419b-b628-9e63302523fa">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c05deda5-54cb-432e-a79f-e9cb0c38ecad">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01611</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/37968c4c-67a8-4824-980f-e5e5ea18a08a"/>
        <dc:identifier>DB01611</dc:identifier>
        <rdfs:label>Hydroxychloroquine</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/bfde4c43-3f00-4f34-b3d9-f5c3360e519d">
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ced40f03-c8a8-4ad3-bdad-fc192d6a3433">
        <dc:identifier>HP:0012103</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
        <rdfs:label>Mitochondrial oxidative stress</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/370af287-dd04-47be-80c5-52922ef40b0a"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e1c68149-55d6-4ff6-a469-e5f255ce0ba5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/49a97d7d-4752-4293-b976-3ba95719dc0d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17296905</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/64c92643-2aff-47f8-a59d-d9e666acd052">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4d5a00b-a173-4534-a5c1-f7f16b40e19e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007367</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CNS damage progression</rdfs:label>
        <dc:identifier>HP:0007367</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f02480da-e665-417f-9aad-2bc7bbb2d178"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31846a8a-ecf1-4d6f-8760-931c0993393f">
        <rdfs:label>abnormal polymorphonuclear leukocyte function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001874</ddiem:url>
        <dc:identifier>HP:0001874</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d826332-8275-41f4-9d1f-51bf1fb35fba">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002718</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
        <rdfs:label>Susceptibility to Bacterial infection</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17206463</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c18ae31d-8268-4e9f-a97b-d59e505abeef"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72671f25-4167-453e-8a40-e3ad432c33ea">
        <dc:identifier>HP:0001877*</dc:identifier>
        <rdfs:label>Short erythrocyte survival (Abnormality of erythrocytes)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9c8db20-a867-429c-9707-de155c7f7e20">
        <rdfs:label>abnormal microtubule assembly</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/852e709e-5a72-4930-98af-18543e58901c">
    <rdfs:label>Glycine betaine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5ed21d6a-30ca-4ca7-8da9-e08b6ed50cf2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06756</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/966594d1-ec09-4824-8f16-d537457f55ec"/>
    <dc:identifier>DB06756</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e9f9f595-225b-4794-9eaa-05e4c275ef4a">
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/6b2d1a47-08fd-4e60-8480-ace7726bbaab">
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af78da97-93a3-489a-a4b7-ba270e01994e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602390"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4ff91c31-f861-49cb-8a63-8b6118848d82"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/107/7/2952.abstract</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/314493225_Clinical_management_of_hemochromatosis_current_perspectives</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <rdfs:label>hepcidin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/75fcef6b-b71a-4c3c-af85-3ad9742f83e4">
    <rdfs:label>GNE gene lipoplex</rdfs:label>
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/5a0edd8a-7320-4159-9ff6-d4acb91baf58">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a385505-e3f6-4ba0-9009-0f81e6122ddb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ed8d8bd-39e1-4a6b-9d77-33113d1b5b56"/>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f38a91cf-d014-47fb-ba2b-07330a927831">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04815</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c77d3480-7137-4cb2-ae41-b7a61de44342"/>
    <rdfs:label>Clioquinol</rdfs:label>
    <dc:identifier>DB04815</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/795aab8d-b8cc-4cc4-9991-60257a7c3e7d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/00e06947-ff12-453f-a4c8-e5446482552c"/>
  </rdf:Alt>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/34085d7c-f90c-40f2-a380-85121a5d6300">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7357085</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/819a69df-e3d0-4b2e-9b0e-5cf94c0e63e7">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002196</dc:identifier>
        <rdfs:label>Myelopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002196</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c4d5ca2-4adc-438e-b20d-bec42933a2c2">
        <rdfs:label>Elevated blood homocystine</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002160</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8be0effd-37a5-4d92-b6e4-40b5c862f18d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b81e8ae-7557-4931-93ce-acf79f002414"/>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1367da0-7071-4a68-82ef-a94c140f6eca"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6749192</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5ad216af-c570-41ac-a78c-1b8971ae550c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e974fe73-acaa-426b-8a9a-05168e3d2292"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29f60cc8-d202-47c6-930a-1699125e448f">
    <dc:identifier>HP:0005961</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
    <rdfs:label>Low plasma arginine levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4739322e-aa4c-42ed-88de-71e405c551b9">
    <rdfs:label>Delayed mylination</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012449</ddiem:url>
    <dc:identifier>HP:0012449</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/91ec16a7-f876-40bc-8101-1e60603379b1">
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1cf6604-1071-4c79-ae1d-898a2e002268">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b172c7b8-c525-4dd2-8f86-c3453fcf9c7b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c9ec8a8-de4b-4d6b-aa92-e64ce4a8beaa"/>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ade38c9e-9ef4-4e53-9585-dd0f848f8ecc">
    <rdfs:label>Pregabalin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c50fccc4-35bc-4166-b28d-7cbddfac3216"/>
    <dc:identifier>DB00230</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00230</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec567e09-9048-4dae-811b-49cef374360b">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21df6067-bcab-41be-b32a-ac5b3782524e">
        <rdfs:label>Carbonic anhydrase inhibitors</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8623bb4e-7bbe-4123-9c0b-dcc07c208b0a"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01EC</ddiem:url>
        <dc:identifier>S01EC</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/763c9d8b-d6bc-4ce0-984d-43a9dac398ab">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c867f38-79cf-4506-8aba-dbb9a541f55a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fd805776-08bc-4dc0-9316-0e34ee6c2416"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/806e3708-08cf-46b3-988a-e0debec1640b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43a180c5-ea30-49b4-b7be-9a483c0d2f8e"/>
    <rdfs:label>Beneprotein</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9e62ea1d-6bc7-45bd-b145-11a7d227aba4">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/01de3514-693e-4aeb-aec8-114a2f3e2300">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07cd2096-4dfc-470c-a03b-f2fc0265f3c1"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27520363</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8a832cf-d44f-4678-bdf9-ac83fd7c3678"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11635</ddiem:url>
    <rdfs:label>Tocofersolan</rdfs:label>
    <dc:identifier>DB11635</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/30f0e103-d299-44ed-b0d7-e6d8e842c415">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00145</ddiem:url>
    <dc:identifier>DB00145</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/96d3ba48-54bd-407c-adab-d4193590591a"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/c8ea1978-b035-4748-887f-8c91881c6f2d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d84a6e4-9fc0-4fe4-88c9-ffdb76ec1634"/>
        <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec57f2e9-f607-4061-b4da-0996016f8e79"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
        <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23601642</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <rdfs:label>Glycine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b15d5adc-e4a4-4e35-9ede-ced050e883ac">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Irritability</rdfs:label>
    <dc:identifier>HP:0000737</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d36672d-e0d0-47cd-846d-ed2c1084ad7f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
    <rdfs:label>Low IQ</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001249</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be740917-06b8-4285-bb01-b1e05e6b8055">
    <rdfs:label>fasting ketogenesis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946,HP_0025212</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001946,HP:0025212</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c91dec14-f180-420c-a418-2488d32fd771">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0bef26f2-f61f-4e94-888d-c5286ce3cdce"/>
    <rdfs:label>AAV9-TAZ</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fe537ea2-944c-4d8d-8658-7dbd161209b3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84e5134b-678f-4252-b020-81b3f9b60912"/>
    <rdfs:label>Nicotinamide Mononucleotide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03227</ddiem:url>
    <dc:identifier>DB03227</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2c7ec841-0f07-4db2-9cb9-b3dc153e2b1b">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db39fea1-5673-4794-a3fb-d90982d76b24"/>
    <dc:provenance>http://www.babysfirsttest.org/newborn-screening/conditions/beta-ketothiolase-deficiency</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff8d2f27-b34e-4e8f-ace6-fa481eba043a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <dc:identifier>HP:0001941</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Acidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>Abstract</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f48087ad-d7ec-4aa9-9ba7-4fa5c54d3347">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/057d2cd0-9ca0-43da-9d44-01e4aa9a8b1a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5edb3d61-bb7d-4ea7-bfd3-557b4d4ad5fc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/064a1a28-b67b-4367-82c3-31e84a94725c"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00712738</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6ba24d19-0e9d-4ea6-ac5d-4f9ba7d8cb7e">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c4c721a4-6553-41e9-8918-a5ce873894d8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21126241</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/19bf2889-8d23-4b46-8090-1889303689ad"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <obo:RO_0003304>Spa</obo:RO_0003304>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce585cd1-695a-4038-8f3c-48de01da7452"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cedf9583-1e92-4c47-b1c8-f3bde7f98734"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00404</ddiem:url>
    <dc:identifier>DB00404</dc:identifier>
    <rdfs:label>Alprazolam</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2a6f2ff1-2c05-412c-9f06-76da33be72b4">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4358cebd-d072-4344-bdac-dfdf24e12a65"/>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd63c576-f445-4b81-bf91-33a0e70e6f27"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d3006738-1d7d-4d12-b54b-cdd717b23f35">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b85f15c-d5db-48af-9e50-296a82d3f245"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18839211</dc:provenance>
    <obo:RO_0003304>compound V377I and I126T mutations</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9b2bc7e5-ba1c-4f8f-b238-38d55924b36a"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/478f321c-b723-46ce-8306-b35239f370c0">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
    <dc:identifier>HP:0011123</dc:identifier>
    <rdfs:label>Acrodermatitis (Dermatitis)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/65ab1081-036d-43fc-ae5f-0098adee915e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5304b6f9-6d6f-4cc7-acbc-cb87d25dac2f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
        <rdfs:label>unalertness</rdfs:label>
        <dc:identifier>HP:0002329</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86e9555c-c998-4d8f-a4ce-f6d3e06120a1">
        <rdfs:label>excessive adventitious movements</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613163">
        <ddiem:iembaseAccessionNumber>36</ddiem:iembaseAccessionNumber>
        <rdfs:label>GABA-TRANSAMINASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d6ca18be-d8a3-44d9-b95b-dd46f7d8929c"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/36</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/613163</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80fe9cc5-292e-4e32-9304-833eeb5a373f"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28411234</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/797bc606-d9ff-4ce5-951a-f75bf797d8e0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8caf362d-e4c6-4e6a-95bf-a3ba6bfa2e57">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10886507-3773-43c0-aad4-86bb21f15326"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89bec3bb-1654-4724-bd3d-76bc8bbaa15c">
        <rdfs:label>hypersomnolence</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100786</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6de9720f-208d-4a49-a5f4-0c4ad22a5ccc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c200ffdf-5bbf-46c7-8d29-e089a1cfc5cc"/>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0bb1b2d6-1bd4-403e-bf55-4b6f082344d7">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613150">
        <dc:identifier>https://www.omim.org/entry/613150</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/353</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e6b1d7d9-a9ea-494b-bee3-5d2881f599d9"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2</rdfs:label>
        <ddiem:iembaseAccessionNumber>353</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980384</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cbc2c8bf-43ee-4228-a2bf-df2e3479349a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/963134e9-7185-4f69-aba4-6ccd6006b381">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>congestive cardiac failure</rdfs:label>
        <dc:identifier>HP:0001635</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41ed0904-1499-4dda-8d00-9883154711e9">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002789</dc:identifier>
        <rdfs:label>tachypnea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002789</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8104bbb-eeac-4e0b-a462-ab938937bed0">
    <dc:identifier>HP:0000964*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000964</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Nummular eczema (Eczema)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/8a7231a3-c782-4455-a680-e156d1706405">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261515"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d973893-ad7e-4af7-bdd4-a40a25f6aa20"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2affbe48-72e7-4a46-a544-7b6ead8660e9"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bdb3ed3d-a9c6-4f17-bfd1-2099abba5709">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7d1ce3e2-8a8a-4b13-9f82-e6f1c3d7727a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/3dacb91a-22da-45a2-9214-ebd2541db22d">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a08640c-6a82-492c-865c-d8022abd0728"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16040264</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a05bb60e-fafd-46e4-b0af-508d04c4d9af"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f873176-49b7-4590-98a5-43a805a98731">
        <rdfs:label>Reduced visual acuity</rdfs:label>
        <dc:identifier>HP:0007663</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46548bdd-00e3-42e2-9f2b-49ad41d58efc"/>
  </obo:DDIEM_0000010>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08f3bf23-f1ca-441d-a233-9fe7e2a02e06">
    <rdfs:label>pyruvic acidemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001941</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e929394d-6c72-4ba8-96b3-2ffc01b630f2">
    <dc:identifier>HP:0002757</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002757</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>bone fructure</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/18eac25b-6667-4bbc-bb57-6843bd78d01e">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5296b6d3-94cf-496b-9f0f-851435fed790"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e09bbbc8-5cc7-41d3-9bf2-771e05752ad0">
        <rdfs:label>Growth impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008897</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008897</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/016cc0fb-be76-406f-85b1-cfe3ef32beda">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671896</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4739322e-aa4c-42ed-88de-71e405c551b9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30389272</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e43a246-c7c9-4f38-80cc-d7564cf5dc99">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor traction response</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59e4035f-f6ad-4828-90ea-ac39c8cf5487">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011448</ddiem:url>
        <rdfs:label>Foot clouns</rdfs:label>
        <dc:identifier>HP:0011448</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671893</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5a45a84-b1fd-424e-b845-5c19477ec4ce"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f21ea7a6-bba5-4e02-be4f-873c40859b8e">
        <dc:identifier>HP:0001290</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:label>Poor traction response (Poor muscle tone)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d53213b7-46fa-4a2b-8b49-c54370055ef9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d36672d-e0d0-47cd-846d-ed2c1084ad7f"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/435eebf6-c973-44a8-834e-3c9121940000">
        <rdfs:label>Neurodevelopmental abnormality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250850">
        <dc:identifier>https://www.omim.org/entry/250850</dc:identifier>
        <ddiem:iembaseAccessionNumber>1283</ddiem:iembaseAccessionNumber>
        <rdfs:label>METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7370ffb9-dd4a-4c62-84c6-e95e322c8b09"/>
        <rdfs:comment>Recommendation and guidlines in treating this disease and other inherited methylation disorders can be found in this link: https://www.ncbi.nlm.nih.gov/pubmed/27671891</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1283</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfe07b21-35c7-4f1b-81e2-61db1a5693f6">
        <dc:identifier>HP:0007266</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007266</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Brain demylination</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671894</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd49e531-6c5f-4708-ac11-8d2228049b59">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Behavioural abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48a09e4b-48ab-417f-8a1d-652f7b68b456"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a710785-b5db-428e-82cf-2cd1da18b92b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6820758-2041-4382-9e3d-a3a8fbafc526">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:label>Neurodevelopmental abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f479a4a-bed1-45cd-bda8-e986b38f3a1d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671892</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/617ae625-a458-44c6-95f2-af93d7730ddb">
        <dc:identifier>HP:0001347</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperreflexia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a48fda36-7f88-4aa5-8bd1-2a4a9ce402eb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b15d5adc-e4a4-4e35-9ede-ced050e883ac"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c47bf190-dd24-4a6f-a689-453edbf13ffd">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001270</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
        <rdfs:label>Delayed motor milestone</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e9d01e60-4081-4d37-9a22-9b3f21fe8cf9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671891</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b172c7b8-c525-4dd2-8f86-c3453fcf9c7b">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d35bd9be-e260-4301-b168-ddf2a8549a05">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11486915</dc:provenance>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10896280</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d249e0c-b69e-48d3-a47a-de4d6a286164"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1cf6604-1071-4c79-ae1d-898a2e002268"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
        <dc:provenance>https://link.springer.com/content/pdf/10.1023%2FA%3A1010545811361.pdf</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00123</dc:identifier>
    <rdfs:label>L-Lysine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b476e67b-24eb-4cb8-9d51-6a6132bcff16"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/91ec16a7-f876-40bc-8101-1e60603379b1"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00123</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/e33d58cf-e1d5-4055-a759-4f2572d5aced">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a9b6e05-b885-45ee-9b02-fe9537e17fec"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac5799d5-cc35-4d20-8974-81ddc715cc9c"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/50f806f7-84b1-4fc1-a63a-3a33ece6a530">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a09e003c-7885-4eb8-b1e0-275af1157274"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/d869c586-fba8-4ca1-bbdb-d7646d79a260">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/340d185c-39f7-4626-affd-7691a7dfdf64"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00473655</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c50cd74f-04f8-4a6f-97a8-7060fd9cd689"/>
        <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d768d5f4-97bb-4cc8-abee-5da1cde8a66b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d50c25d2-1803-4355-9569-cd1f0c2837be"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8811363-7595-48f2-8b80-5010ee342d86"/>
      </obo:DDIEM_0000009>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/e186f153-45ec-4a0c-a721-78b247965a43">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8811363-7595-48f2-8b80-5010ee342d86"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6d1ddb78-804a-4a32-b21a-5980720285db"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19530961</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
        <obo:RO_0003304>TT-1131</obo:RO_0003304>
        <ddiem:failedToContributeToCondition>C-1131</ddiem:failedToContributeToCondition>
        <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01098</ddiem:url>
    <rdfs:label>Rosuvastatin</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ba2dbc94-33bb-42e7-9daa-a5932eaf01a6">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d768d5f4-97bb-4cc8-abee-5da1cde8a66b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23323877</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/340d185c-39f7-4626-affd-7691a7dfdf64"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f6ad41b4-b216-477d-ac0a-173c0a570001">
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/340d185c-39f7-4626-affd-7691a7dfdf64"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/db486d65-e4ba-425d-a211-511978a786aa">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02705547</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/340d185c-39f7-4626-affd-7691a7dfdf64"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
        <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB01098</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c53d2f9-0050-499a-9603-3123e89fb8f0">
    <rdfs:label>Cystathioninuria</rdfs:label>
    <dc:identifier>HP:0003153</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003153</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a0d82bd3-2fd1-4263-a7c7-d62671569587">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1ae99aae-ed51-445e-bb94-83a01e66a4a4">
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:comment>Due to its strong copper chelation capability, a copper salt should be added simultaneously</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5f5374c4-80be-4a26-978b-06092b9baab9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0614de91-f885-4fad-a662-3a597555c8ef"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00166</dc:identifier>
    <rdfs:label>Lipoic Acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00166</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/4125d50a-2d5d-4fb7-a252-c4559b8a3e33">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/08f3bf23-f1ca-441d-a233-9fe7e2a02e06"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5f5374c4-80be-4a26-978b-06092b9baab9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f87dc0a-c82f-4272-810e-3dc661c28788"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6418873</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11687750</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/67fb37ea-0490-416c-852b-b8718c93e243">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3423c1f5-5e44-4055-8b2b-47b162e8f5f2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5f5374c4-80be-4a26-978b-06092b9baab9"/>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72d43680-393f-45b9-9226-6175be214012"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/39010e2d-e911-4363-adb4-260ab12c3ef1">
    <rdfs:label>r LCAT</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/435d60ba-2ee6-4b66-aebb-321fd282969e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20605907</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c6a0c88-262f-489e-acce-c78a69f776d9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e9a19c4-9db2-4de4-9344-913a9813fa70"/>
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb441ffd-cb6b-4bfd-bf8c-bed99db20bb7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/01695a31-7dff-43ba-96d7-825508a9635b">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/16a1138e-31a0-4766-9a29-5f26db6ee79f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>According to a retrospective study, 11 of 12 patients who received Glyceol died, whereas both of 2 patients who received D-mannitol survived.https://www.ncbi.nlm.nih.gov/pubmed/15050970 
D-mannitol is unlikely to affect cytosolic NADH production even in citrin de ciency. Therefore, it is highly recommended to administer D-mannitol but not Glyceol to treat brain edema in patients with CTLN2. https://www.ncbi.nlm.nih.gov/pubmed/16449956</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d36152c-504a-4914-afb9-884a782bcf90"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f427446-586a-4c57-98c0-a7c68379c077"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16449956</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00742</ddiem:url>
    <rdfs:label>Mannitol</rdfs:label>
    <dc:identifier>DB00742</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/65e8e7d8-ea52-417e-9c76-3add2cb21f25">
    <rdfs:label>Sucrose</rdfs:label>
    <dc:identifier>DB02772</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a4187e57-15ff-4dc0-8dca-457fac6874b2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02772</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/734310c8-3d78-456a-916a-529aae385667">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>working spatial memory impairment*</rdfs:label>
    <dc:identifier>HP:0002354</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6a792ec-cfbd-4140-bd1b-96e5847db826">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
    <rdfs:label>fine motor dysfunction</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0007010</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62e9860d-01ef-4d69-9f1b-162f4ebf6d39">
    <rdfs:label>"hippocampal Na+, K+-ATPase reduced activity"</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/852d4cbb-1eb9-437b-b249-95d14e2d3045">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20cf8494-c924-4f21-865f-b08586368cc6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001640</dc:identifier>
        <rdfs:label>cardiomegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bbfa84bb-053f-470b-92f6-0159510823c8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9f9a4f6-70d3-42f2-900d-bce670d70b56">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012213</dc:identifier>
        <rdfs:label>low renal glomerular filtration rate</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d8b479f0-2367-447a-b668-de4f6ba5d606"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03018730</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/003a8ea8-9554-41f2-84bf-15a95581e735">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f8215a69-50b6-4b22-9923-24bf885d5d49"/>
    <rdfs:label>Somatotropin</rdfs:label>
    <dc:identifier>DB00052</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/57c879b5-e7ef-4c93-8a28-17b686469904">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e7cdfeb-3b4f-49ea-a861-3460e571d6a7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9559978c-f7e7-45d7-a09c-e9ac804b0a6b"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f419d28e-775e-4b39-bd36-87934855b06b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/187521ea-9398-4569-befd-adbbe1a09b22"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00052</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c07a8e8e-32d4-4dce-9dc2-2026c7186639">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bada332c-52bd-478b-8472-8a2eaf661e80"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8154a4e7-aaa9-4b23-a91b-95003e615a56"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f419d28e-775e-4b39-bd36-87934855b06b"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0fc8382d-3f28-47b9-b9f4-f9d4c6168251">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/187521ea-9398-4569-befd-adbbe1a09b22"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16775724</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28a56229-9da8-472e-b642-974c7dce184e"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f419d28e-775e-4b39-bd36-87934855b06b"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9157bb0d-7abc-4f5a-bcdd-cb6b49802100">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f419d28e-775e-4b39-bd36-87934855b06b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/187521ea-9398-4569-befd-adbbe1a09b22"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/44d754b1-c581-491f-b8df-5c22ab8c4931">
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/4f2239f5-eb50-4e7c-8f4a-ebba7a67738c">
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5bbaa4b7-fa65-4ef2-9dc5-8c289dc18ee6"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80fe9cc5-292e-4e32-9304-833eeb5a373f"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12747882</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00114</ddiem:url>
    <rdfs:label>Pyridoxal phosphate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e310935-23da-4d18-ab99-72ad7066c9f0"/>
    <dc:identifier>DB00114</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/33dbc0d5-44a4-46e7-a845-bd5fa44d7590"/>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/d2ff69e0-8709-4d51-816d-ad0b632f396f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a7f1ffd7-1158-46ce-be15-0bfc78a01036"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0003304>Ser72Pro/Trp168X</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. A potential therapy based on results of a study conducted by Banning et al. 2016 https://www.ncbi.nlm.nih.gov/pubmed/29247835 Consistently, AMX is currently under strong clinical development for rare metabolic diseases by the company Apteeus (Terence Beghyn, Apteeus, personal communication). The drug as released in Banning et al. study works by inhibiting NMD and causing a translational read-through, it facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. "This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. " It posses the ability to cross the BBB. "Our data show for the first time that Amlexanox might provide a valid therapy for AGU." https://www.ncbi.nlm.nih.gov/pubmed/29247835</rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/topic/amlexanox/510418</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d84a6e4-9fc0-4fe4-88c9-ffdb76ec1634"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9bef5087-dde2-4008-a1d4-95fdd8b5b1c0">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a98f65eb-1f57-413a-94bb-fb17e1ea8255"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14d29dac-847f-4efb-b83e-0a1e451c54ab"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ba7cbc3-c463-43fa-9c64-05f7841ad3c5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high EMA levels</rdfs:label>
        <dc:identifier>HP:0003219</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003219</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc455227-b676-41e7-8232-ecdc72cbd433"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d0b5572-3cfe-4969-b472-76f156f87a8f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
        <dc:identifier>HP:0002014</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/012c5ab3-91e7-4a99-ae87-ca16b9df9072">
    <dc:identifier>HP:0008064</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ichthyosiform erythematous plaques</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dff69edc-458c-473b-b090-0e3bbf7a3e9d">
    <dc:identifier>HP:0008344</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
    <rdfs:comment>Study ws done in pups: Administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival.</rdfs:comment>
    <rdfs:label>Branched-chain amino acid accumulation</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5d8fb7a4-8bf2-4324-ba96-ee0f819e1fdd">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/58202caf-abf6-4f14-af2d-bd1c59aab05f"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d4eb118d-a336-41df-a42c-27a2bc38a7e7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1b8743b9-c4b2-483b-b35d-7de038053dab"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/478f321c-b723-46ce-8306-b35239f370c0"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0cf44ad-4c55-411e-bf43-580fb7bfdf80">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040181</ddiem:url>
        <dc:identifier>HP:0040181</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Perioral dermatitis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14354277</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1a5f3fb-a905-4200-93b6-55893a076da6">
        <dc:identifier>HP:0001596</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001596</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Alopecia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ebe086cf-2f79-4ed7-a4ee-2c20ce1022e1">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300971">
        <dc:identifier>https://www.omim.org/entry/300971</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ca2266be-5027-4717-812b-73991154d1ac"/>
        <rdfs:label>BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5</rdfs:label>
        <rdfs:comment>Among antenatal Bartter syndrome, the transient form was defined as a regression of clinical symptoms and normalization of biologic parameters allowing the arrest of treatment. https://www.ncbi.nlm.nih.gov/pubmed/29146702
This condition can be successfully treated with close monitoring and fluid and electrolyte replacement, avoiding the potential harmful effects of indomethacin. This diagnosis is important for clinical management and parental counseling regarding overall patient prognosis. https://www.ncbi.nlm.nih.gov/pubmed/29594084</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea0f0c7c-192f-4209-96ce-a0397fde1055">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bcc36826-d5f5-49a9-9258-2da8c7e0d761"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/058c9b0c-f619-46df-8163-4c09e0c234e1"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/80b65f56-f797-4453-8013-ab1ebb7953d9">
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55d58b0e-cdb7-4402-83b5-a20d9358b7af">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:label>Brain pathology</rdfs:label>
        <dc:identifier>HP:0001298</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23337983</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/43ed4011-055e-492d-90c4-fcda5897694c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad84938a-907c-43ce-8abf-4e6d9401aa78"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230600">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/91b5385a-0db8-438f-b80a-b807753fa580"/>
        <dc:identifier>https://www.omim.org/entry/230600</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE II</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a70f2f26-a195-4dd4-8598-676d0d2195e9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600721">
        <rdfs:label>D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/166</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>166</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/41299985-4d17-40fb-beb7-52766e835cc9"/>
        <dc:identifier>https://www.omim.org/entry/600721</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd84caa4-e20f-4376-88d7-e56956f68f85">
        <rdfs:label>DNA damage (Abnormality of DNA repair)*</rdfs:label>
        <dc:identifier>HP:0003254*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea361b85-5737-43a2-bfa4-8bf60e6c608d">
        <rdfs:label>lipid peroxidation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2ed3938-e310-4097-b62b-e56941be96af">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Protein oxidation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21eac4e5-a632-492f-af9a-ae4080791802">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025463</ddiem:url>
        <rdfs:label>oxidative injury*</rdfs:label>
        <dc:identifier>HP:0025463</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28396261</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/666902b3-ae73-4541-8829-00227108b30c">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2e5caf2d-7e4e-4fff-ab0c-3c61a8ade337"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <rdfs:comment>The drug has beeen weaned when patient developed visual hallucinatuion before his presentation with a status epilepticus attack. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a16ec15-e81d-4071-b083-c0307a65f87c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>sleep cycle disturbance</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/95c5fca5-b04f-4ded-b798-a7d2be093a6a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00121</ddiem:url>
    <dc:identifier>DB00121</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c46991d2-fbf7-43d4-9ce6-e6ecc7212865"/>
    <rdfs:label>Biotin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd4bd56f-ca60-4909-beb6-4e85b97b3786"/>
  </ddiem:Drug>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/85033d15-1e7e-41c8-80f9-bf7489d38ab1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e63c3b73-4fe4-4202-b317-d4f434d93f0b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0212c985-f816-47e4-995e-a214d71ae8cc"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d5c10c4f-f122-49db-9c50-5e4a2dca570f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/113ac053-6573-443b-a5d0-c4c2c6fd4ec6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12930917</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613027">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/613027</dc:identifier>
        <ddiem:iembaseAccessionNumber>1259</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6c6ea88c-7453-43f0-bcd5-1f5aa3dce26e"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1259</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXc; GSD9C</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000010>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d58a0e40-487e-42f3-bda9-b693b1144852">
    <rdfs:label>Increased muscle fatiguability</rdfs:label>
    <dc:identifier>HP:0003750</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/535a489e-dec2-407b-9108-f88eeaedec9a">
    <dc:identifier>D07A</dc:identifier>
    <rdfs:label>CORTICOSTEROIDS, PLAIN</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=D07A</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a11c52a4-2669-44bf-a104-6449d5b11f82">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/227c436e-c014-4140-bfb5-061ef97c088c"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830701</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8104bbb-eeac-4e0b-a462-ab938937bed0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6e0084c8-75fd-481a-822f-771be4dd821d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60ac0b6f-6fb6-4464-8e26-16f6cb7ee5aa">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011227</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated C-reactive protein</rdfs:label>
        <dc:identifier>HP:0011227</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f01cc27c-bbcb-4081-9d91-319f4d576517">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a20d75bf-e382-4742-bc04-a3a32de94332"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f4af4fa-c9f0-431e-82e7-16a19ea0f2c1">
        <rdfs:label>High serum amyloid A protein</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56645760-0f2d-4eeb-b2bf-1a9944c64af0"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609286">
    <dc:identifier>https://www.omim.org/entry/609286</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b7b80e23-9def-4a47-a337-d9976e93ec7c"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 3; PEOA3</rdfs:label>
  </ddiem:Disease>
  <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00055442">
    <ddiem:url>http://purl.obolibrary.org/obo/ECO_00055442</ddiem:url>
    <dc:identifier>ECO:00055442</dc:identifier>
  </ddiem:Evidence>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b250bad-931c-4456-8a7c-53155bcbd5f9">
    <dc:identifier>HP:0031429</dc:identifier>
    <rdfs:label>low bone formation biomarkers</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031429</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/de290e85-1aa6-4319-9ddf-01429e8dca6a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b1cbfbe1-3710-4def-be37-30b20d774082"/>
    <rdfs:label>leucine-restricted diet</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/57448952-cc8a-4c23-bf72-29080ad77cf8">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fb1ca65-c5ab-4286-8031-a48097ce898c">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>cognitive impairment</rdfs:label>
        <dc:identifier>HP:0100543</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8de508e3-8ba6-4ebd-8a39-d37859a973b7">
        <dc:identifier>HP:0011025</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cardiac dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/401864ab-b737-47ae-9982-3219fc0d9421"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606175">
        <dc:identifier>https://www.omim.org/entry/606175</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/671</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>671</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3561ca19-275f-426f-80b9-5b319d814557"/>
        <rdfs:label>CARNITINE ACETYLTRANSFERASE DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be740917-06b8-4285-bb01-b1e05e6b8055"/>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/712223cb-98eb-4e2d-8077-d08d984c2f88">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e9237a72-3743-4c2b-876c-f49bfcbb7366">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dcb8cde3-49a3-47cc-b32a-d31a599a772c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a131156-709d-43eb-a778-024922187e42">
        <rdfs:label>oromandibular dystonia</rdfs:label>
        <dc:identifier>HP:0012048</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012048</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/6eaf7ee1-38a1-4bc7-9a3d-1074ca908002">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f68ad24-746b-450e-8d2d-0eb9b3f11623"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4e62b4f-6170-401a-9efd-b5a397dbb8de"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7148673d-633f-4aa9-9416-93e8f29b6764"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29cb624c-fba8-4f3d-a2a1-ee20de66b393">
        <rdfs:label>Bone mass loss</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7720804b-de65-4500-8c74-1124f3db8022"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac03822c-91b2-4f45-9b54-b905d4dddab0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/3772d059-a7eb-435d-9dab-b4279d231cb7">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b81e8ae-7557-4931-93ce-acf79f002414"/>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59edccfd-6d11-44eb-9fa1-e253aede5da9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001913</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001913</dc:identifier>
        <rdfs:label>Granulocytopenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e3b0fc2-a2d4-4924-8993-0e94b62c9de7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d75b202-4b45-4462-888a-58f6dc4cb3f6">
        <dc:identifier>HP:0002907</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002907</ddiem:url>
        <rdfs:label>Microhematuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd715810-073d-4ecb-aad2-83900afb0765">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002160</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <rdfs:label>Elevated plasma homocysteine concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5cf23e9e-7c23-44c2-bf7c-4d5e48bfd8e5"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e974fe73-acaa-426b-8a9a-05168e3d2292"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80fe9cc5-292e-4e32-9304-833eeb5a373f"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250940">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dc2e14c3-72b0-400f-ac08-fe380cc91c24"/>
        <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>30</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/30</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/250940</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/12b6d969-c94b-48a3-a696-f73b3504a207">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00695</ddiem:url>
    <dc:identifier>DB00695</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0672df24-ab67-4e18-9099-fa40a82aad18"/>
    <rdfs:label>Furosemide</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9a2b9f44-ca01-42fb-b172-b0cf04fb5487">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d07808a7-8cab-4413-b2a3-17aa20951973">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000572</ddiem:url>
        <rdfs:label>Visual loss</rdfs:label>
        <dc:identifier>HP:0000572</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26448041</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/300ad90f-3655-4fe7-ba66-057e7c40a527"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300753</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd078890-d786-4409-80e1-76d60bc64230"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f36819e6-3d96-4b4b-ab31-51464cad14e5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aafb630a-2e7c-4676-9663-9a7711df6cf6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa7104d7-ac4a-4909-a614-7b8ed6ec05ae">
        <rdfs:label>Retinal ganglion loss</rdfs:label>
        <dc:identifier>HP:0000479</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b4eff64-8f36-4eb5-8b7c-7f210ce59df9">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003040</dc:identifier>
    <rdfs:label>Arthropathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003040</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72b71650-d5ce-4fbb-b844-cc2981103e33">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002069</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
    <rdfs:label>Generalized tonic-clonic seizures</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41bd6022-5769-4127-b1f3-bae9666bebc5">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>insufficient anaerobic glycolysis of skeletal muscle</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c5fbc45d-bf23-4ace-91fa-5abcea52f65a">
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7be2207-9248-440c-b331-5c32d3323b2c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b31ee72-0875-492c-aa29-970420b7c8ef">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003688</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased activity of cytochrome C oxidase in muscle tissue</rdfs:label>
        <dc:identifier>HP:0003688</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/764dfbac-9c68-4a90-bdcc-3761962ca0a6">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/04aa6534-e231-42e4-ae3b-47dc818537ad">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5942f73-7a80-4453-8e1a-a26325d862f9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18362286</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fa288dfb-051b-4956-bbac-6d75264a10e8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e23094b-609f-4c1a-92a4-d94bac2f3e19"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b5e60aef-cb6c-44c0-b88a-b8e41cdf9fc4"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
        <dc:provenance>https://n.neurology.org/content/70/13/1051</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05d76b5c-9c84-4ad0-b2d1-033ddd09cc35"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0678e392-36a7-4da8-9825-434563e26dcc"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03147</ddiem:url>
    <rdfs:label>Flavin adenine dinucleotide</rdfs:label>
    <dc:identifier>DB03147</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6e3a1291-2da7-4ff0-8293-c36098c64a3d">
    <rdfs:label>Antisense morpholino oligonucleotides (AMOs)</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fe525e5a-55d9-4e8a-84fe-62a13c94d005">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/707e8247-fd66-4fb7-a221-16c946e23de7"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832064</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aee57e05-dbf5-44a1-bdbe-ce6ea5ce8d8e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21542064</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0003304>"c.84−322A&gt;T, c.163 + 695_163 + 751del57, or c.164−712A&gt;T"</obo:RO_0003304>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1d029be-84d3-4d23-bd24-23e88977188b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011966</dc:identifier>
    <rdfs:label>High plasma citrulline levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/483cfb09-ea90-455d-bfc0-364abe822163">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012433</ddiem:url>
    <rdfs:label>abnormal interactivity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012433</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8d33ca8f-6ac6-4333-9091-a2fe8f641273">
    <rdfs:label>Methylene blue</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09241</ddiem:url>
    <dc:identifier>DB09241</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b817444d-69d9-4fc7-9649-a52c8ad12227"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/228000">
    <dc:identifier>https://www.omim.org/entry/228000</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cec1947e-288f-47cb-bdf3-b1b3194567f5"/>
    <rdfs:label>FARBER LIPOGRANULOMATOSIS; FRBRL</rdfs:label>
    <ddiem:iembaseAccessionNumber>1297</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1297</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cb9020df-7a4a-4097-9277-8aef5b345c16">
    <dc:identifier>A11E</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11E</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2c4d98c4-c1fd-46fa-a4a7-6a931e37723c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bad09885-124d-4357-aef6-e02d01e5d3fa"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c5d424ca-bb37-48eb-9a79-a83124016861"/>
        <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6bf3376a-4e5e-4288-be45-b1421ad69ee6">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/81f1876f-4bea-4cc2-9d23-7f11b5ca5efa">
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602579"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4994a2d5-a825-4e00-9171-e833886f9125"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/719f665d-18a7-4a31-8a98-675f73a4dafc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/36d22bbe-f844-4f09-9083-04eb5a447b85"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4cc9f7e2-f617-4158-b1af-69a1199937e8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c17bceb-8528-4dfd-8b9c-af41a1ecfea8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f28378bd-0d72-407b-9827-94dddf675969"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3244dfb4-3d0b-4057-9c9a-dc8cee21c939"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525984</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10484808</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc1746d2-0477-4cda-912f-b447777fe5da"/>
        <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Mannose</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12907</ddiem:url>
    <dc:identifier>DB12907</dc:identifier>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000005">
    <rdfs:label xml:lang="en">mechanistically predicated therapeutic procedure</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T17:59:32+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure which directly addresses the effects of a protein defect produced by the mutation, its structure, activity or end product. Therapies which target the local interaction or regulatory network or pathway in which the affected proten lies are also regarded as mechanistic therapies. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
  </owl:Class>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5e406a12-33fa-4de9-b94a-664afd60e104">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7c647cd-ae7d-461a-a2ea-a4ef38820ad8">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000842</ddiem:url>
        <dc:identifier>HP:0000842</dc:identifier>
        <rdfs:label>Hyperinsulinism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096481</dc:provenance>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28621098</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23295286</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d60b73ee-efd8-40c7-b57d-dec68de6452e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20936362</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6dc61da4-a737-4ddf-bae4-a604e96eed6b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abc8f20f-3f93-42fe-8151-7183c566a1ce">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>epileptic seizures</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301835">
    <rdfs:label>ARTS SYNDROME; ARTS</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/301835</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/33a445a3-160b-46b7-a552-d8e558f9a3d6"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e6aac6bf-f4fa-428f-a59b-2096064b49ec">
    <dc:identifier>CHEBI_32030</dc:identifier>
    <rdfs:label>Kaliumbromid</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32030</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/dbf24faa-ab19-42e5-8b3f-9c09257237ef">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e6be0f3f-38c2-4a76-b190-cc3d3351ff6b"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90b1c9f8-f705-44e4-b2c7-72ee7934fc28"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/36b1cce6-1fae-4a4c-9e79-c5c2376d2a4b">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f392dc1-5378-4ad8-a0e1-019a374edb35"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ffebcfa-f201-410d-8e07-396d0d529147"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11400757</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a72a674-2be8-44ea-b377-02c3240574e2"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250950">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>58</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/250950</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/58</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ece186d0-e074-4774-a683-90d408e04e74"/>
        <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12f9d4be-747a-4f34-b8e3-3e77e97eab57">
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Metabolic Decompensation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358122</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b277fb74-fafe-4c2c-8942-1e5d8ca958a4">
    <rdfs:label>Low lumbar spine bone mineral density(bnormality of bone mineral density)*</rdfs:label>
    <dc:identifier>HP:0004348</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1962eb54-67ea-48b8-b1e5-331942143bb1">
    <rdfs:label>D-2-hydroxyglutaric aciduria</rdfs:label>
    <dc:identifier>HP:0012321</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012321</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a9c3cf1-428b-4ae9-bcbf-86fc18c5743d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001609</ddiem:url>
    <dc:identifier>HP:0001609</dc:identifier>
    <rdfs:label>Hoarseness</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bf380560-66f0-4dda-bce8-e21282edd54c">
    <rdfs:label>Orlistat</rdfs:label>
    <dc:identifier>DB01083</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01083</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9d3fc971-5173-4d1b-b498-26ec8fcfa86d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fbe7c50f-a4b9-47e1-a7fe-65f0fb0a49b5"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c04eff7f-45bb-44ff-8f68-2f168ca147c7">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
    <dc:identifier>HP:0003455</dc:identifier>
    <rdfs:label>Abnormal elevated level of VLCFA in plasma</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25f26fa2-c0df-4d93-ab3b-c5ea3dae0b83">
    <rdfs:label>Hearing impairment progression(Rapid progression)*</rdfs:label>
    <dc:identifier>HP:0003678*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0a0a4c2-e126-4b78-9200-90ae17ac586a">
    <dc:identifier>HP:0009830</dc:identifier>
    <rdfs:label>neuropathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/1a518ef8-c99c-4d44-9e56-4f645a5530f3">
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3c332815-b641-4cee-a3a9-9217f1e3be0b"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3fa7adc9-7363-4a8e-bf13-1b1c80ffce4d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f229e06-448d-471b-9e4a-2d45db0d7e10"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb47b3a7-635a-44a4-bb5d-f2b09ad06b02"/>
    <dc:provenance>https://academic.oup.com/ckj/article/9/6/800/2709623</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5576d0a-5524-43ca-8b1f-5000b2e4299b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fd42896-46b0-46a0-a595-f262ad5379c2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26157418-579a-4565-886b-77a67496560c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dbf2cca4-075b-4f5b-823f-48d760186d5a"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614723"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2ee3e7e-ed9f-4be6-8487-7bf9eadc0a54"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8d5924a1-041e-4ffd-97c3-dbd0f0c6a832">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68101e8f-05cb-42b8-8b1a-836b4f3b17df"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/caa8210e-27b3-455f-8261-931862f7d033"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/20138b0d-b58b-48c6-ba76-6722272bc113">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0b80eaa0-d928-4595-a3d2-9d9de1aeb13a"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c86485cd-da75-4324-9ac0-da8de090d6c4">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03514420</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2726c467-6793-4eeb-9d6c-73b690496fbe">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155*</dc:identifier>
        <rdfs:label>high fasting triglycerides</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ed5af167-0902-4d65-8afe-21dc32bd4e04">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f0e3ca00-e37f-4f19-b977-1ebd02a21fb1"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c873567c-68e9-4726-9b50-9d58839cccae">
    <rdfs:label>Pamidronic acid</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4543b548-b4b5-4810-93d0-ab0f8064b2d4">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8af56489-1b8f-42f7-acf8-060f3aa443c0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19773212</dc:provenance>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f419d28e-775e-4b39-bd36-87934855b06b"/>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f2a42e9-aad0-4f28-aa23-06e900e9085b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a70dd99-d145-4fe4-abb0-8cfc9f7ddf08"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00282</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00282</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/61d144c3-3515-463c-8fd8-25c87b51610d">
    <dc:identifier>DB00200</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3772d059-a7eb-435d-9dab-b4279d231cb7"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7bf20db5-fe65-4371-8f6a-c99a8f321263"/>
    <rdfs:label>Hydroxocobalamin</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d49ffa9d-76b6-48bd-a7b4-54f01a7ccbef">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bf399c66-bf0f-4870-96cc-c906ddbe3041"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
        <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eb931e2d-83c6-4a01-b88e-e0383a6f5b51"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eded7d73-1f55-4560-a229-962960b3df3a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e974fe73-acaa-426b-8a9a-05168e3d2292"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916316</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5bcb4ae-3396-46ad-9ffe-cc6643343487"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9e1561c-0e13-4e71-9030-b57f5f7468cc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00200</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/34085d7c-f90c-40f2-a380-85121a5d6300"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6b533850-ad9a-4e16-ba09-12f05a345b48">
    <rdfs:label>Agalsidase beta</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00103</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/852d4cbb-1eb9-437b-b249-95d14e2d3045"/>
    <dc:identifier>DB00103</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a301c207-034e-4b3a-85fe-247165c87102"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/230b0552-75c0-44c3-b9c1-9aa843b34b15">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/333a3281-1860-4af0-b70e-76ae48850d98"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d9e135a6-2782-437b-8e76-3e4157d17bc7">
    <rdfs:label>Piracetam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09210</ddiem:url>
    <dc:identifier>DB09210</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df00d891-b86c-4693-b490-ef6114b02947"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/136120">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/528</ddiem:iembaseUrl>
    <rdfs:label>FISH-EYE DISEASE; FED</rdfs:label>
    <rdfs:comment>Fat restriction is recommended as it leads to progressive mesangial and glomerular sclerosis.https://www.ncbi.nlm.nih.gov/pubmed/2068059. 
and as well another author have suggested that low fat/calorie diet mainly consisting of vegetables may inhibit the progression of the renal disease.https://www.ncbi.nlm.nih.gov/pubmed/2634146</rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e878929c-ba13-47ae-96fb-30a54ef9f120"/>
    <dc:identifier>https://www.omim.org/entry/136120</dc:identifier>
    <ddiem:iembaseAccessionNumber>528</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/76cb9c88-941d-4cd0-b838-07667427c700">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5f64588-8ebf-4603-9753-7b35c2b7d026">
        <rdfs:label>inflammation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001845</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0001845</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/012c5ab3-91e7-4a99-ae87-ca16b9df9072"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/80b38d56-06f2-487c-b768-5027208c94bd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe759c94-15f6-48e6-b89a-189ab04865f8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100725</ddiem:url>
        <dc:identifier>HP:0100725</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>skin thickening</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8910537-132c-4003-81fc-88cd4a1ae9ec">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>Accumulation of toxic metabolites in cholesterol biosynthetic pathway</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/151583e0-32da-4b7e-9a69-cf3a50d9fab2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>waxy scaling plaques</rdfs:label>
        <dc:identifier>HP:0040189*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000015>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/49b3c591-fc14-41b8-a850-0cb3d64f0186">
    <dc:identifier>DB15146</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB15146</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/b45c7304-46da-494b-95fe-adfac5cf5536">
        <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48bc9d38-9d88-4136-9a6e-531a43ad413e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1fcfca63-7a28-47c2-97b3-d7aac1c5cf7a"/>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607625"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/33924b76-49f6-4b6b-a4b2-bbbf0a6ea35b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90f21327-2750-4c46-a3dc-fa878e125d2c"/>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <rdfs:label>Adrabetadex</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/facc55a6-64b8-4447-867d-1a44b41a7448"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5ba521a8-4a13-47b8-af59-e57cc012aa54">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23817215</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17446099</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607155">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bc50df2e-ece5-4281-a67a-389034aaffb8"/>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/607155</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c540aa5-84f4-4c10-a7bf-7219ee50fd5b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334834</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25048216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28480302</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ec52056d-a661-482c-8852-3b28db273dda"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac11091f-737b-4157-bc59-9aacdf5ffc3e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ffebcfa-f201-410d-8e07-396d0d529147"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/757917bc-5a11-4bfd-8902-1696ed01891f">
        <dc:identifier>HP:0040081</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040081</ddiem:url>
        <rdfs:label>Abnormal serum creatine kinase</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/48105f8a-a5a7-451a-ac9f-0aff85b5039f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3b56e47-af56-4d74-90ef-f8a218a77c49">
        <rdfs:label>Myositis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100614</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28931339</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28107841</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9b2bc7e5-ba1c-4f8f-b238-38d55924b36a"/>
  </obo:DDIEM_0000013>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/c3d6e276-a327-4b3f-9e9e-23148ed71921">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8e610e23-47fd-48ca-a44e-f2a64067d531">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/921e5da9-8103-42b1-803c-0005439727a4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2bea802f-6dfe-4987-a50f-11bd196cf79c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8900123</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/aff5d654-6e25-41c3-a08a-1bae70714bea">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9193f29e-cc9f-4029-bf00-b5cf5d190469">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c4977792-2f51-4990-88a2-1d8a973a7386"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d72a5e03-72f6-4b9c-91b8-2ce7825e66d1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/00bbed6f-2c39-4d64-9471-50211163fd49"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6289fc90-15a9-4a86-8a90-6af49314e36f"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29da295f-7948-43b2-a0bb-ff65cedd0589"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8881997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/38ed1308-10ef-4488-b2bc-9fd8bf29fcd0">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7289dc16-f09b-41b9-82d8-fea373c377b1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Acute decompensation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9db00aeb-b7e5-483e-999c-2d27b2dd37aa"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0ac9755c-32d6-4fa1-9ef0-97cc93ea4608"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
  </obo:DDIEM_0000009>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/a969d16d-6b82-4d50-8197-ccc5fbcd918b">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT01379625</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c1db53f-f606-4885-898a-780dd5e1f37e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a5586b2-afeb-451d-b0d7-3c5f07770d7f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21f012e3-33d8-4eb3-8f0a-c51d34af7f83">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
        <rdfs:label>Myalgia</rdfs:label>
        <dc:identifier>HP:0003326</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c09b80de-cc43-420b-98f1-f493c8be005d">
        <dc:identifier>HP:0011025</dc:identifier>
        <rdfs:label>Abnormal cardiac function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34a59523-c14e-4115-bd28-a2d55af63766">
    <rdfs:label>Elevated serum ferritin concentrations</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003281</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/749b0d19-76d7-4d26-bca6-64f55116be92">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06742</ddiem:url>
    <rdfs:label>Ambroxol</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/d0ba6bcc-4346-4273-9d05-a560f4f08150">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a3932ada-1b3f-458a-82f3-75811e29cca9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce918572-175a-42fa-97e5-4f01d912bf82"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/573e1e98-415f-4db0-9bf6-2a36ee84dcb1"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15505381</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01463215</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c80b4d8-49c5-406f-8f29-8cf409faf399"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1e77ac9-9d7d-4ea3-9c34-da4299e1e8eb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8b84423-ceff-4b0c-b18e-3c1267f88324"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1fa53f0a-a8dd-4fad-aed9-5acaff3798ee"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16285070</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16199246</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <rdfs:comment>The drug was used in a pilot study.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd94ef5c-3c70-4ad0-bc36-1461c6f8bf58"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12064906</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <dc:identifier>DB06742</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/94086f82-581a-4f53-8a5f-52813a751111">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01524757</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c8d4249-76ec-4bb5-ba5a-4d8242030e9e">
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:label>High serum ferritin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea2eb874-c312-4da4-84e1-841502cd6990">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1b1c9a7f-316f-432c-8c74-32d479da8d15"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/235200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/add7ebd6-b523-4c5c-b200-49a6f0e6c8d2">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ab996365-e43c-428b-b15a-6c3b06c63921"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d8d932b-bda1-45bb-b377-aa41663118cf">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>Low HDL-cholesterol</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2653622</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d50c25d2-1803-4355-9569-cd1f0c2837be"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23633496</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12709436</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79953a81-4aef-4358-8e10-9a3c0f25f1fd">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <dc:identifier>HP:0003362</dc:identifier>
        <rdfs:label>High level of very low-density lipoprotein</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00007121">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00007121</ddiem:url>
        <dc:identifier>ECO:00007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8811363-7595-48f2-8b80-5010ee342d86">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>hypertriglyceridemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d20c0ae8-eef1-47d1-8d38-dbe5fc85b46d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00688</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d7375d1e-db78-4433-a4e3-21a3d31cdd99">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01399047</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/858a4bdb-d678-48de-875b-48aff56f81cf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/463bd382-1512-4be2-a4d0-fc40750b05d8"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204200"/>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Mycophenolate mofetil</rdfs:label>
    <dc:identifier>DB00688</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5786a40a-2213-4b33-a233-06cda4599bba">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67ec5c8f-17ee-4daa-985c-02d68394129a">
        <dc:identifier>HP:0040006*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased life expectancy (Mortality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de50c17d-fb59-4518-bae6-8e89cc225562"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77ef2c5f-2eda-4be7-94bc-2c34daf7d1d4">
        <rdfs:label>Deleterious prognosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/349fc753-4be8-48b2-9a63-5b636324c2a9"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca4b058c-b246-4024-b150-fd2641fd34f0">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated urine mevalonate levels</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cb9a5cc5-8422-419b-940c-be3c90b2814c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26251718</dc:provenance>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02fc265e-db92-410a-ad48-10056d034e21">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
        <rdfs:label>High calcium excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002150</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/46334648-2527-45ae-991c-a6b2251c3781">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b74dac50-7c6c-4798-9fdf-8afc2fe17dfa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/80863ea8-b36d-4a60-b1eb-598845ad1ec7">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34f1d3b9-927a-43c3-a54e-40447ce9ee7b">
        <rdfs:label>subclinical hypothyroidism</rdfs:label>
        <dc:identifier>HP:0000821</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17132287</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef15784b-6a56-45fb-be97-edce61d5b0b0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230000">
    <rdfs:label>FUCOSIDOSIS</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/259</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/230000</dc:identifier>
    <ddiem:iembaseAccessionNumber>259</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/caf3c17a-cc1b-45e8-bb87-ab4b1073f45d"/>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d7cb6931-afe5-48e6-9765-f9e624f2a754">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9c0c8a73-974e-426f-8f9f-d40447e006e6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/debcd386-d897-4760-b20d-4349c437c69f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25620325</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cfb26d15-7024-45b8-9923-cc5c26edd92b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc613b33-87ae-42d0-9201-faeb2f731a6f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79600bdc-75b4-44ae-af83-93055813d6b7">
        <dc:identifier>HP:0011923</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011923</ddiem:url>
        <rdfs:label>Decreased activity of mitochondrial complex I</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/020a38c0-06d4-47be-9e75-307a6f11231e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High ganglioside accumulation</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/cb11b31a-597f-40de-a850-834658ccc0ea">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d049ecbd-2f89-4de3-8a2d-ec94a90cc58b">
        <dc:identifier>HP:0040006*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low survival rate (Mortality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3bea209a-11c8-4917-90c1-baf7a7341c5c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ea73ebb3-3c6f-4383-905a-27536fffba94"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0dff28ac-b071-4d29-807d-84a9eb87fc73">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f36cde0-0106-450b-b69b-0a05c3b74de4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d37de9ad-cbcf-4b3a-ad97-743ac9f3c34a">
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28583ca2-9811-4459-a689-66f03d629fcd">
        <dc:identifier>HP:0002715</dc:identifier>
        <rdfs:label>immune dysfunctions</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002715</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f186e460-f942-45d5-a3f5-60bd1d1156c3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9fabbfd1-a4c8-4617-a150-5208f1ac75dd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/886e94b8-3d14-4e65-bad4-4a40d7ea5596">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurological malfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/1c62876b-0bf3-4ecf-afa5-a71adcdcd0fc">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1490314</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/79daa1d4-64f5-4578-b028-21c1505064f4"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba4b6177-e8fb-445e-94ed-d460b27a41d0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:label>Asterixis-like movement(Abnormality of movement)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3fbc5d5c-5008-46c8-84bb-598fd024acea">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00273</ddiem:url>
    <dc:identifier>DB00273</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/331614cb-3494-424b-9656-92e3268a56c4">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d81f3043-d7a6-4592-a57b-306577f32c21"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
        <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1a7a4f45-863d-4529-885e-6e4483aa72ac">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d81f3043-d7a6-4592-a57b-306577f32c21"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ac651de-d910-4ff0-8c6b-6aae081d11ff"/>
    <rdfs:label>Topiramate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/23c0f88e-1e44-48ca-a7f5-e4fcb086837a">
    <dc:identifier>DB00533</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00533</ddiem:url>
    <rdfs:label>Rofecoxib</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c6c0f789-1701-486d-a5ec-48076b777047">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0085253816306020</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/202859f5-0790-4bf0-ac15-0324142e976e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c51aa641-7e8a-40f0-98ed-7f6c5e5d09a5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72afb3e1-47c3-478a-8d2e-3d4c990c8afc"/>
        <rdfs:comment>The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12141411</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8e5ac806-aacd-4ddc-9938-ad1ec6ea410b"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602579">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/322</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/602579</dc:identifier>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a15a5356-2f67-485a-93d7-46a1be505f73"/>
    <ddiem:iembaseAccessionNumber>322</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5fab875-7c46-4464-8cec-2c64c025d9d0">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:label>Elevated serum toxic intermediates in isoleucine pathway</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24459c26-d408-4e20-ba9d-8ab34f430a3d">
    <rdfs:label>Study was Terminated (Interim analysis demonstrated the treatment was not effective)</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46ca9565-9ba9-4f49-a42b-3d01d8930588">
    <rdfs:label>Low cell autofluorescence</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/26b5b2c9-b572-4dc1-a24f-0ffcf8e340d8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09081</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/735e2d37-dddd-4b20-a807-9b2953cc34dd"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/667007de-3083-4d61-b403-fe6d8a4b6556">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17573650</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3e394a20-247f-4db1-8b0e-e164d248e783"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b825356-3adc-48d0-9569-aa588ac017f6"/>
        <obo:RO_0003304>"m.3460G&gt;A, m.11778G&gt;A, and m.14484T&gt;C"</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00747487</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d992690c-733e-40cb-a209-2d0072a0cd93"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/931a6903-0271-4ef7-b8f0-d2f415ec0823"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/300ad90f-3655-4fe7-ba66-057e7c40a527"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb77d0cf-35d2-423d-b15b-3106ca5cd2fa"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
        <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b85f9e89-a329-46f6-9092-5332fae8725c">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/931a6903-0271-4ef7-b8f0-d2f415ec0823"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/de03cdb0-7875-46bc-aee1-7f519f38d751"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00887562</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Idebenone</rdfs:label>
    <dc:identifier>DB09081</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5fc114fc-a4df-4aed-ac1c-bd0b73310e31">
        <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/931a6903-0271-4ef7-b8f0-d2f415ec0823"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b02b79e0-6533-4495-b577-b4e8e67f46e3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003473</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low energy level</rdfs:label>
    <dc:identifier>HP:0003473</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/503cb4ad-af94-4661-b115-a0cb51d7e86e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5bccca2b-e447-4bd8-a8f1-41d64c34678b"/>
    <dc:identifier>DB01032</dc:identifier>
    <rdfs:label>Probenecid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01032</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e0cc1ded-df6e-4719-8a5a-14b8510027a9">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
        <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/243ed329-3a10-4833-8292-10f2c0378134"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8ad89e8-e71a-435b-b3f7-1ecc7a9ab0c6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301530</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e043ecaa-cab3-4222-8a93-7b5c38e58dbb">
    <rdfs:label>Disaess progression(Progressive)*</rdfs:label>
    <dc:identifier>HP:0003676</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/418ab40e-4825-423a-96d4-0880465e75f6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12373585</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29b2b044-fdce-4971-b811-19d5135a0d72"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e9373b17-00bc-43e3-98f5-a69cf42a1769">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/df310fb4-5939-41ad-b6dc-a60673ba7117"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec89e6c0-7a08-4281-8402-61623c0663f0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f0d1d267-4605-4a98-94b1-e3e3bff54301">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20490928</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0003304>R266K</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>H65R</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c9155580-ba80-4c9a-bede-62d47f2c909e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/12453dbf-3ad7-4e32-87f9-9b32c31ed3fd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0003304>R125Q</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ea6d9d9-8d88-40a3-8ea2-ecbcc1e4a717">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <dc:identifier>HP:0012379*</dc:identifier>
        <rdfs:label>Misfolding of cystathionine β-synthase(Abnormal enzyme activity)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1cdc586e-0792-410c-b1cf-466633453272"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/caac4fe9-52be-4343-a986-003e95c7c7f3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01406977</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b250bad-931c-4456-8a7c-53155bcbd5f9"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae6973c4-a629-4d2b-bf3b-20022dcb8589">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>bone weakness</rdfs:label>
        <dc:identifier>HP:0002749</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002749</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/755b2bf3-d0aa-465c-9eaf-2ea651ba21ba">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dbf64387-eb6c-4225-9b35-51cd7effe7ef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e929394d-6c72-4ba8-96b3-2ffc01b630f2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9712f2a2-c5c0-464c-aefd-471bb732e65d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004349</ddiem:url>
        <rdfs:label>low bone mineral density</rdfs:label>
        <dc:identifier>HP:0004349</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
  </obo:DDIEM_0000015>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ff508487-4b5e-46a0-985a-7d6eb752c5be">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76ecfba6-e996-4122-813d-98e08d13cf16">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:label>high  Chitotriosidase Level(Abnormality of lysosomal metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004356</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f3404d3d-4c95-4f34-8e11-43994992d83b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/de664994-88d1-40a3-90b2-1a703eeff22a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/112580dd-b155-4757-98fa-02e8f52070f8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>primary low heamoglobin level</rdfs:label>
        <dc:identifier>HP:0001903*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f53af980-5c6a-4deb-9935-9f7e4e43fb58">
        <rdfs:label>elevated Chemokine Ligand (CCL-18) Level [ng,mL]</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a66e8c4f-08fc-42d6-83cf-fbeb0cccf39a">
        <rdfs:label>high angiotensin- converting enzyme</rdfs:label>
        <dc:identifier>HP:0000841</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000841</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c80b4d8-49c5-406f-8f29-8cf409faf399"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT02770625</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa153830-03f8-457a-920b-358d8c7c3c8c"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38da0a3a-29bd-4d3e-9754-5086341db422">
        <dc:identifier>HP:0001744</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>splenomegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9951f54a-7d65-4537-baad-3e439843057b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220120"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9a5535b-2a1c-4698-a6b8-5d875556eec5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26247153</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46548bdd-00e3-42e2-9f2b-49ad41d58efc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>http://www.scielo.br/scielo.php</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/5215a4d4-fc42-41cf-a263-c9e323a5e357">
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/730f68e6-7db6-46eb-9292-981074a7f8ee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c0ee1069-b8cd-4661-b8f8-3084a84f88ef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5475389d-b1e3-46da-a8df-0cee74892bc9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>neurologic deficits</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29688815</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d72def93-23c6-47a1-a8a9-c4c5b5711616">
        <dc:identifier>HP:0002540</dc:identifier>
        <rdfs:label>loss of ambulation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca1b21e0-f1dd-4101-a903-4758b2248b1c"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d281a535-15f9-4603-ac34-65ae98e75eb0"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4668a898-948b-4470-8d3f-aaee1e152565">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurological disease</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/264070">
    <rdfs:comment>Protein and phenylalanine restriction should be maintained in order to avoid disease progression.</rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3e1aec0a-65e3-4405-8bfa-60c379534827"/>
    <ddiem:iembaseAccessionNumber>6</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/264070</dc:identifier>
    <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/6</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9ce7f257-f12f-44ff-bacc-1146b10cf7bd">
    <rdfs:label>Rilonacept</rdfs:label>
    <dc:identifier>DB06372</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06372</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a26f09a8-504d-4879-b88e-dbb38478c52c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07da2db9-fa15-4f72-bbf2-58f43f73d95f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4821bb6b-81f7-4984-b3f4-4f2ae99708fc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
        <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7dd5bee8-a3ac-4dd1-9a3b-caaabdcfa01b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba1dfe92-daf2-488a-944a-dfb0220cd874"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02520934</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0a0a4c2-e126-4b78-9200-90ae17ac586a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0baeacd9-ac6c-4714-a987-07abb47df2a1"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f3404d3d-4c95-4f34-8e11-43994992d83b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a896443-36b5-41f4-a030-4a038a89e7e9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <dc:identifier>HP:0002069</dc:identifier>
        <rdfs:label>generalized tonic-clonic seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17433057</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f0e3ca00-e37f-4f19-b977-1ebd02a21fb1">
    <rdfs:label>ISIS 703802 (AKCEA-ANGPTL3-LRx)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c86485cd-da75-4324-9ac0-da8de090d6c4"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/64aa090c-abde-409a-863d-f92c3e63c815">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/14943264-34b9-44b1-a847-03244b8842b1">
        <dc:identifier>DB01076</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc28eb65-0925-443a-974d-e8ed24c4375a"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e186f153-45ec-4a0c-a721-78b247965a43"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01076</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/479e5835-7538-4351-b310-590a64ad060e"/>
        <rdfs:label>Atorvastatin</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bef15350-cd2d-407e-8c6d-33dde0b8730d"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4c5d1be6-cabe-4c2d-96cd-df5e4fe5c901">
        <rdfs:label>Bezafibrate</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bef15350-cd2d-407e-8c6d-33dde0b8730d"/>
        <dc:identifier>DB01393</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ddccfdfd-7b31-46f8-9c4d-1a50e9fd92e3"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01393</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/89cbfa4e-0372-4e08-8343-63a6f7d2b376"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b5db0363-d1b5-4643-b4f1-f4e98a7c72eb"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/342e0104-c713-433f-a2c7-d3e5d8b49d40">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37753791-aaac-42b6-8d6f-a3c87adec1a3">
        <rdfs:label>Amyloid deposition</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003216</ddiem:url>
        <dc:identifier>HP:0003216*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b515eaf8-34ce-4b70-87e2-18f1c58cce6d">
        <rdfs:label>Low circulating levels of free sialic acids</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012363</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012363</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b15a00e-8c4c-4bc4-9e6d-e2783a2efb88">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012350</ddiem:url>
        <dc:identifier>HP:0012350</dc:identifier>
        <rdfs:label>Decreased sialylation of muscle glycans</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8d171777-02a6-494e-989d-41db811c4458">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f09a14a-d56f-4a7d-ac8a-4d4c830a21c1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7044cec3-83f0-4261-a374-ed44b4348882"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605820">
        <dc:identifier>https://www.omim.org/entry/605820</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1299</ddiem:iembaseUrl>
        <rdfs:label>NONAKA MYOPATHY; NM</rdfs:label>
        <ddiem:iembaseAccessionNumber>1299</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/89f43dda-fa23-427e-a77b-68a4c040eb6a"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02346461</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84bcb46c-49e2-49a6-af10-16fa27a4272e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003233</dc:identifier>
    <rdfs:label>low HDL level</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c2c7564e-b75a-4b1f-80d9-f403b39b015f">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/39a83564-85eb-4518-b07b-a2768498e538"/>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68101e8f-05cb-42b8-8b1a-836b4f3b17df"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3940717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e23094b-609f-4c1a-92a4-d94bac2f3e19">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002415</dc:identifier>
    <rdfs:label>Leukodystrophy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ecc88989-d95e-4041-935b-aec94da5e1dc">
    <rdfs:label>Lithium citrate</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9ecc736d-2590-4c5e-8a3d-80265b0f0b29">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cb5c1cbf-a2c4-4d10-9fbd-ab90e2085e08"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ee74172-9eca-4587-ac16-95c2efd185af"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28202261</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB14507</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14507</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/56de1a0d-943e-4e1c-ace4-5b220c9738c3">
    <dc:identifier>A11EA</dc:identifier>
    <rdfs:label>Vitamin B-complex, plain</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EA</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/797d5669-3118-4aee-a858-826c1c4eb8bc"/>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/08b21dba-390e-43f3-b274-932d7d6dadbc">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231690">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/537</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ef720db8-d282-4336-95b9-e3699f62303a"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GLUTARIC ACIDURIA III; GA3</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/231690</dc:identifier>
        <ddiem:iembaseAccessionNumber>537</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55cb595f-634f-450d-aeeb-bb23bba5a121">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Bacterial glutric acid production</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766179</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9f18b2a-8911-4dc7-9b99-08a2bdb73ce8">
        <rdfs:label>Cyclic vomiting (Vomiting)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002013</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002013</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac5799d5-cc35-4d20-8974-81ddc715cc9c"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c499d5d8-aa14-46e9-9394-c13a9639ac8e">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d281a535-15f9-4603-ac34-65ae98e75eb0"/>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/38be0675-ba8f-4b03-8801-a7f903e0e5e4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
  </obo:DDIEM_0000007>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/40f52608-d9ad-411b-8ffa-29ae70c413cc">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8f1afddd-b0e7-4740-8ca1-8fcf97d891f9">
        <rdfs:label>Testosterone</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00624</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fcb473d7-023e-43b0-9ec7-2be7e00a0005"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1f483195-3c96-47f5-9442-b4526d38d562"/>
        <dc:identifier>DB00624</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d999daf3-f2da-466c-948f-72c77e65e94c"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2ecf762-8414-4b46-8032-0f12248f900c">
    <dc:identifier>HP:0002149</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>hyperuricaemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ce3a15e3-16b8-487e-9402-04eef77ad35f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf492b00-c36d-482c-8571-7aecc0a5d1ff"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b476e67b-24eb-4cb8-9d51-6a6132bcff16"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/3f7dd9b7-e5c2-4fdc-a3f2-c34efd780b88">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12837870</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610006"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6bbc8d0-3608-4314-88fa-9f7b3df3e22d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d5fab875-7c46-4464-8cec-2c64c025d9d0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000009>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c54c896b-db96-44fd-b360-49e1ebb86816">
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>Abstract</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1110863016300763</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/438321da-7963-4ab7-8690-5f1aa3887810"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b898fef3-7a50-49e6-b9db-f18f38c8280e">
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <dc:provenance>https://pdfs.semanticscholar.org/3a8e/bd8dda73113f384215ca26d7df0fe61441a1.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1480</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c19f091c-fc6f-4dcb-ab89-bd30f8562faa"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/57448952-cc8a-4c23-bf72-29080ad77cf8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36b1cce6-1fae-4a4c-9e79-c5c2376d2a4b"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/2fc743bd-1e81-4851-93ea-640fb9bfd7f9">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17968484</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6bbc8d0-3608-4314-88fa-9f7b3df3e22d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10485305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155631</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7851807e-6c03-434b-bf3f-41271a0d937a"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2583520d-d3be-4570-a15f-80c607fb8f5a"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b502f9a5-d3ea-4bff-8867-96c18d8592d8"/>
    <rdfs:label>Levocarnitine</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d9a4e906-0f0b-4e37-8fe4-049a47706614">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c086b95-78f9-4339-8bc1-342d342a3b9f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00583</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1dd5a056-2302-4c63-ba80-add87e962e55">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71a6d526-76b5-4335-858b-d3431cef0bf0"/>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4740b575-1f51-48d3-944e-2b55878a6065"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7321cdc3-9cef-4253-a8cb-ce308972349d"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/eb295f1d-a889-4d90-abea-e24bad804f43">
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c2d99e2-5cd6-4123-901b-21bde3603abf"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7f6f7ddd-0da2-4856-8428-c5d0ab1d8bc4"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/288ba401-5b26-41bd-95a5-28a8970e2636"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a883f259-41b1-4624-a614-6a4d278cd75f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8e2d9875-b3bf-4dd1-8b85-877238b530ef"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04aa6534-e231-42e4-ae3b-47dc818537ad"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/e5f825ca-4a49-478a-942e-949cf3bd32cf">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e5ca86d-f24e-48fb-99ea-07ad3330f49f"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a70f2f26-a195-4dd4-8598-676d0d2195e9"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8c572c61-c618-4ef8-ab2d-1d0a164fbd2d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9b4e8a62-bf89-4721-a1df-cd48265164ec"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00583</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/756d1482-55a9-4481-b0fc-1650a0716690">
    <rdfs:label>Noctornal difficulty breathing</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
    <dc:identifier>HP:0002098</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f07bc20-7e93-41a4-9b25-49aab7715aff">
    <dc:identifier>HP:0003281*</dc:identifier>
    <rdfs:label>high brain and liver iron stores</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/70404064-330f-4f0f-a6bf-7b739801e7ff">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8ad89e8-e71a-435b-b3f7-1ecc7a9ab0c6"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5296b6d3-94cf-496b-9f0f-851435fed790"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff2d375d-1ef9-42d4-9b88-f45f82e47546"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
  </obo:DDIEM_0000010>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/c9e1296d-512c-45c7-9a2d-1d3fc4c41d23">
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ffebcfa-f201-410d-8e07-396d0d529147"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b15a00e-8c4c-4bc4-9e6d-e2783a2efb88"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8d171777-02a6-494e-989d-41db811c4458"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c3656336-d843-4d94-b1b1-7a19e5bff86d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/28eaa3e9-984a-4ef2-b762-d17939b2611f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/791e510a-5f54-4c05-93ab-1f3548766b07">
    <dc:identifier>HP:0012026</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
    <rdfs:label>high ornithine level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32261513-76d0-4445-a8f8-d6f74f3f158a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Liver lysosomal storage abnormality</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4a132ed-af29-455f-badb-3d0c6a20a740">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Terminated (Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f7167c0c-714c-4d30-8c25-cb48fd4c7aaf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204200">
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/204200</dc:identifier>
        <ddiem:iembaseAccessionNumber>307</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4c94be1a-9f11-4b65-87e6-133ce8f588e4"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/307</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46ca9565-9ba9-4f49-a42b-3d01d8930588"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1de59c80-f7e0-429e-9191-4c8b88a1fb36">
        <rdfs:label>membrane fluidity alterations</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbfa4b51-db4e-4b5c-902e-1a26fe809488">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Blood-brain barrier (BBB) impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/705b78f1-b396-44ae-b238-e11882c853c4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/30ec0e1b-03e1-44fc-a54f-3286be14de2e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd24445a-e761-4124-b742-5e2e20c58652">
        <dc:identifier>HP:0011018</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011018</ddiem:url>
        <rdfs:label>extended G1 interval</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29660499</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aafb630a-2e7c-4676-9663-9a7711df6cf6">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/558b5112-2b1b-4832-9ed6-cf1647ede665">
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f36819e6-3d96-4b4b-ab31-51464cad14e5"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277410"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a2b9f44-ca01-42fb-b172-b0cf04fb5487"/>
    <rdfs:label>Vatiquinone</rdfs:label>
    <dc:identifier>DB11917</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/edb180b0-d634-4f4d-8033-5ba19b8ea6e7">
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f36819e6-3d96-4b4b-ab31-51464cad14e5"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72d43680-393f-45b9-9226-6175be214012"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11917</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d712f439-7393-4324-affa-fa99ca89c832">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2e0af97b-b69c-4e56-b3ab-2b135c560a56"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ce3758b-6596-4268-b2fc-e08ccb5e6e1b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100022*</dc:identifier>
    <rdfs:label>Abnormalitilty in voluntary movements(Abnormality of movement)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb568912-4c79-4d42-936b-2b16d420e8d9">
    <dc:identifier>HP:0003236</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased creatine kinase activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9ce4cb72-1df7-4039-9fe5-b7eff15e67a9">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e8dabcf9-a90e-4613-890e-14845b3dad49">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/be914773-1d6a-43c2-bac0-6d25abdd0106"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28958576</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ebf7c6e-1e24-45c4-8ee0-62b2890c8236"/>
        <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d06b68f5-f5b8-4c9a-965e-3692ce152e0e"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>GNeo-IDUA</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74cdff4b-823e-4172-b679-89397f4c29f2">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04854</ddiem:url>
    <dc:identifier>DB04854</dc:identifier>
    <rdfs:label>Febuxostat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c2bb701-f9ed-4d3c-a200-71936c83da2e"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0cb3f6b4-f878-49d6-a956-2ceaf07c6025">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24848070</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7f2e40c5-c2c7-4670-8790-c0c6e5aeb1dd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/89e490b4-18e1-41e8-9ea4-fdd7d1750f76"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d76a5c0c-8c91-40e8-854b-087b57692335">
        <dc:identifier>HP:0005978*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005978</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PCBD1-diabetes (Noninsulin-dependent diabetes)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/264070"/>
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6b42f453-00fe-4555-b93d-ee3a58dc59df">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7b7c7180-1f2c-40c5-9414-934b6cd05001">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9721226b-b6a8-4c13-89f8-4bc448a68cb3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3728152</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/097f6e6f-7d29-46b9-81bf-daf2835f4706">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>No result was accessible</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b8fdf3ac-a47e-4c09-a7b0-6d6840e94392"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/657d159a-f0d8-40d3-8bb0-22f616721793">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/050e4ad7-9522-4300-8597-a6cd502a6274"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e5ca86d-f24e-48fb-99ea-07ad3330f49f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e394a20-247f-4db1-8b0e-e164d248e783">
    <dc:identifier>HP:0002171</dc:identifier>
    <rdfs:label>Gliosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002171</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa2e5b93-8284-4c0d-89ce-124c136a3cd7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
    <rdfs:label>progression of neurodegeneration</rdfs:label>
    <dc:identifier>HP:0002344</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a742266a-8ec3-4e29-9788-d9c701db2948">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:label>Neurologic abnormalities</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2ecfe815-173d-4f8c-b676-d3ab78f0f432">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608013">
        <dc:identifier>https://www.omim.org/entry/608013</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20e645ce-1935-4826-b4d5-d1df5b464a51"/>
        <rdfs:label>GAUCHER DISEASE, PERINATAL LETHAL</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ea835101-844a-4479-9d15-eb4a1dea965e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e3b0fc2-a2d4-4924-8993-0e94b62c9de7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c80b4d8-49c5-406f-8f29-8cf409faf399"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1e77ac9-9d7d-4ea3-9c34-da4299e1e8eb"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b277fb74-fafe-4c2c-8942-1e5d8ca958a4"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/45de394e-39f0-48ac-bb6a-d3ae8b56fbcc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f738d10e-1ab1-4316-9743-5445913f5308"/>
    <dc:identifier>DB00672</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00672</ddiem:url>
    <rdfs:label>Chlorpropamide</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/86eaf9ff-afc6-4b23-909c-ce313f1c0d87">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585269</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/29f60cc8-d202-47c6-930a-1699125e448f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f1a93807-f7ab-4a06-ac32-884eb698cd15"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23040521</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11fd1364-acae-4cea-aa04-43460e590a88">
        <rdfs:label>abnormal hepatic function tests</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90702586-1063-4a62-932a-e7be3aefefbc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
        <dc:identifier>HP:0008281</dc:identifier>
        <rdfs:label>Acute hyperammonemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/727a886a-6723-41c2-9c05-0715e88a4c68">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
    <dc:identifier>HP:0001903</dc:identifier>
    <rdfs:label>low heamoglobin leval</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/32904b23-1449-47d5-96e8-1b15910deea4">
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/71eb452d-fad2-4c8e-930f-fc4fb9882df7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/31456f30-5dca-407a-bcd4-e4a550a5afd6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42d44b81-31ca-4c95-8a85-2510f5d4da20"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9559978c-f7e7-45d7-a09c-e9ac804b0a6b"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/680ba767-34c4-4ca8-b281-0a88150c19d8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f93fb2ef-4fcd-4817-b472-8e096ed9d975">
        <dc:identifier>HP:0002829</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002829</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Arthralgia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2bae0e9-fec0-4c02-8455-01c251e0eff2">
        <rdfs:label>Arthritis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
        <dc:identifier>HP:0001369</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f264601f-32a2-4493-ae0c-f8db1f8b34c9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a9cbfeb7-315d-4b44-82e5-b568cbf2d9fd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/076079ac-f87b-4005-96ef-7561a6a159cd">
    <dc:identifier>MP:0020582</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High cermaide level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/effa7e6b-1f00-435e-9a4c-cf2645299380">
    <rdfs:label>Tuberoeruptive xanthomas</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001013</ddiem:url>
    <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
    <dc:identifier>HP:0001013*</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4ac7822c-49d2-4571-9d0f-19658a9a21a4">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5131d15-399e-467e-9f36-6d2ec021541a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Palmitate plus lactate-induced cell death</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d344c0d2-8200-4008-ba22-de4a35ccf146">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/61799d9a-7406-4a64-a180-1f363abf9f7e"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ebdb9a9e-1371-4217-85da-84b1a352c175">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1aae468-62be-4e91-be9c-f090e134a32f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d271fa0b-3356-4a83-986e-2604015d9867"/>
    <dc:identifier>DB01068</dc:identifier>
    <rdfs:label>Clonazepam</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d42962a2-7833-4154-8532-982382402835">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756475</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/79daa1d4-64f5-4578-b028-21c1505064f4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac671000-9beb-41fb-bb25-3428296ff70f"/>
        <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1c62876b-0bf3-4ecf-afa5-a71adcdcd0fc"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9e999c88-d877-46f2-a65b-e5a92aee5f8c">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/90b1c9f8-f705-44e4-b2c7-72ee7934fc28"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/79daa1d4-64f5-4578-b028-21c1505064f4"/>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/912d4571-a9bd-41ea-ab33-a3a4443769a3">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5da22643-0ef0-4c64-9963-5f5584de3659"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/41df5f33-1dab-4d94-818b-ab20ddfe61c4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14981187</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01068</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c30e2a28-c40d-4071-9647-fe3f4ffcbc30">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004295</ddiem:url>
    <rdfs:label>Gastric mucosal atrophy(Abnormality of gastric mucosa)*</rdfs:label>
    <dc:identifier>HP:0004295</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000008 rdf:about="http://ddiem.phenomebrowser.net/a169cd09-bdeb-4a62-a71e-cec7aa99dfe0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b97f0d4d-708b-4743-a786-413025edd26a">
        <dc:identifier>HP:0003198</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>myopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2924a4ea-7a1d-4b90-b550-d2b329b313db">
        <rdfs:label>delayed growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b03fe735-b584-4f2f-9f0f-371941d10889">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/78a91cc3-c5d5-4ea0-aafa-4fec0dcffb16"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8245377</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb730ef1-3b9d-4b49-8066-073296723a9c"/>
  </obo:DDIEM_0000008>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/245680fd-271c-43c0-a0b7-ef5b106c8625">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75c3e08b-c1d7-4340-80f4-d6fa798d183a">
        <rdfs:label>High VLDL triglycerides</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc7784ce-2b56-4cb5-aadd-9619ce723c61">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:label>high non-HDL-C (Abnormality of lipid metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/37cea92d-a8a9-45cb-98e1-1177132bdf27"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a7722b9-2c6a-4b45-99ec-3a054d800731">
    <dc:identifier>MP:0003193</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0003193</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal cholesterol efflux from cells</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cf164f8d-6f6e-4620-bb5a-a93349169edb">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e5b73543-3fbe-43e4-9d38-9a61165743e0"/>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90b1c9f8-f705-44e4-b2c7-72ee7934fc28">
        <dc:identifier>HP:0011167*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011167</ddiem:url>
        <rdfs:label>tonic seizures ( Focal tonic seizures)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615398">
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1147</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/615398</dc:identifier>
        <ddiem:iembaseAccessionNumber>1147</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6ee0847e-3470-43fe-beae-5eb5ce8afb41"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f085ddb-4926-49bc-9838-bd6ffa02161e">
    <rdfs:label>High α-ketoisocaproate level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cd9367f-66ef-4af3-8763-f2f24d11c540">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004364</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004364</ddiem:url>
    <rdfs:label>Abnormal renal nitrogen elimination</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b4280f1-49b2-4418-a441-75c943ec66c0">
    <rdfs:label>Low IQ score</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001249</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d06b68f5-f5b8-4c9a-965e-3692ce152e0e">
    <dc:identifier>HP:0002180*</dc:identifier>
    <rdfs:label>neurodegenerative astrogliosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/bef15350-cd2d-407e-8c6d-33dde0b8730d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/64aa090c-abde-409a-863d-f92c3e63c815"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21354122</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/756e35cb-9bc4-4c88-bd26-ff16be21f371">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Atherogenic dyslipidemia(Dyslipidemia)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <dc:identifier>HP:0003119*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dc57c075-c6cb-4d4f-a2c3-401d8e37a049">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6cbc708e-9b7d-45ea-af3e-87fdad26b808">
        <rdfs:label>High total plasma cholesterol leve</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/37cea92d-a8a9-45cb-98e1-1177132bdf27"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2702860</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/817dfd47-a510-4baf-8122-f4c84bfc2b1d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee53194d-2d8f-4552-a5ea-15916a8b73e9">
        <dc:identifier>HP:0012238</dc:identifier>
        <rdfs:label>Hyperchylomicronemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012238</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc920f3f-c399-413e-9547-2ca69a099fda">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated LDL-C level</rdfs:label>
        <dc:identifier>HP:0003141</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e00d529e-8a0a-44e4-a1fe-83d4757779f6">
        <rdfs:label>Low HDL-C</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/effa7e6b-1f00-435e-9a4c-cf2645299380"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c869d736-15b1-4df4-8d24-96a64ab34c9b">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18645163</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/255120"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e02a3859-f26a-4e60-b046-a78611a24273"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e29db0b-a44a-4f67-a033-518d38054748">
        <rdfs:label>abnormal SF-36 physical composite scores</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a5586b2-afeb-451d-b0d7-3c5f07770d7f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f56c2fbe-c27c-4d65-8825-8c601849cde7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>PMC2676979</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a70b01f-5c45-4b72-ac2b-df87f9fd0330">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010876</ddiem:url>
    <rdfs:label>Defect in protein synthesis (Abnormality of circulating protein level)*</rdfs:label>
    <dc:identifier>HP:0010876*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6ffb08df-b6e4-4610-b457-9b896219b2b8">
    <rdfs:label>GNT0003</rdfs:label>
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/40998f2b-ca5f-40b0-a310-4e50c149636d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c9efebe-ad53-48ae-b0b4-ce21bddca905"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a724f22e-5d97-4043-bb2f-502fca95987b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/8e6f3abe-2612-4cf7-a7bd-f782235993be">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28213743</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96885fc1-34dc-4f2a-bce4-8518ee81334c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031799</ddiem:url>
        <dc:identifier>HP:0031799</dc:identifier>
        <rdfs:label>Decreased apolipoprotein AI level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bd2f082-8db1-48d7-871c-89150614de4b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002633</ddiem:url>
        <dc:identifier>HP:0002633</dc:identifier>
        <rdfs:label>Vasculitis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d4dcc7e-f145-442e-a4de-616849bdd37a">
        <rdfs:label>Arterial pluque</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002621</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2434def5-dc2c-484a-8b7b-68c432973069">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9f1ca712-c561-4172-b6e9-ffbae99285ac"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/896688e7-6206-4ef0-a71c-151cfbe54f91">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:label>Decreased plasma HDL-c levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00055442"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f0f62ff-c25d-4582-ad6e-bc1769527aca">
    <rdfs:label>Niflumic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04552</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/af3a20b2-566d-4246-bc22-6d53d8cfe75f"/>
    <dc:identifier>DB04552</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9ec8a4b-73ed-49f4-ae82-1b1d1fa4ed67">
    <rdfs:label>Lysosomal expansion in neurons of deep cortex</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004356*</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/e8385b0a-4e9d-4bdc-9b2c-0f79a3fa3226">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc48ef98-5434-42d2-9b20-7d4c68da2cee">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003117*</dc:identifier>
        <rdfs:label>Serotonin deficiency</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2b61387-b1b7-4463-9836-e5ec6d785004"/>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c261ce57-0baa-4172-b5e2-84dc3acaf7ff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac671000-9beb-41fb-bb25-3428296ff70f">
    <rdfs:label>Involuntary movement</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004305</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2b3bee94-42ee-43e0-8e6f-a45434136608">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d8dbcbc-6052-4ab2-bd22-a2dcca1b10b8"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b998d9f1-b897-4c4d-b9d4-8b08dabe836d">
        <rdfs:label>cerebral folate depletion</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012446</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/43be8a39-0201-4105-b8c6-418392b0a40b">
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a43f9b1e-a89b-4dbc-b429-63a19d564618">
        <rdfs:label>Defected mucle plasma membrane</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c1db53f-f606-4885-898a-780dd5e1f37e"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c245a0c6-ea66-4a98-8253-fa02d7ee1796">
        <rdfs:label>Defected neuronal plasma membrane</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7748366</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0757f199-d9dc-4f21-97d3-4be93340a776"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/698d32ca-e3b8-45aa-bbef-890811bc86a4"/>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da3bbf3c-7ef5-4230-86ed-19dc8451ef5d">
    <rdfs:label>Tizanidine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00697</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/40dda43a-a1e4-459f-b182-5d569a828550"/>
    <dc:identifier>DB00697</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/275d7605-0c5f-437d-9e57-353496b9268e">
    <dc:identifier>DB14751</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14751</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/895fe58e-b5e8-4aaa-9482-1c4df26c1989"/>
    <rdfs:label>Mecasermin rinfabate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79ab3ecd-d255-40ee-838d-5fd353a9377a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100851</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100851</dc:identifier>
    <rdfs:label>Behaviour abnormalities</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c19f091c-fc6f-4dcb-ab89-bd30f8562faa">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003234</dc:identifier>
    <rdfs:label>secondary carnitine deficiency (Carnitine deficiency)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/dd6abc63-1592-46ae-9079-ad56adf14e7e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07c2259f-20df-4f9c-ad9a-9e7425ce0691">
        <dc:identifier>HP:0000704</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000704</ddiem:url>
        <rdfs:label>Periodontitis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e42592ce-0c43-4ba1-a4b1-87f708085a06"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6750ee3-f3c8-43d2-9a30-770b3a740542">
    <dc:identifier>HP:0005952</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased pulmonary function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241200">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/146de796-7979-46ab-bd73-1abc442f739f"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>BARTTER SYNDROME, TYPE 2, ANTENATAL; BARTS2</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/241200</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07cd2096-4dfc-470c-a03b-f2fc0265f3c1">
    <rdfs:label>No Studies were done on this drug.</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/116596db-d7fd-49e7-8a45-4a76352f16e9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2249d6d4-77f8-4a7a-8c6e-b54419b82903"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08909</ddiem:url>
    <dc:identifier>DB08909</dc:identifier>
    <rdfs:label>Glycerol phenylbutyrate</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9a1b3d1f-adab-4580-a047-57dd15741699">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241510">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a94bcb4c-d724-4c97-85db-f121cee5e4d1"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/241510</dc:identifier>
        <rdfs:label>HYPOPHOSPHATASIA, CHILDHOOD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/56cc5489-3bd8-431f-bae5-b3abb63fbbaa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/beefc986-da24-4a19-86f5-826cd2627516"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96bd1b96-c153-47e3-8ede-dfa41361d2f6">
        <rdfs:label>epilepsy</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316461</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac87aea3-1b3b-45f9-91fc-589373b2af5c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High serum GDF15 level</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9f1623fa-17a0-4d89-a03b-190187934b43">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/02f4b1ea-6f6e-4711-b41a-a7d0126be09a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d3f8bf61-5992-4592-a0fb-723a7107375d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10048-015-0444-2</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/179d516d-54cf-45f7-bc7f-eca1557fb4cc"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615395">
        <rdfs:label>COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16</rdfs:label>
        <ddiem:iembaseAccessionNumber>961</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/615395</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/69aa418d-2138-43ea-8f4a-56e67e29b660"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/961</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfdccb8d-7c2c-4566-ba8c-f3ed695e8814">
        <dc:identifier>HP:0012378</dc:identifier>
        <rdfs:label>low physical capacity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/caf71b6c-68e9-454c-992d-9b6c5e7ea006">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c77aac69-5c8f-4164-bb21-128404cd10b4">
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:label>skin photosensitivity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/33760351-9bac-4d79-af63-f1864e350c3f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42913905-8d8b-4c12-b6fc-9a63b75627d3">
        <rdfs:label>premature degradation of misfolded UROS mutants</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4c9e6b0-cfd9-4f09-80f5-ff54539c1979">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <dc:identifier>HP:0012187</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high porphyrin accumulation in circulating RBCs</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334762</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37bb2290-1aa1-4718-aedd-ba8329fdb536">
        <dc:identifier>HP:0010473</dc:identifier>
        <rdfs:label>abnormal porphyrin accumulation in urine</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010473</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24145442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
  </obo:DDIEM_0000012>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601776">
    <ddiem:iembaseAccessionNumber>1130</ddiem:iembaseAccessionNumber>
    <rdfs:label>EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c3c6f8ff-917d-400a-8e47-b97899f3374f"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1130</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/601776</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b404fbb1-cc0e-4b9d-8119-42b8c1cc79ae">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6adb3af9-0a44-4596-a331-b8d175f3245f"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S0002962915356895</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac907aa2-37d2-4aca-88de-1e9bbbfdba65"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56299ed1-51f7-40ca-854e-78b6c53d0b87">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Six Minute Walk Test</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ef2ab2ac-5eb0-41ff-b892-e6e23b122df9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04159</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b2b54444-1bfc-4e79-ac85-c707a62bf08f"/>
    <rdfs:label>Beta-Hydroxytryptophane</rdfs:label>
    <dc:identifier>DB04159</dc:identifier>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/metabolic_disease_treatment">
    <obo:IAO_0000115 xml:lang="en">a treatment strategy or plan which the clinician beleives will cure or ameliorate a disease caused by a deleterious genetic variation in a patient, affecting their metabolism. It may modify some or all of its signs or symptoms, or alter the prognosis and course of the disease, either by severity, timecourse or phenotypic quality.</obo:IAO_0000115>
    <dc:creator xml:lang="en">https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:label xml:lang="en">metabolic disease treatment</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </owl:Class>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/fbefa59d-6274-4746-9809-cd1243da470f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a212a56-60ec-4265-8408-335ae9eca2e9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8d4c8048-d350-4fe4-98b1-2eaead55fd24"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e63c3b73-4fe4-4202-b317-d4f434d93f0b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000010>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0517cf6b-8dc1-40ab-adf5-02f2596bb32f">
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0d98d41-2b74-48ea-9731-6c13bccec654">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/438a0b33-ca48-49a0-add4-9f351e4dc105"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/11e461e4-10fc-4ce5-a7f6-5b668083b859"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230500">
        <ddiem:iembaseAccessionNumber>284</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/91b5385a-0db8-438f-b80a-b807753fa580"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/284</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/230500</dc:identifier>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE I</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ebeefc1f-eebb-4c30-9102-42abd610562d">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/344eef3f-4588-4083-8b1f-904b20ec5547">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4734b689-d6ff-439a-a1ad-3063e6b781fc"/>
        <rdfs:label>antisense oligonucleotide (VMO AED cocktail)</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/3af4de53-3080-4bdd-8a62-911c264aa0d4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab5fe614-de6a-4cdf-a287-5686de31eef2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Pathological apoptosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27329125</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26758319</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3d11fbe-9baa-4151-8141-6fc010e892f3">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:label>low hb level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e61ca603-c385-4204-8b7c-cc4a88cb8c29">
        <dc:identifier>HP:0025034*</dc:identifier>
        <rdfs:label>erythroid progenitor depletion</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025034</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dca02a0b-2fab-4f2f-90a9-07d9b0969aee">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012130</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012130*</dc:identifier>
        <rdfs:label>premature differentiation of erythroid cells</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/698d32ca-e3b8-45aa-bbef-890811bc86a4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/caa45d6a-0379-4a52-831e-6c7f77cdeb5f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>low quality of ife</rdfs:label>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/caa3f8f5-4663-4677-8bfd-40fe1f28d593">
    <dc:identifier>HP:0025521</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025521</ddiem:url>
    <rdfs:label>Abnormal Body fat composition</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/18b2fa95-d35e-4f1b-a8f7-04aacff79969">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb24e0a4-2374-4832-b0e3-96ee1dd12a0b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Unified Parkinson's Disease Rating Scale (UPDRS )score(Abnormality of neurotransmitter metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7221f3c3-fa39-4562-8ab9-419a7999f3f2">
        <rdfs:label>Behavioural Disability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b29c64d7-26dd-4650-a436-07a82c1c56f6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:label>Movement Disability</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19704083</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b41c6fc-964c-4b9c-ba1e-b2b3004f386a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000870</dc:identifier>
        <rdfs:label>High prolactin level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c66b905-7861-425c-ab5c-c634487728bd"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/aa99cef8-9fb9-4fa0-b454-b9884e64262d">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/993268e8-f6a3-4c77-9d63-71165b666b85">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/890f6522-4cbc-49ca-be86-a4362391f6a7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f047a774-cd71-40b6-b32e-89af0de1bf9e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High CSF MAN2-oligosaccharides</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609458">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ee5580bd-7602-45d1-83e7-e8161ecea5ac"/>
        <rdfs:label>MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/609458</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5eb8c926-24d7-434e-bf43-d7462984ca55"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83e3b1c5-282a-496d-b6db-bf1a4c6e9cba"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e54f5ee8-8b22-4bb2-80fe-907391a06f2b">
        <rdfs:label>Low FVC%</rdfs:label>
        <dc:identifier>HP:0030878*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030878</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0b2ab47-163a-47da-b296-8358ba98dcf1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated GFAP(Glial fibrillary acidic protein) level in CSF</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ffd4deb-599a-452f-a98c-70cf1f29bbdb">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High NFL (neurofilament light signature ) in CSF</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01681940</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eacf0656-6cc0-4e28-9163-5cb7669ec5f7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:label>Reduced pulmonary function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bb9832d0-db30-444f-a6de-7decd9ee893a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4e62b4f-6170-401a-9efd-b5a397dbb8de"/>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eff4a4ba-7a5f-404c-a462-2e7fc0e2a729">
        <dc:identifier>HP:0004918</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004918</ddiem:url>
        <rdfs:label>Metabolic acidosis (Hyperchloremic metabolic acidosis)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c65fb4e2-8bb3-4dd0-be7f-49f3d8f771d8"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ca924aa6-2f2e-45a1-834a-40cf214253f0">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7383c373-1c42-4efb-a866-f25a2b3a3c83"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ffebcfa-f201-410d-8e07-396d0d529147"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9d582de-5c0a-4a11-a256-5e07c7070c1e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Muscle inflammation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
        <dc:identifier>HP:0100614</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb518fef-6976-4d8a-9d42-a23f85f69a4b">
        <dc:identifier>HP:0003713</dc:identifier>
        <rdfs:label>Muscle necrosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21726969</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601780">
    <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/601780</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b05a3e90-e2ba-4638-9eb9-6d3cee066d3d"/>
    <ddiem:iembaseAccessionNumber>311</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/311</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/800e9639-8309-4837-8c2c-b91c795c0e20">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2c093f1d-9c41-482d-9e28-396dd911a4be"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15795909</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/613f3ae9-cb61-495f-8920-34d57ad9525c"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e708af81-cb94-4341-802d-3ed68a817986">
        <dc:identifier>HP:0031851</dc:identifier>
        <rdfs:label>Reduced hematocrit</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031851</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000008 rdf:about="http://ddiem.phenomebrowser.net/d708facd-54b3-49be-b2ad-f028e2834942">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffa3038a-246a-450a-8c15-04339991d6ed">
        <rdfs:label>high creatine kinase</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <dc:identifier>HP:0003236</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0194b000-0831-4a9e-b1f4-32cf39b88393">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011025*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
        <rdfs:label>low energetic state of heart(Abnormality of cardiovascular system physiology)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb730ef1-3b9d-4b49-8066-073296723a9c"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fb568912-4c79-4d42-936b-2b16d420e8d9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d111ccfa-e2bc-41fb-beda-476da24fb9cd">
        <rdfs:label>abnormal blood levels of ketone bodies</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3429cb8e-eaf6-4f41-b305-c200523748fe">
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:label>low energetic state of skeletal muscle</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0ce0e61b-4827-4c8f-a797-b0f4b9da5029">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/903462d2-82d3-4177-b95b-99aa1de313df"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62c152bd-998e-42db-85d5-d189a4d61df1">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004359</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
        <rdfs:label>Abnormal blood levels of  fatty acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000008>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74e9a744-cd74-47a2-8bf9-0b2a4a63953d">
    <dc:identifier>DB09393</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09393</ddiem:url>
    <rdfs:label>Amino acids</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/70dce652-239e-4028-adf4-e52874c8e000"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2fde3d91-6902-46ca-a6c4-cd72c569e9cc">
    <dc:identifier>M01AX</dc:identifier>
    <rdfs:label>Other antiinflammatory and antirheumatic agents, non-steroids</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M01AX</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/60410984-acce-4769-aebd-290766a0e015"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/37968c4c-67a8-4824-980f-e5e5ea18a08a">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b4eff64-8f36-4eb5-8b7c-7f210ce59df9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9195122</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f93fb2ef-4fcd-4817-b472-8e096ed9d975"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3581032c-5db2-419b-b628-9e63302523fa"/>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb4db383-456d-4556-a99d-670ba5e12b3e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1e50cf77-c19d-4b66-95d0-c1d64e806183">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e453709-1902-49f1-b87e-498fd25f8c97"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5380c406-a6e7-4641-a3bd-9e51bb83eda8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/acad12a5-7b29-4223-b747-aed7076d01ab"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/296d7146-5164-48f1-8bfd-6d73b7a5697b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1770278a-4990-4aa6-aafa-553aaf0b1e3d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Limitation of the Joint range of motion</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
        <dc:identifier>HP:0001376</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c667f817-3c55-4a17-91d7-c37b23030d7d">
        <dc:identifier>HP:0002111</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low Forced Vital Capacity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002111</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56299ed1-51f7-40ca-854e-78b6c53d0b87"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6750ee3-f3c8-43d2-9a30-770b3a740542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/715153a8-4770-47e5-842d-6da3958398bb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
        <dc:identifier>HP:0010535*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High Apnea,Hypopnea Index(sleep apnea)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00912925</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c80b4d8-49c5-406f-8f29-8cf409faf399"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aa16214d-2a07-421d-89a1-cedd8d6ac1a3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a3a066dd-96ac-42e1-832e-ad91dceebadd">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a1c87669-9ce0-46f9-adfd-6d643f47552f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb2bb3db-34be-4d7a-9c91-6082cc6993f3">
        <rdfs:label>Enlarged lysosomes in NCL NSCs and fibroblasts (Abnormality of lysosomal metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004356*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf61cdbc-ba59-42cc-942f-78c41fe16473">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/069f5cf7-1e7a-4a4b-a568-bb9b9bb7e107"/>
    <dc:identifier>DB08830</dc:identifier>
    <rdfs:label>Dehydroascorbic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08830</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20f819b1-463a-409c-b40b-b1203165d86e">
    <rdfs:label>Low serum testosterone levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_004017</ddiem:url>
    <dc:identifier>HP:004017</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b7434c0-7549-4851-8b23-228ce0fb527b">
    <rdfs:label>Abnormal lecithin:cholesterol acyltransferase activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:0011598</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0011598</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8f397831-e018-4812-8f33-af8b52e5174a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8bdb6b61-5b9f-4138-89c8-3d48de9078a8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a48fda36-7f88-4aa5-8bd1-2a4a9ce402eb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6de9720f-208d-4a49-a5f4-0c4ad22a5ccc"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/050e4ad7-9522-4300-8597-a6cd502a6274"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b0ae05fa-1957-44a8-ac1a-5aa99dce2bbf"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b3eb8cc-8331-4bc4-b045-a9512ae83379"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25558587</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3726733-25b0-4e9e-af42-a0800e091627">
        <rdfs:label>Tonic-clonic seizures</rdfs:label>
        <dc:identifier>HP:0002069</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/89cbfa4e-0372-4e08-8343-63a6f7d2b376">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1e7d2f0-c16a-4151-8a4d-3ba39e203737">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ER (endoplasmic reticulum) stress</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93996b7a-6442-4207-bb5d-cc8f78eb32f9">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012240</dc:identifier>
        <rdfs:label>Increased muscle lipid droplets</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012240</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c06f6f01-74be-41ed-9cfc-79c68f87c75c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5fed5815-61bf-45cc-94db-085601825efb">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003713</dc:identifier>
        <rdfs:label>fiber necrosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/268200">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b9ed7797-e613-46f7-b5ac-3eb37ba5a2fb"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/750</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/268200</dc:identifier>
        <rdfs:label>MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE</rdfs:label>
        <ddiem:iembaseAccessionNumber>750</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3859ccef-a4cf-4315-94cb-cc0c88a71d5e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5db1f51a-8465-4e4d-8b66-a1ebeb133640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4fdf5931-e425-4ce0-a412-a1a3a845c8c9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012405</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012405</dc:identifier>
    <rdfs:label>Hypocitraturia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9ff3c6b-2c5b-494d-9c58-ad3f974e18e7">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High remnant-like particle (RLP)-cholesterol</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2123dcd0-4c64-4a23-8dba-cd35f00280e5">
    <dc:identifier>HP:0002910</dc:identifier>
    <rdfs:label>Elevated liver enzyme levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a32c4c30-14e2-4d36-9001-d12c04816c94">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9718357</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a398f01-eff2-4ae8-bd5b-70956eba085c">
        <rdfs:label>Abnormal chondrocyte growth</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7be2207-9248-440c-b331-5c32d3323b2c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8df31bb-956e-4d1e-b293-0a2b091908f2">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004355</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004355</ddiem:url>
        <rdfs:label>abnormality of proteoglycan metabolism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd078890-d786-4409-80e1-76d60bc64230"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e7730218-6e60-4529-817f-db7e28c347b5">
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09aff4c9-0dee-4d5a-a754-b421fa657547">
        <rdfs:label>elevated intraneuronal cholesterol</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2e8db47f-953c-4f02-a129-47d1cdacd28b"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/076bb526-a86a-4498-bf76-087c81aa5cf9">
        <rdfs:label>CD failed to ameliorate cholesterol or glycosphingolipid storage in GM1 gangliosidosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8964b843-5af1-4079-8c45-ee5d2c455c99">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ebdb9a9e-1371-4217-85da-84b1a352c175"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/be895ad4-c298-459a-ab29-b49e0287a57a">
        <rdfs:label>Midazolam</rdfs:label>
        <dc:identifier>DB00683</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00683</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1aae468-62be-4e91-be9c-f090e134a32f"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fc934995-65ac-4357-a9f4-dc4d5c5e7053"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d92a9077-3572-4cb4-a2e6-3982b0483afb">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e5bdd56f-a47f-4866-bf47-82402ea36138"/>
        <dc:identifier>DB01174</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01174</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0da032c4-f7f8-4b57-84cf-e5161d3f2034"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/30942e63-41ed-4e84-87c0-fbf423fb9cdf"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1aae468-62be-4e91-be9c-f090e134a32f"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd92846a-5e19-4355-9883-df5da80afe5c"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf164f8d-6f6e-4620-bb5a-a93349169edb"/>
        <rdfs:label>Phenobarbital</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4a4f3f49-9494-4490-924f-5c66dd5cef58"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/9f6f1d0e-ae5f-4001-88e1-e2a6b667668e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601905</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b27a420-785b-49d0-ba4e-0d739a9875c7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
        <rdfs:label>High ornithine plasma level</rdfs:label>
        <dc:identifier>HP:0012026</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6a16fb45-31d7-4f8f-9474-74c5e3d9f5e4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5357ea59-5975-4c25-90d9-c24cf7c861ed">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cf51c9ff-f9bc-4806-a187-65c3a1d847c1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1311351d-87c3-4d41-8107-bbe3aacc534a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
  </obo:DDIEM_0000009>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/528d2054-6394-4632-92ce-94cfb4635674">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High lactate ,pyruvate ratio</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b7fbc6c8-130d-4ee2-b364-dd369f5101cf">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00175</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/eb2f5f82-d61d-4fac-8c95-6d2172d0c63f">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/496af2a4-8ccc-4878-bb7d-5aba54f939ff"/>
        <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5cc1584-39f2-4bdf-96df-335a316e3258"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24636183</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/32381a97-5889-4541-b1c7-06d782817fa6"/>
    <dc:identifier>DB00175</dc:identifier>
    <rdfs:label>Pravastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6226a622-bfe2-4c7a-a266-1dedf4f8ea18"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f18afcc-8b46-4798-be47-058461b08ab7">
    <dc:identifier>DB00136</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00136</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e8a0c0c6-70a0-4a4a-b1cb-84c7b7eca1ec">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5bbc2c9e-dbfe-48e3-ad18-e138546cc759"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d2ca97b8-c346-444d-bb4f-7c71ca4384f2"/>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6cd8a294-7e8b-4207-85ae-0a217091262f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/99d3aa8c-d4b6-4978-a0e4-1ff3755b97d0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2017228</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/24925285-ca27-4c6c-ad25-edbc617e37cf"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Calcitriol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/db5906e6-ef64-447b-84b7-c88f806fee89">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00808</ddiem:url>
    <dc:identifier>DB00808</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee4e95ef-ce26-4d8f-be35-50ec9240ff00"/>
    <rdfs:label>Indapamide</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aea0f4c5-7e29-4cbc-bcf9-6f7c976fb4e9">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e4e3fc47-d0a9-4f5c-90ca-f49042ac4854">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a7c978ac-7e93-4762-9d1e-39fe95f0894f"/>
        <rdfs:label>AAV2CUhCLN2</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9d01ce9-6a0a-4efa-b6c7-f8310fdab7ba">
    <rdfs:label>low calcium urine excretion</rdfs:label>
    <dc:identifier>HP:0003127</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003127</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8bc74339-eda6-4ced-b758-d2c4412d5164">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2798ff1a-2a44-4dac-b14d-e9cc1affca61"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c848568b-22a5-4e46-8ea4-16474dbdb381">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/011e1928-55b7-4b28-9b31-aa9f91bf8564"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4c111f7d-9d7f-4e02-a98b-252557747f70">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50e7c550-0fe7-4ce2-8764-884f7313eee8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:label>Extreme frailty (Fatigue)*</rdfs:label>
        <dc:identifier>HP:0012378*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20677779</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a0846e61-057d-4e40-8357-065a507ce73a"/>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6a912b0-a5fc-40a4-bc5c-67532ee30a43">
    <dc:identifier>HP:0011023</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011023</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal prostaglandin level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c1ab4300-f43f-4a20-b34b-6cf288e9e2ec">
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/976c0141-5009-4149-a7db-08f763d51cc8">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b41ebe6-0912-407c-97cc-c62d9d3d19af"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/27ee30c9-c4b3-4848-b6d7-6d75b331a4b6"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3ada3bf1-9ea9-42e1-9063-7fd7f3b38510"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <dc:identifier>DB05386</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05386</ddiem:url>
    <rdfs:label>Regramostim</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96d15a47-d589-43ce-9bf1-13019a29b906">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001266</ddiem:url>
    <rdfs:label>choreoathetosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001266</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/12558b7a-64d3-45c1-9d9d-fc905c3a427d">
    <rdfs:label>Sirolimus</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1cdbec1d-6098-4607-b178-832b816ae630">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/358d4f5d-ca39-46b4-9ec9-aedf0bfe9aa1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24578415</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b365b3fd-5b65-457e-ba9b-7c3c37957f93"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bdb3253c-49d0-4742-a047-ed629dda9f88"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00877</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00877</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e7d0c47-4da1-4c9e-82d8-a91a3384b8d3"/>
  </ddiem:Drug>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/0b2ad5c5-8bab-44e5-a437-df8ac73e6344">
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02030015</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b42bab0a-54af-4c63-ba40-c15e53fe7dfd"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/020a38c0-06d4-47be-9e75-307a6f11231e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0baeacd9-ac6c-4714-a987-07abb47df2a1"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
  </obo:DDIEM_0000015>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/47964666-2e50-4608-9d5d-c52d13b01197">
    <rdfs:label>Retrovirus</rdfs:label>
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/75cde5af-cd13-488d-9387-b097f9ccfbc2">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2912023-b19c-45f0-9fcd-7be39495ca18"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2bea802f-6dfe-4987-a50f-11bd196cf79c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9457971</dc:provenance>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a7d9a496-e565-45b8-a46f-3da8e58afc5d">
    <dc:identifier>DB09395</dc:identifier>
    <rdfs:label>Sodium acetate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09395</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fcb361a0-5422-4c32-b138-ed718598d967"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d162eed2-1cad-4bc0-b712-536bb794d1da">
    <dc:identifier>DB00140</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e33d58cf-e1d5-4055-a759-4f2572d5aced"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd81c200-2a49-4037-b1d1-752e6a423483"/>
    <rdfs:label>Riboflavin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08b21dba-390e-43f3-b274-932d7d6dadbc"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e5b76842-75fe-40a2-8109-5a2fe4a8b690"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00140</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2cd0b598-86ef-4c46-8b81-8f2df64b9a9c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d8d4a879-0d19-47b2-8e27-00e116a4328b">
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/a63a8449-e389-427f-a122-23e978ab976a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dd3b14f8-2e4f-4791-b9aa-bcf69887059c"/>
        <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/312648e7-8dbb-42cd-aef9-d2afa62716b2"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/57db5a7f-4391-4e30-b7b9-8e318d82bf21"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1e164de4-66cf-4889-9155-eee42f7f8909"/>
    <dc:identifier>DB11981</dc:identifier>
    <rdfs:label>Elamipretide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11981</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/255124ab-d1b4-4988-9e4c-ea17dd292486">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83e3b1c5-282a-496d-b6db-bf1a4c6e9cba"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/26b81adb-b2ac-40f3-b88e-d7b7bca5e522"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/692cf1f3-a7de-4992-bb31-71e2d750223c">
        <dc:identifier>HP:0004356*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Lysosomal enlargment (Abnormality of lysosomal metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/49ba89bf-43be-4366-a70a-d5a2685f74db"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/755fe4f3-e5e1-4a18-8093-be045b6d29cf">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0f392dc1-5378-4ad8-a0e1-019a374edb35"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d0d99ed-b03c-47e1-bcbd-a90f08d11f01">
        <rdfs:label>hypocholesterolaemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003146</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003146</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2f9d7323-ef0b-4196-8635-eded467df1f1"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c4ee235-99ff-4388-a71e-2cd40b6479ac"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2ecf762-8414-4b46-8032-0f12248f900c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f02480da-e665-417f-9aad-2bc7bbb2d178"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d5d54ab-2914-4090-8b3d-7f5182c18221">
        <dc:identifier>HP:0005135</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>T wave abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005135</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7833193</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5340856f-c877-4584-b9cb-50f1dcaf1ad6">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03180840</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01981720</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca2f82a6-c38f-4758-afd1-ea2cf35ada1f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01769001</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ffadd795-6de5-4111-8c40-bba94a087334"/>
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01678898</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a2b32131-bcb4-4090-b25a-6f3725ce05e2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c861792-9018-4078-8bdd-9443b7517c7a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low serum HDL-cholesterol</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f29c042c-2d7d-47ba-8b9c-53b87aa4b56d">
        <rdfs:label>Proteinuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
        <dc:identifier>HP:0000093</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e9a19c4-9db2-4de4-9344-913a9813fa70">
        <rdfs:label>Abnormal lipoprotein profile</rdfs:label>
        <dc:identifier>HP:0010979</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010979</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was accomapined with fat-restricted diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6866321b-f658-4e71-92e2-9f228c404ca8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23522979</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2dcdf96b-9958-4ddb-999b-e87356a9dd2a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300818">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9a37a2d2-872f-4547-9cf0-8a91ef76a95a"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
    <rdfs:label>PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1</rdfs:label>
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/300818</dc:identifier>
    <rdfs:comment>PNH is caused by somatic mutations in PIGA https://www.ncbi.nlm.nih.gov/pubmed/28516949</rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5dd98f4d-1316-4efb-8628-1cdc656c8d3c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB13245</ddiem:url>
    <rdfs:label>Thiram</rdfs:label>
    <dc:identifier>DB13245</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/68b6384c-e743-4eeb-99e7-73c8f204b279">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0dff28ac-b071-4d29-807d-84a9eb87fc73"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9542101b-8ca4-4707-a19f-053f4a4c6322"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b20d0761-43fb-4b1a-ad80-504c63c79776"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/409fb37d-5700-409e-b7e8-585b801da7ca"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815746</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7daf9f2a-428a-4718-80c5-ca02ec625382"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05da1106-be65-4c86-ad4c-913cb5994dfe">
    <rdfs:label>acute arthritis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001369</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a999c19c-d06f-430c-9650-4bc2184d98be">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001879</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001879</dc:identifier>
    <rdfs:label>Abnormal eosinophil counts</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/16cdcab8-7620-4e3f-bb5a-b2488d109991">
    <dc:identifier>DB00860</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5b8cdb9f-aa01-42d5-87b6-ac5b1ad817f3">
        <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c30e2a28-c40d-4071-9647-fe3f4ffcbc30"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9b2bc7e5-ba1c-4f8f-b238-38d55924b36a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/921733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Prednisolone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5ba521a8-4a13-47b8-af59-e57cc012aa54"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2a6f2ff1-2c05-412c-9f06-76da33be72b4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00860</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b2db3476-a813-46c2-9715-8b87f05baaae">
    <dc:identifier>DB04272</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04272</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/12cfcc54-f4e0-4f84-b920-4d5cd3322042"/>
    <rdfs:label>Citric acid</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/839ecd09-58f1-409f-852a-97ac6ca43ab1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8811363-7595-48f2-8b80-5010ee342d86"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc920f3f-c399-413e-9547-2ca69a099fda"/>
    <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5679950</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1894760</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e607d268-2ac1-49d6-b07b-3359725cb5c1">
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:label>High total plasma cholesterol</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/94ec5b3d-dad0-4eb0-97b1-98ff07eae288"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18001312</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e00d529e-8a0a-44e4-a1fe-83d4757779f6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/817dfd47-a510-4baf-8122-f4c84bfc2b1d"/>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/116e45aa-8a83-4621-89ef-e773d5d1f2b0">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/21685bb8-0f2e-4b84-bb24-057e425d9c43"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0f469917-24b6-431e-addf-4db4832d4e9f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/efcd0e34-ea17-4f10-b39e-67440c698151"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/de664994-88d1-40a3-90b2-1a703eeff22a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ff508487-4b5e-46a0-985a-7d6eb752c5be"/>
    <rdfs:label>Imiglucerase</rdfs:label>
    <dc:identifier>DB00053</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00053</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37053121-dd8e-45ef-aacd-df4940de86b2">
    <dc:identifier>HP:0009830*</dc:identifier>
    <rdfs:label>Painful neuropathy(neuropathy)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f375392-d956-4c14-a51a-2151459925c2">
    <dc:identifier>HP:0000989</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
    <rdfs:label>pruritus</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fa53f0a-a8dd-4fad-aed9-5acaff3798ee">
    <rdfs:label>Anemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
    <dc:identifier>HP:0001903</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/0e940a3c-5176-40c5-b7d8-5a3b61b9b6ad">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/406cb769-7cf2-4653-b750-f04d39a2fdc7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7b495e78-7bc0-4d67-8364-5a9994bf3109"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02452372</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30766957</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ff44b93-187d-4825-aaf0-4f133b559408">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <rdfs:label>Abnormal circulating porphyrin concentration</rdfs:label>
        <dc:identifier>HP:0010472</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30726693</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24821812</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/05b61bfb-65a2-4ba2-9a2d-c3e32c59760d">
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/7d2fb27e-1f9b-49f5-b04c-a5616f468387">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609242"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0e150a74-d580-4ab2-bdcb-f354a2b8ba4e"/>
        <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC0:0005542"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <rdfs:label>Migalastat</rdfs:label>
    <dc:identifier>DB05018</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05018</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/967e1522-1169-4186-a259-9b3a2be46b6f"/>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/655cddd4-1b87-47d2-9997-04d150ebc45d">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601987">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/601987</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/16731945-f72e-4cc3-8216-f566c2a4e776"/>
        <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I, MUSCLE; CPT1B</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5296b6d3-94cf-496b-9f0f-851435fed790"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2ed8b7c-3030-41c7-8326-00256ed8a2b6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurological damage</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d60b73ee-efd8-40c7-b57d-dec68de6452e"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/10325/carnitine-palmitoyltransferase-i-deficiency-muscle</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9370a5b-bad3-4b41-9ae6-ce809837861b">
    <rdfs:label>Acidemia</rdfs:label>
    <dc:identifier>HP:0001941</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7d1ce3e2-8a8a-4b13-9f82-e6f1c3d7727a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8a7231a3-c782-4455-a680-e156d1706405"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14555</ddiem:url>
    <rdfs:label>Ursadiol</rdfs:label>
    <dc:identifier>DB14555</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/37488d15-141e-4cad-9a5c-2e7ab75d33bb">
    <dc:identifier>DB00988</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43bbf76c-cc35-470c-ba17-8558e9ec532b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00988</ddiem:url>
    <rdfs:label>Dopamine</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/09516cea-bcf1-4d1f-afed-4f02cfa1e75d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300818"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28516949</dc:provenance>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/87e8e780-270a-4a95-95cc-c8b0cd7dd1eb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f86f2b22-28fa-411e-8632-4ea1dc9634a1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b86e82d1-8fbd-4748-a2fa-7d592666bcd1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004818</ddiem:url>
        <dc:identifier>HP:0004818</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Paroxysmal nocturnal hemoglobinuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dcb8cde3-49a3-47cc-b32a-d31a599a772c">
    <rdfs:label>Benserazide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/712223cb-98eb-4e2d-8077-d08d984c2f88"/>
    <dc:identifier>DB12783</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12783</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/246a144a-bb7e-480d-9ad4-bb36f6616554">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
    <dc:identifier>HP:0001249</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Diminished intellectual abilities</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7c9079f4-0c79-484f-9d63-2ce9e9d4e0f1">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28126686</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/22e0e709-24d8-409a-97dc-e1a1a4104cdb"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a1685a5a-4e65-4aeb-9377-8da6f66e1f59">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6d7a710d-c029-4ec7-a9d2-3569991203a1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5cf654f9-b54e-4bc6-b871-e75c38a81e27"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/fa26e8ca-194b-4494-939a-ed1094a76dfe">
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79f0c787-0cb4-4ae9-aa1f-6d4175f8a71e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>No result was added</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3736c856-61fc-413f-b5a2-bca4da517a30">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8fb3ad73-c8d0-4879-881e-08bf1958a67c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004314</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1b1c9a7f-316f-432c-8c74-32d479da8d15">
    <dc:identifier>DB00213</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00213</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/94086f82-581a-4f53-8a5f-52813a751111"/>
    <rdfs:label>Pantoprazole</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3bf63761-3aa1-443b-8036-79a6dcd1fa2f">
    <rdfs:label>Gemcabene</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05123</ddiem:url>
    <dc:identifier>DB05123</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/99643801-5ccc-4c2b-a486-c237eed6f91e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a666bdd-5f17-4cc5-8c4d-cd42ae5534ba">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002151</dc:identifier>
    <rdfs:label>Elevated serum lactate level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002151</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb7fde9d-2fac-4743-9bd0-50cc415f533c">
    <dc:identifier>HP:0001508</dc:identifier>
    <rdfs:label>failure-to-thrive</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a8ea370-9fd1-424a-9d8f-2b983ed93412">
    <rdfs:label>Defective argininosuccinic acid excretion</rdfs:label>
    <dc:identifier>HP:0001939*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ba7aba2-520f-496e-ac11-94b3935ccfa8">
    <rdfs:label>Speech and languague delay</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/af09704b-b6a2-4a20-b93d-5ee3f4a64277">
    <dc:identifier>DB11991</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/547bbe19-d1d7-4b1e-bb2f-99b203e07e28"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11991</ddiem:url>
    <rdfs:label>Oprozomib</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d992690c-733e-40cb-a209-2d0072a0cd93">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001112</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal retinal ganglion cell function</rdfs:label>
    <dc:identifier>HP:0001112</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/668a6c34-1c8a-47ad-b6b3-740ad46d5903">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4358cebd-d072-4344-bdac-dfdf24e12a65"/>
    <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3e7b87e-fea3-4831-9d25-85eade85fea4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/102700">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/142</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>142</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/102700</dc:identifier>
        <rdfs:label>SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/54ea5323-d50f-46c5-966b-ee5a7e062dd8"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/db1d87a8-0d6a-4a4f-8eae-e87a2ad5e255">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d8dbcbc-6052-4ab2-bd22-a2dcca1b10b8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11d4ba1a-cd2d-42f6-b0a0-41dd1cc54f36">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012335</ddiem:url>
        <dc:identifier>HP:0012335</dc:identifier>
        <rdfs:label>abnormal folate homeostasis in the CNS</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a369c53-b875-4001-b9eb-b45522d51f08">
        <rdfs:label>depletion of cerebral folate</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <dc:identifier>HP:0012446</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/340e4eb1-419c-423b-88bf-26ad6d773afd">
    <dc:identifier>DB00098</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ba219a8b-ba12-4b68-ab2f-be9e1b1a77a2"/>
    <rdfs:label>Antithymocyte immunoglobulin (rabbit)</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00098</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/dc16c660-9ccc-470a-aa80-6078872fd5f6">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/29116606</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f4d54a5-5651-4817-9b04-c1f28a66cb22">
        <dc:identifier>HP:0000819</dc:identifier>
        <rdfs:label>Diabetes mellitus</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fdffb76a-5a3d-4338-9a2e-28fcb1851f26"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/d46f8d2c-4c3a-422f-8b89-d38392c6315f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794686</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ab80903-b20f-4b05-9ee0-76fcca9ad887"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d249f4af-7d79-441f-bd32-1ce29a700254"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/240600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33f8bbb9-7ce6-43ad-a52b-382626546fb9">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012051</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012051</ddiem:url>
        <rdfs:label>MorningHypoglycemia (Hypoglycemia)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000010>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/23fa88af-b2f6-4727-9d82-a8d694170895">
    <rdfs:label>flavanols</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76d4f44f-d86e-4ac4-b6ff-9f4594a80a9b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76fb6939-8dc9-4298-ae45-08d5f9673f18">
    <dc:identifier>HP:0007010</dc:identifier>
    <rdfs:label>Impaired fine motor skillls</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/168b3348-4dad-4f7e-9ecb-439eefcb54a6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8ff54c8a-fd4f-4e29-95f5-85bfa4de6606">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1a14fd85-a77d-4bce-bfcb-cb2a4d846479"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
  </obo:DDIEM_0000012>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000004">
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T10:19:07+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a genetically defective protein is replaced by a canonical source of the same protein, genetically as in gene therapy, or by some other means of delivery, whose completion is hypothesized by a health care provider to eliminate a disorder or to alleviate the signs and symptoms of a disorder or pathological process. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">direct complementation of genetically defective protein</rdfs:label>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf1fe05d-e41a-4560-b7c6-d774616f1d03">
    <dc:identifier>HP:0003119</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal tissue lipid profiles(Abnormality of lipid metabolism)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/491266db-69e8-4450-b386-e6009ca1abb6">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b3eb8cc-8331-4bc4-b045-a9512ae83379"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12122118</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4983ff2e-5f7e-42c6-8fc8-b66817b5f0cc">
        <rdfs:label>Cardiomyopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <dc:identifier>HP:0001638</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a5586b2-afeb-451d-b0d7-3c5f07770d7f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16763896</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea6b61b5-4a88-434a-bcaa-10d64e94d190"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ffebcfa-f201-410d-8e07-396d0d529147"/>
  </obo:DDIEM_0000010>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cafaa4c4-382a-4554-b297-a429340f857f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e01e917-be00-4670-bad1-07d9256da75d"/>
    <rdfs:label>RT001 (11,11-di-deutero-linoleic acid ethyl ester)</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e4db3cd6-de0b-4804-b577-d10ad14baf87">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/10e48954-ca8d-4bc9-b75a-ba1bae880e6e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8870064</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6978e9bd-803c-4c18-820f-5c35e608922b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f60efebb-4955-4bfd-a8ca-5fa6f1c858c8">
    <rdfs:label>Pioglitazone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1e8d7fc0-18fe-4d44-9ee9-8b40243c06f3"/>
    <dc:identifier>DB01132</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01132</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0d71802-13b2-4b22-8f3b-77d7ef9c217f">
    <rdfs:label>High plasma levels of hexacosanoic acid</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/722830d7-4181-46d5-bac9-c246b443ea2a">
    <dc:identifier>DB06720</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9700d529-d9e7-4092-807f-b129a799f787"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06720</ddiem:url>
    <rdfs:label>Velaglucerase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/30d8601e-8146-4593-8b7e-f0d233489104"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4a60771-697f-4d37-b21f-3dbcacfefe4a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>encephalopathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
    <dc:identifier>HP:0001298</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ab058cda-e056-4233-93aa-013096f38513">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/300ad90f-3655-4fe7-ba66-057e7c40a527"/>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/09b422b8-dac2-47a7-9261-f17a82de40cc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3891343d-1e5e-4307-985b-e629fd8aac8a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01267422</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a97ccde3-9e03-468b-9b3c-caec3521e755">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d6696c12-0f38-4ddd-9363-370e2463880a">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b9a392bc-d1bb-44f3-81d8-bbecc53dae97"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB02209</ddiem:url>
        <dc:identifier>DB02209</dc:identifier>
        <rdfs:label>Pyridoxine phosphate</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/3134cc11-1d8c-4c3a-80a5-12800b4185e3">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9185508</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <rdfs:comment>Probucol is a non-Statin cholesterol-lowering drug and a potent inducer of apolipoprotein E (apoE) production in peripheral circulation. https://www.ncbi.nlm.nih.gov/pubmed/12946703</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/884ca168-7b7a-4d3c-a690-c3de994dcb34">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
        <dc:identifier>HP:0002621</dc:identifier>
        <rdfs:label>Atherosclerosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/340b5a7b-6372-4a50-aec3-da94e6290858">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7dc76710-e5f7-476c-9efb-9d495a2af4f5"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ee77fbec-cfd9-4813-a7ec-4898537ae88e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/200e9314-88ac-48bf-9bee-aabb518404f4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09144</ddiem:url>
    <rdfs:label>Uridine triacetate</rdfs:label>
    <dc:identifier>DB09144</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dbb76147-47fd-48c5-93d3-2bb7fed387da">
    <dc:identifier>DB00926</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00926</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/323e21c8-c82d-4b89-85f4-486652aed2ee">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07a20493-03c0-4ef5-a2a2-986ff31b1ace"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b026d28-ef9b-41c0-a009-696b12a11c68"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10738634</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c95e2d6f-03cf-49d9-a9d8-93ecd73d32b7"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Etretinate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ad3eb7e-adbf-41f1-a433-d295b9786c93">
    <dc:identifier>HP:0012410</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Pure red bllod cell aplasia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012410</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dbf64387-eb6c-4225-9b35-51cd7effe7ef">
    <dc:identifier>DB14778</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/caac4fe9-52be-4343-a986-003e95c7c7f3"/>
    <rdfs:label>Setrusumab</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14778</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3c53bb6d-04f2-4b5e-bde6-3d51b2b9375f">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612953"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a849d856-3663-470b-9d58-a6f4ee8ffd88">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <rdfs:label>parkinsonism</rdfs:label>
        <dc:identifier>HP:0001300</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613933</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a47fc4c-5ccd-47a0-b159-e9bab1b3cbf3"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdfs:comment>It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d5bce564-04d5-4896-b670-ccd710edbf61">
    <dc:identifier>DB09154</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09154</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ae546ef4-261b-4603-8a14-944ff538a837">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2cd9367f-66ef-4af3-8763-f2f24d11c540"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/db39fea1-5673-4794-a3fb-d90982d76b24"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Sodium citrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2c7ec841-0f07-4db2-9cb9-b3dc153e2b1b"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c96b3ce1-0028-4160-8f74-54c4dc0cdb67">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f25b9c51-91e5-41f0-9454-7d055424ab6a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low Apo B protein level</rdfs:label>
        <dc:identifier>HP:0025201*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc2edd9e-b650-45b0-973f-aff1cffd33cb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low HDL-C level</rdfs:label>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db6d5a13-b533-4cf7-9813-3d0a4b0c6eb0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>proteinuria</rdfs:label>
        <dc:identifier>HP:0000093</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/958b44cf-8a64-4b32-9af1-0056fa20575e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>dyslipidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003949</ddiem:url>
        <dc:identifier>MP:0003949</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84bcb46c-49e2-49a6-af10-16fa27a4272e"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a89fb5f3-3ee8-4989-9c19-00916bd0acb4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c844ffa2-3ae3-45a2-9e3b-9aabdc268dce"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a7722b9-2c6a-4b45-99ec-3a054d800731"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/97dffd65-e589-4c5f-973d-4f52bf03e1dd"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/203bbb5e-7ee2-4b0b-bdaa-01d40155e9c2">
        <rdfs:label>anemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245900">
        <dc:identifier>https://www.omim.org/entry/245900</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/380</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>380</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e878929c-ba13-47ae-96fb-30a54ef9f120"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b7434c0-7549-4851-8b23-228ce0fb527b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d1f36b4-71e0-40b0-bf15-c1f0698002e3">
        <dc:identifier>HP:0025201*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
        <rdfs:label>low APO A level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237400">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>161</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/237400</dc:identifier>
    <rdfs:label>HYPER-BETA-ALANINEMIA</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/133fedd3-9df3-4e02-87bc-73023f9564fd"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/161</ddiem:iembaseUrl>
  </ddiem:Disease>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/ae610e5d-fa33-454c-baee-3ce96dcc169e">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607330"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/80fe9cc5-292e-4e32-9304-833eeb5a373f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d7cae9f-9f7f-466e-b55b-723ddbf5c20a">
        <rdfs:label>Abnormal neurodevelopmental profile</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f525cfba-e833-4a32-a16b-83042d6153c3"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0003304>p.K148E and p.D210E</obo:RO_0003304>
    <rdfs:comment>The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/80b38d56-06f2-487c-b768-5027208c94bd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24142275</dc:provenance>
    <ddiem:failedToContributeToCondition>c.479C&gt;G p.(Pro160Arg) and c.630C&gt;A p.(Asp210Glu)</ddiem:failedToContributeToCondition>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1a754800-c60f-43fb-b76b-4a1229177b85">
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b58c0ba0-0396-49e2-be97-9331ea769d1e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7e0bb323-9c41-44fa-9cfe-ddeeda8c36b5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6cf7ee8c-023d-4e5e-9549-11478072c8eb"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00229619</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c39ada66-0f76-426d-a16e-60bfce8e2ebf">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ce3758b-6596-4268-b2fc-e08ccb5e6e1b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a57dd1e-220a-428d-998c-2d64137efa2e"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d62c06cf-1be7-4bc3-bc70-a3a3d4ab3e30"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/318dce09-2960-4491-9184-d03479e8fd27">
        <dc:identifier>HP:0002375</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
        <rdfs:label>hypokinesia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/627846c9-0954-4f50-b9f8-8e359238b2b7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c9b6831b-67d5-4b41-83f7-00df500f2da6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f3d3d4a-5660-4117-832a-b143183d2a0f">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008936</dc:identifier>
        <rdfs:label>axial hypotonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008936</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0678e392-36a7-4da8-9825-434563e26dcc"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b45ea33-600a-40a0-961d-069626c0cf82"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffa867a0-c1a2-462e-a2e9-a21bf1ef9b37">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
        <rdfs:label>Oculogyric crises</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010553</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/96d15a47-d589-43ce-9bf1-13019a29b906"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a91c7f4d-79f6-40c6-ac47-88a6a217f41b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4424fdb-5cb2-4c17-ae40-a6b9cbced43b">
        <rdfs:label>concentration of TNF-alpha in plasma</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011118</ddiem:url>
        <dc:identifier>HP:0011118*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72d43680-393f-45b9-9226-6175be214012"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02583672</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01427517</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14d29dac-847f-4efb-b83e-0a1e451c54ab"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67cf48a6-f130-49d0-9fce-0dfcdf14670d">
        <rdfs:label>Inflammation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
        <dc:identifier>HP:0012649</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8cabbd0-db80-42bd-a538-a8e5a605462a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f72affa6-3246-4b92-b53e-8fd728ed18da">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0012604</ddiem:url>
        <dc:identifier>MP:0012604*</dc:identifier>
        <rdfs:label>Low blood glutathione redox ratios</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261600">
    <ddiem:iembaseAccessionNumber>1</ddiem:iembaseAccessionNumber>
    <rdfs:label>PHENYLKETONURIA; PKU</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3260d6b2-3663-4d76-9133-5913e2cbe455"/>
    <dc:identifier>https://www.omim.org/entry/261600</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1</ddiem:iembaseUrl>
    <rdfs:comment>Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in lifeDrug name: Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub</rdfs:comment>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/e6f53fbe-37cb-422d-a226-fd26addfd1eb">
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28935503</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ea835101-844a-4479-9d15-eb4a1dea965e"/>
    <obo:RO_0003304>CYP2D6</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30264864</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a360719-e6c1-4d98-ba19-77c78cf8b54e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87556a3b-4cf9-4417-b772-d84f47654da6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eccc5e3c-4652-4c3a-9247-42e4725569a8">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025547</ddiem:url>
        <dc:identifier>HP:0025547</dc:identifier>
        <rdfs:label>low mean hemoglobin concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29680197</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa153830-03f8-457a-920b-358d8c7c3c8c"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b182f6b0-5893-4782-a857-145b5ff8a901">
    <dc:identifier>HP:0001959</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Polydipsia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bd7d6658-1ad6-479c-8950-ad9b759fb43f">
    <dc:identifier>DB02659</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe4373b0-e5cf-47d0-ac55-b5e3a823c73e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eb4bda6a-5dc3-4023-adde-5b76ede316e7"/>
    <rdfs:label>Cholic Acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02659</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/63589499-8a5a-4421-88b7-9b87bd055888">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/97f01d50-c8e0-4819-89a8-83c0325161fd"/>
    <rdfs:label>Chenodeoxycholic acid</rdfs:label>
    <dc:identifier>DB06777</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9756b4bd-f558-4cb7-916c-87e16ba341e8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a1fedd1-ea98-4518-a4f5-f5c11178d29a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e013f14-ee35-488c-b9d3-5c8ba2fbbaca"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06777</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b807e186-d1ab-437d-8717-7fa03e676466">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/99f5ca40-02b7-4e40-a193-b97a804f342c"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cf255b2a-de80-47c6-a1fd-000f7f158fe0">
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/563b9f24-45ce-43f3-9725-e8d2e5ad76ff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65d6195a-e099-4715-aa22-c59b4da3069e"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da257674-c765-4798-b101-aea48c6252fd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>verruciform xanthomas</rdfs:label>
        <dc:identifier>HP:0031517</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1c767694-d37d-44ac-86c3-25fd32293f3a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cebb1f44-7440-4c2e-8122-9d4e81c5f734"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>"ENB-0040</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f6ca4216-2b4e-4ae6-944a-b8973429e241">
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/810fa7e5-ac4b-4c6a-9533-9d802880bb93">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <rdfs:label>High liver triglyceride level(hyperlipidemia)*</rdfs:label>
        <dc:identifier>HP:0003077*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/297ede21-cceb-4d87-8d08-97de62639b43">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da404887-3c84-46dd-abf8-c06a96a1495d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02430077</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2eafb20b-075e-4950-9a00-7a6856ee01ca"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3669352b-d95f-4ade-9f08-0647eefb77d6">
    <rdfs:label>Neurological abnormalitis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <dc:identifier>HP:0000707</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2e8cc184-4ae9-40b0-a75b-68b75f20d192">
    <rdfs:label>Recombinant apolipoprotein A-I</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fa4076c6-bc63-43cb-812a-cb7ec3ff7fbe">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/884ca168-7b7a-4d3c-a690-c3de994dcb34"/>
        <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11425766</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f1c6ad1-a20c-4ab7-966d-78356d297e5b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8908f606-916d-478a-9a76-5fe75d3cfd7c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/258037f7-6317-40b8-a13a-d6753aa36f08"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B02BA</ddiem:url>
    <rdfs:label>Vitamin K</rdfs:label>
    <dc:identifier>B02BA</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/49a423b2-ec20-4b62-8a0f-bd6cedbabcf8">
    <rdfs:label>ARC-AAT</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b600de9d-68ff-46b2-8ef7-30be2d68f217"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f10c805-6334-4122-9ce6-b94d77bc1491">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
    <rdfs:label>metabolic acidosis</rdfs:label>
    <dc:identifier>HP:0001942</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ffa9fdf0-596c-4148-a74b-4a806cdc6e7d">
    <dc:identifier>DB14644</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2ff939d6-4ea5-4b56-8cbd-3b70c60e0c61">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86f95ca1-1845-4e65-ad3e-3aafb9c50822"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4358cebd-d072-4344-bdac-dfdf24e12a65"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ee75eb3-561f-4d78-81fc-77a72375c62e"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Methylprednisolone hemisuccinate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14644</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8154a4e7-aaa9-4b23-a91b-95003e615a56">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low phosphate reabsorption</rdfs:label>
    <dc:identifier>HP:0000117</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000117</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/135516c5-c0c9-41b6-9204-0a46d083d489">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ac0310fa-e5a7-4166-bd35-f3ef16a834dd">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/349fc753-4be8-48b2-9a63-5b636324c2a9"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300971"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2c53e357-9915-48d4-ad83-6f418e96730a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00328</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/97574d18-611b-4ce6-ac16-677d4f1aad50"/>
    <dc:identifier>DB00328</dc:identifier>
    <rdfs:label>Indometacin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5786a40a-2213-4b33-a233-06cda4599bba"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7f572240-6263-40ad-89f9-4cd1925de043">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1d029be-84d3-4d23-bd24-23e88977188b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c41b780b-b823-4875-8d26-9d6f321898db"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26427088</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29651749</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dcac70a0-6dbb-4fa3-bff5-c15f56ef401d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001987</dc:identifier>
        <rdfs:label>High blood ammonia level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5296b6d3-94cf-496b-9f0f-851435fed790"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e81e39b-06be-4bba-b860-19be4a957675">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
        <dc:identifier>HP:0010903</dc:identifier>
        <rdfs:label>low plasma glutamine levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/942f92d5-0daa-4946-ad5a-00c0565c147a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e043ecaa-cab3-4222-8a93-7b5c38e58dbb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3c332815-b641-4cee-a3a9-9217f1e3be0b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12205338</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/60de23d0-2b75-4192-af22-7079626081fa"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8ad89e8-e71a-435b-b3f7-1ecc7a9ab0c6"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/ab051cbc-a4b9-4eb5-b49c-40f2f51211db">
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/37cea92d-a8a9-45cb-98e1-1177132bdf27"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2b31ea5-c2ee-4503-860e-abfe8e287b7e"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9493705</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4602dfdc-f44b-4846-9ac3-99ec1e2c55ce">
    <dc:identifier>HP:0010836</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>hypocupraemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/594c1e23-f5bb-4225-a694-4ae072c30753">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040134</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>elevated liver iron concentration</rdfs:label>
    <dc:identifier>HP:0040134</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9b77b213-d261-4912-a623-4cca121eee50">
    <rdfs:label>Linoleic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14104</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/388c6c75-5f7a-4ae0-a10e-4284613c7dbb">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1c206d0-4f80-434d-b04f-2214c8a514c6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48a584ad-6104-4afc-893e-195e604fac4a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779298</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB14104</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8b923afa-2ef7-4b2d-9fe6-2ce69ccccdf6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c9d0ee4a-77ce-4fa5-8b85-3e007835c2ea"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10925336</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6108e9f5-015c-4cb9-8b05-09d9172d8d3e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e8b481dc-5bca-4f9c-8c3d-76d49cb3eabb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c915ec27-5605-4eff-91d6-bd7afa7a1747"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34a59523-c14e-4115-bd28-a2d55af63766"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/98b32afb-474b-4a67-82d0-ecf5049c9b74">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ec890bbb-a952-48a9-9d2e-f59c74852474"/>
    <rdfs:label>Phosphate ion P-32</rdfs:label>
    <dc:identifier>DB14573</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14573</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/a7070428-bd7b-4e89-b5c8-f7053dfc0418">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4fdf5931-e425-4ce0-a412-a1a3a845c8c9"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615182">
        <ddiem:iembaseAccessionNumber>924</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/924</ddiem:iembaseUrl>
        <rdfs:label>COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/615182</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bd6e6b0a-d863-4ee1-91aa-b348138dd0e5"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1962eb54-67ea-48b8-b1e5-331942143bb1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c65fb4e2-8bb3-4dd0-be7f-49f3d8f771d8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05d76b5c-9c84-4ad0-b2d1-033ddd09cc35"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24687295</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0974aa4-d29c-445c-917b-d7f7bce957ed">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low urinary excretion of TCA cycle intermediates malate and succinate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/f602b3aa-4f01-4526-82ba-5377d6116410">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03737214</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3695570c-5cb0-4625-96d2-43d5b6449d85">
        <rdfs:label>High Gb3(globotriaosylceramide) accumulation.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02930655</dc:provenance>
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28088251</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29982630</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03425539</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eeb2cc89-1967-4c0a-8950-86e36f24fe99">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/66453411-52ba-4df0-872b-8965a88e5162"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31cc2ef0-08d7-4342-a4b9-3e831375e883">
    <rdfs:label>Functional disability(Constitutional symptom)*</rdfs:label>
    <dc:identifier>HP:0025142</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8bc80e95-56fd-4011-9fd8-83472b95b67c">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040006*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
    <rdfs:label>Low life span (Mortality)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f427446-586a-4c57-98c0-a7c68379c077">
    <dc:identifier>HP:0002181</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Brain oedema</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002181</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d88db206-e04d-4a68-8190-5e9e87fdfaab">
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6289fc90-15a9-4a86-8a90-6af49314e36f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/08d2cc99-fbf7-4493-b5a0-17b9f29f4ebc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1a231475-c425-48f3-ba76-d2013ec667fd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6aa2bda0-86b5-4802-839d-c204e7e60d94"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/c28700a0-d52a-4336-86b9-11bb1215962c">
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02926066</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4781f960-3fad-4c69-b9fd-2026e71417a5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
        <dc:identifier>HP:0002275</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>motor malperformance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37083b00-093f-4d26-a364-220a5624a900">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012654</ddiem:url>
        <dc:identifier>HP:0012654</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>increased dopamine and serotonin levels (neurotransmitter levels)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/03ff864b-209e-4223-b1de-0c73e7115922">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a98c922c-3c87-4e1d-9230-54b607d3377d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/357814c2-a93d-43b1-bb9f-4a64a74712a5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01233</ddiem:url>
    <rdfs:label>Metoclopramide</rdfs:label>
    <dc:identifier>DB01233</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/800e9639-8309-4837-8c2c-b91c795c0e20"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a09b17c7-8eb7-4c78-9f9a-59553495e90b">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ba81b890-4182-4ee7-af3e-18f95e46b390">
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
        <obo:RO_0003304>SpDEx7];/p.[Q49R;Y395C]/c.[478_480delTTC];[?]* no mutation was in the second all</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bb142444-e7ac-4632-b00e-567363f7cdde"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f3f73bd-69a6-4f27-aba5-0e4d9ec45721"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26259553</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256540"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>N-octyl-4-epi-β-valienamine (NOEV)</rdfs:label>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cc28eb65-0925-443a-974d-e8ed24c4375a">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d94d13aa-9a3b-4da5-a911-67c081405f3c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12801620</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a4753e6-c2da-4f4a-aba7-483733cf6cfd"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/37b39088-f7bf-4af5-adb4-714fab448a75"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9ff3c6b-2c5b-494d-9c58-ad3f974e18e7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3eeddbb2-c79d-4e72-95f2-cdececb5320a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60ce1ce5-c971-43fd-95f8-49bfede8b8eb">
        <rdfs:label>Elevated VLDL-cholesterol,serum TG ratio</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <dc:identifier>HP:0003362</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86816794-7903-4dc0-9eb5-7a3bcf9daf8d">
        <rdfs:label>Elevated apolipoprotein B level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031798</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031798</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cb7133ec-57ea-445c-9a77-cdd1f752986d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4c2382e-bec9-417b-b28b-3f5cc37151de">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Tricusped incompetence</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
        <dc:identifier>HP:0005180</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc8d258f-56c8-4e39-a9ec-6a24e91df84b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbfb5ba3-d95d-42f3-8b6a-bdd419692ba6">
        <rdfs:label>Mitral incomptence</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001653</ddiem:url>
        <dc:identifier>HP:0001653</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2d7c388-f4d7-4f5e-add7-9dad0a4937af"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6652d908-1bc4-47d7-80cd-1a4af59cd459">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/854b8eaa-1f88-47f1-a0ac-9941e5b6f0e1">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00555</ddiem:url>
        <rdfs:label>Lamotrigine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/15d8dbae-529e-416d-bd3f-a906ef29fe84"/>
        <dc:identifier>DB00555</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fe0a4a89-cd56-4af8-ba22-50306057efbc">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01041</ddiem:url>
    <dc:identifier>DB01041</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7fa35c00-1795-431c-b811-27221d4d8fc3"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/585feef4-ba32-4577-9cc1-d401c61540e8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11504824</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1e0aeef-654a-4f75-8fea-54632e3df659"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/be4ae9df-db61-499b-89b6-153394e7fa8f"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Thalidomide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07da2db9-fa15-4f72-bbf2-58f43f73d95f">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025303</ddiem:url>
    <dc:identifier>HP:0025303</dc:identifier>
    <rdfs:label>Recurrent repisode of flares (Recurrent)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/410b8317-fa9d-41ef-ae68-15a2602d140f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/37053121-dd8e-45ef-aacd-df4940de86b2"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2325319d-28e2-40f2-883a-fb401e228946">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Congestive heart failure</rdfs:label>
        <dc:identifier>HP:0001635</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0bd6e4b-d7d6-4a74-a0ef-264302729297">
        <rdfs:label>Pancreatic beta-cell dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0006279</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006279</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76371140-d59b-48ef-91e5-cb7965a50b66">
        <dc:identifier>HP:0002401</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Stroke-like episodes</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26954033</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15728297</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f1a93807-f7ab-4a06-ac32-884eb698cd15"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6e812288-5389-47d0-bbee-dd6dc5871f6a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fd4ea1dc-5b6d-4b33-aab2-de479fbe803a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/97794909-f8ee-463b-a85d-a27124b4bc7a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9a5535b-2a1c-4698-a6b8-5d875556eec5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d8aa129-5ab4-4ed6-84e6-ac812dfadd7d">
        <dc:identifier>HP:0001941</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>acidosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b7cc8aa-7d8b-490a-ac39-06fc056804d1">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Kidney failure</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000083</ddiem:url>
    <dc:identifier>HP:0000083</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0d9f1bac-ceb1-4194-b2ef-d26961392415">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/701468b4-0acf-4e6a-aad5-c265865bb2a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/260dd508-9ee8-45dd-b35a-976126f133bd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22dddf27-ee9d-4e4c-8e1b-72e2903c81de">
        <dc:identifier>HP:0000491</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000491</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Nummular keratitis(keratitis)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a9812ec-19f5-47c9-adab-c427fabea2b8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:label>Decreased visual acuity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007663</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656398</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffef8e03-d39e-44d6-9081-c8b433e23b45">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000559</ddiem:url>
        <dc:identifier>HP:0000559</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Corneal scar</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/121270">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>COPPER DEFICIENCY, FAMILIAL BENIGN</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/121270</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b0d83319-0110-4160-b080-56d5b443ca00"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/692b5bdb-c711-4763-b166-a1fe2520764c">
    <rdfs:label>Decreased physical function</rdfs:label>
    <dc:identifier>HP:0025142</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/a4d94ba1-0f12-4812-8df7-673621553509">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01161576</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e5a087b0-8cc9-4e1d-8720-1fa736ecc4bc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c5c6430e-6b8b-4d3b-b54b-391c2dce1a3f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/31456f30-5dca-407a-bcd4-e4a550a5afd6">
    <dc:identifier>DB02691</dc:identifier>
    <rdfs:label>Glycocholic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/32904b23-1449-47d5-96e8-1b15910deea4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02691</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/12453dbf-3ad7-4e32-87f9-9b32c31ed3fd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f0d1d267-4605-4a98-94b1-e3e3bff54301"/>
    <dc:identifier>DB00855</dc:identifier>
    <rdfs:label>Aminolevulinic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00855</ddiem:url>
  </ddiem:Drug>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/671f70f8-fdd0-4cb0-8ceb-32aa63a1e9ad">
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86329ed5-a360-4115-b24d-0d1301958694">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2f01d9d9-0885-42d7-b52d-511452266c3d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc66167c-7869-4114-8874-5ea46ca7e768"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609458"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/903462d2-82d3-4177-b95b-99aa1de313df">
    <rdfs:label>Modified Atkins diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d708facd-54b3-49be-b2ad-f028e2834942"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/15d8dbae-529e-416d-bd3f-a906ef29fe84">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24777537</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6652d908-1bc4-47d7-80cd-1a4af59cd459"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d81f3043-d7a6-4592-a57b-306577f32c21"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614462">
        <ddiem:iembaseAccessionNumber>836</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/836</ddiem:iembaseUrl>
        <rdfs:label>HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES; HGCLAS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/614462</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/38282cec-6bac-4999-9967-e2518f52ec06"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/463bd382-1512-4be2-a4d0-fc40750b05d8">
    <rdfs:label>The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5bcb4ae-3396-46ad-9ffe-cc6643343487">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal serum Methylfolate Level</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/9a2f3427-8ed5-4e47-ba45-824b7b469208">
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a742266a-8ec3-4e29-9788-d9c701db2948"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/695bddb1-f312-47cb-9200-94a714a47c94">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b877fe1a-614e-4f99-bbb7-e0d01d9e72da"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/33a6d78c-58d8-4730-b640-51c18048074c">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f4d54a5-5651-4817-9b04-c1f28a66cb22"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fdffb76a-5a3d-4338-9a2e-28fcb1851f26"/>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25092642</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b4fb6897-3f0d-4969-8bb9-fb94b69dd85b">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
    <rdfs:label>myoclonic seizures</rdfs:label>
    <dc:identifier>HP:0002123</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5920a7a1-99d8-413a-8ba5-4753c944d584">
    <rdfs:label>Teriparatide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06285</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0c0ca672-8f6f-4ae7-9e2f-3ce2c2c32044"/>
    <dc:identifier>DB06285</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/faa16291-d0e9-4713-ae3c-f5d0579037cc">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased niacinamide level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a779525-ef84-40d9-9afe-fc6f7e0ab824">
    <rdfs:label>Limb dystonia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
    <dc:identifier>HP:0001332</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3b2bff41-82a5-4f1b-a9a0-99c46d5285d7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b27a420-785b-49d0-ba4e-0d739a9875c7"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a01474dc-559b-4ce3-b2ef-6bbf02c9d0f6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/26edca03-9175-4f13-8032-e56ffd4b4e1c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fa2404c-9a2c-44cd-9473-d81440edc0a5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012103</dc:identifier>
    <rdfs:label>mitochondrial toxicity*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0942cfb5-8246-4bee-897c-ee609fbeb042">
    <dc:identifier>HP:0001945*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>hyperpyrexia in case of acute encephalopathic crises(Fever)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b54a0656-7831-46aa-a018-b8d2a3f424ee">
    <rdfs:label>cyclodextrins</rdfs:label>
    <dc:identifier>CHEBI_23456</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_23456</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e7730218-6e60-4529-817f-db7e28c347b5"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/197b802e-31e1-4a85-8ccc-265bc4ab014e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9559978c-f7e7-45d7-a09c-e9ac804b0a6b"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d249f4af-7d79-441f-bd32-1ce29a700254"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8ec08c69-d2d9-48d9-8eb5-5c2ff7360ec1">
    <rdfs:label>Potassium</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a25941fc-8591-46ad-b4df-8675697ccc68"/>
    <dc:identifier>DB14500</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3a91a4fb-9f92-46ac-b45e-0241af918852"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14500</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/73c41e2b-8c2d-4f57-8c1e-92be9e791574">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5176242c-ba0d-4bee-b331-64d42ffdc313"/>
    <rdfs:label>iminosugar DGJNAc( 2-acetamido-1,2-dideoxy-d-galactonojirimycin)</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/241029ae-e751-419f-a2e7-5da7bbb82d17">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c958c81a-eb1b-480b-bc4c-99fa7353c008">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9851f290-e350-49d1-93d2-172c95dd01dc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8bc80e95-56fd-4011-9fd8-83472b95b67c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30127521</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:DDIEM_0000007>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1ae499ea-5338-4546-a724-09484f40758b">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6e4f2b0c-e654-46f0-b9b3-423537b19adc">
        <rdfs:label>Potassium bicarbonate</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB11098</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/49bcd89e-8496-4779-8e29-9bf326bca3b6"/>
        <dc:identifier>DB11098</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3336696-d296-41bf-8b08-ed0126981836">
    <dc:identifier>HP:0000982</dc:identifier>
    <rdfs:label>Palmoplantar keratoderma</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55dffc74-4a89-43a4-942e-05802a3f9608">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal levels of urine total alkanes</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c5003593-bee7-4654-a8dd-d5598a825d60">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd715238-e547-4c61-bf32-511bd9b8ed25">
        <dc:identifier>HP:0001992*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
        <rdfs:label>pyroglutamic aciduria(Organic aciduria)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/397212c5-8772-42f5-9152-c9a25daec3d3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>secondary glutathione deficiency(Abnormality of metabolism,homeostasis)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f10c805-6334-4122-9ce6-b94d77bc1491"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63f9fdd1-a00c-49fb-b297-fec1a9db7f6b">
        <rdfs:label>decreased appetite</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004396</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14d29dac-847f-4efb-b83e-0a1e451c54ab"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/87972fe5-c397-43bf-af04-9441eae8d882">
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_15724</ddiem:url>
    <rdfs:label>Trimethylaminoxid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ad6dbc44-ba31-4ce3-9c98-3d8954e5170f"/>
    <dc:identifier>CHEBI_15724</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/822c17ac-70a9-40f4-9787-fea17d0b87d7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Developmental abnormality</rdfs:label>
    <dc:identifier>HP:0012759</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2ad3407-3949-4426-92ba-8f493a59fb1d">
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/296fa45b-f64d-4dec-99fe-a0bc84743b0d">
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fbf8345e-5920-4b07-b8de-319989ff48cf"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02725580</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31331814</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/601780"/>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
    <rdfs:label>scAVV9.CB.CLN6</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2966b3c3-8655-4a58-bf98-a62f24a980f0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6b4ae746-06bc-4614-8ebd-60cb3cf0367f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00252</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cad38f76-9ec9-45d5-975d-5c4cda399cc8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/761252a2-b41b-49a2-97ce-079be058fe8d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <rdfs:comment>The drug is occasionally effective especially when started early in status epilepticus.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00252</dc:identifier>
    <rdfs:label>Phenytoin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/939b295c-e30e-4890-b5db-98c6119376f7">
    <dc:identifier>HP:0000002</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>delayed growth(stature)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/00c538c3-dade-4c76-8e0b-4e1a57155e28">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1ed4f798-ec6b-4898-8184-3817e5fed96f">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9bbef355-9cb8-4cf3-a903-3c94d784d88f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9ec8a4b-73ed-49f4-ae82-1b1d1fa4ed67"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21575633</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb35b965-b600-40ae-879b-1fbee19d171c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/438bf50c-a748-403b-aa7e-dabc3369937b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ac7f0bd-f165-4718-8609-825368f2600f"/>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78d3e2ec-d660-4729-a512-1a6f1fa939fc"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/16b78222-4946-4c72-b66c-c940e6c19701"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/daf44a11-d4d2-4996-b94a-d67c52aac3ce"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8efba906-1f02-4ad1-b7ae-6081f5ace59f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/345e05cc-5f44-4956-a9d6-8d7bfd08818e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d4b0df9-82af-4f07-b23f-3c8fd120c382"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd65a028-207e-4294-a036-940c16756000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38df2bff-29d6-4dea-8237-2bfb30453551"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>recombinant canine α-l-fucosidase enzyme</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6003e2ad-70b3-451d-94b7-440bb9ff501d">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300559"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/db37f8c2-4bc2-4d1e-beef-219704c7806b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fcc1d1e6-4359-4696-b6cb-ff4015f2980f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15637709</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a905453-b801-4f07-864d-a27f583f6de0">
        <rdfs:label>Muscular hypotonia</rdfs:label>
        <dc:identifier>HP:0001252</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001252</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f41d2505-f39b-4a8b-a44b-8e1a0e5c71a1">
    <dc:identifier>HP:0002463</dc:identifier>
    <rdfs:label>language impairment</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002463</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d7c51391-c766-44a5-94ce-879287db4284">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00334</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/da1cb120-d82a-4528-a244-71b3c32bd311"/>
    <dc:identifier>DB00334</dc:identifier>
    <rdfs:label>Olanzapine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/876fe46b-340c-4766-9e98-2255f18e192a"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bc6e7cd6-c29a-4904-ab43-6912c237f57b">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/808d782b-8326-446e-9325-5981db12c1ae">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7be2207-9248-440c-b331-5c32d3323b2c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b365b3fd-5b65-457e-ba9b-7c3c37957f93"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5fbc45d-bf23-4ace-91fa-5abcea52f65a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00126</ddiem:url>
    <rdfs:label>Ascorbic acid</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/04bbccd9-be9f-41d2-9130-419048d15ab0">
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7be2207-9248-440c-b331-5c32d3323b2c"/>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14206878</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26226126</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e212eac-7662-4990-962c-93536e182efe"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <dc:identifier>DB00126</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a32c4c30-14e2-4d36-9001-d12c04816c94"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b3ffffca-9759-4993-900e-1537e947dd93">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/675c0160-a161-42b4-b5f9-8adb2c59651a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2e5ca86d-f24e-48fb-99ea-07ad3330f49f"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fd805776-08bc-4dc0-9316-0e34ee6c2416"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/763c9d8b-d6bc-4ce0-984d-43a9dac398ab"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/91b50b1d-630e-459c-87ec-383fded7e5ee"/>
    <rdfs:label>Benzoic Acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03793</ddiem:url>
    <dc:identifier>DB03793</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/24286b28-37e9-4723-b1a8-bd22b77d036f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/33a6d78c-58d8-4730-b640-51c18048074c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d83b479-72a1-4db8-a7a0-96077ce2dcdb"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dc16c660-9ccc-470a-aa80-6078872fd5f6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00030</ddiem:url>
    <dc:identifier>DB00030</dc:identifier>
    <rdfs:label>Insulin Human</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24925285-ca27-4c6c-ad25-edbc617e37cf">
    <rdfs:label>Hyperparathyrodism</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
    <dc:identifier>HP:0000867</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/479e5835-7538-4351-b310-590a64ad060e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/025a4793-3247-4ccf-b1e1-93f051ed5c0f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Study was terminated due to lack of safety</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8eba84a2-f57a-4175-b788-567dd5eb51c0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/952f8799-0f11-409e-b76a-9f26a88b3362"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a4753e6-c2da-4f4a-aba7-483733cf6cfd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <rdfs:comment>Study was terminated due to safety issues.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00145431</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99d3aa8c-d4b6-4978-a0e4-1ff3755b97d0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
    <rdfs:label>Renal rickets</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002748</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3b5d4fba-a135-41e4-b01a-c4b1364e6dee">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14933</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9fba7075-849c-4c90-b195-88238a96cea7">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <rdfs:comment>A potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373892</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/faa16291-d0e9-4713-ae3c-f5d0579037cc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40bb2e11-f096-43dd-9d4f-b66af1d1bfe6"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Nicotinamide riboside</rdfs:label>
    <dc:identifier>DB14933</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da404887-3c84-46dd-abf8-c06a96a1495d">
    <dc:identifier>DB05990</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05990</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f6ca4216-2b4e-4ae6-944a-b8973429e241"/>
    <rdfs:label>Obeticholic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c141705-a817-4b46-b4a0-ad5b0de89151">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>pathogenic exon trapping</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6cd8a294-7e8b-4207-85ae-0a217091262f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2f18afcc-8b46-4798-be47-058461b08ab7"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b22cef9b-458e-4def-95c6-2e56296342a3">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d1f7b6dd-3934-41e2-a825-4e28fb98ebae">
        <rdfs:label>AAV9-MCK-fukutin</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/766e92d5-f171-4964-bede-7adbbaef5320"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/07a7a332-c9f6-4079-9a34-b66fc9b61b7f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16390715</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2acb1b72-7b0e-4c14-98b6-425a62ae0063">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5efbe78c-cdde-4864-9774-01346641c480"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fd01df13-69e6-455e-ab03-debd744d4e65">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/306af4bb-5826-4735-adec-f388c35e8c17"/>
  </rdf:Alt>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/b272893a-7e73-40e8-b28e-23e8a610e920">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1929112</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219750"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/afc5eab7-3ee0-4e84-8709-3d0cb42ec2a9"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f140baef-c8c6-4cf1-99cf-adf75bf27b25"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12488257</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12370309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/36ac6404-db4a-45ea-9ee9-c16adbd7592f">
    <dc:identifier>DB01348</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f33e1b7-ae88-4703-ba24-8ef056d4a7e7"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01348</ddiem:url>
    <rdfs:label>Spirapril</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/3b0844f4-8d85-4794-8b57-062b27860f24">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1e7d2f0-c16a-4151-8a4d-3ba39e203737"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9dfd665e-65db-4fbd-b974-2e77bfe55e33">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>High triglyceride levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ffebcfa-f201-410d-8e07-396d0d529147"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/268200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/257bdd0f-a43f-4aea-b3f2-19d0fdd8d4a4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/73bd8a72-e4b6-43b4-a903-bf1a5447f558"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1bd89647-8017-45d7-b9cd-f49e48194520">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e44f225e-65c2-4dc3-8469-2db7d845d8b6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14098</ddiem:url>
    <dc:identifier>DB14098</dc:identifier>
    <rdfs:label>Cobalamin</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/954230de-a684-45bd-b295-b98179dc1cd0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3b0ce0ba-6d45-4999-b0e3-529cb646d373"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/64247a2a-cabd-4bce-ad2c-f2c7d662d96e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0d51ebda-1951-4e61-a921-169b48bcd493"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/00731be4-0dea-40b7-9550-24193a1d46fb"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e575b2cb-1f62-430f-a6ee-d5ba838c8f65"/>
    <rdfs:label>Vitamin E</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/926f7bfd-6090-491d-afbb-b8ec08d2d475"/>
    <dc:identifier>DB00163</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ed3467fb-0061-49b0-ab5c-fb4a563bbc03"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/7cb1b13b-0272-43f9-8bc9-95df1c6940ba">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277460"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9931538</dc:provenance>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd078890-d786-4409-80e1-76d60bc64230"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1b00a0a2-6819-49ec-9198-f54769594e75"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301419</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ed072718-8beb-4823-b1ba-cee7c817e412"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4f71708d-06a4-47b6-bf55-554c4c76f118"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3669352b-d95f-4ade-9f08-0647eefb77d6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11554913</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0416cbe5-b97c-4548-8f9b-51c5fc3ab99a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/64c92643-2aff-47f8-a59d-d9e666acd052"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00163</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a7dc9857-68ce-4138-b320-e155ad00437d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b2ad5c5-8bab-44e5-a437-df8ac73e6344"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7dd5bee8-a3ac-4dd1-9a3b-caaabdcfa01b"/>
    <rdfs:label>Miglustat</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00419</ddiem:url>
    <dc:identifier>DB00419</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fbf8345e-5920-4b07-b8de-319989ff48cf">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2ad3407-3949-4426-92ba-8f493a59fb1d"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ebf7c6e-1e24-45c4-8ee0-62b2890c8236">
    <rdfs:label>glycosaminoglycan accumulation</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004371</ddiem:url>
    <dc:identifier>HP:0004371</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/26edca03-9175-4f13-8032-e56ffd4b4e1c">
    <rdfs:label>Alpha-Aminoisobutyric Acid</rdfs:label>
    <dc:identifier>DB02952</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3b2bff41-82a5-4f1b-a9a0-99c46d5285d7"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02952</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39026671-7172-48ac-97ae-211e9fc7ff5b">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002155</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
    <rdfs:label>Increased plasma triglycerides</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c17bceb-8528-4dfd-8b9c-af41a1ecfea8">
    <rdfs:label>urinary tract infection</rdfs:label>
    <dc:identifier>HP:0000010</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208920">
    <dc:identifier>https://www.omim.org/entry/208920</dc:identifier>
    <rdfs:label>ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/efa27a7e-30fa-4493-9f7d-8b2bdad62f9b"/>
  </ddiem:Disease>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000006">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:02:30+00:00</dc:date>
    <rdfs:label xml:lang="en">compensatory complementation of a genetically defective protein</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the normal product of a defective enzyme or protein is provided to alter its concentration or availability by delivery, stabilisation or modulation of turnover. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/df70152f-bb04-4c7c-a9f6-ea31b7d72dac">
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/405c43e0-b0c8-4d6a-8d40-bc1246fb0bbd">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/06acacb0-9d76-4e0d-8722-908dc894a0cb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0212c985-f816-47e4-995e-a214d71ae8cc"/>
        <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
    <rdfs:label>FIV-hAAT-G6Pase</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e5bdd56f-a47f-4866-bf47-82402ea36138">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e5b73543-3fbe-43e4-9d38-9a61165743e0"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610090">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/76</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/610090</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>76</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e7455160-93fc-4af8-bfb4-5da2d32ec8ae"/>
        <rdfs:label>PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9bbef355-9cb8-4cf3-a903-3c94d784d88f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Astrocytosis in cerebral cortex</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002446</ddiem:url>
    <dc:identifier>HP:0002446</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f41387ef-a003-4160-87e1-056b791f2447">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated Phe level in blood</rdfs:label>
    <dc:identifier>HP:0004923</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7fa5c056-cc23-412b-9886-24e786235007">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e4ae2b6-c9bc-4a7a-8b4a-16c9b8e62a13"/>
    <rdfs:label>AAV-GLUT1</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613077">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 5; PEOA5</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/613077</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3f3c7aa0-7598-486c-b7ce-8a66d5ceff70"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7b495e78-7bc0-4d67-8364-5a9994bf3109">
    <rdfs:label>Givosiran</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0e940a3c-5176-40c5-b7d8-5a3b61b9b6ad"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB15066</ddiem:url>
    <dc:identifier>DB15066</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/45401c42-e121-4e0e-ad6d-4acf40360ff4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12937245</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9a5535b-2a1c-4698-a6b8-5d875556eec5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05ee9fd9-f5a9-4e3f-bd5f-ae103a8bcb43">
        <dc:identifier>HP:0000114</dc:identifier>
        <rdfs:label>Proximal tubular dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/30ec0e1b-03e1-44fc-a54f-3286be14de2e">
    <dc:identifier>DB02329</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02329</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f7167c0c-714c-4d30-8c25-cb48fd4c7aaf"/>
    <rdfs:label>Carbenoxolone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/78a91cc3-c5d5-4ea0-aafa-4fec0dcffb16">
    <rdfs:label>high protein diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a169cd09-bdeb-4a62-a71e-cec7aa99dfe0"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5a5a4dbc-6065-41dc-8f3c-85f4ec23ccc1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4a542af1-180f-4d60-a46e-5ff208349158"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a20d75bf-e382-4742-bc04-a3a32de94332">
    <rdfs:label>Canakinumab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e0084c8-75fd-481a-822f-771be4dd821d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5922b398-4400-4fa1-8bef-48c13a5ed888"/>
    <dc:identifier>DB06168</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06168</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d64ea982-5ee0-4e76-b064-d4798bd4750d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3e7b87e-fea3-4831-9d25-85eade85fea4"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1aed956e-41c2-4a69-b8a6-759bbab798ae">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:label>Ataxia Progression(Rapid progression)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a473f6c8-89c1-412c-bdef-8021efbca21b">
        <dc:identifier>HP:0003678*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>Progression of retinal degeneration ( Rapidly Progressive)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cdee3d21-76e1-4acb-9f09-5950e2854a2a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low levels of purines</rdfs:label>
        <dc:identifier>HP:0004369</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004369</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38b23fae-e657-438b-b2e1-d540bf994fdf">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>frequent hospital admission</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e9d01e60-4081-4d37-9a22-9b3f21fe8cf9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25f26fa2-c0df-4d93-ab3b-c5ea3dae0b83"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0002929707613470</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301835"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20380929</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17701896</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/756d1482-55a9-4481-b0fc-1650a0716690"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23190330</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219500">
    <rdfs:label>CYSTATHIONINURIA</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bf723a27-1a27-4baa-af46-60f12e899773"/>
    <ddiem:iembaseAccessionNumber>28</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/28</ddiem:iembaseUrl>
    <rdfs:comment>Cystathioninuria not associated with vitamin B6 dependency is an evidence of genetic heterogeneity in primary cystathioninuria. https://www.ncbi.nlm.nih.gov/pubmed/417288        https://www.ncbi.nlm.nih.gov/pubmed/5707897</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/219500</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/914f274b-76b2-4d89-9a8f-acaba9e8798e">
    <dc:identifier>HP:0003165</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Elevated circulating parathyroid hormone level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e378d3f7-6819-456a-9c68-365a33487c39">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02285</ddiem:url>
    <rdfs:label>Protoporphyrin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c4642e9-8122-437b-b0d1-c7c867785b21"/>
    <dc:identifier>DB02285</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/20ac9339-dc30-4334-a3a8-2e9be8876707">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3ed02313-776c-4e46-ac45-8b003bf60c8b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6245ada-3da1-4d9d-a0da-57e5fb8bfd8d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23605132</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bd6d73f-ade9-45ed-9e83-5dc34a5ce951">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012825</ddiem:url>
        <dc:identifier>HP:0012825</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mild attack</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4167c5a-548a-4c5e-9819-2a33162569a0">
        <rdfs:label>"(abdominal pain, nausea, vomiting)"</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027, HP_0002017</ddiem:url>
        <dc:identifier>HP:0002027, HP:0002017</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/db57bce8-ba22-444e-ad7d-981c94c85484">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a999c19c-d06f-430c-9650-4bc2184d98be"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7256b2df-833a-4b95-9f36-39dd3b430766"/>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <dc:provenance>https://adisinsight.springer.com/trials/700243447</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfcfeb90-b50a-452f-a1cd-a19aca1d623a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2123dcd0-4c64-4a23-8dba-cd35f00280e5"/>
    <dc:provenance>https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1009485f-617c-4534-9c08-3cc5a4b11531">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b9648dac-3ead-46af-aac6-583875b6f933"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70006cab-f884-4898-8fa0-90d11e0d8644">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002960</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Thyroid antibodies (autoimmunity)*</rdfs:label>
        <dc:identifier>HP:0002960</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/891ca67c-a98d-43ac-982e-1b4378be1b22">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
        <rdfs:label>Abnormal immune function</rdfs:label>
        <dc:identifier>HP:0010978</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/336475f0-03ac-4c3d-95db-857694ebf343">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hemolysis</rdfs:label>
        <dc:identifier>HP:0001878</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8dd408bc-328f-43ec-9f29-1c7fcf1961f7">
        <rdfs:label>lymphopenia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001888</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001888</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b137b5c-88b6-45d8-9563-340e9e748257"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5823ff14-f7b1-4363-9c5c-b095e2955740">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High biliary cholesterol saturation index</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1c848433-bb10-414c-b9cb-cec82264b580">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d5a41ebd-636a-4541-8769-54b3c020ae97">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00186</ddiem:url>
        <dc:identifier>DB00186</dc:identifier>
        <rdfs:label>Lorazepam</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a8f8ddc0-1934-4f68-8cad-e95f852d9d48"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/16f79aba-fc38-4ebb-86ab-9180b731efd3">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5296b6d3-94cf-496b-9f0f-851435fed790"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63730b2a-57d7-424b-a199-563af03a4e23">
        <dc:identifier>HP:0001508</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>failure to thrive</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5dd17a8a-2e1f-46f4-9bd5-c5eca0138101">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>growth delay</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5685f19-401d-4ff6-943f-78b5c0255bd3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low β2 microglobulin,creatinine ratio</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1250facf-e711-4dad-9675-921a7bbe26cf">
        <rdfs:label>hemolytic anemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <dc:identifier>HP:0001878</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bd0fcec-d36e-47c9-b38e-6ba8a7a9d2ac">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal reflexes</rdfs:label>
    <dc:identifier>HP:0001347</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d24ff93-812c-4270-b7e2-e259c815011c">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/16f59753-eb80-4994-b65f-ffb8576973ff">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00682</ddiem:url>
        <rdfs:label>Warfarin</rdfs:label>
        <dc:identifier>DB00682</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/11f215d4-0d75-49fb-ab75-bb042c6aba70"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d62a5ca-9e85-481d-9bd4-a98b7517f325">
    <dc:identifier>HP:0012212</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Glomerular hyperfilteration (Abnormal glomerular filtration rate)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012212</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/28eaa3e9-984a-4ef2-b762-d17939b2611f">
    <dc:identifier>CHEBI_17012</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_17012</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/8bdb8795-2689-4b71-8e15-0c2adb4ae742">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ffebcfa-f201-410d-8e07-396d0d529147"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c3656336-d843-4d94-b1b1-7a19e5bff86d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9e1296d-512c-45c7-9a2d-1d3fc4c41d23"/>
    <rdfs:label>NeuAc</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb9c8f74-7dd5-4c41-a040-86404bbec8fb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>involuntary movements</rdfs:label>
    <dc:identifier>HP:0004305</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/994a3003-824c-4ea3-a8a9-c10f4c248a16">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030098</ddiem:url>
    <dc:identifier>HP:0030098</dc:identifier>
    <rdfs:label>Abnormal fukutin mRNA expression</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/91866c24-466b-4a81-a72d-a9d18fce3bc9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/80b38d56-06f2-487c-b768-5027208c94bd"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc7784ce-2b56-4cb5-aadd-9619ce723c61"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75c3e08b-c1d7-4340-80f4-d6fa798d183a"/>
  </obo:DDIEM_0000013>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/946b9a23-8f75-4d48-9233-3362b80411c9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/536e69b4-8abf-4cfc-97a6-66cdec3d3138">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/002bddca-1a6d-42fe-9cfc-d632dc8c6b80"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0112ffb1-3a72-4221-9f81-18c3b5d0fb29">
        <rdfs:label>Low muscle mass</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253600"/>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a162c3f2-da04-4652-978d-e32865e80200">
    <dc:identifier>HP:0008993</dc:identifier>
    <rdfs:label>Increased intraabdominal fat</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008993</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/84c60feb-31e9-4355-8fda-04902f9f2329">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb4db383-456d-4556-a99d-670ba5e12b3e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25315665</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec906edb-cfba-432a-ae55-10b1592fcd58">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3ec5291b-f0d2-4f29-8212-e9a24083d871"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f93fb2ef-4fcd-4817-b472-8e096ed9d975"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d983d5c2-1e08-4849-ae0b-bee1b594d10f">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
    <dc:identifier>HP:0003072*</dc:identifier>
    <rdfs:label>high serum ionized calcium concentrations</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7e1d2fa-36b9-4c6e-858d-0a8c65f33b44">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001369</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
    <rdfs:label>Joint inflammation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0474f3f0-38ad-45cd-ab9e-a0f72d0ed130">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00641</ddiem:url>
    <rdfs:label>Simvastatin</rdfs:label>
    <dc:identifier>DB00641</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76cb9c88-941d-4cd0-b838-07667427c700"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/da773fbf-f333-4830-85ac-4411eb42e130"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ae610e5d-fa33-454c-baee-3ce96dcc169e"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/429d43da-f133-4423-bf5f-cd3d13326c09">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc2cce28-10f1-47bd-9a19-0d46dcfeb5df"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16848116</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/80b38d56-06f2-487c-b768-5027208c94bd"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/91866c24-466b-4a81-a72d-a9d18fce3bc9"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e2912023-b19c-45f0-9fcd-7be39495ca18">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/47964666-2e50-4608-9d5d-c52d13b01197"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/97794909-f8ee-463b-a85d-a27124b4bc7a">
    <rdfs:label>Potassium cation</rdfs:label>
    <dc:identifier>DB01345</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e812288-5389-47d0-bbee-dd6dc5871f6a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01345</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b51ac73c-3f7d-42fa-9768-c06f64fca88b">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76909eab-7335-46b6-9079-2f9b80e8ff4d"/>
    <rdfs:comment>THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/db6d5a13-b533-4cf7-9813-3d0a4b0c6eb0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b3cfb3c-5f2c-4b2d-9be8-4dbd71dd120d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b7cc8aa-7d8b-490a-ac39-06fc056804d1"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/93e7080f-5501-4957-b112-15ee0ae8e6f2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/10422376-d10a-40c2-b012-09a24ab25c75"/>
    <dc:identifier>DB00741</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00741</ddiem:url>
    <rdfs:label>Hydrocortisone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607091">
    <ddiem:iembaseAccessionNumber>338</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/338</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eecff73d-cb0b-4b4f-9b9d-ce2c8a01c3b9"/>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/607091</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/b16bb431-e522-47cd-8a5d-fc67f4c00f8a">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ea6d9d9-8d88-40a3-8ea2-ecbcc1e4a717"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <obo:RO_0003304>I278T</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/33760351-9bac-4d79-af63-f1864e350c3f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/811f329e-3c0b-4d33-9fdb-46d3bb4a141e">
    <rdfs:label>low bone marrow fat fraction value</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a735fbd-991f-48c4-9d84-efc4ba2506f0">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012011</ddiem:url>
    <dc:identifier>HP:0012011</dc:identifier>
    <rdfs:label>EEG with parito-occipital spike waves</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8623bb4e-7bbe-4123-9c0b-dcc07c208b0a">
    <rdfs:comment>The cystoid changes responed to treatment with systemic immunosuppression and a topical carbonic anhydrase inhibitor (CAI), recurred when treated with topical CAI monotherapy.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/54bf7bf9-1a8f-4e6e-a906-4b0523267392"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/31253c01-9e5b-407e-9992-067368e54909">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b471d0fb-b2ad-4ca2-ac23-e00c1a72163e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec567e09-9048-4dae-811b-49cef374360b"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c25adf43-1f80-438f-94b2-7ee9796dfc3c">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/897cd158-48ca-42c8-b477-1d8755ea0d67">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/eac8f1ca-9b9e-4ef7-bc1f-a52101310174"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26358771</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95794466-ece5-40df-b6bd-86242204716f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/829c1c9e-bd72-48a7-b412-41560e1e0f97"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03378531</dc:provenance>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd078890-d786-4409-80e1-76d60bc64230"/>
        <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2ef41cd7-f966-4f40-8883-0064f49716ba">
    <rdfs:label>AAV2/5-PBGD</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9c2ada1-0115-4563-a289-cc7e5db7693b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6be001bc-2562-4645-99af-c6918c03cc7a">
    <rdfs:label>Desipramine</rdfs:label>
    <dc:identifier>DB01151</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5283f9e-407d-40fd-bd5e-bbcbb376d4a9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01151</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/452f232d-9d66-4324-a8a3-8b1a99087923">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/269920"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f6e1b087-325a-44d2-8fe0-2e6eaf5e32bf"/>
        <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b9648dac-3ead-46af-aac6-583875b6f933">
    <rdfs:label>Elapegademase</rdfs:label>
    <dc:identifier>DB14712</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/db57bce8-ba22-444e-ad7d-981c94c85484"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14712</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5fb8bfc7-2cc9-4634-bbff-ee574f9a1932">
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7148673d-633f-4aa9-9416-93e8f29b6764"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/341539e4-f7d4-4843-87b7-783f37edb4d2"/>
  </obo:DDIEM_0000013>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy">
    <rdfs:label xml:lang="en">direct complementation of a genetically defective protein by gene therapy</rdfs:label>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <obo:IAO_0000115 xml:lang="en">Insertion of one or more normal copies of a genetically defective gene into the genome of affected cells.</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0da634fd-b049-463c-b137-09954d0da1df">
    <rdfs:label>Ethosuximide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/35cf5313-7721-4e4d-9ce2-9ed31ab815c2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00593</ddiem:url>
    <dc:identifier>DB00593</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d9d78765-6201-45e0-8e35-d16eb426abd7">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d49ba23-6f45-4afa-8fb6-85f36321676b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208740</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab614ee7-d637-47df-b1ca-e4622a708e3a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
        <rdfs:label>Eevated porphyrin precursors porphobilinogen</rdfs:label>
        <dc:identifier>HP:0012217</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed072718-8beb-4823-b1ba-cee7c817e412">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100513</ddiem:url>
    <rdfs:label>Abnormal vitamin E level(Vitamin E deficiency)*</rdfs:label>
    <dc:identifier>HP:0100513*</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c015589f-f648-47bc-80c1-96e1be5c946b">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bf935035-e181-4bd6-8511-d70e7dea246e">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d02256a2-4e36-45e6-bba7-2230d1eb191a"/>
        <dc:identifier>DB13191</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB13191</ddiem:url>
        <rdfs:label>Phosphocreatine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/28f83b4c-421d-4536-9695-1141c8578b39"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/286dc748-fa39-4a43-8374-5517aec1f85f"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/73fdff04-cb37-4dcc-a061-a3c2b86d41e7">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/485583f9-7a5f-401e-b7c5-81303b52e053">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00458</ddiem:url>
        <dc:identifier>DB00458</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5887727-4a24-4a28-8211-318cd1edadb0"/>
        <rdfs:label>Imipramine</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86cef96e-5909-46c2-8e14-032c9f42de2a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012040</ddiem:url>
    <dc:identifier>HP:0012040</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Corneal Oedema</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6ff27127-1cda-442f-ae19-e18f931a74a4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/74f10a4c-7eab-4303-9cad-ceb43232ff3b"/>
    <dc:identifier>DB13961</dc:identifier>
    <rdfs:label>Fish oil</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13961</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ffbfc6a5-8cc0-47fc-9d47-d2b64067c19b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ce18dcb4-df6e-43ad-87c4-11f0880615d7"/>
    <dc:identifier>N06AB</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N06AB</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d88f31d4-9685-4da3-840f-9da02d5fc02a">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02023866</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4a132ed-af29-455f-badb-3d0c6a20a740"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/afc5eab7-3ee0-4e84-8709-3d0cb42ec2a9"/>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/618098">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1336</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1336</ddiem:iembaseUrl>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 5; PEOB5</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1d5c4cc9-599f-42bc-8111-675f1aa36a9c"/>
    <dc:identifier>https://www.omim.org/entry/618098</dc:identifier>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/269920">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/14bb194f-3521-472d-9bab-4f9565633c4a"/>
    <dc:identifier>https://www.omim.org/entry/269920</dc:identifier>
    <ddiem:iembaseAccessionNumber>267</ddiem:iembaseAccessionNumber>
    <rdfs:label>INFANTILE SIALIC ACID STORAGE DISEASE; ISSD</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/267</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6f998dc8-cdb8-42d1-835a-2f5698928a6f">
    <dc:identifier>DB00182</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00182</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/40dda43a-a1e4-459f-b182-5d569a828550"/>
    <rdfs:label>Amphetamine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ea2f9902-d8e2-4815-b788-ccfc059355cb">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09125</ddiem:url>
    <dc:identifier>DB09125</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb9832d0-db30-444f-a6de-7decd9ee893a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a7070428-bd7b-4e89-b5c8-f7053dfc0418"/>
    <rdfs:label>Potassium Citrate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e7ddb27-09ae-4b89-8094-06e05383ecb2">
    <dc:identifier>HP:0008281</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
    <rdfs:label>acute hyperammonemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ec9bb2a1-ddeb-4303-8cf6-233ca06eb71e">
    <dc:identifier>DB00936</dc:identifier>
    <rdfs:label>Salicylic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00936</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/03a1730c-bf7d-4069-8320-1e63534fd2c3"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/df310fb4-5939-41ad-b6dc-a60673ba7117">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00244</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/418ab40e-4825-423a-96d4-0880465e75f6"/>
    <dc:identifier>DB00244</dc:identifier>
    <rdfs:label>Mesalazine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/638b890c-f99f-4069-8164-c921cfa57ff2">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00151</ddiem:url>
    <rdfs:label>L-Cysteine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c1d86c60-4f5c-48c6-adaf-45d4a50eae79"/>
    <dc:identifier>DB00151</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1fc05532-973d-43cb-a975-c157215414bf">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/86b71a2c-43b6-45a7-9bfa-09ca293fbbab">
        <dc:identifier>DB06755</dc:identifier>
        <rdfs:label>Beta carotene</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25b5f8c8-39b2-442c-9a48-52fb2a81be44"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB06755</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1fbb362d-b4c0-4b88-8f4e-6ea0c93cf0f0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2b3bee94-42ee-43e0-8e6f-a45434136608"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dc8bee80-5fb6-4faf-989c-5bf5236dbf4f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/db1d87a8-0d6a-4a4f-8eae-e87a2ad5e255"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/13e02bb5-9877-4586-9140-daf64836ad5d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84f0882a-ab54-46a0-9185-248a8f66fc00"/>
    <rdfs:label>Leucovorin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00650</ddiem:url>
    <dc:identifier>DB00650</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/984080b6-e31d-44f3-b001-a7a79a09ffc8">
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04402021-12b9-4f1b-a663-000f967d624b">
        <rdfs:label>Renal tubular acidosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001947</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001947</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9a5535b-2a1c-4698-a6b8-5d875556eec5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/49bcd89e-8496-4779-8e29-9bf326bca3b6">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b4e62b4f-6170-401a-9efd-b5a397dbb8de"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ae499ea-5338-4546-a724-09484f40758b"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0d2620ac-da76-4ca3-9701-efbdc7af885f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b923afa-2ef7-4b2d-9fe6-2ce69ccccdf6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4dd980c2-b98b-4db9-b88b-9f5cdc39c4fe"/>
    <rdfs:label>Omega-3 fatty acids</rdfs:label>
    <dc:identifier>DB11133</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11133</ddiem:url>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000002">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a treatment directly or indirectly compensates for the loss or gain of activity of a genetically defective protein within the network or pathway of which that protein is a member. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <rdfs:label xml:lang="en">complementation therapy</rdfs:label>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9762aca0-6dfb-47b0-a91a-7d592c8b130e">
    <rdfs:label>Abnormal H50 (The erythrocyte resistance to oxidative stress)</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32009a6b-54a8-4f42-9777-515ae2266d89">
    <dc:identifier>HP:0031544</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031544</ddiem:url>
    <rdfs:label>High blood malonylcarnitine level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b7c74f92-c768-4091-8ddc-622f5b1f00e5">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/308ee8d8-c8c5-4039-8805-05a848a5dcfc"/>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/da07152c-f7cb-4544-978b-0722b64057a0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29a4309e-6ccc-498d-b279-8d6ce22b2144"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d984ca51-6a28-4c76-85e8-e956a1226dca">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:label>Generalized tonic–clonic seizure</rdfs:label>
        <dc:identifier>HP:0002069</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b0dd6d1-9c34-43d1-aafc-8797237e6154">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007359</dc:identifier>
        <rdfs:label>Focal seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007359</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fac60057-d0f4-4cba-80cd-21a466ca0848">
    <rdfs:label>Rifampicin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01045</ddiem:url>
    <dc:identifier>DB01045</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fcfaab81-e84d-457e-84bc-d55657d41c33">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12012642</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26264947</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fc714a7b-1ae5-4eab-b7a2-a37d0e448a8c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f375392-d956-4c14-a51a-2151459925c2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16083704</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237500"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5823ff14-f7b1-4363-9c5c-b095e2955740"/>
        <rdfs:comment>Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974C→G nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5a75dfb-efac-4a03-9e3c-7a84568d3eda"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b942c222-9608-4dd0-8a16-e90e8f71a199"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16952291</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec998174-5a50-412e-b983-d15f9853636e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d365f58-de50-4748-8715-8b20e34ab3c1"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cc9f7e2-f617-4158-b1af-69a1199937e8">
    <rdfs:label>hypoproteinemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:0005567</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0005567</ddiem:url>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/a7c978ac-7e93-4762-9d1e-39fe95f0894f">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151216</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/aea0f4c5-7e29-4cbc-bcf9-6f7c976fb4e9"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7fa6e39b-1512-425c-a49a-8262191e1924">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/748e48a6-0baa-4378-b828-754b897d0317"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d565de12-cbcf-4d13-b441-dee9ec3de9fb">
    <rdfs:label>High plasma level of very-long-chain fatty acids</rdfs:label>
    <dc:identifier>HP:0003455</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6546f832-f14d-4fb6-880d-57e2879774bc">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5f8ec830-b66f-4dca-8512-1607f9f87940"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cc5589cd-ee32-4a05-a4c0-c7d47d3f112a">
    <rdfs:label>Urea</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03904</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/03a1730c-bf7d-4069-8320-1e63534fd2c3"/>
    <dc:identifier>DB03904</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e9b517e8-bdfd-4cc8-9d53-7937454c7a42">
    <rdfs:label>Milrinone</rdfs:label>
    <dc:identifier>DB00235</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00235</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43bbf76c-cc35-470c-ba17-8558e9ec532b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b27c60bf-ef97-487a-bf6f-fdacc6bdee6a">
    <dc:identifier>HP:0012514</dc:identifier>
    <rdfs:label>Lower limb pain</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012514</ddiem:url>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000012">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:23+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which  generally small molecules are delivered to the organism in order to to directly increase, decrease or alter the activity or stability of a genetically defective protein.[PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein</rdfs:label>
  </owl:Class>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/17dc4fc2-6329-4d30-af71-c448a9497760">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/050e4ad7-9522-4300-8597-a6cd502a6274"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f77882a1-bccb-4c7c-b9eb-b53d7bb7c075">
    <dc:identifier>DB00451</dc:identifier>
    <rdfs:label>Levothyroxine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/38fec408-49db-42a2-8d1f-d6e4e9e0ef72"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/80863ea8-b36d-4a60-b1eb-598845ad1ec7"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00451</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/521e1a72-00b6-474b-a96d-9175304d9e97">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/073d8403-1258-494f-8caf-1dbfc69094d3"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8b1c9d6-9541-45e8-9988-ebadbade08bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/48effd6e-f42c-4e36-9812-a417cb00fc64">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cec66c8c-60a8-48d0-bba4-fcaffcd6840c"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/46b8f948-5b4a-45ef-b674-a1398b7ad383">
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5346fc1b-27e5-4deb-ab57-b62f2bac89e4"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72d43680-393f-45b9-9226-6175be214012"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55dffc74-4a89-43a4-942e-05802a3f9608"/>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB02701</dc:identifier>
    <rdfs:label>Nicotinamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02701</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bdd63169-fed9-4b95-acae-2c6c07b1a7d9"/>
  </ddiem:Drug>
  <obo:DDIEM_0000008 rdf:about="http://ddiem.phenomebrowser.net/d4baf90c-6abd-43c9-8bc1-289d673e613f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5296b6d3-94cf-496b-9f0f-851435fed790"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/32009a6b-54a8-4f42-9777-515ae2266d89"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248360"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62200a1d-15f5-4f77-bc4d-a43fe3cd0bd0">
        <dc:identifier>HP:0025142</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>Low endurance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f76e45e-a412-4d56-b741-82a8fa593cee"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/baab0737-274e-42c3-b7be-ce6f78735a07"/>
  </obo:DDIEM_0000008>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85874332-8ee0-43d5-97a9-21f9e70689f9">
    <rdfs:label>Low expression of AGA enzyme</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5efbe78c-cdde-4864-9774-01346641c480">
    <dc:identifier>DB09539</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07a7a332-c9f6-4079-9a34-b66fc9b61b7f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09539</ddiem:url>
    <rdfs:label>Omega-3-acid ethyl esters</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2c74d52-3d61-47b9-a754-dab5c86fad42">
    <rdfs:label>Abnormal linear growth (Decreased linear growth ,Abnormal body height)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000002</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9542101b-8ca4-4707-a19f-053f4a4c6322">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5dd98f4d-1316-4efb-8628-1cdc656c8d3c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/89e490b4-18e1-41e8-9ea4-fdd7d1750f76">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0cb3f6b4-f878-49d6-a956-2ceaf07c6025"/>
    <rdfs:label>Tolbutamide</rdfs:label>
    <dc:identifier>DB01124</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01124</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/31f6cf3b-10c0-4b86-9ba6-f3ba4d29ed95">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10574582</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f23aaa9-c55e-4a04-9178-f5e0559f8f0a"/>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6a912b0-a5fc-40a4-bc5c-67532ee30a43"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ffebcfa-f201-410d-8e07-396d0d529147"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9da6d03b-025a-4ceb-996a-8a6a43d39af2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16803637</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b27c60bf-ef97-487a-bf6f-fdacc6bdee6a"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a16a41bd-cc8a-4ad6-b9d8-179c5a280f9b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0e4178f4-e244-4b1c-be72-29f938d9079a"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b224b948-1057-46ab-b3e2-976c066b9553">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0672df24-ab67-4e18-9099-fa40a82aad18"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01197</ddiem:url>
    <rdfs:label>Captopril</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5fb8bfc7-2cc9-4634-bbff-ee574f9a1932"/>
    <dc:identifier>DB01197</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d94e0b70-0eb9-438d-a127-db37f156ee93">
    <dc:identifier>DB00118</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/016cc0fb-be76-406f-85b1-cfe3ef32beda"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43288d54-b218-4a5b-9fa9-4481a8ffe48d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d64ea982-5ee0-4e76-b064-d4798bd4750d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a84e6db3-89a0-4b97-b736-f1388eb8d6a7"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00118</ddiem:url>
    <rdfs:label>Ademetionine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a3a1b0e-8e50-4eb6-a4b5-4e77b492a326">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>skin inflammation</rdfs:label>
    <dc:identifier>HP:0011123</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/79d213a5-5b97-435b-a6bf-6971fce2292e">
    <dc:identifier>DB00916</dc:identifier>
    <rdfs:label>Metronidazole</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9bef5087-dde2-4008-a1d4-95fdd8b5b1c0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00916</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce585cd1-695a-4038-8f3c-48de01da7452">
    <dc:identifier>HP:0003808</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal muscle tone</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003808</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d19ca533-7a2b-407d-bd5d-2858145b0872">
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3006738-1d7d-4d12-b54b-cdd717b23f35"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/952f8799-0f11-409e-b76a-9f26a88b3362">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06281</ddiem:url>
    <rdfs:label>Torcetrapib</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/479e5835-7538-4351-b310-590a64ad060e"/>
    <dc:identifier>DB06281</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bd92846a-5e19-4355-9883-df5da80afe5c">
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29273094</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e5b73543-3fbe-43e4-9d38-9a61165743e0"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615181"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/88aaf58f-dee6-4010-84b1-f62902452642">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1dfcb8da-ac04-42b2-bba1-a13ee6e8ba81"/>
    <rdfs:label>AAV-based gene therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b83872f5-6828-4989-beb3-dfa1e21ac050">
    <rdfs:label>Cholecalciferol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00169</ddiem:url>
    <dc:identifier>DB00169</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6fc32a45-a1b6-4922-8f5e-f41e4ae2137e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2710a753-d32b-4b78-8d13-76da4478060a">
    <dc:identifier>DB04173</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f9dc2fcd-e93b-44f6-9aeb-9f822575d7db"/>
    <rdfs:label>Fructose</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04173</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/fcf29599-1ad6-4727-ae95-a74309d19f32">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d249f4af-7d79-441f-bd32-1ce29a700254"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/870499c3-a73d-45fe-ae65-4d2e22545398">
        <rdfs:label>hypoglycemic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002173</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002173</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0225fda0-3f44-41ab-a90b-178cc46931c6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3dce3c7e-f61a-4367-98d9-3385fe71302e"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
  </obo:DDIEM_0000010>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f66fff85-fe9f-4739-8be5-73532b5580f2">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6ac13eed-bae9-491a-a9b9-db3fd3f90009">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01109</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b1656cf6-e31c-4f16-89b5-0d716b27de1e"/>
        <dc:identifier>DB01109</dc:identifier>
        <rdfs:label>Heparin</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0e4178f4-e244-4b1c-be72-29f938d9079a">
    <dc:identifier>S01BC</dc:identifier>
    <rdfs:label>Antiinflammatory agents, non-steroids</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01BC</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/31f6cf3b-10c0-4b86-9ba6-f3ba4d29ed95"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9fabbfd1-a4c8-4617-a150-5208f1ac75dd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d37de9ad-cbcf-4b3a-ad97-743ac9f3c34a"/>
    <rdfs:label>Inositol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13178</ddiem:url>
    <dc:identifier>DB13178</dc:identifier>
  </ddiem:Drug>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/766e92d5-f171-4964-bede-7adbbaef5320">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6a2a7ae9-44f0-4417-9035-3c9d44695115">
        <rdfs:label>Imapired muscle function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011804</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b22cef9b-458e-4def-95c6-2e56296342a3"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d999daf3-f2da-466c-948f-72c77e65e94c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2e32fde-8a2d-428b-bc30-05f1ba6d74eb">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:label>decrease muscle strenght</rdfs:label>
        <dc:identifier>HP:0001324</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47e4c218-8492-4c82-9c47-bcb3cf39a00f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040306</ddiem:url>
        <dc:identifier>HP:0040306</dc:identifier>
        <rdfs:label>decreased male libido</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40f52608-d9ad-411b-8ffa-29ae70c413cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28160246</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f21f459-62f8-4efd-9456-ba8ad5d75b05">
        <dc:identifier>HP:0025142</dc:identifier>
        <rdfs:label>low physical activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0da032c4-f7f8-4b57-84cf-e5161d3f2034">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604369"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e5b73543-3fbe-43e4-9d38-9a61165743e0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794688</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd94ef5c-3c70-4ad0-bc36-1461c6f8bf58">
    <dc:identifier>HP:0001873</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
    <rdfs:label>Thrombocytpenia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b864d7aa-9258-4b8b-870d-c97b5b68e1b8">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Self-injurious Behavior</rdfs:label>
    <dc:identifier>HP:0100716</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f66608ee-ee6c-498d-b261-9bb8fe809044">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8d750b0e-7d79-4233-a8e6-91edecaf2180"/>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/11f215d4-0d75-49fb-ab75-bb042c6aba70">
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d24ff93-812c-4270-b7e2-e259c815011c"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de92af8b-e721-49ce-b35b-e02d86c0ae76">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002625</ddiem:url>
        <dc:identifier>HP:0002625</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Deep venous thrombosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11320193</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a91ecba0-fbeb-4b3d-af05-cd1ce6b94a43">
    <rdfs:label>Cabozantinib</rdfs:label>
    <dc:identifier>DB08875</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08875</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/00ac772a-310b-47df-973b-fc5ded34edac"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86f95ca1-1845-4e65-ad3e-3aafb9c50822">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ffa9fdf0-596c-4148-a74b-4a806cdc6e7d"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5da22643-0ef0-4c64-9963-5f5584de3659">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
    <dc:identifier>HP:0002123</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Myoclonic epliepsy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1f6a4e42-d3d4-48bc-88de-9ae88f0d48e6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/255124ab-d1b4-4988-9e4c-ea17dd292486"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eacb9cc8-cb87-4bda-a082-a5bc735ad27f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11251</ddiem:url>
    <rdfs:label>Tocopherol</rdfs:label>
    <dc:identifier>DB11251</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cde44932-4cc6-4b14-9ef6-09eea6b98399">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982212</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/49ba89bf-43be-4366-a70a-d5a2685f74db"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3035daba-4609-4935-8c07-777bb6b8961c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/901d5197-1a51-460a-bcf4-7ab8982b31f4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dd35b9f3-5c45-4ccc-bad2-98fc01894907">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/796c913a-3af1-45fc-b3e9-8da2638c76f6">
        <dc:identifier>HP:0031377</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031377</ddiem:url>
        <rdfs:label>Abnormal cellular proliferation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10947080</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac03822c-91b2-4f45-9b54-b905d4dddab0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/312b5078-83bb-4fc7-9b4c-d337c9cf5b2d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/40da2e40-466e-45ad-90db-1906ea504a26"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5a75dfb-efac-4a03-9e3c-7a84568d3eda">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>hyperbilirunbinemia</rdfs:label>
    <dc:identifier>HP:0002904</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/27b478fd-e117-4279-b912-b55e04e93dc1">
    <dc:identifier>DB09278</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09278</ddiem:url>
    <rdfs:label>Activated charcoal</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1273a14c-4bcb-44de-ba40-4cd9b7c79a3e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f6c451a-89ce-462b-9504-7e52b81caf2a">
    <dc:identifier>HP:0025142</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
    <rdfs:label>Low physical capacity (Constitutional symptom)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a14fd85-a77d-4bce-bfcb-cb2a4d846479">
    <rdfs:label>St. John&amp;apos;s Wort</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01323</ddiem:url>
    <dc:identifier>DB01323</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/168b3348-4dad-4f7e-9ecb-439eefcb54a6"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/47d6665c-05c9-4f15-9831-eff5445a39d7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12839</ddiem:url>
    <dc:identifier>DB12839</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/26bc5ed5-899c-4a60-9198-36d8a9c5df99">
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719218300210</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/98abc80a-49d3-4b13-bae7-b54dcd89c7eb"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1525001605000845</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261600"/>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c87ce811-f394-4ea5-8052-c3396c7b80cb"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Pegvaliase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03b4bc1c-7eb4-4301-8e88-bb129b4476f9">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>secondary hyperparathyrodism</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
    <dc:identifier>HP:0000867</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/254aae89-dd77-451f-9c56-a73158f6166c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24aae510-f7af-4fb2-bbb1-1f91ad4b9fb2"/>
    <rdfs:label>Eltrombopag</rdfs:label>
    <dc:identifier>DB06210</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06210</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bada332c-52bd-478b-8472-8a2eaf661e80">
    <rdfs:label>retarded growth</rdfs:label>
    <dc:identifier>HP:0001510</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/58f6cb34-5266-4b8f-ab09-96488dc6f50c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b73d7d14-c647-4579-a7ce-3d5a7b4c8fd2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <rdfs:label>Intellectual disability</rdfs:label>
        <dc:identifier>HP:0001249</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b8fdf3ac-a47e-4c09-a7b0-6d6840e94392"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2e72105-1de0-456d-91b4-a597c2357555">
        <dc:identifier>HP:0002188</dc:identifier>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002188</ddiem:url>
        <rdfs:label>Delayed CNS mylinaton</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/435eebf6-c973-44a8-834e-3c9121940000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5cf23e9e-7c23-44c2-bf7c-4d5e48bfd8e5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2412352c-e1e4-4bda-8fe5-ca54b580f917"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a2b61387-b1b7-4463-9836-e5ec6d785004"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d919e2a8-ad4f-4d5a-8f5a-90515983762d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5ccaa8d0-1eb3-417c-9f9b-bff4a02fb0d3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f7a9458-accb-4638-a81a-9314c57d3f5d">
    <dc:identifier>MP:0020582*</dc:identifier>
    <rdfs:label>High intracellular cermaid level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b2e9d95-134a-48d1-ad8e-357d09a7ec22">
    <dc:identifier>DB01586</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/44aec5f7-7115-4f9f-98e3-62a17040c99e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01586</ddiem:url>
    <rdfs:label>Ursodeoxycholic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e44c4c46-102b-40b0-94ad-e6f73b742b4e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/11b77c2b-db56-47f4-97f7-5a582732d164">
    <rdfs:label>CoCarbs + HPro</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/30e66cb0-3cf1-4889-950b-2b936523ae55"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/299f3f53-15bf-4f10-b641-1a0b1d039682">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2e0af97b-b69c-4e56-b3ab-2b135c560a56"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a20d75bf-e382-4742-bc04-a3a32de94332"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6d7a710d-c029-4ec7-a9d2-3569991203a1">
    <rdfs:label>Uridine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02745</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c9079f4-0c79-484f-9d63-2ce9e9d4e0f1"/>
    <dc:identifier>DB02745</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/409fb37d-5700-409e-b7e8-585b801da7ca">
    <rdfs:label>Low Brain Copper (Abnormal copper levels)*</rdfs:label>
    <dc:identifier>HP:0010836*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92a442f5-a2c0-4f64-974e-2582b473d55c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
    <rdfs:label>Heart failure</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001635</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118610">
    <dc:identifier>https://www.omim.org/entry/118610</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fccb6ce4-1730-44e3-a117-00e8de1704c8"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CHONDROCALCINOSIS DUE TO APATITE CRYSTAL DEPOSITION</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2c256e9f-0dc7-495b-ab38-6a4466916586">
    <rdfs:label>Dextrose, unspecified form</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09341</ddiem:url>
    <dc:identifier>DB09341</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/20ac9339-dc30-4334-a3a8-2e9be8876707"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d715a5a3-8237-42d8-ac8b-fdacb180b3d2"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8169752f-c6c8-488a-a327-0dd5a89c7d5e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/145b0442-4a46-4eb2-83a2-db98b4fd7f77"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/921e5da9-8103-42b1-803c-0005439727a4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3d6e276-a327-4b3f-9e9e-23148ed71921"/>
    <rdfs:label>Ad-hBUGT1</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ab8488e-3c7e-408c-98f5-7ebf50957730">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0005346</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005346</ddiem:url>
    <rdfs:label>Abnormal facial expression</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bb142444-e7ac-4632-b00e-567363f7cdde">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a09b17c7-8eb7-4c78-9f9a-59553495e90b"/>
  </rdf:Alt>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000010">
    <rdfs:label xml:lang="en">dietary supplementation</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with foodstuffs containing molecules closely related to the products or end processes of a genetically defective protein, which occur naturally in the diet. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:54+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c931eeb-b756-422d-8386-593a93504aa8">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ipsilateral brain neuronal storage abnormalities</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fe31fc67-b97e-4b51-a099-53e699b10cf4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7268fc07-4cd0-4a8e-a008-ca15e525dd50"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1742906c-6665-4a33-a675-b6b22e5b693e"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8ad83207-49cf-42a3-ba0a-a0c6b4622485"/>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e44ef7c0-5b92-48cd-b33f-6979b4288ea8">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2445ffee-829b-4530-9093-43fdd2d3c005"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2bae0e9-fec0-4c02-8455-01c251e0eff2"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649943</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/93293824-f33b-4cbd-9e7d-a403627f8bcb">
    <rdfs:label>Gabapentin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00996</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/78760dff-2dab-49c6-b2ca-27b8bbe117b1"/>
    <dc:identifier>DB00996</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78d3e2ec-d660-4729-a512-1a6f1fa939fc">
    <rdfs:label>Purkinji cells apoptosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0000880</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:0000880</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/429889a4-bb3e-4d94-b761-460f7fdcfa38">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01</ddiem:url>
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/06926a0a-4f79-413c-bde3-735a6afd2f3f"/>
    <dc:identifier>B01</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/522ea7f9-df67-4c0c-8cc8-c5fcb5ce96fd">
    <rdfs:label>Chimeric oligonucleotide(oligonucleotide-based gene therapy)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3158450-3608-4e7e-b22c-d5dc9d0e8003"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bcc36826-d5f5-49a9-9258-2da8c7e0d761">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B05BB01</ddiem:url>
    <dc:identifier>B05BB01</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ebe086cf-2f79-4ed7-a4ee-2c20ce1022e1"/>
    <rdfs:label>electrolytes</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53f31c32-df23-43a5-9808-5810e5726528">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100512</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>concommitant low vit D level</rdfs:label>
    <dc:identifier>HP:0100512*</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/fc924188-8bab-4e29-b3b8-3c2679712930">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a600bcb6-795c-48f8-8ecf-8c4ffa57b8ed"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f86f2b22-28fa-411e-8632-4ea1dc9634a1">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01257</ddiem:url>
    <dc:identifier>DB01257</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/096fc118-3a37-4473-bb30-4fd807d2b077">
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9dae116-6346-4bb4-9460-ff8a4b05c6eb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35cb7ecc-cbf7-44d3-96d1-52a5b20f2d4d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/250940"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e3b0fc2-a2d4-4924-8993-0e94b62c9de7"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d75b202-4b45-4462-888a-58f6dc4cb3f6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/87e8e780-270a-4a95-95cc-c8b0cd7dd1eb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1fa53f0a-a8dd-4fad-aed9-5acaff3798ee"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Eculizumab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/09516cea-bcf1-4d1f-afed-4f02cfa1e75d"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/66453411-52ba-4df0-872b-8965a88e5162">
    <dc:identifier>DB14872</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14872</ddiem:url>
    <rdfs:label>Lucerastat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f602b3aa-4f01-4526-82ba-5377d6116410"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f60f594f-ea23-4694-84be-0df2af41849d">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6602cbd1-c48d-41e0-b0f7-afdd60be6bfe">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/600d2efd-a78f-4489-af5f-0fa6db83cdb4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/734310c8-3d78-456a-916a-529aae385667"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a51c88d-701c-49e1-82d0-53d60dfd74c2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62e9860d-01ef-4d69-9f1b-162f4ebf6d39"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c29ce27-f5d6-44be-be72-7875c21b9b35"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72d43680-393f-45b9-9226-6175be214012"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16214240</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c7be2207-9248-440c-b331-5c32d3323b2c"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB14476</dc:identifier>
    <rdfs:label>DL-alpha-Tocopherol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14476</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a9cbfeb7-315d-4b44-82e5-b568cbf2d9fd">
    <rdfs:label>Colchicine</rdfs:label>
    <dc:identifier>DB01394</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01394</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/680ba767-34c4-4ca8-b281-0a88150c19d8"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c8ddd255-6782-47f1-b0ed-1415b11d4ee6">
    <rdfs:label>Pramipexole</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00413</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/18b2fa95-d35e-4f1b-a8f7-04aacff79969"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0e2bdd18-df46-4287-a3c8-91f8136b119f"/>
    <dc:identifier>DB00413</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8782994a-3851-469c-ae44-57e42d90889d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012758</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012758</dc:identifier>
    <rdfs:label>neurodevelopmental delay</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/a67854e0-d06b-4e4d-abe7-923876cc083a">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee118783-11d0-48af-84e9-b7ad6b7577e7"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d0b5572-3cfe-4969-b472-76f156f87a8f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f713776-2314-4baa-9d95-25494f4aeca8">
        <dc:identifier>HP:0000712</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
        <rdfs:label>emotional disturbances</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8850a3a5-bf8f-462b-8b1e-557956afbad5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1a5f3fb-a905-4200-93b6-55893a076da6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48a584ad-6104-4afc-893e-195e604fac4a"/>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a3a1b0e-8e50-4eb6-a4b5-4e77b492a326"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/beefc986-da24-4a19-86f5-826cd2627516">
    <dc:identifier>DB00147</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a1b3d1f-adab-4580-a047-57dd15741699"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00147</ddiem:url>
    <rdfs:label>Pyridoxal</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4821bb6b-81f7-4984-b3f4-4f2ae99708fc">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9ce7f257-f12f-44ff-bacc-1146b10cf7bd"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be5d3ec0-415a-44e6-a2d5-d90767e6baf7">
    <dc:identifier>HP:0002063</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Rigidity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002063</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c3911094-6b07-4e57-8d4d-8f8b83f3df3f">
    <dc:identifier>DB01914</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/b83a4ce8-b14f-4812-b88b-d950266ebe15">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29203193</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/229700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0212c985-f816-47e4-995e-a214d71ae8cc"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0ac9755c-32d6-4fa1-9ef0-97cc93ea4608"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/38ed1308-10ef-4488-b2bc-9fd8bf29fcd0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/325eda88-4454-4525-8f26-016ff6406192"/>
    <rdfs:label>D-glucose</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01914</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/478962b6-56b7-41b4-993b-0b88ee10ff47"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c57e210d-9381-44a0-bfc9-d1866b338683">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dafe7f59-83a7-4142-9a8b-a84c4f520e20"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e21183d8-1315-4e65-803a-78f624f9b58e">
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C04</ddiem:url>
        <dc:identifier>C04</dc:identifier>
        <rdfs:label>PERIPHERAL VASODILATORS</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5857501d-2c5d-4301-a574-bd01bbe39174"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7d554dfe-6436-4b7d-8f12-f9f38ccfe7c1"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c5656230-eccc-4130-8c3d-0e3af63838f9"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/73bd8a72-e4b6-43b4-a903-bf1a5447f558">
    <dc:identifier>DB08834</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3b0844f4-8d85-4794-8b57-062b27860f24"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08834</ddiem:url>
    <rdfs:label>Tauroursodeoxycholic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5942f73-7a80-4453-8e1a-a26325d862f9">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>defected  L-2-HGDH enzyme activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229700">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/483</ddiem:iembaseUrl>
    <rdfs:comment>The therapy is based on avoiding prolonged fasts, glucose infusion, and a specific diet, rich in glucose without fructose intake. https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&amp;Cmd=Retrieve&amp;list_uids=29390242&amp;dopt=abstractplus
Fructose, glycerol and oral medicines that may contain sucrose and sorbitol should not be given during acute illness. https://link.springer.com/chapter/10.1007/978-3-642-15720-2_9</rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ac495996-d401-47cc-9457-481d6bfd32a9"/>
    <rdfs:label>FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/229700</dc:identifier>
    <ddiem:iembaseAccessionNumber>483</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7b0d65c2-448c-49b7-a28d-7b2cc86d16e2">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01593</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e5fd5a55-6986-42ce-a4b7-78bbdf27deec"/>
    <rdfs:label>Zinc</rdfs:label>
    <dc:identifier>DB01593</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e76ad43d-bc65-4062-9b0b-e0e0c6555f31">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/48a584ad-6104-4afc-893e-195e604fac4a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b116b242-25e5-48de-a2e9-4bcfbcbacbeb"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a67854e0-d06b-4e4d-abe7-923876cc083a"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f921a694-0939-47e6-881e-4d44c131b001">
    <dc:identifier>HP:0005110</dc:identifier>
    <rdfs:label>Atrial fibrillation</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005110</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5e3efd6e-8c10-4dbe-aae9-019aca2c113d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9a5535b-2a1c-4698-a6b8-5d875556eec5"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603358"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0173310e-f251-478b-97fb-0e5e4eb0064c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>lactic acidosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <dc:identifier>HP:0003128</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22970607</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/724ac8a8-4f1a-4b53-99f8-10101c0e2c09">
    <rdfs:label>(6R)-Folinic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4369b02f-6e9f-4be3-b472-0c63262c409b"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/d36305ad-7474-4a53-8c4b-7fba7a294306">
        <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8864759</dc:provenance>
        <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e300d134-5196-4150-a346-ff2b6a495f88"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d80052db-0724-45ab-bbee-67f5b72384e4"/>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03256</ddiem:url>
    <dc:identifier>DB03256</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cebb1f44-7440-4c2e-8122-9d4e81c5f734">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf255b2a-de80-47c6-a1fd-000f7f158fe0"/>
    <rdfs:label>Glycolic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03085</ddiem:url>
    <dc:identifier>DB03085</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/2166a51d-ab7c-4eaf-97c7-ad779cb7965e">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253280"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15184894</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac11091f-737b-4157-bc59-9aacdf5ffc3e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cf733780-1834-4f7e-9487-4b2bf25147d5"/>
  </obo:DDIEM_0000007>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/45f61106-65f3-4899-b6bb-ce04fdcddc6a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10a18bf8-94d0-4ad1-acbe-55502bf2bc73"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/937eccef-c2d9-430e-957c-924bd352bf50">
    <dc:identifier>HP:0000992</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <rdfs:label>Cutaneous photosensitivity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/76c55779-d21e-4b3a-b00a-98f6e5af3572">
    <rdfs:label>MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1c65e740-6eb3-49e0-a644-07d039a036ce"/>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/04570ff1-433d-4a20-8ff5-813a451a128a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/401864ab-b737-47ae-9982-3219fc0d9421"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11095909</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231950"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38850</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20868666</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11089562</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78cd2c43-59bb-4b92-bd7e-e7c839ccf69e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14d29dac-847f-4efb-b83e-0a1e451c54ab"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ec3534f-1ac9-4537-bf20-26a33ee75625">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low reproductive capacity (infertility)</rdfs:label>
        <dc:identifier>HP:0000144</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000144</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/48ed57bb-e1cb-43b7-a328-f1e67eb1be46">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b70a4ff6-6db6-42b6-90a2-61bbd8847ecb"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b04c51da-c6f8-477b-afba-204236505da6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fcf29599-1ad6-4727-ae95-a74309d19f32"/>
    <rdfs:label>Starch, corn</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d46f8d2c-4c3a-422f-8b89-d38392c6315f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/197b802e-31e1-4a85-8ccc-265bc4ab014e"/>
    <dc:identifier>DB11599</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11599</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/119ae1fb-0617-4107-82cb-1a776bdcf7d3">
    <dc:identifier>DB05294</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05294</ddiem:url>
    <rdfs:label>Vandetanib</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fac8d097-d1ea-49b0-bbeb-aac190d18a11"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/aee57e05-dbf5-44a1-bdbe-ce6ea5ce8d8e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6e3a1291-2da7-4ff0-8293-c36098c64a3d"/>
  </rdf:Alt>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/b1656cf6-e31c-4f16-89b5-0d716b27de1e">
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34fc3774-2b73-4319-8f9c-8110049c1d74">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001735</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001735</ddiem:url>
        <rdfs:label>Acute pancreatitis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f66fff85-fe9f-4739-8be5-73532b5580f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1800965</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000007>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3705d19d-529b-4578-82dd-b611a8051fba">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/37488d15-141e-4cad-9a5c-2e7ab75d33bb"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78393129-1fff-4b51-bb69-c5400df391cd">
    <dc:identifier>HP:0002123</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Myoclonic epilepsy</rdfs:label>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/90830352-21db-4e63-870d-6eb2c632362f">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/99a0c201-7bf4-43ca-aa6b-fce9afa56a83">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ea5feb6e-62b0-4ae0-8913-28a1eb40e40b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4bd39c6a-f24a-4b07-b3f9-c45a90f3776f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8864759</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb0d269d-54b1-447d-b515-4835d58a13c2">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025280</ddiem:url>
    <rdfs:label>Pain in the skin</rdfs:label>
    <dc:identifier>HP:0025280*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95794466-ece5-40df-b6bd-86242204716f">
    <rdfs:label>Unstable neurological function (Abnormality of the nervous system)*</rdfs:label>
    <dc:identifier>HP:0000707*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28e98e6b-c12b-4260-9883-35237087b7d5">
    <dc:identifier>HP:0001386</dc:identifier>
    <rdfs:label>joint swelling</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/64da993a-aadd-46d6-b8bc-9e1b00bc8715">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4983ff2e-5f7e-42c6-8fc8-b66817b5f0cc"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26067811</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8ddd8d7c-d571-49c6-8ea3-044711acf277"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ba981c1c-43f9-4329-a1eb-c87f110a155c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dafe7f59-83a7-4142-9a8b-a84c4f520e20"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d9e2589-33a4-4bc8-8783-faa23ee710b7">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>Abnormal movement</rdfs:label>
    <dc:identifier>HP:0100022</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d768d5f4-97bb-4cc8-abee-5da1cde8a66b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High LDL level</rdfs:label>
    <dc:identifier>HP:0003141</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/02802ab4-afae-4d95-9edf-28445301d511">
    <dc:identifier>CHEBI_2786</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f8e42e25-0887-4be8-8ae1-c5712180318f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7c21636-6998-49c3-9e7a-bb1509bbb98e"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5516aa8e-14ee-4066-a956-f4ccebfcc5f6"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_2786</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237500">
    <dc:identifier>https://www.omim.org/entry/237500</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ec09757c-bb91-4b11-b865-ebe56ace0677"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/554</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>554</ddiem:iembaseAccessionNumber>
    <rdfs:label>DUBIN-JOHNSON SYNDROME; DJS</rdfs:label>
  </ddiem:Disease>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000008">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <rdfs:label xml:lang="en">dietary regime modification</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with or depleted in molecules  closely related to the products or end processes of a genetically defective protein which occur as natural products in the diet. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:52+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/109bf726-5bbf-45f3-9c6d-70fdbdc033cd">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00502</ddiem:url>
    <dc:identifier>DB00502</dc:identifier>
    <rdfs:label>Haloperidol</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/27a8465b-7c76-432d-869f-f25672e95e84">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11449034</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5535ff32-3c8f-42a6-b02b-8f2ea37ed86e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e136c711-b751-48b6-9d38-949adb40bbc5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/12b19cb2-0e0c-4e13-882e-48ae16f76265"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5e2107d0-b29c-4599-a192-16a62d1a1330">
    <rdfs:label>Diazepam</rdfs:label>
    <dc:identifier>DB00829</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00829</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4c721a4-6553-41e9-8918-a5ce873894d8"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3ec5291b-f0d2-4f29-8212-e9a24083d871">
    <rdfs:label>Methotrexate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00563</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84c60feb-31e9-4355-8fda-04902f9f2329"/>
    <dc:identifier>DB00563</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6b215f53-e162-409e-9d6b-33c6cd2ac1a3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12449</ddiem:url>
    <dc:identifier>DB12449</dc:identifier>
    <rdfs:label>Tempol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/50521a69-46e0-4f91-b34f-bef4d46b94c6"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6475ebb3-e284-46c3-85eb-6f05f15c21fe">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
    <dc:identifier>HP:0010919</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High total homocysteine level</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a8f8ddc0-1934-4f68-8cad-e95f852d9d48">
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c848433-bb10-414c-b9cb-cec82264b580"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4214c438-dde2-4add-b71b-f931a4a14b5e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e612443-097f-4c53-8280-28075ce6154b">
    <rdfs:label>Clonic contractions</rdfs:label>
    <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38df2bff-29d6-4dea-8237-2bfb30453551">
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:label>Abnormal neurololgical function</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d4645af7-7d71-4681-836a-2380df08e471">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00586</ddiem:url>
    <rdfs:label>Diclofenac</rdfs:label>
    <dc:identifier>DB00586</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1e162bb-2474-4218-957e-949418eab82b"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a6a13fe6-89b6-4686-8e06-1902282c219d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00635</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a46f6aaf-3b67-48f7-9898-22f6b16aec56">
        <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
        <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27790033</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/698d32ca-e3b8-45aa-bbef-890811bc86a4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2bae0e9-fec0-4c02-8455-01c251e0eff2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b4a86e98-f1ae-47db-9386-5d7efd66b9ae"/>
    <dc:identifier>DB00635</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3af4de53-3080-4bdd-8a62-911c264aa0d4"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43be8a39-0201-4105-b8c6-418392b0a40b"/>
    <rdfs:label>Prednisone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/151a4e92-8cf6-4f92-ab8f-b9d907e6482b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001892</ddiem:url>
    <rdfs:label>Bleeding tendency</rdfs:label>
    <dc:identifier>HP:0001892</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/2d545b0a-4756-4d70-ad07-0c7ab3cfeb3c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17505475</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0212c985-f816-47e4-995e-a214d71ae8cc"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/50cd4bf4-ce17-489b-9036-6ef225f95496">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/79a6951d-e825-48c2-bb81-27d927dffde4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/1f483195-3c96-47f5-9442-b4526d38d562">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3c884f2d-7729-4738-9d4b-f122abfb89d8"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40f52608-d9ad-411b-8ffa-29ae70c413cc"/>
    <rdfs:comment></rdfs:comment>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c866c760-2fc0-44cf-9ea3-6a2a189c9078">
    <rdfs:label>Ad5/CMV/hUG-Br1</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/90759ed4-c6ce-44ba-bc20-73d7e8e02364"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bb29d0d0-6dde-4b22-a443-b2cad37d0b49">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b06da0b-5948-4e5e-abd4-1a26bf90831e"/>
    <dc:identifier>DB09422</dc:identifier>
    <rdfs:label>Soybean oil</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09422</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c77a3805-0000-44be-80e6-f5804c7c3f1a">
    <rdfs:label>5-methyltetrahydrofolic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04789</ddiem:url>
    <dc:identifier>DB04789</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d49ffa9d-76b6-48bd-a7b4-54f01a7ccbef"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/157640">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/157640</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/451bbd3a-512a-4a5d-8513-97be22d4cce9"/>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/901d5197-1a51-460a-bcf4-7ab8982b31f4">
    <rdfs:label>Abnormal Adipose tissue tocopherol level.</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1af21ce0-5ea8-485c-a43e-0e3d43b5fa70">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high plasma MCP-1</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/50310ee7-c2ed-4279-8b00-cfaf874e4044">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8908f606-916d-478a-9a76-5fe75d3cfd7c"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2d52ab9c-bfee-4f66-b14a-3403cb8cc923">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/94ec5b3d-dad0-4eb0-97b1-98ff07eae288"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc47106d-1d6b-491e-beb3-b18d7aa9a469"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d94169f-c427-4ce7-b378-83b926370b90">
    <rdfs:label>Mucosal lesions</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8cadf86b-bc9c-4584-a372-5a9385103eaf">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ae3b22a9-5d43-4c20-97e9-3a143c64b63c">
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00440</ddiem:url>
        <dc:identifier>(DB00440</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2a269430-1536-4a53-900b-f7165d52a3d9"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/de071454-261e-4187-a7d4-6183690597fb">
    <rdfs:label>No medical treatment is available in DDIEM</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3f4a65d2-ed1e-427a-85c8-358a11fe0f49">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/681b7089-d608-4f92-b4e9-4b176eca8167"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/249900"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75547b05-14b2-43f1-a7bc-d2f01c837f32">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040215</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040215</dc:identifier>
    <rdfs:label>Abnormal circulating insulin level</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f98ec712-7715-486c-bfcf-36f72ac77d90">
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af204d25-8065-4dd1-96b3-93b4250a2c39"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/57aa9eea-012f-4bec-bf63-3e68bef2ab59">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c3f610c3-7541-4b24-ba0a-db710638be05"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300233</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/096817af-6956-4825-8258-b04749cfc1e0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/69ab7f4c-9f5d-47bc-bc42-ced988aa0f23"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cab6bbf8-c4ec-401b-8d75-c8407368557a">
    <dc:identifier>HP:0045082</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low lean body mass</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6e222f0a-d5e3-4fde-a44a-e3ba58688673">
    <rdfs:label>Cholestyramine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/161c729c-b280-4ec2-b592-fb08d5c7893e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/51500251-46c2-4679-b6ea-feffa22e7293"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01432</ddiem:url>
    <dc:identifier>DB01432</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d8dfd25e-7c8a-4b44-91d7-172a4cc21ab9">
    <rdfs:label>Potassium chloride</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4a69408f-cdc4-413b-b4e5-248bebc5d96a"/>
    <dc:identifier>DB00761</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/521e1a72-00b6-474b-a96d-9175304d9e97"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00761</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/20cbfb04-f9c5-4e3b-891b-5152d3140dae">
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/247100">
        <dc:identifier>https://www.omim.org/entry/247100</dc:identifier>
        <rdfs:label>LIPOID PROTEINOSIS OF URBACH AND WIETHE</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1dd1fa8d-18a2-4095-8559-5696ebb40344"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1360b9ad-d615-405d-9f6b-6c6c864a75fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18808438</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e42592ce-0c43-4ba1-a4b1-87f708085a06"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28720532</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23259080</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6d94169f-c427-4ce7-b378-83b926370b90"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b6ac43cf-368a-4d00-bff2-d49192892a90"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24748909</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2a9c3cf1-428b-4ae9-bcbf-86fc18c5743d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28681064</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76ed51b7-f12f-42da-bf0b-0198b465fffe">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Skin papules</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200034</ddiem:url>
        <dc:identifier>HP:0200034</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f0fb45d-e0a8-4a33-ab11-b71e929f877e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c470041-1671-4ade-8eda-f9907e95d543">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011122</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011122</dc:identifier>
        <rdfs:label>Skin lesion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1b8743b9-c4b2-483b-b35d-7de038053dab">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d8fb7a4-8bf2-4324-ba96-ee0f819e1fdd"/>
    <rdfs:label>Diiodohydroxyquinoline</rdfs:label>
    <dc:identifier>DB09115</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09115</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b116b242-25e5-48de-a2e9-4bcfbcbacbeb">
    <dc:identifier>HP:0025464</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased ROS formation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bdb3253c-49d0-4742-a047-ed629dda9f88">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>elevated CSF GHB levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21f39591-67bd-4376-958c-8b2293090c4c">
    <rdfs:label>signal abnormality of the cortex</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030178</ddiem:url>
    <dc:identifier>HP:0030178</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c127406d-1822-4242-badc-87717a8c1882">
    <rdfs:label>enanthate</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32362</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a947b60b-f3a0-412a-9675-ca6072e3e1c8"/>
    <dc:identifier>CHEBI_32362</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f5f805d-8509-48e7-ad71-beae600077d6">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Generalized muscular hypotonia</rdfs:label>
    <dc:identifier>HP:0001290</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/011e1928-55b7-4b28-9b31-aa9f91bf8564">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8bc74339-eda6-4ced-b758-d2c4412d5164"/>
    <dc:identifier>M02AA</dc:identifier>
    <rdfs:label>Antiinflammatory preparations, non-steroids for topical use</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M02AA</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d6e8190c-0fbc-4e44-9871-6c64e87253f7">
    <dc:identifier>DB00437</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f3f6e103-685e-471b-b727-0c8ca8ed67b2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fcea0c81-e7de-4426-9571-113e6aaa4bd4"/>
    <rdfs:label>Allopurinol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00437</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/942f92d5-0daa-4946-ad5a-00c0565c147a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1a518ef8-c99c-4d44-9e56-4f645a5530f3"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bc586e9d-c82f-4a73-80cd-233048164786">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/add7ebd6-b523-4c5c-b200-49a6f0e6c8d2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9aa4f1fb-bb58-4678-ba46-babcfa5fe5ec"/>
    <dc:identifier>DB13873</dc:identifier>
    <rdfs:label>Fenofibric acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13873</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f01d9d9-0885-42d7-b52d-511452266c3d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/671f70f8-fdd0-4cb0-8ceb-32aa63a1e9ad"/>
    <rdfs:label>AAV1vector expressing α-Mannosidase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67144ca8-202e-439a-89b2-26d822cab09e">
    <rdfs:label>Rickets</rdfs:label>
    <dc:identifier>HP:0002748</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b9a392bc-d1bb-44f3-81d8-bbecc53dae97">
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a97ccde3-9e03-468b-9b3c-caec3521e755"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24173411</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33924b76-49f6-4b6b-a4b2-bbbf0a6ea35b">
    <rdfs:label>Elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
    <dc:identifier>HP:0003107*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/5e4cf248-3bab-450e-a878-ae59062c1987">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/22e0e709-24d8-409a-97dc-e1a1a4104cdb"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607091"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000010>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9e8ce014-5337-4edc-9af2-2fdacd2487c2">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3d342810-93c4-4d09-9b37-488e4de63ad3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/92a442f5-a2c0-4f64-974e-2582b473d55c"/>
  </obo:DDIEM_0000013>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000009">
    <rdfs:label xml:lang="en">dietary exclusion</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:24+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is depleted in molecules closely related to the products or end processes of a genetically defective protein which occur naturally in the diet. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/66ff20dc-233c-4f97-a285-bfd0b120f5a7">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e8b481dc-5bca-4f9c-8c3d-76d49cb3eabb"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/594c1e23-f5bb-4225-a694-4ae072c30753"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00350662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b769d425-22e3-4953-83c8-055cbfa6e6d8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3513d0cd-d453-4c36-b238-3cde7a16fa56"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB07425</ddiem:url>
    <rdfs:label>Sobetirome</rdfs:label>
    <dc:identifier>DB07425</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ea4a58b-49d3-41b9-8f6f-1f753b1e2d98">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002353</dc:identifier>
    <rdfs:label>Abnormal EEG results</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb4d2913-9222-49ef-a4b0-16e606c7e3d3">
    <rdfs:label>Tremor</rdfs:label>
    <dc:identifier>HP:0001337</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/efb19376-26e4-41e7-93d2-3270bdd30f9d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c5656230-eccc-4130-8c3d-0e3af63838f9"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e5ac806-aacd-4ddc-9938-ad1ec6ea410b">
    <dc:identifier>HP:0002900*</dc:identifier>
    <rdfs:label>Refractory hypokalemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fcb473d7-023e-43b0-9ec7-2be7e00a0005">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/40f52608-d9ad-411b-8ffa-29ae70c413cc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19217094</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/20f819b1-463a-409c-b40b-b1203165d86e"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0537f0d4-e531-4f7d-8cc1-c13b670a5f0a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ddbdabb5-c9b8-4800-8a68-b0a41db5b8c1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ee4bfee7-3613-48e9-acc4-720a50ac3157"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9bd387f-d7ea-4044-b79f-c788e7bd1959"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d8812d34-73d0-4a95-8c87-a35b2ca84de7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/18eac25b-6667-4bbc-bb57-6843bd78d01e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/70404064-330f-4f0f-a6bf-7b739801e7ff"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43143756-b976-491b-b749-4bb94f224b75"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/16f79aba-fc38-4ebb-86ab-9180b731efd3"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4baf90c-6abd-43c9-8bc1-289d673e613f"/>
    <dc:identifier>DB13959</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13959</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/655cddd4-1b87-47d2-9997-04d150ebc45d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7f572240-6263-40ad-89f9-4cd1925de043"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ca48ef1-a8d3-449d-aa16-0c603887a47f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8c1c00e7-c0c7-4deb-8a25-6d24e477f86d"/>
    <rdfs:label>Medium-chain triglycerides</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4734b689-d6ff-439a-a1ad-3063e6b781fc">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/994a3003-824c-4ea3-a8a9-c10f4c248a16"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.nature.com/articles/nature10456</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c141705-a817-4b46-b4a0-ad5b0de89151"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ebeefc1f-eebb-4c30-9102-42abd610562d"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/25b5f8c8-39b2-442c-9a48-52fb2a81be44">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791288</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1fc05532-973d-43cb-a975-c157215414bf"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15bee290-4c3c-4fb7-be34-87559ad852ab">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:label>intolerance to sunlight</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb0d269d-54b1-447d-b515-4835d58a13c2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/341955</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6c0b6cea-1c59-4663-b0b1-c66ed0d77c89">
    <rdfs:label>Copper Histidine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3781f25d-0e41-468b-91f4-fe21d4d5798c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5ddfb152-0bac-498a-a449-1ee969ee6859">
    <rdfs:label>Tanespimycin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/00803d2e-1fbc-4e9b-9ad0-c8ffb90fbe51"/>
    <dc:identifier>DB05134</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05134</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c74e1b2-646b-4e52-a6ea-d0caf1b5e915">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003470</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>paralysis</rdfs:label>
    <dc:identifier>HP:0003470</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4f3e5315-1ab4-4494-a692-051e9913dcfa">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/05e3db90-dac4-4d8c-98c2-5c20d0c5ecdd">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01001</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/156c46d5-0bf7-4336-9ad3-c5ba3d8b0487"/>
        <dc:identifier>DB01001</dc:identifier>
        <rdfs:label>Salbutamol</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/561512a9-20b0-400e-a3af-48f4ffd042e7">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/52472773-b6b8-4394-a447-ec5306c8fbb8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08b24a10-ebfa-4fe9-8b5c-c4600c6837dc">
        <dc:identifier>HP:0000817</dc:identifier>
        <rdfs:label>Poor eye contact</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3fbc7dfe-fe17-4123-90d2-36780ef071c0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0c992f83-81e6-4d52-ad01-ef39685056bb"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da7d8cc3-82fe-49c3-806e-b7a89c960a67">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c420fb2a-2262-4d4b-9aa1-4236c4259ac6"/>
    <dc:identifier>DB00376</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00376</ddiem:url>
    <rdfs:label>Trihexyphenidyl</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/40dda43a-a1e4-459f-b182-5d569a828550"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2d616101-299e-4296-a43e-5a3435f09d0f">
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2f085ddb-4926-49bc-9838-bd6ffa02161e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dff69edc-458c-473b-b090-0e3bbf7a3e9d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c44b266f-00d0-477c-b77a-fd3bba8902b9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bacfe943-981d-405b-b58e-b24e37e94d72"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5a71a273-c72b-43fa-ba09-fab8045cc438"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7834cbee-6234-40c7-aa78-45697e564d8b">
    <rdfs:label>Alpha-D-Fucose</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03485</ddiem:url>
    <dc:identifier>DB03485</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/68459880-66b7-47c7-a7dc-6c80820793f1"/>
  </ddiem:Drug>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/fc3ca157-b8a1-481d-a302-e7068616498c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0b98ffd-2fe1-4d93-a5a0-c4b8b281813c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/094f3e0d-fe72-4d82-b524-c160e0def6d5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/228000"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
    <rdfs:comment>The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18376404</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e71a71d7-95e6-4777-abb8-e4e95258a0f3">
        <rdfs:label>Abnormal pulmonary ceramide level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/38aa475f-f568-4e55-a3fb-2d2ee7c80a58">
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5699ec1d-3568-4a83-85f9-4556d6b0e49c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bef67d5b-641e-4ff7-82f2-6b117f1de8fa"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/72d43680-393f-45b9-9226-6175be214012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6020f029-c549-48f8-8ded-164245d8aa08">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8c6f7f9-76ed-48b3-862d-5fd00ab0ce6b">
        <rdfs:label>constipation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002019</ddiem:url>
        <dc:identifier>HP:0002019</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6adb3af9-0a44-4596-a331-b8d175f3245f"/>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/601776"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21744491</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/719f665d-18a7-4a31-8a98-675f73a4dafc">
    <dc:identifier>HP:0001928</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001928</ddiem:url>
    <rdfs:label>blood coagulation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/54015d46-01a7-40f9-b4df-85f27db5edd5">
    <rdfs:label>rAAV-PPCR</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/546062e7-b391-493b-84f3-d9228b9ac30e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/956037de-9e37-421b-bb86-97727822104e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00035</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1e50cf77-c19d-4b66-95d0-c1d64e806183"/>
    <rdfs:label>Desmopressin</rdfs:label>
    <dc:identifier>DB00035</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3b9ec1c3-0518-4317-9475-231316b53d11"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/480ad416-06bc-4698-abbd-9ebdf0d918de">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/340e4eb1-419c-423b-88bf-26ad6d773afd"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f17079af-69f4-4e3c-8539-b521b0f15020">
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c44e9878-2271-49dc-85b6-f8807b8bffb1"/>
    <rdfs:comment>There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df9e89c3-8aca-4d93-a28f-cc79999803c9">
        <rdfs:label>pathology in many somatic tissues</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000924</ddiem:url>
        <dc:identifier>HP:0000924*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b0cac478-455b-42e5-97d4-92395015e5aa"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/89c0dfef-6aa1-4566-8404-fbe9579d5c02">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fc0b274e-2d6f-4677-a20a-a5f34ca32d7a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10657992</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/df3a0c89-0c1d-4c4a-a4d7-874e27fcaddb">
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>High amount of Man2GlcNAc2-Asn in in nonneuronal tissues ( Metabolism abnormality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7e0bb323-9c41-44fa-9cfe-ddeeda8c36b5">
    <dc:identifier>DB00073</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1a754800-c60f-43fb-b76b-4a1229177b85"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00073</ddiem:url>
    <rdfs:label>Rituximab</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7ffbd90e-d318-42f3-9fd3-e312b0d650db">
    <rdfs:label>Doconexent</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3dacb91a-22da-45a2-9214-ebd2541db22d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03756</ddiem:url>
    <dc:identifier>DB03756</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b74dac50-7c6c-4798-9fdf-8afc2fe17dfa">
    <rdfs:label>Quinethazone</rdfs:label>
    <dc:identifier>DB01325</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01325</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cb9a5cc5-8422-419b-940c-be3c90b2814c"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/05b3ea4e-4b62-44c5-9030-5e1651ed2f04">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f77edfd0-4417-45ab-a1c3-d7e3e936ec5a"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4fb78ca1-b3d8-48de-b338-b0b82d11707a">
    <dc:identifier>N05A</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ec5182c5-a0ec-4c11-abbb-d3adfc880b0d"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N05A</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c915ec27-5605-4eff-91d6-bd7afa7a1747">
    <dc:identifier>DB08826</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/66ff20dc-233c-4f97-a285-bfd0b120f5a7"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6108e9f5-015c-4cb9-8b05-09d9172d8d3e"/>
    <rdfs:label>Deferiprone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08826</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/19bf2889-8d23-4b46-8090-1889303689ad">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6ba24d19-0e9d-4ea6-ac5d-4f9ba7d8cb7e"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5e2107d0-b29c-4599-a192-16a62d1a1330"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c0ee1069-b8cd-4661-b8f8-3084a84f88ef">
    <dc:identifier>DB13173</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13173</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5215a4d4-fc42-41cf-a263-c9e323a5e357"/>
    <rdfs:label>Cerliponase alfa</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d5887727-4a24-4a28-8211-318cd1edadb0">
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e02aa49f-2390-40cc-b373-22e88233c8e6"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/73fdff04-cb37-4dcc-a061-a3c2b86d41e7"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5ddc6bcb-25ac-40b8-b2f3-89979a9ef550"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b3b2955b-70cb-4be4-91c0-f81cab44a37e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2e5caf2d-7e4e-4fff-ab0c-3c61a8ade337"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/30101edc-5346-49ff-826c-b3fb956c9543">
    <dc:identifier>A06AA</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A06AA</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0f6ad7bd-e3de-44b3-ac7d-d36554a72411"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4a69331-cd7c-4b12-b857-45834af1d474"/>
    <rdfs:label> Softeners, emollients</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07475bdb-9b39-4c3e-abf7-c3ab4def0aa4">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased life expectancy</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/fc2f7563-d83e-4b1c-a8f9-8d4693ee2bf0">
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7fe689e1-8437-4fcd-9bf9-44f21808e820">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a4ca4e5f-6c67-42f5-924f-c7498d015041"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f07bc20-7e93-41a4-9b25-49aab7715aff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77db340b-64c5-4f81-a749-27c4a8238c92"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604290"/>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9dae116-6346-4bb4-9460-ff8a4b05c6eb">
    <dc:identifier>HP:0012594</dc:identifier>
    <rdfs:label>Microalbuminura</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012594</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/02cf2e1f-4a1f-4e97-a4e0-f60998e9d9f3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03614</ddiem:url>
    <dc:identifier>DB03614</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d29c3c5d-11fe-45f6-be40-a088ea0ffbcb"/>
    <rdfs:label>Methylcobalamin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4994a2d5-a825-4e00-9171-e833886f9125">
    <rdfs:label>hypoglycaemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001943</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5fc1089d-cfb0-4839-9cdd-502d35ab9e3c">
    <dc:identifier>DB00158</dc:identifier>
    <rdfs:label>Folic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7cd22a83-1c97-4e4b-a2f6-6efbb5307c77"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00158</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/596fa10a-b37e-4454-b1a6-61e402b9e0ce">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca6824d1-2185-462d-9401-14dccc8e4291"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cb303eed-482f-45a1-bdbd-697516f589c0"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/094f3e0d-fe72-4d82-b524-c160e0def6d5">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fc3ca157-b8a1-481d-a302-e7068616498c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00321</ddiem:url>
    <rdfs:label>Amitriptyline</rdfs:label>
    <dc:identifier>DB00321</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/010452d6-3bdd-46ee-b51a-c1ac5f16a261">
    <rdfs:label>Icosapent</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9056694a-07aa-4158-9897-725af2d7eb22"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00159</ddiem:url>
    <dc:identifier>DB00159</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8824cd9-de48-4074-8af0-955fd6d830fa">
    <rdfs:label>Paroxysmal movements</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
    <dc:identifier>HP:0007166</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9721226b-b6a8-4c13-89f8-4bc448a68cb3">
    <rdfs:label>Hypoxanthine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6b42f453-00fe-4555-b93d-ee3a58dc59df"/>
    <dc:identifier>DB04076</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04076</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/707e8247-fd66-4fb7-a221-16c946e23de7">
    <rdfs:label>pseudoexon activation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c4977792-2f51-4990-88a2-1d8a973a7386">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01563</ddiem:url>
    <dc:identifier>DB01563</dc:identifier>
    <rdfs:label>Chloral hydrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aff5d654-6e25-41c3-a08a-1bae70714bea"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3c6a0c88-262f-489e-acce-c78a69f776d9">
    <rdfs:label>Low HDL-C  level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003233</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6659f8a4-f2b6-4bec-97ae-792bc4086ed2">
    <rdfs:label>Dichloroacetic acid</rdfs:label>
    <dc:identifier>DB08809</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08809</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f14dd22-7b77-44ff-b1b5-7cddbc1e1a76"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddad58a5-e21d-41f9-b684-23075c7b7022">
    <rdfs:comment>The findings reported here support the possibility that supplementation might reduce symptoms or augment recovery of patients with schizophrenia, particularly targeting those with elevated proline, who may represent over one quarter of the schizophrenia population.</rdfs:comment>
    <rdfs:label>schizophrenia</rdfs:label>
    <dc:identifier>HP:0100753</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100753</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f37fad38-4595-4d67-8603-60a71bec098e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/494806d5-37fd-4edc-bb63-25412f6784dd"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7569b878-33bb-4800-a6d2-eda4e9997502"/>
    <dc:identifier>DB11677</dc:identifier>
    <rdfs:label>Triheptanoin</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/88cef591-95c2-4651-b155-740d1179b348">
        <rdfs:comment>A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process. https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&amp;rank=1</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232800"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03642860</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7a5586b2-afeb-451d-b0d7-3c5f07770d7f"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/23fa01d3-0b10-45d7-854d-652b0bb9267c"/>
        <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2059e8e3-76ca-46dc-87d0-00a2adcaefc3"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c869d736-15b1-4df4-8d24-96a64ab34c9b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/491266db-69e8-4450-b386-e6009ca1abb6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11677</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a969d16d-6b82-4d50-8197-ccc5fbcd918b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81f26cc2-f9cd-42e7-a22c-31491a42b510">
    <rdfs:label>High total cysteine levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
    <dc:identifier>HP:0010918</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/212ef555-70cd-4feb-91c6-b3aa9a294ca6">
    <dc:identifier>DB00869</dc:identifier>
    <rdfs:label>Dorzolamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00869</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bdba2e41-fbcd-4ab5-bb62-2319ec964d28"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6f774927-8fba-43f5-80d4-be854042353a">
    <rdfs:label>Vigabatrin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e2c7bb17-e98f-4979-a801-666570e4ba78"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/da07152c-f7cb-4544-978b-0722b64057a0"/>
    <dc:identifier>DB01080</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01080</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/155e839b-8a1a-46a3-b8d8-a218bc3a7c9b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c36d5a99-51cc-430b-9578-fe3fb1b0950f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1e0aeef-654a-4f75-8fea-54632e3df659">
    <rdfs:label>Limited Efficacy of the drug.</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b850fd26-6dab-49f5-ad0d-b23802d823f9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031034</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal circulating IGFBP level</rdfs:label>
    <dc:identifier>HP:0031034</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/429c7bfc-1f8f-4637-9218-a5876556aa2f">
    <rdfs:label>High urinary levels of primapterin (7-biopterin)</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86574687-e7fc-40be-8bfd-0ae187830193">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009124</ddiem:url>
    <rdfs:label>Rapid progression in body fat mass( Abnormality of adipose tissue* )</rdfs:label>
    <dc:identifier>HP:0009124*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/debcd386-d897-4760-b20d-4349c437c69f">
    <rdfs:label>Trolox ornithylamide hydrochloride</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7cb6931-afe5-48e6-9765-f9e624f2a754"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0614de91-f885-4fad-a662-3a597555c8ef">
    <dc:identifier>HP:0010836*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:label>Copper storage abnormalities (Copper storage abnormalities)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/1692f29a-c95a-4424-9310-435ed758b7df">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0dff28ac-b071-4d29-807d-84a9eb87fc73"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4602dfdc-f44b-4846-9ac3-99ec1e2c55ce"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/121270"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a177c6d0-1617-4266-95cc-4255ccbd1b61">
    <dc:identifier>DB01373</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01373</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0d441434-a972-40dd-8306-680662213563"/>
    <rdfs:label>Calcium</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4740b575-1f51-48d3-944e-2b55878a6065">
    <rdfs:label>Decreased plasma carnitine</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003234</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e300d134-5196-4150-a346-ff2b6a495f88">
    <rdfs:label>Abnormal serum folate</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040087</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fcc1d1e6-4359-4696-b6cb-ff4015f2980f">
    <rdfs:label>Cortisone</rdfs:label>
    <dc:identifier>DB14681</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14681</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6003e2ad-70b3-451d-94b7-440bb9ff501d"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6be6eb4a-3e07-49ed-9fac-311b94d9b412">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0032367</dc:identifier>
    <rdfs:label>Abnormal circulating GH level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0032367</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1fb17853-bdb4-47f2-8a13-13885b755f9d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a91c7f4d-79f6-40c6-ac47-88a6a217f41b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04570ff1-433d-4a20-8ff5-813a451a128a"/>
    <rdfs:label>Acetylcysteine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5003593-bee7-4654-a8dd-d5598a825d60"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5bce9469-dd75-40d7-982a-8ab32d3edd37"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06151</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8fa2b33d-08cb-4830-87ff-8f27333c9aa7"/>
    <dc:identifier>DB06151</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3323c563-efe0-4553-82eb-ec66d99d8fd1">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4b85634e-c67a-4105-bcb5-4fd78ec70d9d">
        <ddiem:url>https://www.drugbank.ca/drugs/DB12319</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4f3756fa-a628-40bb-b023-11bfe6d83915"/>
        <dc:identifier>DB12319</dc:identifier>
        <rdfs:label>Benzbromarone</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f48800f-7681-484c-b337-155d20997483">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00396</ddiem:url>
    <dc:identifier>DB00396</dc:identifier>
    <rdfs:label>Progesterone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/32a66e8d-ff14-4b3b-bce6-717f0512cee7"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/456d3fa3-bac1-4038-9cd8-325a63675896">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
    <dc:identifier>HP:0012647*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High macrophage infiltration into tissues(Abnormal inflammatory response)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23978571-f50c-44a7-b2f2-6d45d6441582">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Developmental impairment</rdfs:label>
    <dc:identifier>HP:0001270</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ab6affd1-d3e1-4f5a-85f0-44c23f3e9a71">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ff5748d8-9f09-42b4-889f-92a3f677d6bf"/>
    <rdfs:label>Immune Globulin Human</rdfs:label>
    <dc:identifier>DB00028</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00028</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/668a6c34-1c8a-47ad-b6b3-740ad46d5903"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4d266870-6f77-4338-b833-ba2b43d623f3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d2d00ad-d0bf-416c-b3dd-656d9f73a102"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1dde7d5-017f-444a-a1b1-052bdae12134"/>
    <rdfs:label>Hemin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/59548f91-9ae4-4861-b9e0-b699d2ca6f70"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03404</ddiem:url>
    <dc:identifier>DB03404</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6b85f15c-d5db-48af-9e50-296a82d3f245">
    <rdfs:label>Azathioprine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00993</ddiem:url>
    <dc:identifier>DB00993</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d19ca533-7a2b-407d-bd5d-2858145b0872"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2a6f2ff1-2c05-412c-9f06-76da33be72b4"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d1a2d32a-10bd-4363-979c-5f4be5c8cebb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/839ecd09-58f1-409f-852a-97ac6ca43ab1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2d52ab9c-bfee-4f66-b14a-3403cb8cc923"/>
    <dc:identifier>DB00627</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e168e8e3-9532-412f-a6ce-01182ec7b9dd"/>
    <rdfs:label>Niacin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00627</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/05d5f451-7757-4a68-9ae3-339d53d7aefe"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/83a689b4-1518-409d-a1e5-5f9eea82e161"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3cae0a3f-a2c0-4705-aeab-256058f358ec">
    <dc:identifier>DB01202</dc:identifier>
    <rdfs:label>Levetiracetam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01202</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8f397831-e018-4812-8f33-af8b52e5174a"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d2e5a5ab-a434-4d21-8f8e-e01e62b7144f">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
        <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/050e4ad7-9522-4300-8597-a6cd502a6274"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6534979-aa4b-4ddf-a57c-0bd73b57be7d"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7f72e186-6e9e-44ac-b162-a2326096dfac"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/657d159a-f0d8-40d3-8bb0-22f616721793"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/912d4571-a9bd-41ea-ab33-a3a4443769a3"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/17dc4fc2-6329-4d30-af71-c448a9497760"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb77d0cf-35d2-423d-b15b-3106ca5cd2fa">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000630</dc:identifier>
    <rdfs:label>Retinal thickness</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000630</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/249900">
    <ddiem:iembaseAccessionNumber>293</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/249900</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/293</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2ba5130f-42dc-47eb-9173-78924e3e1a42"/>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7fc862ac-975d-4199-9afb-d491aaaf52cd">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c8c7da9d-0460-4880-96f8-306f0ab18bcc"/>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277460">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a1e90020-b91d-4c14-b945-946d40b1bff5"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/277460</dc:identifier>
    <ddiem:iembaseAccessionNumber>658</ddiem:iembaseAccessionNumber>
    <rdfs:label>VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/658</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f0e86c3-bce8-4a46-bbea-a28a21c09773">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/589b6c55-c697-4ff1-949b-172be6a4426c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00620</ddiem:url>
    <dc:identifier>DB00620</dc:identifier>
    <rdfs:label>Triamcinolone</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ca391e15-bc7f-474c-9667-19877ef6e369">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3deb9538-a69e-413f-9107-99b75c70a89e"/>
    <rdfs:label>AAV-cG6PGH</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/90c7967b-33d1-4fd5-b8d0-5ffaa8abc304">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e8d1447-e396-4fcf-8749-5b14cbb6bad7"/>
    <dc:identifier>DB01247</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01247</ddiem:url>
    <rdfs:label>Isocarboxazid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de03cdb0-7875-46bc-aee1-7f519f38d751">
    <dc:identifier>HP:0011925</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased activity of mitochondrial ATP synthase complex</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9ebc23ba-5a11-4248-8d40-47b4a96e26a8">
    <rdfs:label>Lenalidomide</rdfs:label>
    <dc:identifier>DB00480</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/169e27b1-7c4e-48cc-ab09-060319fc08ed"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00480</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4a894dbf-1b4c-4a47-b176-9241557444bb">
    <rdfs:label>Galactose</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c83ae905-2fde-4b68-8fff-e29d61dcd589"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5e4cf248-3bab-450e-a878-ae59062c1987"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11735</ddiem:url>
    <dc:identifier>DB11735</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/daf44a11-d4d2-4996-b94a-d67c52aac3ce">
    <rdfs:label>High level of fucosyl-linked oligosaccharide accumulation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/be914773-1d6a-43c2-bac0-6d25abdd0106">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9ce4cb72-1df7-4039-9fe5-b7eff15e67a9"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4472242-3ab7-44d9-bcc2-31cf3b222e90">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012075</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012075</dc:identifier>
    <rdfs:label>Personality disorder</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607625">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/304</ddiem:iembaseUrl>
    <rdfs:label>NIEMANN-PICK DISEASE, TYPE C2; NPC2</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/607625</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7b276dba-de35-49b4-822a-1aafdc6d18cf"/>
    <ddiem:iembaseAccessionNumber>304</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a98c922c-3c87-4e1d-9230-54b607d3377d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c28700a0-d52a-4336-86b9-11bb1215962c"/>
    <rdfs:label>AAV2-hAADC ( Gene therapy)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/736e10c1-47fd-4ae0-9166-6143e27c9bc9">
    <rdfs:label>Abnormal gait</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
    <dc:identifier>HP:0001288</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10886507-3773-43c0-aad4-86bb21f15326">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/65ab1081-036d-43fc-ae5f-0098adee915e"/>
    <rdfs:label>Flumazenil</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01205</ddiem:url>
    <dc:identifier>DB01205</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ac47c4ee-0fa9-4fa7-bed1-2974ea0ce7db">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b16bb431-e522-47cd-8a5d-fc67f4c00f8a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/caf71b6c-68e9-454c-992d-9b6c5e7ea006"/>
    <rdfs:label>Bortezomib</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00188</ddiem:url>
    <dc:identifier>DB00188</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/364b99a2-befb-490f-8d54-1695c2d59c54">
    <rdfs:label>High urinary LTE4 excretion (Abnormality of leukotriene metabolism)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030390</ddiem:url>
    <dc:identifier>HP:0030390*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4ec70ffe-c318-4864-adbe-2a41920ab953">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05271</ddiem:url>
    <rdfs:label>Rotigotine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a550e427-b9cc-4d67-bd91-d734ebacb544"/>
    <dc:identifier>DB05271</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/13ee20cc-c256-4015-a8d7-3c89db721d4c">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8f10c805-6334-4122-9ce6-b94d77bc1491"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9a5535b-2a1c-4698-a6b8-5d875556eec5"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/98c7cf49-ad8d-4ca5-baf3-fcc1cd9f386d">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Brain lysosomal storage disease</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fae7f8ce-ef90-45cb-9a99-42df4e2a4d8b">
    <rdfs:label>Risperidone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00734</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f818105a-884a-4f7e-aad7-37946348c7be"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e4db3cd6-de0b-4804-b577-d10ad14baf87"/>
    <dc:identifier>DB00734</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1d439aaf-d698-4d3c-8fb6-8b078b7a207e">
    <rdfs:label>Etanercept</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4f3429a4-e358-4f81-a73d-f5d1defd8e19"/>
    <dc:identifier>DB00005</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00005</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c08cfb2f-0dad-4d77-bec9-3f214ee1e459">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00125</ddiem:url>
    <rdfs:label>L-Arginine</rdfs:label>
    <dc:identifier>DB00125</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/86eaf9ff-afc6-4b23-909c-ce313f1c0d87"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/84088f7e-93b1-4aef-a01f-2793b3baa165"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/410b8317-fa9d-41ef-ae68-15a2602d140f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b476e67b-24eb-4cb8-9d51-6a6132bcff16"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/79094c0e-5053-49a4-898d-61a9b740036a">
    <rdfs:label>Recombinant alpha 1-antitrypsin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05481</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/368173d6-afc0-43ac-9289-4994c84c34dd"/>
    <dc:identifier>DB05481</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be605169-915b-4bc3-b71a-f42a1ece1f99">
    <rdfs:label>Increased lateral ventricular lactate level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ecb471e2-f982-4819-8f1f-3ef7e05bc070">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High plasma branched chain keto acids</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f09a14a-d56f-4a7d-ac8a-4d4c830a21c1">
    <dc:identifier>DB12536</dc:identifier>
    <rdfs:label>N-acetylmannosamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/342e0104-c713-433f-a2c7-d3e5d8b49d40"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12536</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b877fe1a-614e-4f99-bbb7-e0d01d9e72da">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a2f3427-8ed5-4e47-ba45-824b7b469208"/>
    <rdfs:label>(5aR)-5a-C-Pentyl-4-epi-isofagomine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/db40982a-b256-4930-8d94-d745b5bd075c">
    <rdfs:label>mitochonic acid 5</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a6c8862-92e8-4b4d-894d-64ba617594ce"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2949c60d-dc79-4947-81bd-7a88f405e2df">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
    <rdfs:label>Increased total cholesterol</rdfs:label>
    <dc:identifier>HP:0003124</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94505e12-4dcd-469d-8401-cfce82fbf6cc">
    <rdfs:label>Refractory Arthritis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031375</ddiem:url>
    <dc:identifier>HP:0031375</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/98abc80a-49d3-4b13-bae7-b54dcd89c7eb">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/47d6665c-05c9-4f15-9831-eff5445a39d7"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a1345ce3-00e4-49a5-89e5-386f54baa0aa">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/18d514f9-7381-4bd3-a36c-a20b9ad47d32"/>
    <rdfs:label>AAV-treated βgal</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0798c296-0721-4d8a-9ae1-e9877ed55ff0">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237400"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00726-017-2462-x</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bef67d5b-641e-4ff7-82f2-6b117f1de8fa"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7fa2404c-9a2c-44cd-9473-d81440edc0a5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27023909</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/951d351c-2c8f-426d-a5c8-4cc91d1e36e6">
    <rdfs:label>Glutathione</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00143</ddiem:url>
    <dc:identifier>DB00143</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/186668ff-2260-43ed-b5cd-8df9efc9dae1"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c95e2d6f-03cf-49d9-a9d8-93ecd73d32b7">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000166</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000166</dc:identifier>
    <rdfs:label>Aggressive periodontitis(Sever periodontitis)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/43f9b245-b11c-4e52-a233-b4d0f4936be0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00181</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0bc14c38-9393-4874-ba4d-5a564d2cc99c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e9a82f6-59ff-45ab-9285-91622a1c7d91"/>
    <dc:identifier>DB00181</dc:identifier>
    <rdfs:label>Baclofen</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3b66edb-e7a0-470d-b38b-efb38be92189">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
    <rdfs:label>low hemoglobin concentration</rdfs:label>
    <dc:identifier>HP:0001931</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf9cef5a-4083-48fd-b900-751782184f5c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00016</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7cd22a83-1c97-4e4b-a2f6-6efbb5307c77"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b255c57e-97de-4df3-875a-9ba9c020dc98"/>
    <rdfs:label>Erythropoietin</rdfs:label>
    <dc:identifier>DB00016</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50d08471-0f96-4d07-b05a-3e2a9dc90b35">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Defect of bone mineralisation</rdfs:label>
    <dc:identifier>HP:0004348</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/babe350b-02f7-469c-915d-fecb22e1a3dc">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
    <rdfs:label>Poor eye contect</rdfs:label>
    <dc:identifier>HP:0000817</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600740">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/600740</dc:identifier>
    <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b82bad66-5bda-418e-86d0-98a3b4dc38c5"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4950dcbd-0ef7-45f8-8e7a-d3a6fef555b9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/79da0c2c-6fac-495a-bbb4-e0763265a620"/>
    <rdfs:label>OTZ (L-2-oxothiazoline-4-carboxylic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c5996faf-5642-4fa4-b7d1-bce2482eda82">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b8537ed8-2ec6-4076-9ff0-6737624dea80"/>
    <rdfs:label>rAAV-GPE-G6PT</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602360">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/602360</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/425355a4-0532-4623-92dd-27eff1c11ae7"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07a20493-03c0-4ef5-a2a2-986ff31b1ace">
    <dc:identifier>HP:0000982</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
    <rdfs:label>Keratoderma</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ea73ebb3-3c6f-4383-905a-27536fffba94">
    <dc:identifier>CHEBI_25548</dc:identifier>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_25548</ddiem:url>
    <rdfs:label>nitrilotriacetate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cb11b31a-597f-40de-a850-834658ccc0ea"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/325a4743-3c73-437a-8861-86511897e97c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
    <rdfs:label>Recurrent vomiting</rdfs:label>
    <dc:identifier>HP:0002572</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c50cd74f-04f8-4a6f-97a8-7060fd9cd689">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025201*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
    <rdfs:label>High Apoliporprotein B level(Abnormal abpolipoprotein level)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/87d89192-2231-4ad8-95b7-0370c6707142">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2ecfe815-173d-4f8c-b676-d3ab78f0f432"/>
    <rdfs:label>Eliglustat</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09039</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ca84407d-b2d4-4a87-82b3-8a967fcd4349"/>
    <dc:identifier>DB09039</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e6f53fbe-37cb-422d-a226-fd26addfd1eb"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8fcfff63-3e85-47c7-9f82-e242902fb9af">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/101194d7-e980-4801-8fb1-8523e46028f6">
        <ddiem:url>https://www.drugbank.ca/drugs/DB0084</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43bbf76c-cc35-470c-ba17-8558e9ec532b"/>
        <dc:identifier>DB0084</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/58e514b8-a976-423a-8f24-6b1538427fe0">
    <dc:identifier>DB01390</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5e3efd6e-8c10-4dbe-aae9-019aca2c113d"/>
    <rdfs:label>Sodium bicarbonate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/13ee20cc-c256-4015-a8d7-3c89db721d4c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/45401c42-e121-4e0e-ad6d-4acf40360ff4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01390</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9951f54a-7d65-4537-baad-3e439843057b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3f3ecfa4-0675-4c5c-b599-579bb1cfba84"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/984080b6-e31d-44f3-b001-a7a79a09ffc8"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8cd611dc-4724-4c81-8817-9b0d52ed3975">
    <dc:identifier>HP:0005952</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
    <rdfs:label>deteriorating pulmonary function</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/002bddca-1a6d-42fe-9cfc-d632dc8c6b80">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/946b9a23-8f75-4d48-9233-3362b80411c9"/>
    <rdfs:label>(r) AAV2/1-mediated calpain 3</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/666d7fd1-dcfe-4a7c-a666-7834798460e4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02959</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/58f6cb34-5266-4b8f-ab09-96488dc6f50c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8385b0a-4e9d-4bdc-9b2c-0f79a3fa3226"/>
    <dc:identifier>DB02959</dc:identifier>
    <rdfs:label>Oxitriptan</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b13a6653-d80c-4746-bd2a-8234f0897b2c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3f57ac71-bbf8-4138-bf09-68a35836eca9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/296d7146-5164-48f1-8bfd-6d73b7a5697b"/>
    <rdfs:label>Laronidase</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00090</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0efdc51b-ad6f-4b01-addd-8efcdd65e62b"/>
    <dc:identifier>DB00090</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ea5feb6e-62b0-4ae0-8913-28a1eb40e40b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/90830352-21db-4e63-870d-6eb2c632362f"/>
    <rdfs:label>Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ee565eb-bdaa-48e6-a238-c9363318769e">
    <rdfs:label>Abnormal developmental milestones</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <dc:identifier>HP:0012759</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b825356-3adc-48d0-9569-aa588ac017f6">
    <rdfs:label>Functional loss of vision</rdfs:label>
    <dc:identifier>HP:0000572</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000572</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/62236951-8d8f-4c64-935a-5d15dfa0836e">
    <rdfs:label>LJPC-401(Synthetic human hepcidin)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c848dbdd-6d35-425d-b5eb-543b7b43cc71"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dcc78ddf-e6da-4633-99a8-984e12ba8e9e">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0030980</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
    <rdfs:label>Low brain glutamine concentration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145980">
    <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1</rdfs:label>
    <rdfs:comment>In majority of cases, there is no need for treatment until thecalcium level is very high, it becomes necessary to treat FHH.https://www.ncbi.nlm.nih.gov/pubmed/21986511</rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1e3388b2-cfdd-420c-aac1-2ff8811e3c1a"/>
    <dc:identifier>https://www.omim.org/entry/145980</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5edb3d61-bb7d-4ea7-bfd3-557b4d4ad5fc">
    <rdfs:label>Nifedipine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f48087ad-d7ec-4aa9-9ba7-4fa5c54d3347"/>
    <dc:identifier>DB01115</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01115</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/38af40a0-600c-4667-b5b2-19ba4adba65a">
    <rdfs:label>Gene Therapy ??</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a428b82b-392a-4feb-a455-013b5ade52f3"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba064729-83fa-46f3-a913-93c19e855f2c">
    <rdfs:label>gross motor dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007015</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0007015</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5b026d28-ef9b-41c0-a009-696b12a11c68">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dbb76147-47fd-48c5-93d3-2bb7fed387da"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39a13856-8663-47ad-8a45-cf249c6f14e3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Drug wasn't effective (Insignificant effect)</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/24ae32fc-08b3-410c-8d04-a7fdeb4bab35">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a66f841-c2e3-44b8-936b-6a17fc01beb7"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9317abc0-16c0-4985-b4d1-4a6d78fa7593"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/17c49188-302f-44d5-acf4-4b83764c200b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cb7133ec-57ea-445c-9a77-cdd1f752986d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00390</ddiem:url>
    <rdfs:label>Digoxin</rdfs:label>
    <dc:identifier>DB00390</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ce56794-5fce-477b-abb6-1fed99e36f4b">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011943</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011943</ddiem:url>
    <rdfs:label>abnormal thiosulfates level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5d424ca-bb37-48eb-9a79-a83124016861">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormality of the nervous system</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/606dc152-2594-4f33-95e0-849ab6748d60">
    <rdfs:label>"No remarkable clinical improvement was observed and therefore, treatment was discontinued"</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c5ccdb5b-8fc8-45a9-879a-56412d13fb35">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/75d055df-1ede-423f-9312-4f04211a3f7e"/>
    <rdfs:label>Resolaris (ATYR1940)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb35b965-b600-40ae-879b-1fbee19d171c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002062</ddiem:url>
    <dc:identifier>HP:0002062*</dc:identifier>
    <rdfs:label>Pyramidal neuron loss</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/41df5f33-1dab-4d94-818b-ab20ddfe61c4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ebdb9a9e-1371-4217-85da-84b1a352c175"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8cb3a162-53c8-441c-a766-cb018fe99ce7"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3cae0a3f-a2c0-4705-aeab-256058f358ec"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bacfe943-981d-405b-b58e-b24e37e94d72">
    <rdfs:label>Norleucine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2d616101-299e-4296-a43e-5a3435f09d0f"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c13f4902-6ff9-4bb5-b4d4-ed16b5146064">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/386e59fc-b0bd-4226-b675-071e358784ec"/>
    <rdfs:label>Metreleptin</rdfs:label>
    <dc:identifier>DB09046</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09046</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ee8f4b47-3a92-4d15-939a-8221981b24f0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c60543f3-b49a-46a5-ad4c-7a56c154f52c"/>
    <rdfs:label>Ad-mG6Pase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4518518e-8f15-434c-b097-109e23a95b50">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1e162bb-2474-4218-957e-949418eab82b"/>
    <rdfs:label>Ethoxzolamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00311</ddiem:url>
    <dc:identifier>DB00311</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce918572-175a-42fa-97e5-4f01d912bf82">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
    <dc:identifier>HP:0002240</dc:identifier>
    <rdfs:label>hepatomegly</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/79a6951d-e825-48c2-bb81-27d927dffde4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2d545b0a-4756-4d70-ad07-0c7ab3cfeb3c"/>
    <rdfs:label>HDAd-G6Pase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3f52931a-0ab2-442d-83f1-68fc2c432700">
    <rdfs:label>Gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/56135b5f-8863-4e75-81cb-7a6efd7b363f"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7dc76710-e5f7-476c-9efb-9d495a2af4f5">
    <rdfs:label>Probucol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01599</ddiem:url>
    <dc:identifier>DB01599</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3134cc11-1d8c-4c3a-80a5-12800b4185e3"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c9b6831b-67d5-4b41-83f7-00df500f2da6">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01200</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c39ada66-0f76-426d-a16e-60bfce8e2ebf"/>
    <dc:identifier>DB01200</dc:identifier>
    <rdfs:label>Bromocriptine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21993d28-82cf-4dd6-b72c-a3416e9344f4">
    <rdfs:label>Dextrothyroxine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/013d1715-45cf-4fa8-aaae-dbfc283013db"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d81c1e5f-9291-42d5-9d2a-8f54bc5b6e79"/>
    <dc:identifier>DB00509</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00509</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d523079-35bb-4aa9-85e1-5f9728d84d77">
    <rdfs:label>rickets</rdfs:label>
    <dc:identifier>HP:0002748</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a3932ada-1b3f-458a-82f3-75811e29cca9">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/749b0d19-76d7-4d26-bca6-64f55116be92"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7979e2e-d0f3-4bed-af39-314165185e46">
    <rdfs:label>Vitamin D insufficiency</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bfe6e931-ffba-4eb6-972d-c6bc4572b6dd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e44ef7c0-5b92-48cd-b33f-6979b4288ea8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06273</ddiem:url>
    <rdfs:label>Tocilizumab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/05b2d37f-6b75-4a47-81e2-62075236b85c"/>
    <dc:identifier>DB06273</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/58cb955c-d387-474d-aeeb-006230a5fd68">
    <rdfs:label>Cyanocobalamin</rdfs:label>
    <dc:identifier>DB00115</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9b6a3c9c-1bd8-4589-84bf-411ea5e72a25"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4f3df1f0-60a1-49fc-a3b7-9a8701b6884c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00115</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b942c222-9608-4dd0-8a16-e90e8f71a199">
    <dc:identifier>HP:0003155</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high serum alkaline phosphatase</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003155</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/890f6522-4cbc-49ca-be86-a4362391f6a7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12374</ddiem:url>
    <dc:identifier>DB12374</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aa99cef8-9fb9-4fa0-b454-b9884e64262d"/>
    <rdfs:label>Velmanase alfa</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dc11941f-cacf-47b5-b28f-a0ea0dc191af">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1731f966-5108-4bb9-82cc-b58438ba50e9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00608</ddiem:url>
    <rdfs:label>Chloroquine</rdfs:label>
    <dc:identifier>DB00608</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/399206db-d805-4c86-aa4a-297f484ec544">
    <dc:identifier>DB01119</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ff345eb3-b2c3-452f-bb80-76b830eca4b9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01119</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4a9b03b9-0df0-4783-9e8a-2fade7fd0b10"/>
    <rdfs:label>Diazoxide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5e406a12-33fa-4de9-b94a-664afd60e104"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a647f38-57a5-4eeb-a7ba-d35102e654d7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14513</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6020f029-c549-48f8-8ded-164245d8aa08"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/37ba3b21-a610-4843-9391-82891b895245"/>
    <dc:identifier>DB14513</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b065e5e8-6364-4fb4-95ce-204a99a2d090"/>
    <rdfs:label>Magnesium</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b404fbb1-cc0e-4b9d-8119-42b8c1cc79ae"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/939903a2-d532-4016-9f7b-a0fa55249d3d">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Vitamin K insufficiency</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d4b0df9-82af-4f07-b23f-3c8fd120c382">
    <dc:identifier>MP:0013438</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0013438</ddiem:url>
    <rdfs:label>Hypomyelination</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/905e2f9d-7a40-4806-8204-cb9cc0d7f6e7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00020</ddiem:url>
    <rdfs:label>Sargramostim</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f0f82032-2d11-4f4f-86f8-92dbb45565cd"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3a8ebf2a-0689-41b0-8229-70b5aa8ed15b"/>
    <dc:identifier>DB00020</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5a658d41-9109-4732-bd29-cd2b74e76b71">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b72292e2-af0a-48ee-8d8b-53af923fc616"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0a15d53-320c-4529-b7fb-836eea805513">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/025178d2-4bee-4909-9a87-7175496a7f6a"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/471e549c-1eb5-450d-b4b6-5e9d7aaed10a">
    <rdfs:label>Acitretin</rdfs:label>
    <dc:identifier>DB00459</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd6abc63-1592-46ae-9079-ad56adf14e7e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0f6ad7bd-e3de-44b3-ac7d-d36554a72411"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00459</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/20cbfb04-f9c5-4e3b-891b-5152d3140dae"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258450">
    <dc:identifier>https://www.omim.org/entry/258450</dc:identifier>
    <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/451bbd3a-512a-4a5d-8513-97be22d4cce9"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 1; PEOB1</rdfs:label>
  </ddiem:Disease>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000013">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <rdfs:label xml:lang="en">symptomatic treatment procedure</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure aimed at amelioration of one or more abnormal phenotypes generated as a consequence of a defective protein or process by a means unrelated to the immediate pathway or network environment of the defective protein. Generally working at the level of the tissue or overall organismal physiology. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:49+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/61799d9a-7406-4a64-a180-1f363abf9f7e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4ac7822c-49d2-4571-9d0f-19658a9a21a4"/>
    <rdfs:label>Propanoic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03766</ddiem:url>
    <dc:identifier>DB03766</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f585f4d9-275b-4b03-b885-f3a280b4a1c4">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high blood S -adenosylhomocysteine level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c5c6430e-6b8b-4d3b-b54b-391c2dce1a3f">
    <rdfs:label>AAVrh.10CUhCLN2</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a4d94ba1-0f12-4812-8df7-673621553509"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ffd07f4d-c0a6-4ab7-984d-4310ab1c6b92">
    <dc:identifier>DB00348</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00348</ddiem:url>
    <rdfs:label>Nitisinone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4c111f7d-9d7f-4e02-a98b-252557747f70"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b543719-3c9d-4d9b-8495-db6592f9e40f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c34ac0d3-da03-455f-bf65-0ac98bf67c70">
    <rdfs:label>Low height velocity</rdfs:label>
    <dc:identifier>HP:0004322</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fc714a7b-1ae5-4eab-b7a2-a37d0e448a8c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fac60057-d0f4-4cba-80cd-21a466ca0848"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9e1561c-0e13-4e71-9030-b57f5f7468cc">
    <rdfs:label>Abnormal Folate level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040087</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23fa01d3-0b10-45d7-854d-652b0bb9267c">
    <rdfs:label>Trial is still in the Recruiting stage.</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ded8c866-aabe-40ae-baf3-60e7328ddb3c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002453</ddiem:url>
    <dc:identifier>HP:0002453*</dc:identifier>
    <rdfs:label>Bilateral abnormal signal intensities in the globus pallidus (Abnormality of the globus pallidus)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232800">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cb795bff-9895-45db-902a-a334d9340974"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/491</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/232800</dc:identifier>
    <rdfs:label>GLYCOGEN STORAGE DISEASE VII; GSD7</rdfs:label>
    <rdfs:comment>The infantile form of PFK deficiency is characterized by the early onset of muscle weakness and multisystem involvement, which often leads to death in infancy or early childhood. Early diagnosis and improved understanding would enable clinicians to provide better clinical care. https://www.ncbi.nlm.nih.gov/pubmed/26108272</rdfs:comment>
    <ddiem:iembaseAccessionNumber>491</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/438a0b33-ca48-49a0-add4-9f351e4dc105">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0517cf6b-8dc1-40ab-adf5-02f2596bb32f"/>
    <rdfs:label>β-galactosidase:RTB lectin fusion</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a160f886-8031-48cf-8c08-61e0d1bfe511">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012133</ddiem:url>
    <dc:identifier>HP:0012133*</dc:identifier>
    <rdfs:label>Decreased red blood cell production</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e7626ec7-8215-4f6f-954c-b1c84943d9d1">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00155</ddiem:url>
    <dc:identifier>DB00155</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5615946a-6dd8-4c41-8142-2a7e2168d764"/>
    <rdfs:label>L-Citrulline</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0b80eaa0-d928-4595-a3d2-9d9de1aeb13a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00999</ddiem:url>
    <rdfs:label>Hydrochlorothiazide</rdfs:label>
    <dc:identifier>DB00999</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8d5924a1-041e-4ffd-97c3-dbd0f0c6a832"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6d1ddb78-804a-4a32-b21a-5980720285db">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/50f806f7-84b1-4fc1-a63a-3a33ece6a530"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/14943264-34b9-44b1-a847-03244b8842b1"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4399f9a9-a307-4ed8-90fb-180d3500f49a">
        <ddiem:url>https://www.drugbank.ca/drugs/DB08860</ddiem:url>
        <rdfs:label>Pitavastatin</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e186f153-45ec-4a0c-a721-78b247965a43"/>
        <dc:identifier>DB08860</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f6463b8-5477-47ef-b085-cab9a87ac8cf">
    <rdfs:label>Dental Defects</rdfs:label>
    <dc:identifier>HP:0000164</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000164</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75d06370-abc8-4adb-9162-1ec99f29dee6">
    <rdfs:label>Low cerebral creatine content</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
    <dc:identifier>HP:0012113*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2e214ac-3274-49e9-b455-2e81bad0e420">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
    <dc:identifier>HP:0002540</dc:identifier>
    <rdfs:label>inability to walk</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2f2a42e9-aad0-4f28-aa23-06e900e9085b">
    <rdfs:label>Hypophosphatasia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002148</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8efba906-1f02-4ad1-b7ae-6081f5ace59f">
    <dc:identifier>MP:0003354</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0003354</ddiem:url>
    <rdfs:label>Astrocytosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2e99b90d-bb55-4ca6-9b31-069fe0ca429e">
    <rdfs:label>hydroxypropyl-β-cyclodextrin (HPBCD)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c499d5d8-aa14-46e9-9394-c13a9639ac8e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f3f73bd-69a6-4f27-aba5-0e4d9ec45721">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low β-gal activity (Abnormal enzyme,coenzyme activity )*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf867fb9-960a-40c9-8366-17048bd603f6">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001129</ddiem:url>
    <dc:identifier>HP:0001129</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Large central visual field defect</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/202859f5-0790-4bf0-ac15-0324142e976e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/23c0f88e-1e44-48ca-a7f5-e4fcb086837a"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aa236b98-a541-4410-9759-0353fff1dee2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3754c395-7335-45c9-8056-b5e4f1d5c3e9"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09C</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9be18b98-7973-4cf0-afaa-c520786073d8">
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6866321b-f658-4e71-92e2-9f228c404ca8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d62a5ca-9e85-481d-9bd4-a98b7517f325"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a2b32131-bcb4-4090-b25a-6f3725ce05e2"/>
    <dc:identifier>C09C</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/965cbc70-a08d-41ca-8ddd-9b4f06a54ab2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8175a131-b2aa-404a-8dcc-6095c47077de"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e7cdfeb-3b4f-49ea-a861-3460e571d6a7">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Decreased serum IGF‐1</rdfs:label>
    <dc:identifier>HP:0030353</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030353</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf3083b4-2e96-4acd-a2b8-f86210065f02">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc7bf555-eda7-450f-8fcc-b8b658494992"/>
    <rdfs:label>Adalimumab</rdfs:label>
    <dc:identifier>DB00051</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00051</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0112790a-4124-4a41-85bc-db93748b70c9">
    <dc:identifier>HP:0003158</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hyposthenuria</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f28378bd-0d72-407b-9827-94dddf675969">
    <dc:identifier>HP:0002243</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>protein-losing enteropathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002243</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0cddf4c7-698f-4bc3-bd41-5981c17abf99">
    <dc:identifier>DB11859</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11859</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3ae50ce2-4819-4660-a95c-39cc4e11ff65"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c6a63e77-f816-4c80-a88e-c89ab3d72c0a"/>
    <rdfs:label>Brexanolone</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/11766663-79c4-4620-8c2e-c789594f448f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/29a9ef5d-27a6-4582-b971-35f3b768ba4f"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/852e709e-5a72-4930-98af-18543e58901c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f36cde0-0106-450b-b69b-0a05c3b74de4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09130</ddiem:url>
    <dc:identifier>DB09130</dc:identifier>
    <rdfs:label>Copper</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1692f29a-c95a-4424-9310-435ed758b7df"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/619406ba-2265-43af-8600-22884ea26874">
    <dc:identifier>DB00060</dc:identifier>
    <rdfs:label>Interferon beta-1a</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7fa35c00-1795-431c-b811-27221d4d8fc3"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00060</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/efcd0e34-ea17-4f10-b39e-67440c698151">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01606</ddiem:url>
    <dc:identifier>DB01606</dc:identifier>
    <rdfs:label>Tazobactam</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/116e45aa-8a83-4621-89ef-e773d5d1f2b0"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c844ffa2-3ae3-45a2-9e3b-9aabdc268dce">
    <rdfs:label>recombinant human LCAT (ACP-501)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c96b3ce1-0028-4160-8f74-54c4dc0cdb67"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eec268b8-2442-4651-81e2-e6c7bdcbfc9f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9827841d-3dfd-4848-be8f-712db601d6b5"/>
    <rdfs:label>rh-HMBS</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8fb3ad73-c8d0-4879-881e-08bf1958a67c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fa26e8ca-194b-4494-939a-ed1094a76dfe"/>
    <rdfs:label>aminomidazole carboxamide riboside</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44ff57d0-294d-48e1-9268-4f9993f73707">
    <dc:identifier>HP:0004732</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Impaired renal uric acid clearance</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004732</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/30df7df2-d253-4cdb-b5e5-d7fd9109889a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00162</ddiem:url>
    <dc:identifier>DB00162</dc:identifier>
    <rdfs:label>Vitamin A</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/72d7a23b-014f-40a0-8ffe-5bc25578e154"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/33c557ca-587a-499b-a78f-b18cb76de1f9"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1a231475-c425-48f3-ba76-d2013ec667fd">
    <dc:identifier>DB04844</dc:identifier>
    <rdfs:label>Tetrabenazine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d88db206-e04d-4a68-8190-5e9e87fdfaab"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04844</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c363a680-deb3-4e5d-997d-b31d37d91265">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4d028282-089e-45d1-814f-040d909f77c0"/>
    <rdfs:label>Adeno-associated Virus 9 Mediated FKRP Gene Therapy</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4f3756fa-a628-40bb-b023-11bfe6d83915">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3323c563-efe0-4553-82eb-ec66d99d8fd1"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3c332815-b641-4cee-a3a9-9217f1e3be0b"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f8ad89e8-e71a-435b-b3f7-1ecc7a9ab0c6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9678437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d0504bf-c2a4-4ebf-883a-df810be03074">
    <rdfs:label>Hypercalcemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003072</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/40e5ed3b-b6be-4498-bd0b-2ba13c7111c3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06667</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c771aa17-a542-4aee-8660-b6d993a04a42"/>
    <dc:identifier>DB06667</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2c742fd6-5610-4767-bfc5-e5cc43b9595c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b28d3294-53af-49cc-a58e-56d19d39dd3b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/803b0366-6346-4a3c-afd0-858dfad05149"/>
    <rdfs:label>DTX401</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/164198d7-4bd7-4ffa-aa89-aa7659f2a7de">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/44d97c1e-b3df-4f99-9aab-f8cda85c6b88"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b55d3d3d-7cb1-4f61-9b83-db583f26833f">
    <dc:identifier>DB00973</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/53de7f24-964f-4e91-944d-bc4fc4f46296"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00973</ddiem:url>
    <rdfs:label>Ezetimibe</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9f367694-96c1-443c-bdb4-fbc9f2693c5b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f87f8d10-25c9-4283-8296-1ca4dcf6b499"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b471d0fb-b2ad-4ca2-ac23-e00c1a72163e">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=L04</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8623bb4e-7bbe-4123-9c0b-dcc07c208b0a"/>
    <dc:identifier>L04</dc:identifier>
    <rdfs:label>IMMUNOSUPPRESSANTS</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3beb7a4-4226-40e7-86e5-2e48ace693bf">
    <dc:identifier>HP:0001744</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal spleen size</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/260dd508-9ee8-45dd-b35a-976126f133bd">
    <dc:identifier>DB00065</dc:identifier>
    <rdfs:label>Infliximab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0d9f1bac-ceb1-4194-b2ef-d26961392415"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00065</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c87ce811-f394-4ea5-8052-c3396c7b80cb">
    <dc:identifier>HP:0004923</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal blood Phenylalanine levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/113ac053-6573-443b-a5d0-c4c2c6fd4ec6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/85033d15-1e7e-41c8-80f9-bf7489d38ab1"/>
    <rdfs:label>Uncooked cornstarch+ Beneprotein</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf51c9ff-f9bc-4806-a187-65c3a1d847c1">
    <rdfs:label>Arginine-restricted diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f6f1d0e-ae5f-4001-88e1-e2a6b667668e"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/88ceaa3c-010a-4830-b2e7-c1c9caa0dedb">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aa548e8d-59b2-496f-a079-9925b0fcf9e1"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6c9a4f7-e30f-4d03-838c-bcfa6da618ab">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>communicative skills abnormalities</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002474</ddiem:url>
    <dc:identifier>HP:0002474*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/87f45f49-db02-456e-8a61-badc2a370edf">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/347ea08b-ddfd-4cc9-b27f-9628a5a75c3a"/>
    <rdfs:label>Gemfibrozil</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01241</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/245680fd-271c-43c0-a0b7-ef5b106c8625"/>
    <dc:identifier>DB01241</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab051cbc-a4b9-4eb5-b49c-40f2f51211db"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dc57c075-c6cb-4d4f-a2c3-401d8e37a049"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e212eac-7662-4990-962c-93536e182efe">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low activity of the immature 4-HPPD enzyme</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/194b84c2-fe62-4746-b18a-59c83d85b771">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d88f31d4-9685-4da3-840f-9da02d5fc02a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b272893a-7e73-40e8-b28e-23e8a610e920"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00847</ddiem:url>
    <dc:identifier>DB00847</dc:identifier>
    <rdfs:label>Cysteamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/012c0892-50e6-4a5a-91d9-4dcd2797abc5"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/3696da7f-131b-46bc-89ba-2934880fcb94">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/afc5eab7-3ee0-4e84-8709-3d0cb42ec2a9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa2e5b93-8284-4c0d-89ce-124c136a3cd7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542</dc:provenance>
        <rdfs:comment>Overall no significant clinical positive effect of Cystagon was seen in the current study involving four patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/</rdfs:comment>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e47036a2-dc7a-4376-a8c7-faf700e57e2f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19d53538-bcfe-4f87-8793-f4a0afa5ba4b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00755</ddiem:url>
    <rdfs:label>Tretinoin</rdfs:label>
    <dc:identifier>DB00755</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/afd06ebc-0f57-4746-bcd1-ef1ce4fd2ebf">
    <rdfs:label>abnormal muscular co-contraction</rdfs:label>
    <dc:identifier>HP:0001257</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ee74172-9eca-4587-ac16-95c2efd185af">
    <dc:identifier>HP:0000725</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000725</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>psychotic  disorder</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5535ff32-3c8f-42a6-b02b-8f2ea37ed86e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/109bf726-5bbf-45f3-9c6d-70fdbdc033cd"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ae5ae804-8702-4f1a-8760-cffd550d86db">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/48118ae8-251f-477a-9ac9-f44745b91bbb"/>
    <rdfs:label>Selenium</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11135</ddiem:url>
    <dc:identifier>DB11135</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/438bf50c-a748-403b-aa7e-dabc3369937b">
    <rdfs:label>Abnormal lysosomal membrane associated protein-1 (LAMP-1) gene expression</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a4ca4e5f-6c67-42f5-924f-c7498d015041">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01609</ddiem:url>
    <dc:identifier>DB01609</dc:identifier>
    <rdfs:label>Deferasirox</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fc2f7563-d83e-4b1c-a8f9-8d4693ee2bf0"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a11f2379-f4d5-4fe8-97a7-fa116a975dd2">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bb033c64-dd1c-4f17-9507-b7ef22eba861"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19a6babe-e5eb-499f-99f7-63ddf5bb016c">
    <dc:identifier>HP:0002020</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002020</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Acid regurgitation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42c4732b-18a4-4226-8353-f7b57d40b35b">
    <rdfs:label>Carbamazepine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24ae32fc-08b3-410c-8d04-a7fdeb4bab35"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e7491583-00c9-43bf-bfa1-a2d1a88a4b01"/>
    <dc:identifier>DB00564</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00564</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5dba5a9-61e2-48bb-b556-9aea28179b37">
    <dc:identifier>HP:0003165</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
    <rdfs:label>abnormal parathyroid hormone level</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e136c711-b751-48b6-9d38-949adb40bbc5">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/89cfbbcd-97d4-4274-b0e3-806083b4f3bd">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01403</ddiem:url>
        <rdfs:label>Methotrimeprazine</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/27a8465b-7c76-432d-869f-f25672e95e84"/>
        <dc:identifier>DB01403</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d365f58-de50-4748-8715-8b20e34ab3c1">
    <rdfs:label>elevated serum concentrations of bile acids</rdfs:label>
    <dc:identifier>HP:0012202</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012202</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a669a65-fdfb-4818-a78a-f916450d781b">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
    <dc:identifier>HP:0002066*</dc:identifier>
    <rdfs:label>paroxysmal exercise-induced gait ataxia(exercise-induced episodic ataxia )</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3244dfb4-3d0b-4057-9c9a-dc8cee21c939">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6bf3376a-4e5e-4288-be45-b1421ad69ee6"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5267d7f2-b156-45ea-95b1-2bec21e7b812">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5daf8595-6925-4068-9596-f4d80758f407"/>
    <dc:identifier>DB00288</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ca924aa6-2f2e-45a1-834a-40cf214253f0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/39c3da32-c855-471b-b27b-45c88ffe1ea9"/>
    <rdfs:label>Amcinonide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00288</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3eefe8ba-1d90-4a62-b12b-c951ba1d35a4"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6dd012eb-b538-45e1-bce3-508b27c29ee4">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00112</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e32829b3-63b1-4c75-aec3-61cf2dd4d655"/>
    <dc:identifier>DB00112</dc:identifier>
    <rdfs:label>Bevacizumab</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/829c1c9e-bd72-48a7-b412-41560e1e0f97">
    <dc:identifier>HP:0010909*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010909</ddiem:url>
    <rdfs:label>Elevated blood arginine levels( Abnorality in arginie metabolism)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b91bd5f5-0172-4abc-9ec3-29bad8660bab">
    <rdfs:label>AT342</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c375259f-1d38-45a5-a86c-1cc2f7a5e048"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95aabe0a-2bdf-49c5-ba22-395caf6eb429">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal muscle phosphorylase activity</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/02e28a23-86ad-4104-8880-f1f5123b0b3d">
    <dc:identifier>DB00067</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/090c8b74-b1de-4527-9058-d05d6d69ade7"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00067</ddiem:url>
    <rdfs:label>Vasopressin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0c2a14a2-2e6f-4035-bff8-69252d6a65e0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11672</ddiem:url>
    <rdfs:label>Curcumin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d059b63-c309-4ec8-8c27-1571749b8074"/>
    <dc:identifier>DB11672</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e1e31d92-5abd-4692-aa23-3d7c1ab5bd8a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/df0c1302-4e51-4f27-897e-089753d0f409"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/22b37368-1fec-4f79-9c6a-fd19a5ea86c5">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e9b517e8-bdfd-4cc8-9d53-7937454c7a42"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/681b7089-d608-4f92-b4e9-4b176eca8167">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/de071454-261e-4187-a7d4-6183690597fb"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5dd317b9-1321-4a92-9686-ad141ec2d172">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/127e4edc-775e-450e-8918-fdf8839439cc"/>
    <rdfs:label>Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/55d6d8e2-eae1-4eb0-afc9-f98720d9917f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c8cb63d-0898-4eee-885a-d828e202b4fc"/>
    <rdfs:label>rAAV8-mediated gene therapy expressing murine HMB-synthase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad84938a-907c-43ce-8abf-4e6d9401aa78">
    <rdfs:label>6S-NBI-DGJ</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/80b65f56-f797-4453-8013-ab1ebb7953d9"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f9bcaf3c-baca-4e7f-900f-4820e3927eef">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00393</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a9abff6f-fcf8-49e8-9e9a-973287886b6c"/>
    <rdfs:label>Nimodipine</rdfs:label>
    <dc:identifier>DB00393</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ae4e0247-d611-42b7-8091-d2d71056b765">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/022079c5-4c8c-42ce-bb33-1a15523a3342"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fc48503f-e081-4680-b75d-d07c2d0e8397">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f5917ea-048d-490b-a33e-26ffafff6e1c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/729db1c2-2157-43e9-87e2-649bf5b70293">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a301c207-034e-4b3a-85fe-247165c87102"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5340856f-c877-4584-b9cb-50f1dcaf1ad6"/>
    <rdfs:label>Pegunigalsidase alfa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14992</ddiem:url>
    <dc:identifier>DB14992</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fc0b274e-2d6f-4677-a20a-a5f34ca32d7a">
    <rdfs:label>Recombinant human Aspartylglucosamidase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f17079af-69f4-4e3c-8539-b521b0f15020"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8af56489-1b8f-42f7-acf8-060f3aa443c0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c873567c-68e9-4726-9b50-9d58839cccae"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/00bbed6f-2c39-4d64-9471-50211163fd49">
    <dc:identifier>DB00679</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00679</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aff5d654-6e25-41c3-a08a-1bae70714bea"/>
    <rdfs:label>Thioridazine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0c992f83-81e6-4d52-ad01-ef39685056bb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/561512a9-20b0-400e-a3af-48f4ffd042e7"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00472</ddiem:url>
    <dc:identifier>DB00472</dc:identifier>
    <rdfs:label>Fluoxetine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b70249f-40f2-4fda-b392-c3860527ef0f">
    <rdfs:label>electrolyte disturbances</rdfs:label>
    <dc:identifier>HP:0003111</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003111</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3891343d-1e5e-4307-985b-e629fd8aac8a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab058cda-e056-4233-93aa-013096f38513"/>
    <rdfs:label>rAAV2-ND4 (recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4))</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/af9c9f2f-06f9-4455-8e04-16f3b5971344">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/230b0552-75c0-44c3-b9c1-9aa843b34b15"/>
    <dc:identifier>DB01306</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01306</ddiem:url>
    <rdfs:label>Insulin Aspart</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01ae9994-c9c4-4b52-aa94-7d0ac290e9d8">
    <dc:identifier>HP:0001987</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High blood ammonia levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6269d9ae-f9c3-4bfd-8fad-888bd6153955">
    <rdfs:label>Pergolide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c53bb6d-04f2-4b5e-bde6-3d51b2b9375f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01186</ddiem:url>
    <dc:identifier>DB01186</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3dee552a-7bd4-4c64-8687-bb80fcbd9750"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/600d2efd-a78f-4489-af5f-0fa6db83cdb4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f60f594f-ea23-4694-84be-0df2af41849d"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6bbc8d0-3608-4314-88fa-9f7b3df3e22d">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormality of muscle physiology</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <dc:identifier>HP:0011804</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277410">
    <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE; MAHCD</rdfs:label>
    <ddiem:iembaseAccessionNumber>316</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/277410</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/316</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2bb7cb65-ba53-465e-8ace-0e4c1176ee0b"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3423c1f5-5e44-4055-8b2b-47b162e8f5f2">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002529</ddiem:url>
    <dc:identifier>HP:0002529</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Neuronal death</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eb59c5bd-2320-4781-9b50-ee7e0c9e74be">
    <rdfs:label>Green tea leaf</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14307</ddiem:url>
    <dc:identifier>DB14307</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d379e882-191c-443e-9e89-1d94add44256"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/053042d6-8ae3-45ab-a817-ae417e1595b1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High lactate ,pyruvate ratio(Mitochondrial respiratory chain defects)*</rdfs:label>
    <dc:identifier>HP:0200125</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/83542bc4-38a5-4491-bd94-f134015c679e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42bfcffd-a21f-48bb-afba-1a64b2649cff"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6738eb64-670a-4254-9265-930e94329078">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
    <dc:identifier>HP:0045082</dc:identifier>
    <rdfs:label>Decreased body mass index</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c7e12c80-e68c-4cd3-911e-011bf3a62492">
    <rdfs:label>Daclizumab</rdfs:label>
    <dc:identifier>DB00111</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f6e4a3ab-c1d8-4a48-8a09-127373522b7a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00111</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5ed8d8bd-39e1-4a6b-9d77-33113d1b5b56">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/75fcef6b-b71a-4c3c-af85-3ad9742f83e4"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9851f290-e350-49d1-93d2-172c95dd01dc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/241029ae-e751-419f-a2e7-5da7bbb82d17"/>
    <rdfs:label>Glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) CuGTSM</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8e2fda41-9a98-4afe-acf8-6691048aacf5">
    <rdfs:label>Ad5-LARGE-eGFP</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2166a51d-ab7c-4eaf-97c7-ad779cb7965e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9874c3ee-f7bd-431d-80ad-8d449b4d4a67">
    <dc:identifier>DB04540</dc:identifier>
    <rdfs:label>Cholesterol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04540</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c354036a-c94c-425c-a662-1fc271d272d5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/960b82ea-83d3-4382-a688-b20704f8febe"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c6cb0da6-f100-47d4-9f9a-d75617bb4572">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/10eebb5a-df3a-4d0b-a0a8-35851eec2399"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eb7c9a63-48ab-457c-a702-00a1356ab236">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b3e710c2-4afe-4297-96d8-f0cb4c6bcaf2"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0bcb4648-c5f1-4621-a658-882975bc7ef9">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d8e5ae88-67ba-4b49-a998-33ec188e0672"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57db5a7f-4391-4e30-b7b9-8e318d82bf21">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025464</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
    <rdfs:label>Increased reactive oxygen species production</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/40bb2e11-f096-43dd-9d4f-b66af1d1bfe6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3b5d4fba-a135-41e4-b01a-c4b1364e6dee"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d3f8bf61-5992-4592-a0fb-723a7107375d">
    <dc:identifier>DB00571</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00571</ddiem:url>
    <rdfs:label>Propranolol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f1623fa-17a0-4d89-a03b-190187934b43"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a0e22046-1c95-40ce-9bf9-4a646208ce62">
    <dc:identifier>DB00435</dc:identifier>
    <rdfs:label>Nitric Oxide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a78fdd24-3239-4e47-a86e-7325aac37737"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00435</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f9af2057-b0b4-4092-a67f-cdff1f460f67">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3d2a50c5-1732-4ae4-b098-b941eaba31ab"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94ef31d2-07aa-4f6f-b72a-694e9a426c8d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
    <rdfs:label>Oedema</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000969</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fb441ffd-cb6b-4bfd-bf8c-bed99db20bb7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/39010e2d-e911-4363-adb4-260ab12c3ef1"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e407d11-6262-4ea7-ba1b-e3457be44973">
    <dc:identifier>HP:0002360</dc:identifier>
    <rdfs:label>somnolence</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/227c436e-c014-4140-bfb5-061ef97c088c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/535a489e-dec2-407b-9108-f88eeaedec9a"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/06acacb0-9d76-4e0d-8722-908dc894a0cb">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/df70152f-bb04-4c7c-a9f6-ea31b7d72dac"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ee4bfee7-3613-48e9-acc4-720a50ac3157">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11</ddiem:url>
    <rdfs:label>VITAMINS</rdfs:label>
    <dc:identifier>A11</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0537f0d4-e531-4f7d-8cc1-c13b670a5f0a"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c29ce27-f5d6-44be-be72-7875c21b9b35">
    <rdfs:label>cerebral cortex acetylcholinesterase inhibition</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c239d38d-9c47-499b-8fee-6b42421c4c11">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ed338e67-b629-45e1-a2a2-ada78b25fa49"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/115664cd-bb6e-4275-8ca6-c44cb58b13dd">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Parkinsonism</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/16b78222-4946-4c72-b66c-c940e6c19701">
    <dc:identifier>HP:0100708</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100708</ddiem:url>
    <rdfs:label>Microgliosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5b8ba935-4a0f-4922-9d81-113b40ea21c1">
    <rdfs:label>Gene therapy *</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/260ef807-5dae-44de-9bcf-08aca6c08880"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0723d5be-09bd-4a9a-bac8-8b4594e2e18c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/46cfbf54-b4ba-414a-b63b-a5aad6d5b26f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11563</ddiem:url>
    <dc:identifier>DB11563</dc:identifier>
    <rdfs:label>Sebelipase alfa</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/140274f6-7b7c-4c13-b011-40847adf8ae1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/68d44795-fc3c-4a06-a8aa-c8473107cde8"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1c206d0-4f80-434d-b04f-2214c8a514c6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9b77b213-d261-4912-a623-4cca121eee50"/>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/156c46d5-0bf7-4336-9ad3-c5ba3d8b0487">
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f3e5315-1ab4-4494-a692-051e9913dcfa"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2897261</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151800"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71a6d526-76b5-4335-858b-d3431cef0bf0"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86574687-e7fc-40be-8bfd-0ae187830193"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a162c3f2-da04-4652-978d-e32865e80200"/>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145981">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bbb76089-05b5-4d7c-8bed-edc92f96102e"/>
    <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/145981</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb5c1cbf-a2c4-4d10-9fbd-ab90e2085e08">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ecc88989-d95e-4041-935b-aec94da5e1dc"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c086b95-78f9-4339-8bc1-342d342a3b9f">
    <dc:identifier>HP:0011804</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <rdfs:label>Abnormal muscle physiology</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8b84423-ceff-4b0c-b18e-3c1267f88324">
    <rdfs:label>High chitotriosidase level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b1a22c7f-1dcf-449a-91b3-0d20a8c12777">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b791d81c-cada-4336-8576-df7ca32ee7bf"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/49a97d7d-4752-4293-b976-3ba95719dc0d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bfde4c43-3f00-4f34-b3d9-f5c3360e519d"/>
    <rdfs:label>AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fc149df-2bb5-4290-add6-547eb15d4707">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased LDL cholesterol</rdfs:label>
    <dc:identifier>HP:0003141</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2984f610-cd41-43bf-9832-0e2200957c91">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bafdb7c3-d259-4649-b28b-032a13b3c43d"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a73b30d5-a61e-404a-ac7b-b1f4d4ea709b">
    <rdfs:label>Glycosade</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c41079fd-d00c-4d0b-a918-c3db2b9aba58"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bf399c66-bf0f-4870-96cc-c906ddbe3041">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c77a3805-0000-44be-80e6-f5804c7c3f1a"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bad09885-124d-4357-aef6-e02d01e5d3fa">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cb9020df-7a4a-4097-9277-8aef5b345c16"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a385505-e3f6-4ba0-9009-0f81e6122ddb">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001324</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <rdfs:label>Decline of muscle strength (Muscle weakness)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c9debeff-8288-447f-811a-ab401a7a8aa6">
    <dc:identifier>DB00603</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6b890cc5-fa76-4ba7-87a0-449aa5195280"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00603</ddiem:url>
    <rdfs:label>Medroxyprogesterone acetate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82d348da-208f-49bd-b2dc-3be8fbba82bf">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High total homocysteine levels</rdfs:label>
    <dc:identifier>HP:0002160</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d0ddfdb-8fef-4319-b4fe-3dfe5712d4f4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1480dbcf-2f3d-4255-9884-d1723e21f81c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b20386d0-145c-42df-afb4-da675a36161f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fd6d2bf9-683c-4775-adfe-92b95f683c2e"/>
    <rdfs:label>AAV2 /1-mSeAP-propmyoD76A</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3ada3bf1-9ea9-42e1-9063-7fd7f3b38510">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c1ab4300-f43f-4a20-b34b-6cf288e9e2ec"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cedf9583-1e92-4c47-b1c8-f3bde7f98734">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000739</ddiem:url>
    <dc:identifier>HP:0000739</dc:identifier>
    <rdfs:label>anxiety</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6f9db924-cfe5-43d0-b3d1-df58993c6498">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b081387e-7142-4e40-b05c-3a34d6f0a2bc"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/345e05cc-5f44-4956-a9d6-8d7bfd08818e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/00c538c3-dade-4c76-8e0b-4e1a57155e28"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e6be0f3f-38c2-4a76-b190-cc3d3351ff6b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e6aac6bf-f4fa-428f-a59b-2096064b49ec"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d36152c-504a-4914-afb9-884a782bcf90">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/01695a31-7dff-43ba-96d7-825508a9635b"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7784d2b7-5d87-4fd9-a8d1-955b55b28414">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/15f6cc84-3100-45c2-9063-dfe45f7888e8"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c3f610c3-7541-4b24-ba0a-db710638be05">
    <rdfs:label>volanesorsen (IONIS-APOCIIIRx)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f98ec712-7715-486c-bfcf-36f72ac77d90"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/59d4cbf7-d48d-4087-9e5f-3ac427fa6e3a">
    <rdfs:label>AAV-mediated gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/70bc8794-e149-4435-9fe2-61993cf25c2f"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3f1c6ad1-a20c-4ab7-966d-78356d297e5b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2e8cc184-4ae9-40b0-a75b-68b75f20d192"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f523ffd8-3e7e-49d4-9bd7-212f4cc69edb">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002530</ddiem:url>
    <dc:identifier>HP:0002530</dc:identifier>
    <rdfs:label>Axial dystonia</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e8a832cf-d44f-4678-bdf9-ac83fd7c3678">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9e62ea1d-6bc7-45bd-b145-11a7d227aba4"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8583a1b5-e1ea-41c5-b62a-7df3e509eab3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0bd0d63c-edda-47e2-9eab-43d8618147d3"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9f1ca712-c561-4172-b6e9-ffbae99285ac">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8e6f3abe-2612-4cf7-a7bd-f782235993be"/>
    <rdfs:label>CER 001, a recombinant high-density lipoprotein (HDL)</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eac8f1ca-9b9e-4ef7-bc1f-a52101310174">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c25adf43-1f80-438f-94b2-7ee9796dfc3c"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b9e761da-05f0-4d26-bbdf-f6aca99e68aa">
    <rdfs:label>AAV2/1-MCK-Sgca</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d6010b1-ff17-4977-8719-7ab7c37448da"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5516aa8e-14ee-4066-a956-f4ccebfcc5f6">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/02802ab4-afae-4d95-9edf-28445301d511"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d249e0c-b69e-48d3-a47a-de4d6a286164">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high ornithine level		HP:0012026</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fdaade5b-1b74-4825-a204-d212dfe1cd6b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fdfe9725-9466-45cb-bb46-83019b6132ee"/>
  </rdf:Alt>
</rdf:RDF>
